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ITHAKA
As you set out for Ithaka
hope the voyage is a long one,
full of adventure, full of discovery.
Laistrygonians and Cyclops,
angry Poseidon-don't be afraid of them;
you'll never find things like that on your way
as long as you keep your thoughts raised high,
as long as a rare excitement
stirs your spirit and your body.
Laistrygonians and Cyclops,
wild Poseidon-you won't encounter them
unless you bring them along inside your soul,
unless your soul sets them up in front of you.
Hope the voyage is a long one.
May there be many a summer morning when,
with what pleasure, what joy,
you come into harbors seen for the first time;
may you stop at Phoenician trading stations
to buy fine things,
mother of pearl and coral, amber and ebony,
sensual perfume of every kind-
as many sensual perfumes as you can;
and may you visit many Egyptian cities
to gather stores of knowledge from their scholars.
Keep Ithaka always in your mind.
Arriving there is what you are destined for.
But do not hurry the journey at all.
Better if it lasts for years,
so you are old by the time you reach the island,
wealthy with all you have gained on the way,
not expecting Ithaka to make you rich.
Ithaka gave you the marvellous journey.
Without her you would not have set out.
She has nothing left to give you now.
And if you find her poor, Ithaka won't have fooled you.
Wise as you will have become, so full of experience,
you will have understood by then what these Ithakas mean.
The poem Ithaka by C.P.Cavafy, Collected Poems;translated by Edmund Keely and Philip
Sherrard; edited by George Savidis, Rev. Ed.1992, Princeton Press, pp.36-37.
One of my favourite poems and one that I often recited to keep me going during these three
years.
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Abstract
Epstein-Barr virus (EBV) is a human herpesvirus that has been associated over the past forty
years with a number of malignancies both of lymphoid and epithelial origin. These include
Burkitt's lymphoma (BL), Hodgkin's disease (HD) and nasopharyngeal carcinoma (NPC) to
name only a few. One of the latent proteins of the virus, latent membrane protein 1 (LMPl)
has been frequently detected in NPC biopsies and it plays a role in the initiation and
development of the disease. Various strains of LMP1 have beed detected, but the LMP1CAO
strain is the one most often encountered in endemic NPC cases. NPC tumours also show a
deletion across chromosome 9p21which leads to loss of the tumour suppressor locus INK4a as
well as deletion or hypermethylation of 3p21.3 that leads to loss of another tumour suppressor
the Rassfl. The aim of the work presented in this thesis is to investigate the exact role LMPI
plays both in the genesis and the development of epithelial malignancies such as NPC.
In order to investigate this, transgenic mouse models expressing two different strains ofLMPl
at their epithelium were used. Use of other transgenic and knock out mice was also involved,
in order to investigate cooperative relationships that LMP1may have with other oncogenes or
tumour suppressor genes. Minimal skin chemical carcinogenesis was employed in order to
determine the role of LMPI in initiation or progression of the tumourigenic process.
LMPI CAO was found to be expressed in a wide variety of tissues in the transgenic mice,
including both tissues of the epithelium as well as lymphoid tissues. LMPI CAO is a weak
initiator as LMPI CAO transgenic mice develop lesions spontaneously and in some cases the
ears of these mice progress from benign keratoacanthomas to malignant squamous cell
carcinomas. LMPlcAO cooperates with loss ofINK4a locus to give an increased lesion load.
Signalling pathways that were found to be activated by LMPI in lymphoid, epithelial cells or
fibroblasts in previous studies, were investigated by Western blotting in order to determine
whether they are activated by LMPI CAO in the epithelium in vivo. LMPI CAO in the epithelium
in vivo, leads to activation of the p38, NF-KB, AP-I and MAPK pathways. Other proteins
were shown to be upregulated or stabilised by LMPI including pS3, pI6INNK4a,caspase-J and
MMP9. Whether this is a direct effect of LMPI CAO or it is a secondary event due to the
phenotype that LMPI causes is still unclear.
13
The similarity between the LMPI transgenic mice and TGFa transgenic mice, as well as
increased levels of the epidermal growth factor receptor (EGFR) in NPC biopsies and NPC
cells in vitro, led us to investigate the possibility that LMPI may be acting via the
TGFalEGFR pathway. Indeed, TGFa levels were found to be upregulated in transgenic
affected tissues when compared to wild type sibling tissues. EGFR activates many signalling
pathways including MAPK. Investigation of the MAPK pathway showed that LMPI does
lead to its activation. In order to determine whether LMPI acts via upregulation of TGFa,
LMPI transgenic mice were cross bred with TGFa null mice to create LMPI transgenic /
TGFa null mice. The phenotype of these mice was observed and it was discovered that
paradoxically, loss ofTGFa- a known oncogene- leads to a worsening of the phenotype.
Further studies into the signalling pathways that may be affected by loss of TGFa showed that
TGFa in this system may be acting as a tumour suppressor by upregulating Rassfl and also
may be acting as a control of some of the signalling pathways activated by LMPI.
The results show that LMP 1CAD is a weak initiator of proliferation but other cooperative
events such as loss of tumour suppressors INK4a and/or Rassfl are needed for progression.
This is consistent with previous studies performed in this laboratory as well as the facts that
are currently known for NPC.
14
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Chapter 1: Introduction
1.1 Epstein Barr Virus (EBV)
EBV is a human gammaherpesvirus that is associated with several lymphoid and epithelial
malignancies. It was first discovered in 1964 by Epstein, Achong and Barr when an endemic
Burkitt's lymphoma (eBL) biopsy viewed under an electron microscope showed what looked
like herpesvirus particles present in those cells. EBV was subsequently shown to transform
resting B cells and induce tumours in non human primates thus providing evidence for the role
of EBV in tumourigenesis (Henle and Henle, 1967; Miller and Heston, 1974; Pope et aI.,
1968).
EBV is a very successful virus as more than 90% of the world population is seropositive.
Primary infection with EBV takes place early in life, especially in developing countries, and
infection is usually asymptomatic. In developed countries with higher hygiene standards,
infection in a proportion of individuals is delayed to puberty or early adulthood. Delayed
infection can lead to manifestation of infectious mononucleosis (1M).
Malignancies associated with EBV include BL, nasopharyngeal carcinoma (NPC), Hodgkin's
disease (HD), Acquired Immunodeficiency Syndrome (AIDS) associated and post transplant
lymphomas and others that will be discussed later.
Viral structure and genome
Within the viral particle, the linear EBV genome is complexed with various DNA binding
proteins and is enclosed within an icosahedral nucleocapsid made up of 162 capsomeres.
Surrounding the viral capsid is a protein tegument that is enclosed in the outer viral envelope.
The viral envelope is made up of glycoproteins (gp) that mediate entry of the virus into the
host cell. Initially viral encoded gp350/220 in the envelope can attach to the host cell via the
cellular complement receptor (CR) CD21/CR2 present on B cells. Other viral envelope
glycoproteins such as gp25(gL) and gp42/38 are complexed with gp85(gH) and can associate
with the major histocompatibility' complex class IImolecules of the host cell, HLA-DR, DP
and DQ for viral entry into the host cell (Knox and Young, 1995). After entry into the cell via
a cytoplasmic vesicle, the virus envelope fuses with the vesicle membrane and the
nucleocapsid along with the tegument is released into the cytoplasm.
The EBV genome consists of double stranded (ds) DNA of approximately 172kb, comprising
O.5kbterminal direct repeats (TR) and 3kb internal direct repeats (IR) that divide the genome
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into short and long unique regions. Once infection takes place, the TR fuse, to form a circular
DNA. Cleavage occurs randomly in the TR to produce linear genomes that will have a
different number of TR unique to each genome. When those linear genomes circularise each
will have a unique number of TR. Thus TR are a useful tool in determining whether latent
infection is clonal or not.
EBV was the first herpesvirus to be cloned in E.coli and sequenced in 1984 (Arrand et al.,
1981; Baer et al., 1984; Hatfull et al., 1988; Parker et al., 1990). Since a DNA BamHI
fragment library was used in the first genome analysis, each gene is given a name according to
where transcription of its open reading frame (ORF) maps. For example, BZLFI refers to
BamHI Z fragment left (direction according to linear map) open reading frame number 1. As
such all the EBV genes have a BamHI map name, but several are also named according to
function or protein localisation as described below. EBV can encode 87 genes, 10 of which
are latent genes and are described later.
EBVtypes
There are two main strain types of EBV, EBVI (or A, prototypes are: B95-8 and W91) and
EBV2 (or B, prototypes are: Jijoye and AG876). The main differences between these two viral
strain types lie in the sequence differences of the Epstein Barr Nuclear Antigen (EBNA) 2,
EBNA3s and EBNA leader protein (LP) genes (Dambaugh et al., 1984; Rowe et al., 1989;
Sample et al., 1990). The two variants ofEBNA2 show 50% homology at the amino acid (aa)
sequence level, and the two EBNA3 variants show 70-80% homology (Adldinger et al., 1985).
EBVI is more prevalent in developed countries whereas EBV2 is more prevalent in Africa and
Caucasian male homosexual AIDS patients (Yao et al., 1998).
Initial experiments where B cells were transformed in vitro with either EBVI or 2, showed
that EBV2 transformed cells had a lower growth rate than B cells transformed with EBVI
implying that EBV2 is not as potent in transformation as EBVI (Rickinson et al., 1987).
However, the finding that Caucasian male homosexual AIDS patients show a 30% increase in
the EBV2 infection as compared to the healthy Caucasian population, as well as the fact that
the Caucasian AIDS patients are coinfected with EBVl, implies that EBV2 may be prevalent
in the Caucasian population but not be readily detected in non immunocompromised
individuals. Despite the fact that there are only two main EBV types, sequence variation
between EBV strains of individual proteins such as LMPI is quite common with as many as 9
different LMP1 strains (Miller et al., 1994b).
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A further EBV type has been identified called the "f variant". This type of EBV is mostly
isolated from Southern Chinese NPCs. This strain has an extra BamHI restriction site in the F
region. This "f variant" has affinity for epithelial cells and is very rarely detected in
lymphoblastoid cell lines (LCLs) from South Chinese healthy individuals, thus implying that it
may be more potent in NPC formation (Lung and Chang, 1992; Lung et al., 1994).
1.2 Natural History of EBV
EBV is an orally transmitted virus. It is still unclear how it infects humans but the currently
favoured hypothesis is that the primary site of infection is the circulating B cells that are found
in the oral epithelia (Anagnostopoulos et al., 1995; Niedobitek et al., 1997). The virus enters
the B cell via the glycoproteins as described before. Once in the B cell the viral presence
leads to an initial T cell response. After this response, the number of B cells carrying EBV
drops to about one in every 105 or 106 cells. In most B cells the virus exists in the latent state
but in some it can be reactivated and enter the lytic phase. This leads to the apoptosis of the B
cell and the release of new virions that are constantly shed into the saliva of infected
individuals. Epithelial cells can also be infected with EBV and it is believed that this could
happen independently of CD21 (Yoshiyama et al., 1997), via another receptor unique to the
epithelial cells (Molesworth et al., 2000; Sixbey and Yao, 1992), or via very low CD21
expression (Fingeroth et aI., 1999; Li et al., 1992) or simply via cell to cell contact with B cells
that have a high viral load (lmai et aI., 1998; Speck et al., 2000).
There is extensive evidence that the infection is maintained in B cells. This has been shown in
patients that have received bone marrow transplants. Their own bone marrow was destroyed,
and after transplant the EBV virus they harboured was that of the donor. Also patients
suffering from the condition X-linked agammaglobulinemea leading to the absence of mature
B cells, show no EBV infection whatsoever, while throat washings of healthy individuals
showed that 94% were infected with EBV (Faulkner et al., 1999).
Lytic Cycle
The lytic cycle has been studied primarily in latently infected B cells that have been induced
by chemicals such as phorbol esters to enter the lytic cycle. The first genes to be expressed
are the immediate early genes BZLFI and BRLFI. Initially the promoter of BZLFI is
activated by a physiologic change in the cell, BZLFI is transcribed and translated. The Z
protein then goes into the nucleus where it binds to activating protein I (API) DNA sites
upstream of both BZLFI and BRLFI, increasing BZLFI transcription and activating BRLFI.
These immediate early genes transactivate the early lytic genes. About 30 mRNAs are
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transcribed from early lytic genes and these include genes that are responsible for structural
viral proteins or proteins that allow the virus envelopment and viral exit from the host cell.
These include genes that encode for viral DNA polymerase (BALFS), the major DNA binding
protein (BALF2), ribonucleotide reductase (BORF2 and BaRF1), thymidine kinase (BXLF1),
BHRFI (homologous to the anti-apoptotic bcl-2), BXRFI (the EBV basic core protein) and
among others the BCRFI which is homologous to human interleukin (IL) 10 and is believed to
attenuate macrophage and natural killer (NK) cell function so as to prevent the host cell
interferon response and allow for successful viral production and also genes needed for the
viral replication. Some of the latent genes such as EBNAI and latent membrane protein
(LMP) 1 and LMP2AIB are present in the lytic cycle as the FQp promoter and the LMP
promoters are active(Rickinson and Kieff, 1996).
Latent Cycle
EBV persists in human B cells in the latent state, as an episome, expressing only a limited
subset of its genes, the latent genes. Latent genes were first identified in LCLs that are resting
B cells that have been transformed by EBV and are permanently infected. These latent genes
include EBNAI, 2, 3A, 3B, 3C, LP, LMPI, 2A and 2B as well as some Bam HI RNA
transcripts which may encode proteins of important biological function. Note that an
alternative nomenclature exists for some of the latent genes, for example EBNALP can also be
called EBNA5. I will use the former nomenclature in this thesis. The ORF name, gene
product, alternative nomenclature and cellular localisation are summarised on table 1.1 and the
position of the latent genes is shown on fig. I. I.
After 12-16hrs post infection, EBV circularises in the infected cell nucleus and the Wp
promoter initiates rightwards transcription. The first latent proteins to be expressed are
EBNALP and EBNA2. EBNA2 can transactivate cellular genes and viral genes (eg. Latent
membrane (LMP) 1 and LMP2) and also leads to promoter switching from Wp to Cp. The Cp
promoter is upstream of Wp and leads to transcription of the longer EBNA mRNA thus
leading to transcription of the other EBNA proteins. LMPI and LMP2A and B are transcribed
in opposite directions (LMP1 is leftforward) from two different unigue to them promoters.
32hrs post infection all the latent proteins are made and EBNAI can bind to the origin of
replication (Ori) P and facilitate the episomal replication at S phase.
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Figure 1.1: The EBV Genome
Figure from Young and Murray, 2003, Oncogene (22):5108-5121.
(a) is a diagrammatic representation showing the position and the transcriptional
direction of the latent genes ofEBV on the circular viral genome. The arrows show
the direction in which the latent genes are transcribed. The latent genes represented
are the EBNA1, 2, 3A, 3B, 3C, LP, LMP I, 2A and B and the EBERs. LMP2A and
B are transcribed from different promoters and their transcripts are positioned across
the terminal repeats (TR). LMPI is transcribed in the opposite direction to the rest
of the latent genes. EBNALP is transcribed from several W repeat exons the
number of which is variable.
(b) is a linear representation of the BamHI map of EBV and the location of the
ORFs of the latent genes. The fragments are named according to their size, with A
being the largest. The Nhet represents the area over which the LMP2s are
transcribed. Since they are transcribed over the terminal repeats which differ in
number from one EBV strain to another the fragment is called Nhet to represent the
heterogeneity that can occur.
LMP1
ORF Gene product Alternative nomenclature Cellular Location
BKRFI EBNAI Nuclear
BYRFI EBNA2 Nuclear
BLRF3-BERFl EBNA3A EBNA3 Nuclear
BERF2a-BERF2b EBNA3B EBNA4 Nuclear
BWRFI EBNALP EBNA5 Nuclear
BERF3-BERF4 EBNA3C EBNA6 Nuclear
BNLFI LMPI LMP Membrane
BARFIIBNRFI LMP2A TPI Membrane
BNRF2 LMP2B TP2 Membrane
BCRFI EBERl,2 Cytoplasm and nucleus
BARFO BamHI transcripts Cytoplasm. .
Table 1.1: ORF, gene product, alternative nomenclature and cellular localisation of the
product of EBV latent genes.
Latent genes are expressed variably in different subsets of B cells in healthy EBV carriers and
also in all the EBV associated malignancies. Based on the variable expression, three major
latency programs have been identified and the genes expressed and their disease association is
given in table 1.2. Naive tonsillar B cells of healthy EBV carriers show expression of all
latent genes corresponding to latency III, whereas memory tonsillar B cells of healthy carriers
show latency II pattern. Peripheral B cells express a very restricted pattern of latent genes
possibly expressing only LMP2 (Babcock et al., 2000; Babcock and Thorley-Lawson, 2000;
Joseph et al., 2000).
Latency pattern Latent genes expressed
Latency I EBNAl, EBERs, Bam A RNAs
Latency II EBNAl, LMP1, 2A, 2B, EBERs, Bam A RNAs
Latency III EBNAl, 2, 3A, 3B, 3C, LP, LMP1, 2A, 2B, EBERs, Bam A
RNAs
Table 1.2: The latency patterns of EBV
The focus of my thesis is LMP1, however a brief description of the other latent genes is given
below.
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EBNA1
EBNAI is 641 aa long and encodes a 65-94kDa protein. EBNAI is expressed in all the EBV
associated diseases and is one of the few latent proteins expressed in the lytic cycle of the
virus. EBNAI is made up of three distinct domains with further subdomains; the basic amino
terminus (l-89aa), the glycine-alanine (Gly-Ala) repeats region (90-328aa), and the carboxy
terminus (328-641aa). The Gly-Ala repeats give the virus the ability to evade the host immune
response by preventing protein processing by ubiquitination, proteasomal degradation and
presentation and also limit self expression (Levitskaya et al., 1995; Levitskaya et al., 1997).
Flanking the Gly-Ala repeats are Arg-Gly motifs that resemble RGG motifs and allow EBNAI
to bind RNA (Snudden et al., 1994). The first region within the carboxy terminus is a Pro-Arg
rich region (327-377aa) that mediates interactions between EBNAI molecules bound to
distant DNA binding sites mediating linking and looping (Goldsmith et al., 1993; Mackey et
al., 1995; Su et al., 1991). Between residues 379-387 lies the nuclear localisation signal,
followed by a serine rich region (375-400aa) which becomes phosphorylated but the
importance of this phosphorylation is still unknown (Hearing and Levine, 1985; Polvino-
Bodnar et al., 1988). Between residues 459-607 is the DNA binding and homodimerisation
region of EBNAI (Ambinder et al., 1990). At the carboxy terminus is an acidic rich region
that plays a role in the episomal segregation into daughter cells during cell division.
The primary role ofEBNAI is the maintainance of the viral episome during cell division (Lee
et al., 1999; Yates et al., 1984). To perform this function, EBNAI binds as a dimer to two
regions in the OriP of EBV. OriP has a region of 20 tandem direct 30bp repeats called the
family of repeats (FR), each capable of binding an EBNA 1 dimer. An EBNAI dimer can also
bind at 4 sites in the dyad symmetry element (DS) lkb downstream ofFR. Binding ofEBNAI
to FR allows FR to function as a transcriptional enhancer for RNA polymerase II transcribed
genes thus allowing for EBNAI autoregulation and regulation of the other latent EBV genes
(Reisman and Sugden, 1986). The DS is essential for episomal replication but without the FR,
DS is inefficient in maintaining transcription, plasmid replication or maintenance. EBNAI
can also bind the nuclear matrix attachment region in the host chromosomes (Jankelevich et
al., 1992).
EBNAI is the only viral protein that can associate with cellular chromosomes during mitosis
and this is thought to be essential for the maintenance of the viral episome. EBNA 1 also binds
cellular proteins, EBP2 (EBNAI binding protein 2) and P32/TAP. EBP2 binds to both mitotic
chromosomes and EBNAI thus mediating the interaction of EBNAI with chromosomes and
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facilitating the segregation of the viral episome into daughter cells (Kapoor and Frappier,
2003).
EBNAI may also playa role in the oncogenicity of the virus, since transgenic animals that
express EBNAI in B cells succumb to malignant B cell lymphomas (Wilson et al., 1996;
Wilson and Levine, 1992). Further, EBNAI is essential in the survival of BL cells as its
inhibition leads to apoptosis and it is necessary for efficient LCL formation, supporting an
EBNAI role in cell survival (Humme et al., 2003; Kennedy et al., 2003). Consistent with
these, are the results obtained from transgenic EBNAI mice premalignant B cells that show
increased Bel-XL(an anti-apoptotic protein), RAG1 and RAG2 levels (Tsimbouri et al., 2002).
Recent data from these mice also show that there is a dependancy for survival on IL-2
signalling that is induced via EBNAI (Tsimbouri et al., in preparation).
EBNA2
EBNA2 is a 487 aa nuclear protein that along with EBNALP are the first to be expressed after
B cell infection with the virus in vitro (Allday et al., 1989; Rooney et al., 1989). EBNA2
cooperates with EBNALP to induce transition of the infected cells from GOto GI (Sinelair et
aI., 1994). EBNA2 is essential for the initiation and maintenance ofEBV transformation ofB
cells in vitro (Cohen and Kieff, 1991; Cohen et al., 1991; Hammerschmidt and Sugden, 1989;
Kempkes et al., 1995). EBNA2 acts as a transcriptional regulator by binding to the cellular
transcriptional repressor RBP-h: (involved in the Notch signalling pathway), which binds to
DNA. By binding to RBP-JK, the repression function is alleviated and transcription of viral
and cellular genes can take place. By binding to recombination binding protein JK (RBP-JK),
EBNA2 can transactivate the LMP2A promoter, the Cp promoter, the LMPI promoter and the
CD23 promoter (Abbot et al., 1990; Fahraeus et al., 1990; Laux et al., 1994; Ling et al., 1994;
Ling et al., 1993; Sung et al., 1991; Wang et al., 1990; Zimber-Strobl et al., 1993; Zimber-
Strobl et al., 1991). EBNA2 regulates expression of some cellular genes such as CD21, CD23,
c-myc, c-fgr, EBIlIBLR2 and the immunoglobulin heavy chain gene (Burgstahler et al., 1995;
Calender et al., 1987; Cordier et al., 1990; Jochner et al., 1996; Kaiser et al., 1999; Knutson,
1990; Wang et al., 1987). Binding of EBNA2 to RBP-JK is necessary but not sufficient for
gene expression induction. EBNA2 requires binding of other cellular proteins such as PU.l
and AUFl.
EBNA2 competes with EBNA3A and 3C for RBP-JKbinding (Johannsen et al., 1996;
Robertson et al., 1995; Waltzer et al., 1996; Zhao et al., 1996).
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EBNA 3A,B,C
The three EBNA3 genes are tandemly located in the EBV genome. They encode nuclear,
hydrophilic proteins with heptad repeats of leucine, isoleucine or valine. EBNA3A and 3C are
essential for B cell transformation in culture whereas EBNA3B is not (Tomkinson et aI.,
1993). The EBNA3s can bind to RBP-JK and compete with EBNA2 for binding to it and also
transcriptionally regulate genes with RBP-JK binding sites (Allday and Farrell, 1994;
Robertson et aI., 1995; Robertson et aI., 1996; Wang et aI., 1990). EBNA3s can block the
EBNA2 activation of the LMP2 promoter (Le Roux et aI., 1994). EBNA3C can block EBNA2
mediated LMP 1 promoter activation via repression of the Cp promoter or cooperate with
EBNA2 and activate the LMPI promoter under different conditions (Allday et al., 1993;Lin et
aI., 2002; Marshall and Sample, 1995). It is thought that since LMPI levels are important for
viral survival, EBNA3C activation or repression of the LMPI promoter is essential in
maintaining proper LMPI levels and inhibiting uncontrolled expression. EBNA3C has been
shown to cooperate with Ras and transform rodent fibroblasts in culture, to weakly interact
with retinoblastoma (Rb) and remove the block induced by p16INK4ain cycle progression
(Parker et aI., 1996; Parker et aI., 2000). EBNA3C can also interact with cellular proteins
including SUM01l3, nonmetastatic protein 23- homologue l(Nm23-Hl) (Subramanian and
Robertson, 2002), histone deacetylase (HDACI) (Radkov et aI., 1999) that are controlling
transcription and also associate with CyclinA (Knight and Robertson, 2004) thus mediating
progression through S phase and entry into mitosis. Despite the above role of EBNA3C in
transformation and cell cycle progression, EBNA3s are not expressed in any of the EBV
associated malignancies or in memory B cells from healthy carriers therefore their role in
malignant disease is not clear. EBNA3s are the latent proteins for which the host cytotoxic T
lymphocytes (CTL) elicit the strongest reaction to, both in healthy virus carriers and upon
primary B cell viral infection and thus their downregulation permits viral persistence
(reviewed in (Khanna and Burrows, 2000; Rickinson and Moss, 1997).
EBNALP
EBNALP is encoded by the leader of each of the bicistronic EBNA mRNAs and its size varies
between the various EBV isolates. It is made up of repeating 22 or 44 aa exons called WI
and W2, two unique exons YI and Y2 and a 45 amino acid carboxy terminus. EBNALP and
EBNA2 are the first proteins to be expressed in the latent infection of primary B cells in
culture and even though EBNALP is not essential for B cell transformation it is required for
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efficient transformation (Allan et al., 1992) mediated by the Yl and Y2 exons (Mannick et al.,
1991). EBNALP and EBNA2 show cooperating effects in stimulating the increase in the
expression ofLMPI and this is mapped to the WI and W2 repeats ofEBNALP (Harada and
Kieff, 1997; Nitsche et al., 1997). EBNALP and EBNA2 also cooperate in activating cellular
genes such as CD23 and CyclinD2 in resting B cells (Sinclair et al., 1994). EBNALP has been
shown to have a weak interaction with p53 and Rb in in vitro biochemical studies but these
results have not been confirmed in vivo (Jiang et al., 1991; Szekely et al., 1993). More
recently other cellular proteins that interact with EBNALP have been identified. These
include the heat shock protein 70 family (hsp72/hsc73) (Mannick et al., 1995), DNA-PK,
HA95, hsp27, u-tubulin and ~-tubulin (Han et al., 2001). The exact role played by these
interactions is still unclear. EBNALP transgenic mice were created showing a phenotype of
premature death due to heart failure (Huen et al., 1993). However, expression of the transgene
was directed to cardiac and other tissue by using the cytomegalovirus (CMV) promoter and as
such the relevance to EBV associated disease is difficult to determine.
LMP2Aand B
The LMP2 gene is transcribed only from the circular EBV genome as the transcription unit
crosses the TR. Two different promoters (3kb apart) are used which give rise to transcripts
differing in length at the 5' end. The translation product of the longer 9 exon transcript is
LMP2A and the shorter 8 exon product (effectively 119aa N-terminal deletion ofLMP2A) is
termed LMP2B. Both LMP2 proteins are transmembrane, consisting of twelve
transmembrane spanning domains (Sample et al., 1989). LMP2A and B have been detected in
LCLs, and in NPC biopsies. In epithelial cells LMP2A may be involved in transformation by
activating the PI3K1Akt pathway (Fukuda and Longnecker, 2004; Scholle et al., 2000). It is
thought that LMP2A plays a role in the survival and persistence of infected B cells in vivo.
LMP2 forms patches at the cell membrane and LMP2A is thought to act like a constitutively
active B cell receptor (BCR) to promote B cell survival in vivo, demonstrated in transgenic
mice (Caldwell et al., 1998). Phosphorylation of its amino terminal domain recruits members
of the src family of tyrosine kinases, specifically fyn and lyn (Longnecker, 2000; Longnecker
et al., 1991). By this recruitment LMP2A activates BCR signal transduction such as calcium
mobilisation and may thus act to block the switch from the latent to the lytic cycle (Fruehling
and Longnecker, 1997; Fruehling et al., 1998; Miller et al., 1994a; Miller et al., 1993). Due to
its lack of the amino terminus LMP2B does not mimick or block BCR signalling but may act
to control the effects of LMP2A (Longnecker, 2000). Therefore, LMP2s playa role in
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maintaining the virus in its latent form, inhibiting reactivation and thus possible recognition by
the host immune system.
Epstein Barr Virus small RNAs (EBERS) 1 and 2
EBERs I and 2 are non polyadenylated, untranslated RNAs that are expressed in all latency
types apart from a new latency type discovered in liver tumour cells (Sugawara et al., 1999).
EBERs are highly expressed in all other EBV associated tumours and thus used in in situ
hybridisations as a marker for the presence of the EBV genome (Khan et al., 1992; Wu et al.,
1991).
EBER genes can be deleted from the EBV genome without affecting the viral ability to infect,
transform B cells in culture, remain latent or switch to the lytic cycle. However, they may
play an important role in maintaining the immortalised phenotype of EBV infected cells
(Greifenegger et al., 1998; Swami nathan et al., 1991).
The two EBERs are expressed from the Eco RI J fragment of the EBV genome, separated by
160 bp and they are transcribed by RNA polymerase III. Expression of the EBERs varies as in
some BL cells EBERl is detected at a 10 fold higher level than EBER2 (Lerner et al., 1981).
Studies have suggested that the difference seen is because EBERl has a longer half life than
EBER 2 (Clarke et al., 1992).
EBERl is 167 nucleotides, EBER2 is 172 nucleotides and they are 54% homologous at the
primary sequence. Their primary sequence is highly conserved among different EBV strains
(Arrand et al., 1989). Both show an extensive and similar predicted secondary structure
(Glickman et al., 1988). Studies in which the predicted secondary structure was disrupted by
replacement of inosine residues for guanosine resulted in complete inhibition of binding of
EBERl to one of the protein targets of EBERs, interferon inducible double stranded RNA
activated protein kinase R (PKR) (Clarke et al., 1991). Thus the secondary structure is
important for the EBER function. In the cell, EBERs are associated with the rough
endoplasmic reticulum and can also associate with chromosomes during metaphase
(Schwemmle et al., 1992).
EBERs can associate with three cellular proteins; the La antigen, the ribosomal protein L22
(or EAP) and PKR.
EBERs compete with viral generated dsRNA in binding to PKR. Usually, PKR is activated by
viral dsRNA thus activating the interferon response leading to apoptosis and growth
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inhibition, protecting the host from viral agents (Nanbo et al., 2002). Binding of EBERs to
PKR thus prevents PKR activation therefore allowing survival of the virus infected cell (Katze
etal., 1991).
An oncogenic property of EBERs has been suggested by transfection of EBERs into Akata
(EBV negative) cells which induced cell growth in soft agar, tumour formation in SCID mice,
conferred apoptosis resistance to the cells and upregulated levels of bcl-Z (Komano et al.,
1999; Komano et al., 1998; Ruf et al., 2000). Similar effects were shown when EBERs were
transfected into Bjab cells (EBV negative BL cell line), NIH3T3 cells and cord blood
lymphocytes (Laing et al., 1995; Zeuthen, 1983). Recently, a binding site in the EBERl
promoter for c-myc was discovered (Niller et al., 2003). This opens up a new scenario for the
involvement of EBERs in the development of BL. Translocation of c-myc in BL could lead to
activation of the anti-apoptotic effect of EBERs in an EBV positive cell, thereby contributing
to the transformation process.
Bam HI A RNA transcripts (BARTs)
BARTs have been identified in NPC, HD, BL, nasal TI natural killer (TINK) cell lymphoma,
post-transplant lymphoproliferative disorders (PTLDs), and the peripheral blood of healthy
individuals (Chen et al., 1999; Deacon et al., 1993; Hitt et al., 1989) but the protein products
have been poorly characterised. RPMSI ORF product binds to nuclear CBFl (a component of
the Notch signalling), preventing transcriptional activation and thus inhibiting NotchlEBNA2
action. Another ORF encodes the A73 protein that interacts with the cellular RACKI that
controls PKC and Src signalling, thus implying that A73 may play a role in growth regulation
(Smith et al., 2000). BARFO was one of the first products identified and is described below.
BARFO
BARFO transcripts have been implicated in NPC but the BARFO protein which is 16-20kDa
has not yet been detected. Experiments using EBV virus deleted for 58kb including BARFO,
transfected into B lymphocytes, led to B cell transformation showing that BARFO does not
play a role in this process (Robertson et al., 1994).
BARF1
BARFI is a 31kDa protein that is secreted from infected B cells and has been detected in EBV
associated NPC. Its gene transcript has been detected in EBV associated gastric carcinoma
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(Decaussin et al., 2000; zur Hausen et al., 2000). It has an immortalising effect when
expressed in primary simian epithelial cells and can transform rodent fibroblasts or human B
cells and can act as a growth factor when added in culture (SaIl et al., 2004; Sheng et al., 2003;
Wei et al., 1997). BARF 1 has been identified to be a receptor of human colony-stimulating
factor 1 (CSF-I) and share homology with the CSF-I receptor, the protooncogene c-fms.
Since CSF-l is a cytokine involved in macrophage differentiation it is possible that BARFI
plays a role in attenuating the host immune response to viral infection (Strockbine et al.,
1998). It has also been discovered that BARFI can activate Bcl-2 (an anti-apoptotic protein)
via its N-terminal region.
1.3 LMP1
Structure of LMP1
The LMPI gene consists of three exons and is read from the right end (as usually depicted) of
the linear virus genome in the reverse orientation to the EBNAs. LMPI is a 63kDa protein of
386 aa. LMPI is a transmembrane protein that is located in cellular membranes including the
plasma membrane where it associates with vimentin in B cells and the cytoskeleton. It has
been recently shown to be located in intracellular lipid rafts and primarily signal from there
(Lam and Sugden, 2003). Once in the membrane LMPI can undergo several post-
translational modifications including cleavage at the carboxy terminus (at Leu 242) to release
a 25kDa C-terminal fragment and phosphorylation on serine (Ser313) and threonine (Thr324)
(Baichwal and Sugden, 1987; Moorthy and Thorley-Lawson, 1993). The half life ofLMPI
varies from 2-15hrs depending on whether it is associated with the cytoskeleton or not and
depending on LMPI strain and cell type.
LMPI comprises three distinct regions; a positively charged short amino terminus (1-24aa)
followed by six transmembrane domains (2S-186aa) and a long effector carboxy terminus
(187-386aa) (Fennewald et al., 1984). The carboxy terminus can be further divided into three
domains, termed carboxy terminus activating regions (CTAR) 1-3 that mediate binding of
several cellular proteins and activate downstream signalling pathways. Within the carboxy
terminus is an 11aa repeat motif, the number of repeats varies among the different LMP1
strain variants (fig.l.2).
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Cell membrane
Figure 1.2: The structure ofLMPl (Not to scale)
LMPI oligomerises at the membrane. LMPI comprises a short amino
terminus (orange), six transmembrane domains (green), and a long
carboxy terminus. There are three regions within the carboxy terminus;
CTARI (red), CTAR3 (blue) and CTAR2 (black) which associate with
cellular proteins to mediate the signalling activity ofLMPl.
Deletion studies have been used as a means to determine the function of the various domains
of LMP!. It was shown that the amino terminus of LMPI is essential for efficient
transformation, orienting LMPI within the cell membrane (Coffin et aI., 2001) and ubiquitin
targeted degradation of LMPI. Deletion of the first 44aa of LMPI - including the amino
terminus and the first transmembrane domain - led to accumulation ofLMPI at the membrane
but failed to induce aggregation of LMP 1 and B cell transformation, showing that
oligomerisation is needed for LMPI to exert its function and that proper orientation and
anchoring in the plasma membrane is essential for LMPI aggregation (Izumi et aI., 1994;
Kaye et al., 1993). A mutant LMPI that had a 12aa acid deletion within the amino terminus,
failed to bind to ubiquitin and thus the LMPI molecule was not degraded (Aviel et aI., 2000).
The transmembrane domains of LMP1 are required for oligomerisation of LMP1 (Kaykas and
Sugden, 2000; Kaykas et aI., 2001) which is essential for its transforming and other functions
(Baichwal and Sugden, 1989; Kaye et al., 1993; Liebowitz et aI., 1992). The transmembrane
domains are required for activating caspase-3 and inducing cell death (Nitta et aI., 2004), are
needed for protein stabilisation (Blake et al., 2001), for efficient signalling and for activating
the small GTPase Cdc42, inducing cytoskeletal reorganisation and phosphorylating the
eukaryotic translation initiation factor 2 (eIF2a) thus inhibiting gene expression (Lam et al.,
2004). Expression of a dominant negative Cdc42 in fibroblasts and B cells, inhibited
cytoskeletal reorganisation and deletion studies mapped the Cdc42 activation site in the LMP1
transmembrane domains (Puls et al., 1999; Wang et al., 1988). The first and second
transmembrane domains are required for the cytostatic effects observed as a result of LMP1
overexpression and for LMPI association with lipid rafts as demonstrated by deletion studies
in epithelial, BL and T cells (Coffin et al., 2003; Kaykas and Sugden, 2000; Sandberg et al.,
2000).
The carboxy terminus is responsible for mediating activation of several signalling pathways
via interaction with cellular proteins and is essential for B cell transformation (Kaye et al.,
1995; Peng-Pilon et al., 1995) (fig!.3). CTARI spans aa 194-232 and contains a PXQXXD
motif that allows binding of tumour necrosis factor receptor-associated factors (TRAFs)
1,2,3,5 (Devergne et al., 1997; Devergne et al., 1996; Devergne et al., 1998; Kaye et al., 1996;
Mosialos et al., 1995; Sandberg et al., 1997). The TRAF binding domain in CTARI is
essential for B cell transformation as shown by a deletion mutant that lacks aa 185-211 (Izumi
et al., 1997). CTAR2 spans aa 351-386 and contains a YYD motif that allows tumour necrosis
factor associated death domain (TRADD) and bone morphogenic protein receptor associated
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Figure 1.3: Signalling pathways activated by LMPI
The diagram shows the signalling pathways activated by LMPI. The
amino terminus and the transmembrane domains of LMPI can lead to
Cdc42 activation which leads to cytoskeletal reorganisation. CTARI
recruits the p85 subunit of PI3K leading to activation of the PI3K1Akt
pathway. CTARI also recruits a TRAF complex consisting of TRAFs
112/3/5. This complex leads to p38 and JNKIAPI activation directly and
via TRAF6 to NF-lCBactivation. Similarly, CTAR2leads via recruitment
of RIP and TRADD and their association with TRAF2 to activation of the
same pathways. CTAR2 can also lead via an as yet unidentified molecule
to ERKll2 activation. CTAR2 associates with BRAM which plays a role
in negatively regulating NF-KB activation. CTAR3 associates with JAK3
leading to activation ofSTAT1I3. Note that activation is indicated by a red
outline, whilst inhibition is indicated by a thick black outline. Pathways
which involve other unknown molecules are shown as dotted arrows.
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molecule (BRAM) binding. The CTAR2 region is essential for maintaining the outgrowth of
LCLs as a mutant lacking the last 155 residues can initiate B cell proliferation but cannot
maintain the growth of LCLs. It is believed that CTAR2 enables this by its ability to bind
TRADD and activating the downstream signalling pathways (Izumi and Kieff, 1997; Kaye et
aI., 1995). It was shown by yeast-two-hybrid experiments that the carboxy terminus ofLMPl
can directly interact with TRAFs 1-4 and TRADD (Brodeur et aI., 1997; Devergne et al.,
1996). Both CTARI and 2 are essential for B cell immortalisation and they are also known as
the transformation effector sites (TES) 1 and 2 (Izumi et aI., 1999). In epithelial cells,
presence of either of these domains enhances TNFa. mediated apoptosis (Kawanishi, 2000).
CTAR3 spans aa275-330 (between CTARsl and 2) and contains two box 1 regions
(PXXPXP) and a box 2 region that mediates binding of Janus kinase (JAK) 3. CTAR3 is not
essential for B cell transformation (Izumi et al., 1999). Its ability to bind JAK3 may be
affected by CTARsl and 2 as use ofa dominant negative LMPI that inhibited CTARI and 2
signalling, led to inhibition of STAT signalling as well (Brennan et aI., 2001).
LMP1 signalling
LMPI is a pleiotropic protein playing a role in cell proliferation, inhibition of apoptosis, cell
cytostasis, control of cell cycle and angiogenesis. It mediates its functions by activating
several signalling pathways and this has very different, sometimes opposite outcomes in
different cell types. The pathways shown to be impacted by LMPI are:
(1) the nuclear factor KB (NF-KB) pathway
NF-KB is a transcription factor usually found in the cytosol as an inactive homolheterodimer
bound to the inhibitory proteins (IKBs). There are five members in the mammalian NF-KB
family; p65, c-Rel, RelB, p50/p105 (when unprocessed) and p52/pl00 (when unprocessed).
Binding of ligands to IL-l receptors, TNF receptors, lysophospholipid (LPL) receptors and
other extracellular signals activate the IKB regulatory kinases (IKK) activating kinases (NIK
or MEKK1) that can phosphorylate and activate IKKs. Activated IKKs, phosphorylate IKBs.
IKB phosphorylation leads to the release of the bound NF-KB that can now translocate to the
nucleus and activate various genes by binding to NF-KB sites in their promoters (reviewed in
(May and Ghosh, 1998).
The NF-KB pathway is activated by both CTAR 1 and CTAR2 of LMPI. CTARI is
responsible for about 20-30% of the total NF-KB LMPI mediated activation whilst CTAR2 is
responsible for the rest (Floettmann and Rowe, 1997; Huen et aI., 1995; Mitchell and Sugden,
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1995; Paine et al., 1995). CTARI associates with the TRAF1,2,3,5 complex recruiting NIK,
phosphorylating hill and releasing NF-KB (Luftig et al., 2003; Luftig et al., 2004; Sylla et al.,
1998). CTAR2 associates with TRADD, recruiting TRAF2 or associates with receptor
interacting protein (RIP), both routes activating NF-KB. Overexpression of LMPI CTAR2
domain and either TRADD or RIP in 293 cells led to the conclusion that TRADD cooperates
with CTAR2 in activating NF-KBbut RIP has only an additive effect on this activation (Izumi
et al., 1999).
NF-KB signalling is essential for the transforming properties of LMPI both in Band Rat-l
cells (Cahir et al., 1999, He et al., 2000). Anti-apoptotic genes (bel-2, A20, Mel-1, c-IAP2),
genes involved in angiogenesis, invasion and metastasis (MMP9, COX-2, VEGF, IL-8, Id-I)
are activated by binding of NF-KB to binding sites in their promoters (D'Souza et al., 2004; Li
et al., 2004; Murono et al., 2001; Yoshizaki, 2002; Yoshizaki et al., 1998). EGFR is
upregulated by NF-KB in HNE2 cells in a similar way (Tao et al., 2004b). In a C33A (a
cervical carcinoma line) cell line NF-KB activity was not sufficient for EGFR upregulation
(Miller et al., 1995; Miller et al., 1997) but both studies concluded that CTARI was essential
for this activation.
NF-KB activity can be modulated by binding of BRAMI to CTAR2. This interaction, inhibits
IKBa phosphorylation leading to inhibition of NF-KB activation (Chung et al., 2002).
BRAMI is therefore acting as a negative regulator of the LMPI mediated functions. LMPI
also modulates NF-KB activity via the A20 protein which is upregulated by activated NF-KB.
Upregulation of A20 leads to A20 interacting with LMPI and competing with TRADD and
TRAFI for binding to the LMPlffRAF1I2ffRADD complex. Displacement of TRADD and
TRAFI from LMPI binding complexes leads to inhibition of CTAR2 mediated NF-KB
activation and CTARI mediated JNK activation. Decreased NF-KB activity, leads to
decreased A20 levels and so TRADD and TRAFI can bind CTAR2 and CTARI respectively,
activating NF-KB and JNK signalling (Fries et al., 1999). In this way LMPI negatively
regulates its own biological functions.
(2) the c-Jun N-terminal kinase (JNK pathway)
CTAR2 mediates the activation of the JNK pathway. It has been revealed with mutational
studies that the last 8aa of CTAR2 are important for this activation. However, a recent study
using mouse embryo fibroblasts (MEFs) from knock out mice (RIP, TRAF6, TRAF2, IRAK4,
TAB2 null) and small interfering RNA (siRNA), challenges the belief that JNK activation was
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dependent on recruitment of TRADD and TRAF2 to CTAR2 and stress enhanced kinase
(SEK) activation. The latter suggests that an unidentified linker leads to TRAF6 association
with CTAR2linking it to a TABI/fAKI complex that then activates JNKKI/2 that will then
lead to INK activation (Eliopoulos et al., 1999; Eliopoulos and Young, 1998; Kieser et al.,
1997; Wan et al., 2004). Active JNK phosphorylates c-Jun leading to homo/heterodimer
formation with other members of the Jun or Fos family thus producing an active API
complex. The TRAF 2,3,5 complex associates with CTARI and recruits TRAFI which also
leads to JNKlAPI activation. A new heterodimer fomation between c-Jun and JunB mediated
by LMPI in the HNE2 cell line, can expand the signalling pathways affected by LMPI (Song
et al., 2004b).
(3) the p38MAPK pathway
The p38MAPK pathway is activated in epithelial cells via the same regions and cellular
effector proteins as for NF-KB but the two pathways separate downstream of TRAF2 as
chemical inhibitors and dominant negative TRAF2 expression studies have shown (Eliopoulos
et al., 1999). Activation of p38MAPK leads to IL-6 and IL-8 upregulation that play a role in
cell survival.
(4) the IAKISTAT pathway
The CTAR3 region contains 2 boxl elements and a box 2 that contain binding elements for
JAK3. Binding of JAK3 to CTAR3 leads to its auto/transphosphorylation leading to
activation of signal transducer and activation of transcription (STAT) 1 and 3, transcription
factors in B and epithelial cells (Gires et al., 1999). Further, LMPI expression in CNE-2 cells
led to activation of STAT3 and 5 and STAT3 activation was shown to lead to the upregulation
of the c-myc gene (Chen et al., 2003). A dominant negative form of LMPI in which the
PXQXXD motif was substituted for alanine (AXAXXA), and the first tyrosine of the YYD
motif in CTAR2 region was replaced by glycine inhibited NF-KB and API signalling by
preventing binding of TRAF2 to LMPI. Surprisingly, even though the CTAR3 region was
intact, STAT signalling was inhibited, implying that intact CTARI and 2 domains playa role
in CTAR3 mediated signalling (Brennan et al., 2001).
(5) the PI3K1Akt pathway
The CTARI region of LMPI can lead to activation of the PI3K1Akt cascade in epithelial cells
by recruiting the p85 subunit of the PI3K either directly or via a linker (Dawson et al., 2003).
40
Activation of Akt can lead to growth proliferation, decreased apoptosis and actin cytoskeleton
reorganisation.
(6) the ERK1I2 pathway.
In rat fibroblasts LMPI has been shown to increase ERK1I2 phosphorylation and this is Ras
dependent. Where this activity maps on the LMPI protein is not known. However, this study
shows that LMPI can possibly transform cells via activation of the Ras pathway (Roberts and
Cooper, 1998). Activation of ERK1I2 can lead to transcription of genes involved in
proliferation, angiogenesis and metastasis. One such factor that is upregulated by LMPI via
the ERK1I2 activation in human epithelial nasopharyngeal cells, is HIF-la which upregulates
the vascular endothelial growth factor (VEGF), and RECK, a metastasis suppressor gene
(Wakisaka et al., 2004). Transfection of an LMPI expressing vector into an EBV negative
NPC cell line (TW04) led to decrease of RECK protein and inhibition of its promoter (Liu et
al., 2003). LMPI transformed MDCK cells show increased levels of Etsl - an ERKI/2 target
- that contributes to metastatic invasion by upregulating c-Met (Horikawa et al., 2001). LMPI
mediated activation of ERK1I2 not only plays a role in proliferation but also in metastasis.
Constitutive LMPI mediated, ERK1I2 activation in gastric epithelial cells leads to TGF~
inhibition thus releasing the cells from the TGF~ mediated growth arrest (Fukuda et al., 2002).
The TGF~/Smad pathway can also be inhibited in an NF-KBmediated way in HEK293 cells
and COS-7 fibroblasts (Prokova et al., 2002).
The role of LMPI in cell cycle control has been investigated in murine and human fibroblasts
where LMPI expression led to their proliferation, downregulation of pI6INK4a and inhibition of
Ras induced senescence (Yang et al., 2000a; Yang et al., 2000b). This LMPI induced pI6INK4a
inhibition, was found to be due to LMPI promoting the nuclear export of Ets2 (transcriptional
activator of p16) and E2F4/5 (downstream mediators of pI6)(Ohtani et al., 2003). Even
though LMPI alone did not lead to transformation, its cooperation with an oncogene (mutant
CDK4, that cannot be pl6lNK4a inhibited) did.
LMPI via CTARI leads to increased epithelial cell sensitivity to DNA damaging factors
leading to micronucleus formation. Accumulation of unrepaired DNA can cause genomic
instability (Liu et al., 2004). LMPI also inhibits p53-mediated apoptosis in both BL and
epithelial cells (Fries et al., 1996). LMPI can also activate DNA methyltransferases via
CTARl, leading to hypermethylation of the E-cadherin promoter, enhancing invasiveness in
epithelial cells.
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LMPI exerts different effects in different cell types but collectively all point to a very
complex molecule that activates pathways associated with tumourigenesis.
LMP1 Function
Even though LMPI has no primary sequence homology with any known proteins it shares
functional similarities and core motifs to the TNFR family of receptors especially CD40.
LMPI has been shown to be constitutively active and be independent of ligand dependency
(Gires et aI., 1997; Hatzivassiliou et aI., 1998). Expression of LMPI independent of ligand
allows for continual proliferation of human B cells infected with EBV. This proliferation is
also possible with CD40 signalling. However, both LMPI and CD40 induced proliferation
was found to be EBNA2 dependent. In experiments where EBNA2 expression was inhibited,
B cells did not maintain proliferation either in the presence of LMPI or in the presence of
CD40 (Kilger et aI., 1998; Zimber-Strobl et aI., 1996). Even though LMPI signals in the
absence of a ligand, it can regulate its activity. Increased levels of LMPI can lead to
cytostasis thus protecting the host cell from excessive signalling and can lead to inhibition of
gene products transcribed from the Cp and LMPI promoters thus regulating its own
expression as well as inhibiting cellular protein synthesis (Hammerschmidt et al., 1989;
Sandberg et al., 2000).
Another role that LMPI may have in the viral context is that it activates interferon regulatory
factor (IRF) 7 that regulates latency via preferred promoter usage and also activates the
cytotoxic T cells, enabling the host's immune system to kill cells that are undergoing
uncontrolled proliferation induced by EBV. This agrees with the role LMPI has in inducing
cytostasis and inhibition of gene expression as described above and with the role it plays in
inhibiting viral lytic cycle induction. Inhibition of lytic cycle prevents massive amounts of
new virus being presented to the host immune system and also prevents extensive cell damage
to the host (Adler et al., 2002). In B cells LMPI expression can upregulate cell activation and
cell adhesion factors such as CD23, CD39, CD40, CD44, CD83, MLH II, IL-I0(Nakagomi et
aI., 1994), LFA-l, ICAM-l, LFA3 and can downregulate CDI0 leading to cell growth and
also elimination of transformed B cells to protect the host. It can also protect B cells from
apoptosis via upregulation of bcl-2 and A20 , both anti-apoptotic proteins (D'Souza et aI.,
2000; Henderson et aI., 1991; Rowe et aI., 1994).
LMP I has been classified as a classical oncogene since it can transform rodent fibroblasts and
Balb/3T3 cells in culture (Baichwal and Sugden, 1988; Wang et aI., 1985) and is essential for
B cell immortalisation by EBV as shown by recombinant virus genetics (Kaye et aI., 1993).
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When LMPI expression is directed under a polyoma virus (Py) early promoter to the skin
epithelium of mice it causes skin hyperplasia (Wilson et al., 1990) and sensitises mice to
chemical carcinogens (Curran et al., 2001). When LMPI expression is directed to the B cell
compartment of transgenic mice it predisposes the mice to B cell lymphomas (Kulwichit et al.,
1998)( Wilson JB unpublished data).
In some epithelial cell lines (SCC12F, RHEK-l) LMPI inhibits differentiation and alters
keratinocyte morphology and keratins expression patterns (Dawson et al., 1990; Fahraeus et
al., 1990) whereas in others (HaCat) LMPI expression led to tumour formation in SCID mice
and (in HaCat, SCC12F and murine epithelial cells of transgenic mice) no inhibition of
differentiation was observed (Nicholson et al., 1997; Wilson et al., 1990) showing that the
genetic backround of the cell used and LMPI levels are important in determining function.
LMPI can also upregulate levels of EGFR protein and mRNA in C33A epithelial cells (Miller
et al., 1995).
1.4 EBV related diseases
EBV was first postulated to play a role in disease in the 1960s when its presence was
discovered in a BL cell line. Since then it has been associated with many other malignancies
and has been classified as a class I carcinogen by the World Health Organisation (WHO).
EBV infection is usually asymptomatic if the individual is infected early in life. However,
immunocompromise due to genetic, iatrogenic or other reasons as well as environmental
agents lead to EBV acting as a tumour promoting agent. Usually when EBV acts in
tumourigenesis it is in its latent phase and there are several latency programs expressed with
each type of malignancy.
Latency Program Tumour
Latency I BL,
Gastric Carcinoma
Latency II NPC, HD, TINK cell lymphomas
Latency III PTDL
Table 1.3: Latency programs and tumour association.
A brief description of the main diseases associated with EBV are given below:
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EBV Associated Diseases
Infectious Mononucleosis (1M)
About 50% of people who contract EBV between the ages of 17 and 25 will develop 1M. It is
more common in developed countries where higher sanitary conditions and a decreased
tendency to breastfeed lead to late EBV infection (reviewed in (Papesch and Watkins, 2001).
The connection between 1Mand EBV came in the 1960s when a known EBV negative worker
in the Henle lab developed 1M. After recovering EBV was detected in her serum.
Primary infection occurs via the saliva and sexual contact as EBV virions have been detected
in the sperm and the squamous epithelial uterine cells. 1M shows a variety of symptoms
including mild fever, headache, pharyngitis, lymphadenopathy, malaise and fatigue. EBV is
detectable at high levels in the oropharynx of 1M individuals. It is usually a self limiting
disease. The prevalence of 1M in adolescence compared to childhood may not be due to the
age but due to the dose of the virus. It is more likely that an individual receives larger
amounts of virus in adolescence through the more expanded social and sexual interactions and
this can increase the initial pool of infected B cells. Once a threshold level of infected B cells
is exceeded the immune system starts work and the T cells respond, producing the symptoms
described above. The course of the disease follows the level of activated T cells in the blood.
Acyclovir (ACV), a nucleoside analog that inhibits lytic EBV infection by inhibiting viral
DNA polymerase, was shown to decrease the EBV shedding but did not alleviate any of the
disease symptoms. This therefore indicates that the symptoms follow the nonproductive EBV
infection in lymphocytes.
In acute 1M B cells resemble EBV infected LCLs in vitro and show a latency III type
expression pattern. Eventually, the disease resolves naturally (Papesch and Watkins, 2001).
Oral Hairy Leukoplakia (OHL)
OHL is almost exclusively found in AIDS patients. Raised white lesions develop in the
tongue epithelium of these patients and EBV particles are found in those cells undergoing lytic
infection. No latent EBV infection is detected (Webster-Cyriaque et al., 2000).
X-Linked lymphQproliferative syndrome (XPLS)
XLPS affects males who inherit the mutated XLPS gene. The gene is located on the X
chromosome and it normally encodes for a protein (SLAM associated protein) that limits B
and T cell proliferation. The mutated gene cannot produce such a protein so upon primary
infection with EBV, a massive tissue destruction probably due to uncontrolled T cell
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proliferation is seen and the patient dies within 2-3 weeks of fatal 1M. Those who survive are
likely to later develop other EBV associated lymphomas in 2 or 3 years (Hsu and Glaser,
2000).
Lymphoid Tumours:
Burkitt's Lymphoma (BL)
BL was the first tumour to be associated with EBV and from which the virus was first isolated.
All BLs are characterised pathologically, by a mass of small noncleaved malignant B cells
interfused with non-neoplastic macrophages giving rise to a "starry sky" appearance. There
are three types of BL. eBL is predominantly a childhood cancer of the jaw that is most
common in Africa and Papua New Guinea, areas that coincide with the Plasmodium
Falciparum malarial zone. Incidence rates are about 6-15/100,000/year and occur in young
children of 5-7years old. Males are more likely to be affected than females in a 3:1 ratio. The
EBV episome has been detected in more than 95% of eBL cases and is monoclonal (Magrath,
1991). Increased IgA antibody titers to viral capsid antigen (VCA) were linked to a 30 fold
increased risk in 42,000 African children (de-The et aI., 1978). There is a possible genetic
component to the disease in that certain carriers of HLA locus (DR7) are found to be more
susceptible to developing the disease (Jones et aI., 1985).
Sporadic BL (sBL), which occurs worldwide, is at least 50 times rarer than eBL. Only about
15-88% ofsBL are associated with EBV. The tumour in sBL is localised in the abdomen and
affects Caucasian children and older adults. The incidence rate is about OJ/I00 OOO/yearand
males are more susceptible than females in a rate of3-4:1.
The third category, AIDS-related BL, occurs in non endemic regions and is an abdomen
tumour affecting people of all ages. Latent EBV infection occurs in about 30-40% of the
tumours and the EBV episome is monoclonal (Ballerini et aI., 1993).
In all three classes of BL, there are common chromosomal translocations. These occur at the
long arm of chromosome 8 (where the c-myc locus lies) and either chromosome 14 (the
immunoglobulin heavy chain region) or with less frequency chromosomes 2 or 22 (in the
region of the immunoglobulin light chain loci). The effect is deregulation of the c-myc
protooncogene (Gutierrez et aI., 1992). Along with these translocations EBV acts to stimulate
B-cell proliferation. In eBL patients the immunosuppressive action of malaria is thought to
make it easier for EBV to escape immune surveillance and infect B cells.
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Despite the fact that EBV is not so common in sBL, one study showed that in a few sBL
tumours, the EBNAI gene may be absent but they still contain a defective EBV genome
(Razzouk et al., 1996). This could imply that the virus was essential for the tumourigenesis
but during malignant progression its presence became non essential and the genome was
reaaranged or lost in what is known as a "hit and run" scenario. If this is the case maybe EBV
is associated with sBL at a much higher rate than that detected in presented tumours.
Viral expression in BL shows a latency I pattern.
Hodgkin's Disease (HO)
HD is a lymphoma that morphologically is presented as Reed-Sternberg cells among other
inflammatory cells. HD has at least five pathological subtypes, all composed of different
proportions of different cell types. It is a tumour of the lymph nodes and even though seen
worldwide, is particularly common in the Western World where it comprises 20% of the
lymphomas. HD affects mostly young adults. The EBV association with HD is strongest in
HDs from developing countries compared to HDs from developed countries. For example,
only 40-50% of the tumours in the Western World are EBV positive but 90% of the tumours
in Honduras and Peru are EBV positive. Some of the first evidence that EBV was associated
with HD came from the fact that individuals who had suffered from 1Mwere 3-5 times more
likely to subsequently develop HD. Also serological studies showed that there was an increase
of IgA titers to VeA and EA years before the development of the disease and those
individuals had 3-4 times higher risk to develop HD. The EBV episome in the EBV positive
tumours is monoclonal. All Reed-Sternberg cells of EBV positive tumors express latency II
(Dolcetti and Boiocchi, 1998).
T/NK cell lymphoma
TINK cell lymphoma is a midline facial necrotic disease. More than 90% of the NK cell
lymphoma cases present with monoclonal EBV episome in the tumour cells. This disease is
rarely seen in the Western World but is more common in Asia and Peru where it constitutes
8% of the lymphomas of those regions.
Post-transplant lymphoproliferative Disorder (PTlD)
PTLD occurs in about 10% of iatrogenically immunosuppressed individuals. The dose of the
immunosuppressive agent and a primary EBV infection are risk factors. Seronegative
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individuals who contract EBV after transplant have higher risks of developing PTLD. The
tumour is more often presented in the central nervous system (CNS) or the brain. More than
95% of the cases show EBV episome in the tumour cells exhibiting latency III (Hopwood and
Crawford,2000).
AIDS-associated immunoblastic and primary central nervous system
lymphomas
These AIDS-associated lymphomas occur at the later stages of the disease. About 90% of the
primary CNS lymphomas and 70% of the immunoblastic lymphomas contain monoclonal
EBV sequences. These lack HIV sequences implying that EBV and not HIV is the causal
factor although HIV induced lack of T cell response must play a major role. The tumours
express latency I or III, depending on the kind of tumour (Hsu and Glaser, 2000).
Epithelial tumours:
Gastric Adenocarcinoma
Gastric carcinoma is common worldwide. About 4-18% of gastric carcinomas are EBV
positive, the percentage depending on geographic location. For example in Japan, 7% of
gastric carcinoma tumours are EBV positive whilst only 4% is reported in the UK and 16% in
the USA. Increased IgA antibody titers to VCA are seen years before the manifestation of the
disease. Salted and certain preserved food consumption along with the infection of the
Helicobacter pylori are potential cofactors for the development of the disease.
The Bam HI A RNAs and the EBERs are always expressed whilst LMP1 and LMP2B are not
expressed. Of the latent proteins, EBNAI and LMP2A or only EBNAI are expressed. EBV
positive gastric adenocarcinomas have a better prognosis and they all share genetic
characteristics such as the loss of p161NK4a.Premalignant gastric adenocarcinomas do not
show EBV infection suggesting that EBV infection is a late event in the process of
carcinogenesis in this tissue (Fukayama et al., 1994; Luo et al., 2005).
Breast Cancer
There is great controversy as to whether EBV plays any role in breast cancer (reviewed in
(Magrath and Bhatia, 1999). Initial studies on medullary breast carcinoma that is
morphologically similar to NPC showed that some cells within a subset of aggressive breast
tumours were positive for expression of the EBNAI gene (Bonnet et al., 1999) but only 50%
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of the tumours examined showed presence of EBERs (Labrecque et al., 1995) and in the EBV
positive cases, the viral DNA was only detected in a subset of the tumour cells suggesting that
either infection took place after tumour initiation or that the virus was no longer required for
cell growth and was lost. The whole story was confounded with several reports showing no
detection of EBV DNA in breast cancer cells (Chu et al., 1998; Dadmanesh et al., 2001;
Glaser et al., 1998; Herrmann and Niedobitek, 2003; Horiuchi et al., 1994; Lespagnard et al.,
1995). This could be due to the methods used. For example, EBER in situs are used as a
standard method for indicating the presence of EBV virus in a tumour. However there have
been EBV positive tumour cases that do not show EBER expression (Sugawara et al., 1999).
Furthermore, the way the tissue is fixed can affect detection of viral proteins. It is also
important to be able to show presence of EBV in tumour cells only. Further doubt arose when
the anti-EBNAI antibody used in the positive breast cancer study was found to cross react
with a tumour specific cellular protein (Murray et al., 2003). Based on these technical
restrictions, weight of evidence is currently against EBV having a role in breast cancer, but
this is not conclusive.
Nasopharyngeal Carcinoma (NPC)
Nasopharyngeal carcinoma is a tumour of the epithelium of the nasopharynx arising from the
Rosenmuller fossa. The WHO has classified NPCs into three distinct categories depending on
their histopathology. Type I NPCs are keratinising, well differentiated squamous cell
carcinomas (SCC), type II are non-keratinising SCC and type III are undifferentiated
carcinomas of the nasopharyngeal type. Type III carcinoma was also described as
lymphoepithelioma due to the infiltration of the primary tumour with T cells.
One of the characteristics of NPC, is its significant geographical variation in incidence. The
highest incidence ofNPC is seen in S. China and South East Asia with intermediate incidence
levels in Arctic and North African populations, Characteristically 80% of all new NPC cases
in year 2000 were in S.China. Even in the high incidence areas there is variation. For
example, in S.China the Kwangtung, Kwangsi, Hunan and Fukin regions have a much higher
incidence than other areas of S.China. The incidence in high risk areas is about 30-50/100,000
cases per year, in intermediate risk areas the incidence is between 8-12/100,000 cases per year
and in the Western world where NPC is a rare malignancy the incidence rate is about 0.5-
21100,000 cases per year. More males are affected than females independent of geographic
location. The ratio of male to female is between 2.5-3:1. The age of onset is between 55-65
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years for Caucasians but it drops to 40-45 for Chinese. In North African populations there is a
bimodal age distribution ofNPC with cases seen between 10-20 and at 55-65.
Symptoms of NPC include blood tinged sputum, a neck mass, nasal obstruction and aural
symptoms such as hearing loss, frequent headaches and neurological symptoms. However,
most often the only clinical manifestation ofNPC is cervical lymph node metastasis.
The aetiology of NPC is multifactorial including environmental, genetic and viral (EBV)
factors. Studies on high risk individuals who emigrated to low risk areas show clearly the
genetic and environmental connection. Studies on Cantonese Chinese who emigrated to
California showed that they had an increased incidence of NPC compared to Caucasians and
that the risk was much higher if they were born outside the US. However their risk was lower
compared to Chinese in S.China. Also second and third generation Cantonese Chinese living
in low risk areas still developed NPC at a higher incidence than the local population
suggesting that NPC has a genetic association or that the environmental factor is diet and
maintained in the subsequent populations (Buell, 1974; Hildesheim and Levine, 1993). A
recent study in Hong Kong showed that there was a 30% decrease in NPC cases over a period
of20 years (1980-1999) implying environmental changes are responsible forNPC (Lee AW,
2003). Sib-pair analysis of affected siblings showed that in high risk populations HLA.A2 ,
B46 and B14 alleles confer susceptibility to NPC whereas in US Caucasians the HLA.A2
allele (which is more common in Caucasians) confers protection (Burt et aI., 1994). Similarly,
the HLA-A*0207 allele was associated with NPC in Chinese but not Caucasians. It is thought
that a gene linked to the HLA loci could be responsible for the NPC susceptibility. Such a
gene could be the cytochrome P450 2El enzyme (CYP2El) that can metabolise nitrosamines
and it was shown that CYP2E 1 c2 allele and NPC show a strong association in Chinese
(Hildesheim et al., 1997). Polymorphisms at other genes such as GSTMI (involved in
detoxification) and XRCCI and hOGGI (involved in DNA repair) are also associated with
increased risk ofNPC (Nazar-Stewart et al., 1999).
The strongest environmental factor associated with NPC is the traditional foods of the high
risk areas (eg. traditional Cantonese style salted fish and spiced meat) that contain volatile
nitrosamines which are known carcinogens. Rats and mice fed with Cantonese style salted
fish developed tumours (Huang et al., 1978). The nitrosamines could be acting as chemical
carcinogens, predisposing the nasopharyngeal epithelium to genetic damage and latent
infection with EBV.
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EBV has been detected in 100% ofNPC lesions. All the type II and III NPCs show increased
IgG and IgA titers to VCA and EA. All tumour cells contain clonal EBV DNA implying that
infection of the cell with EBV took place before the cell acquired its proliferative capacity and
that EBV plays a role in tumour progression (Raab-Traub, 2002; Raab-Traub and Flynn,
1986). There is a controversy as to whether type I NPC is EBV associated or not (Krueger et
al., 1981; Pearson et al., 1983; Sam et al., 1989). Several studies have shown by in situ
hybridisation of EBERs or by EBV expression that there is EBV in all NPC types
(Pathmanathan et al., 1995; Raab-Traub et al., 1987; Vasef et al., 1997). Others however,
reported presence of EBV only in type II and III but not type INPC by using EBER in situs
and polymerase chain reaction (PCR) (Hording et al., 1993; Niedobitek et al., 1991). This
controversy could be explained with the observation that all NPCs from endemic regions
contain EBV whereas only 33% of NPC type I from low risk areas have shown any EBV
association (Nicholls et al., 2004). Other factors such as smoking may also be involved in
NPC type I pathogenesis but not in type II or III.
In the tumour, EBV expresses latency II in which EBNA1, LMP1, LMP2, EBERs and Bam
HI A RNA transcripts are expressed. EBNAI expression has been detected in all the NPC
cases analysed and EBERs have been detected at high levels. LMP 1 expression is more
variable and depends on the detection method used. By RT-PCR 100% of primary NPC
tumours (18 samples) showed LMPI expression (Brooks et al., 1992). Only 60% of the
tumours analysed led to LMPI detection by protein in situ (Niedobitek et al., 1992; Sheen et
al., 1999; Stewart and Arrand, 1993; Young et al., 1988) but 100% of premalignant NPC
lesions showed LMPI expression (Pathmanathan et al., 1995). S. Chinese NPCs that showed
LMPI protein expression grew faster and were larger than LMPI negative NPCs. However,
the LMPI negative NPCs, had greater chances of recurring and metastasising.
LMP2A mRNA was detected in most primary NPC tumours analysed whilst LMP2B mRNA
was detectable at low levels in only a subset of the tumours (Brooks et al., 1992). Using new
antibodies for LMP2A, another group showed that 45.7% of the tumours analysed expressed
LMP2A (Heussinger et al., 2004).
Barn HI RNA transcripts are also implicated in NPC (Gilligan et al., 1991) but protein
detection is unclear. Older studies (Fries et al., 1997) detecting BARFO protein in NPC
biopsies used an antibody that cross reacts with a cellular protein (Schroder et al., 2002). This
issue needs further clarification. BARF 1 transcripts and protein have been detected in 85 % of
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a sample range of Algerian NPC biopsies. Aside from LMPl, BARFI may be another
oncogenic protein playing a role in NPC formation and development.
Expression of the early lytic gene BZLFIIZEBRA has been detected in 100% ofNPC biopsies
analysed by RNA in situs whereas the protein has been detected in 90% of the samples
analysed showing that there is EBV reactivation in these tissues (Cochet et aI., 1993).
In NPC tumour cells several chromosomal rearrangements have been described. Loss of 3p, 9,
11q, 13q, 14q, 16q and gain of 12 are some of the commonest chromosomal abnormalities
observed in NPCs. A number of tumour suppressor genes map to the chromosomes that are
lost and are therefore possible candidates in tumourigenesis. RASSFla maps to 3p, pl4ARF
and p 16INK4a map to 9p, TSLC-l, MLL and ATM map to 11q and loss of 13q, 14q and 16q
lead to loss of EDNRB and changes in E-Cadherin expression. Aberrant promoter
hypermethylation in NPC is another way by which tumour suppressors are not expressed (Lo
et al., 1996).
No p53 mutations have been detected in NPC biopsies to date (Effert et al., 1992; Spruck et
aI., 1992). However, consistent pS3 overexpression of the wild type form has been reported
(Murono et aI., 1999; Niedobitek et al., 1993). There are two theories to explain this
observation; one is that due to loss ofpl4ARF, the MDM2 protein is free to bind and target pS3
for destruction however this is not the case as there is pS3 overexpression and levels of
MDM2 detected in NPCs are low (Kouvidou et aI., 1997). The other more likely theory is that
overexpression of a dominant negative homolog of p53- Delta Np63- may bind to pS3 and
block its function (Crook et al., 2000).
Precancerous lesions and invasive tumours show upregulation of Bc1-2 but there is no
indication that there is any relationship between LMPI expression and Bcl-2 upregulation.
Other factors that are upregulated and may contribute to inhibition of apoptosis are
upregulated metallotheionein (MT), inhibitors of differentiation 1 (Id) and loss of death
associated protein kinase (DAPK) (Jayasurya et aI., 2000; Kwong et aI., 2002). Further
factors that are found to be upregulated in NPC are epidermal growth factor receptor (EGFR),
matrix metalloproteases (MMPs), hypoxia factors (HIF-Ia and CAlX), Cox-2 (Murono et aI.,
2001; Thornburg et aI., 2003) and for some this upregulation is due to LMPI.
Whether ras mutations occur in NPC is still unclear. Immunohistochemistry studies to detect
Ras overexpression in NPC biopsies gave conflicting results (Porter et al., 1994a; Yung et al.,
1995).
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The proposed mechanism for NPC onset and progression is that chemical carcinogens in food
lead to accumulation of mutations that together with genetic predisposition and EBV infection
lead to NPC onset. For example, pre-invasive dysplastic lesions both low and high grade
show 3p and 9p deletions. EBV infection is only seen in high grade dysplasias implying that
the genetic changes happen first and then EBV infection takes place. Loss of 3p and 9p could
lead to clonal expansion of the epithelial cell population leading to low grade dysplasias.
When an EBV latent infection is established in the epithelium, this leads to high grade
dysplasia. Loss of other tumour suppressors such as ENDBR, TSLC 1 leads to invasive
carcinoma. Changes in E-Cadherin expression, MMP9 and other metastatic factors contribute
to invasion and metastasis.
Other carcinomas that have similarities to undifferentiated NPC have been described and these
include carcinomas of the thymus, stomach, lungs, tonsils, skin and cervix and are known as
lymphoepitheliomas but are EBV negative.
LMPl strains
LMPI genes from the different EBV strains are relatively well conserved and are almost
identical in amino acid sequence. There are several LMPI strains and here Iwill describe the
prototype B95-8 and CAO, 1510 and CIS which have been associated with NPC. The B95-8
strain of EBV was isolated from an 1M case and the LMP1895-8 is 386aa, 63kDa. It has 4.5
repeats of the llaa repeat in the C-terminus. LMPI CAD was isolated from a S.Chinese NPC
biopsy (Hu, 1991). It is 404aa, 66kDa and has three extra l1aa repeats. In total it has 7 llaa
repeats. LMPI CAD has a point mutation in its first exon that leads to the loss of an Xhol
restriction site that is present in LMPI895-8• LMPI CAD has several point mutations in the
transmembrane domains, a point mutation in the CTARI (0212 to S) and three point
mutations in the CTAR2 region relative to LMPI895-8• LMPI CAD has a 10aa deletion (343-352)
just N-terminal to the CTAR2 region and a further 5aa deletion in the carboxy terminus (Hu,
1991). The LMP11510 comes from an Asian NPC biopsy and is 95% homologous in sequence
to LMP1895-8• LMP1IS10, has 5 llaa repeats and has a 10aa deletion in the carboxy terminus
(Chen et al., 1992). LMPIC1.5 comes from a Mediterranean NPC that has been passaged in
nude mice. This strain also has the lOaa deletion seen in CAO and 1510 strains.
Both CAO and 1510 variants when transformed in rodent fibroblasts, showed increased
transforming ability (formed larger and more colonies) compared to B95-8. The transforming
ability of LMPI 895-8 was increased when aa343-352 were deleted. The opposite was true when
those aa were substituted in LMPlislO thus implying that the 10aa deletion renders the protein
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more tumourigenic (Hu, 1991; Li et al., 1996; Zheng et al., 1994b). Since the lOaa deletion
maps in a domain necessary for NF-KB activation (Mitchell and Sugden, 1995), the ability of
deletion variants isolated from lID to affect the NF-lCB pathway was examined with negative
results (Rothenberger et al., 1997). ThelOaa deletion LMPI variants were isolated from other
malignancies such as lID and peripheral T cell lymphoma thus leading to the hypothesis that
the lOaa deletion plays an important role in transformation but more recent studies suggest not
(Brousset et al., 1994; Knecht et al., 1995). Furthermore, LMP1 CAO was shown to be less
immunogenic than LMPIB95-8• The latter could convert a non immunogenic mammary
carcinoma cell line (S6C) into an immunogenic tumour rejected by the immune system
whereas LMPlcAO could not (Trivedi et al., 1994) implying that LMPlcAO is less
immunogenic. Further experiments using LMPI proteins isolated from LMPI positive NPC
and LMPI negative (LMPI gene is hypermethylated) showed that LMPI proteins from LMPI
positive NPCs were less immunogenic (Hu et al., 2000). However, the lOaa deletion was not
responsible for this as LMP1 proteins that were not deleted for the 10aa were also less
immunogenic.
From the above results, it is not clear if the lOaa deletion is playing a role in increased
tumourigenicity or immunogenicity of the deletion variants; CAD, 1510 or C15. Instead,
studies have focused on the transmembrane domains of the protein which show point
mutations from one strain to another. Transfection of LMPlcAo, LMPlcI5, or LMP1895-8 in
epithelial cells, showed that LMPlcAO and LMPlc1S could lead to increased NF-KB and API
signalling when compared to LMP1895-8 and this was proposed to be due to the increased half
life ofLMP1cAO (7.25hrs) compared to LMPIB95-8 (2.9hrs) (Blake et al., 2001; Dawson et al.,
2000; Miller et al., 1998a). Use of chimeras, led to the conclusion that the transmembrane
domains of LMP1cAO and LMPlcI5 are responsible for the increased stability and thus the
increased signalling. Transfection of B cells with either LMPI CAO or LMP1 B95-8, showed that
LMP1cAO leads to decreased CD40 and CD54 induction but it increases NF-KB signalling two-
fold when compared to LMP1895-8• Removal of the lOaa from LMP1 B95-8 and replacement of
the lOaa on LMPI CAO, showed that the 10aa deletion was not important for these functional
changes (Johnson et al., 1998). Similarly in epithelial cells, stable transfection of LMP1895-8
led to growth inhibition, block of differentiation, morphological changes and production of
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CD40, 54,44, IL-6 and -8 whereas LMPlcAO did not induce any of these effects (Dawson et
al., 2000)1.
It has also been shown that LMPI B95-8 can induce cell death via activation of caspase-3 in an
NF-KB dependant manner whereas LMPI CAO does not (Nitta et aI., 2003; Sheu LF, 1998).
Chimeras were created by swapping the amino, transmembrane and carboxy domains of
LMPI CAO and LMPI B95-8 in order to identify the domain responsible for apoptosis. The
transmembrane domain of LMPI B95-8 was responsible for apoptosis induction and this was due
to the presence of lIe the 85th aa and Phe at 106th aa. LMPlcAO has Leu at 85th aa and Tyr at
106th aa. The LMPI B95-8 pattern is seen in LMPI from healthy EBV carriers whilst the
LMPlcAO pattern is seen in LMPI from NPC patients. When the two aa were interchanged
between the two variants, it was shown that they were critical for cell death but not
responsible for affecting NF-KB activation levels. Since LMPI CAO leads to increased
signalling of factors such as NF-KB and possibly API that activate genes involved in
proliferation and metastasis and at the same time inhibits apoptosis, it has an additive
advantage over LMPI B95-8 in leading to tumourigenesis. An extensi ve analysis of 9 different
srtains of LMPI including LMPI B95-8, LMPI CAO and other European NPC strains showed that
there are differences between them in NF-KB and API signalling but these differences do not
correlate with a particular sequence variation (Fielding et al., 2001).
An interesting idea that has been examined by Hu et. al., is that initially all cells leading to an
NPC express LMPI. Due to hypermethylation of the LMPI regulatory sequence (LRS) in the
LMPI negative NPC, the LMPI protein is no longer expressed. The LMPI protein that
mutates to avoid immune recognition does not need to be switched off by hypermethylation.
This supplies a reason why LMPI positive NPCs express LMPI protein that is highly mutated
but less immunogenic whereas LMPI negative NPCs, have extensive LMPI
hypermethylation, LMPI gene has fewer mutations and the protein is more immunogenic (Hu
et aI., 2000). This theory is compatible with what is observed with LMPI positive and
negative NPCs. LMPI positive NPCs are larger and grow faster than negative NPCs, but
negative NPCs have an increased risk of metastasis (Hu et aI., 1995).
1 Note that API activity of LMPI CAO was shown not to have any significant difference from
LMP1B95-8 by Dawson et al, 2000. This is the same laboratory that published Blake et. al.,
2001 indicating that different cell types respond differently to LMPI CAO and the response it
has on API signalling.
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1.5 Ras
Ras proteins are members of a superfamily of low-molecular weight guanine nucleotide
binding proteins. The other members are Rho and Rae. There are three mammalian Ras
proteins, Harvey-ras (H-ras), Kirsten- ras (K-ras) and N-ras. These proteins are 21kDa, are
highly conserved among different species and show about 85% homology between them.
They are all expressed in all mammalian cells at low basal levels and under normal conditions
they control cell proliferation and cell terminal differentiation (Barbacid, 1987). K-ras is
expressed in almost all cell types and knock out studies have shown that K-ras is essential for
proper development (Johnson et al., 1997).
Ras proteins bind guanine nucleotides (GTP and GDP) and have a very low intrinsic GTPase
activity. GTPase activating proteins (GAPs) catalyse hydrolysis of GTP from Ras while
guanine nucleotide exchange factors (GEFs) catalyse the replacement of GDP for GTP
(fig.1.4). Initially Ras proteins are released in the cytosol but post-translational modification
by farnesylation is needed to make them functional. Famesylation, enables Ras to be localised
to the inner plasma membrane and thus recruit its appropriate target enzymes. Failure to
localise to the plasma membrane leads to non functional Ras proteins.
Ras activation results from activation of receptor tyrosine kinases such as EGFR. The
activated (tyrosine phosphorylated) receptor binds the src homology domain (SH) 2 of growth
factor receptor bound protein 2 (GRB2) and GRB2 via its SH3 domain binds son of sevenless
(SOS) (Buday and Downward, 1993). This brings SOS to close physical proximity with Ras
leading to an increased nucleotide exchange on Ras (fig.1.4). Ras oscillates from GDP bound
and thus inactive to GTP bound and activated. This dynamic equilibrium is vital to keep Ras
activation under control. When it is disturbed by having Ras constitutively GTP bound and
thus constitutively active, it can lead to aberrant proliferation.
Activated Ras can activate four downstream signalling pathways: the RafIMAPK, the PI3K
pathway, the RALGDS and the PLeE pathways (fig.1.5). Effects of the activation of these
pathways include cell cycle progression, transcriptional activation, cytoskeletal signalling,
vesicle transport and calcium signalling control. Some of these pathways will be described
later.
All three Ras proteins (H, K,and N) have been found to be activated in different human
tumours. About 25% of all human tumours have a Ras activating mutation. Usually K-ras
mutations are found in pancreatic cancers whereas epithelial type cancers show H-ras
mutations. 85% of human tumours with Ras mutation show a mutation in K-ras, 14% in N-ras
and about 1% in H-ras. All mutations prevent hydrolysis of GTP from Ras thus locking it in
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its active state. Mostly mutations in codons 12,13 and 61 are responsible for activating Ras
(Downward,2oo3).
Activated Ras can transform rodent cell lines in culture (Barbacid, 1987; Varmus, 1984). In
mouse skin chemical carcinogenesis studies, application of the tumour inititiator 7,12-
dirnethylbenzanthracene (DMBA) led to 99.5% of the tumours developed, to have an activated
H-ras gene. Activation of Ras genes is an early event during tumour development (Bizub et
al., 1986).
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Activation Signals..
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Figure 1.4: Ras Activation
External stimuli such as growth factors bind to and activate tyrosine kinase
receptors. Activated receptors such as EGFR, can recruit effector proteins
such as GRB2 and SOS that can activate Ras. GAPs catalyse hydrolysis of
the GTP from Ras in order to return it to its inactive GDP bound state. GEFs
catalyse hydrolysis of GDP to allow GTP to bind to Ras and activate it. Note
that Ras proteins are connected to the plasma membrane via an isoprenoid
chain represented by a disconnected line.
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Figure 1.5: SignaDing pathways activated by RaJ
The figure shows the four main pathways that are activated by Ras. Ras
leads to activation of the MAPKIERK 112 pathway and the PI3K1Akt
pathway which are involved in gene trascription, survival and cell cycle
progression. The PLCE and RALGDS pathways are involved in vesicle
transport, calcium signalling and cytoskeJetal signalling. (Figure adapted
from Downward et. al., 2003).
RAS transgenic mouse models
Several Ras transegic mouse models have been created. Here I will discuss only the ones that
are relevant for skin carcinogenesis.
Overexpression of oncogenic H-ras to the skin under the direction of different promoters has
given different results. Directing H-ras to the suprabasal epidermal layer (using the bovine
KI0 promoter) gave rise to skin hyperkeratosis and papilloma formation at sites of mechanical
irritation (Bailleul et al., 1990), whereas directing expression to the basal layer (using a
truncated human Kl promoter) led to epidermal hyperplasia and hyperkeratosis in the
neonates and juveniles that regressed by 5 weeks of age. Adults developed papillomas over
time and their Kl and K13 staining patterns were consistent with benign lesion formation.
This shows that an activated Ras by itself is not enough to lead to malignant conversion and
that a secondary event is needed (Greenhalgh et al., 1993a). However directing expression of
H-ras to the follicular and interfollicular cells of neonates and to the hair follicles of adults
(using a truncated K5 promoter) gave newborn mice acanthotic areas that progressed to
carcinomas and spontaneous papillomas and keratoacanthomas in adults (Brown et al., 1998).
Similar results were obtained when the v-If-ras oncogene was directed for expression to the
hair follicles (using the zeta-globin promoter). Spontaneous papilloma formation was seen at
sites of mechanical irritation and when the mice were treated with a chemical promoter 4 beta-
phorbol 12-myristate 13-acetate (PMA) more than 90% of the mice developed multiple
papillomas that went on to form sec and sarcomas. This study demonstrated that an activated
Ras can replace the need for an initiation step in a chemical carcinogen treatment (Leder et al.,
1990). These mice also develop a variety of tumours including squamous cell carcinomas,
odontogenic tumours and dermal spindle cell tumours. Use of the native Ras promoter to
direct expression of the human H-ras gene led to 50% of the offspring developing tumours
within 18 months and those tumours had mutations at codon 61 (A-T transversion) and codon
12 showing that overexpression of somatic Ras does not necessarily lead to tumourigenesis
but it is the activation of Ras that causes proliferation (Saitoh et al., 1990).
From the above studies, it is clear that the cell context in which activated Ras is found plays a
very important role as to whether there will be a malignant conversion or not. From the
transgenic animal work, it is concluded that benign tumours are more likely to show malignant
conversion if they originated from the hair follicle cells or from the basal proliferating layer.
Use of dominant negative Ras transgenic animals showed that spatial expression of Ras alters
its effects and that normally Ras functions in the basal layer of the epidermis and its primary
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role is in epidermal cell renewal and inhibition of differentiation of cells early in the
differentiating pathway. Ras function divides the epidermis into two segments; the basal
proliferating segment and the differentiating segment (Dajee et al., 2002). In the Dajee et.al.,
study, two sets of transgenic mice harboring a dominant negative form of Ras (RasNI7)
directed for expression at the basal layer (using the K14 promoter) or at the suprabasallayer
(using the truncated human KI0 promoter) were created. A control transgenic mouse
harboring activated Ras (RasVI2) in the basal layer (K14 promoter) was also created.
Whereas HKlO.RasNI7 mice were normal, KI4.RasNI7 mice showed hypoplasia with
widespread skin erosion by 6 weeks of age and non healing loss of epidermis. This is
consistent with a role for Ras in cell proliferation and epidermal self renewal. The
KI4.RasVI2 mice showed massive epidermal hyperplasia with no differentiating epidermal
layers and all mice died at birth. Further in vitro experiments using primary epithelial cells
and modulating doses of active Ras showed that Ras regulates epidermal proliferation and
inhibits differentiation. Where a transgene is expressed is therefore, of the utmost importance
when interpreting what the gene's normal function may be.
Due to the fact that the different Ras proteins can compensate for each other null animals for
H-ras, K-ras and N-ras showed no skin defects (Esteban et al., 2001; Ise et al., 2000; Johnson
et al., 1997; Umanoff et al., 1995). Triple null animals however, could not be created as the
N-ras -/- / K-ras -/- combination is embryonic lethal (Johnson et al., 1997).
Ras and chemical carcinogenesis
A classical chemical carcinogenesis regime in the mouse involves a single topical application
(usually on the back) of a chemical initiator followed by repeated applications of chemical
promoters. An initiator, is a chemical that can change the structure of DNA in such a way that
will lead to an irreversible mutation thus creating a population of "primed" cells. One of the
most common chemical initiators used is DMBA, a polycyclic aromatic hydrocarbon. DMBA
is metabolised to diol epoxides that are reactive electrophiles and covalently interact with
DNA causing mutations (Dipple et al., 1984). About 99.5% of DMBA initiated mouse skin
tumours have a mutation that activates the H-ras gene (Balmain et al., 1988; Balmain et al.,
1984; Bizub et al., 1986; Brown et al., 1990). 95% of these activating H-ras mutations are an
A-T transversion in codon 61. The rest are mutations at codon 61,60,12 and 13. Thus if an H-
ras mutation is involved in the initiation of mouse skin tumours, then by overexpressing a gene
that affects the Ras pathway in vivo in the epithelium, this will make experimental use of a
chemical initiator such as DMBA redundant (Quintanilla et al., 1986). Promoters do not alter
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DNA structure but can activate proliferative pathways. A promoter can stimulate those
"primed" cells to clonally proliferate and form premalignant lesions. Other genetic or
environmental events are then needed for these premalignant lesions to convert to malignant
carcinomas. A common tumour promoter is 12-0-tetradecanoyl phorbol-l B-acetate (TPA)
which is a phorbol ester and a structural homolog of diacylglycerol (DAG). One of the targets
of TPA is Protein Kinase C (PKC). PKC is a ser/thr protein kinase that is activated by Ca2+.
DAG increases the affinity of PKC for Ca2+ thus activating it. TPA is a structural homolog of
DAG and can activate PKC in the same way (Nishizuka, 1984). Activation of PKC leads to
activation of several downstream pathways such as MAPK, JNK, PI3K and downstream
targets include API, cyclic AMP-binding protein (CREB), NF-KB and more. Thus the first
event of promotion is a general epidermal hyperplasia that occurs about 24hrs after first
promoter application, peaks 48-72hrs and disappears 7 days after application.
Relationship between Ras. LMP1 and NPC
There is no clear evidence for association of activated Ras and NPC. There is however a
single report suggesting that LMPI acts in a similar way as activated Ras, producing similar
phenotypes in transfected cells (Dawson et al., 1990). SCC12F cells (derived from an
immortalised non-tumorigenic subclone of the squamous cell carcinoma line SCCI2) were
transfected with either LMPI or activated H-ras. Both cell populations showed similar levels
of CD40 and ICAM-l (markers elevated in NPC) which were increased when compared to
control cells, both populations failed to form stratified epithelia when grown on collagen rafts
and were impaired in their ability to undergo terminal differentiation as they failed to form
cross-linked envelopes. These experiments suggest that LMPI and Ras can cause similar
effects. On the contrary, when NIH3T3 cells transfected with NPC DNA were analysed, H-
ras mutations were evident suggesting that activation of ras is a way by which some NPCs
may gain their malignant properties (Hu et al., 1986). Staining primary NPC for Ras showed
that only 19% of the samples gave intense staining suggesting that Ras is expressed, however
this reflects only whether there is Ras present or upregulated and not whether ras is activated
(Porter et al., 1994b; Yung et al., 1995).
Ras mutations are not common in Western head and neck tumours or nasopharyngeal
angiofibroma. Only 5% of head and neck tumours show any correlation with activated Ras
and it may be that upregulation of Ras protein plays a role in these kinds of cancers and not its
activation (Coutinho et al., 1999; Sheng et al., 1990; Yarbrough et al., 1994).
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Ras. apoptosis and senescence
Overexpression of activated Ras can lead cells to senesce (eg. human and rodent fibroblasts)
(Feig and Buchsbaum, 2002) to differentiate (eg.pheochrocytoma rat ce311s (PC12) into
neuron-like cells) (Bar-Sagi and Feramisco, 1985) or apoptose (eg. rat embryo fibroblasts)
(Joneson and Bar-Sagi, 1999).
Ras induced senescence is mediated by Rafand MEK1I2 leading to accumulation ofpl6, pS3
and p21(Lin et al., 1998; Lin and Lowe, 2001; Serrano et al., 1997; Sewing et al., 1997; Zhu et
al., 1998). Cells lacking p53 or p 16INNK4are readily transformed by Ras suggesting that pS3
16INNK4a. . hanior p overexpression may serve as a cancer protective mec arusm.
Recently, other Ras effectors (RASSFI and NOREIA) have been discovered that may mediate
Ras induced apoptosis. In 293 cells, RASSFlc could bind activated Ras and induce apoptosis
(Vos et al., 2000), however most studies argue that RASSFI cannot directly bind Ras but
instead it heterodimerises with NOREIA or mammalian sterile20-like (MST)1I2 that can both
bind Ras and induce apoptosis (Khokhlatchev et aI., 2002; Ortiz-Vega et al., 2002).
Initially activated Ras overexpression leads to proliferation but its excessive and prolonged
activation leads to cell cycle arrest, senescence, differentiation or apoptosis as a means of
controlling aberrant proliferation. Already immortalised cell lines can be readily transfomed
by activated Ras whereas primary cell lines with an activated Ras require a secondary genetic
mutation in order to become immortalised and transformed. This can also explain why so
many human tumours have mutated or non functional p53 and p16INK43products.
1.6 Ras Association Domain Family (RASSF)
The RASSF family of proteins consists of six members; RASSF 1-6. The founding member of
this family was RASSF5A or NOREIA (Hesson et al., 2003; Tommasi et al., 2002; Vavvas et
al., 1998). RASSFI has several splice variants; RASSFla-e. Only RASSFla along with
NOREla have been characterised as tumour supressors. Their role as tumour suppressors was
unveiled when several studies pointed to the fact that hypermethylation of their promoters led
to their silencing in a variety of human tumours such as NPC (Chow LS, 2004; Chow et al.,
2004), pancreatic carcinoma (Dammann et al., 2003), neuroblastoma and non-small cell lung
carcinoma (Agathanggelou et al., 2003), melanomas (Spugnardi et al., 2003), oesophageal
carcinoma (Kuroki et aI., 2003), HD, myeloma, gliomas (Hesson et aI., 2004), brain
(Horiguchi et aI., 2003) breast and kidney. RASSFla - which is located on chromosome
3p21- is thought to playa role in NPC onset and development as its expression is lost by
deletion or by hypermethylation. To support the hypothesised role of RASSFla as a tumour
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suppressor, RASSFla was reintroduced into a human lung cancer cell line where the promoter
of the endogenous RASSFla was hypermethylated. Re-expression led to a reduction in cell
proliferation, decrease in the number of transformed cells and inhibition of tumour formation
when these cells were introduced into nude mice (Burbee et al., 2001; Dammann et al., 2000).
A single report indicated that RASSFlc may be a tumour suppressor but this has not been
confirmed as yet (Vos et al., 2000).
Both RASSFla and NOREIA proteins contain a Ras association domain (RA) and a
conserved carboxy terminus. Despite having an RA, RASSFla cannot directly bind to Ras.
Instead it has to heterodimerise with NORElA which can bind activated Ras and
simultaneously bind to MST1I2 (a pro-apoptotic kinase) and induce apoptosis (Khokhlatchev
et al., 2002; Ortiz-Vega et al., 2002). RASSFla can also lead to cell cycle arrest at Gl
(Shivakumar et al., 2002), microtubule stabilisation and protection from inappropriate spindle
formation and genomic translocation. Its association with Cdc20 ensures that the cells do not
enter metaphase until the spindle apparatus is properly in place (Song et al., 2004a).
RASSFla interacts with pl20E4F (an ElA regulated transcription factor). Transfection of
NIH3T3 cells with both RASSFla and p120E4F led to increased S phase inhibition (Fenton et
al.,2004). It is also important to note that p120E4F can associate simoultaneously with pl4ARF
(the human homolog of pI9ARF) and p53 and induce growth arrest (Rizos et al., 2003). A
further interaction of RASSFla is with the scaffold protein CNKI. Both NORElA and
RASSFla can associate with CNKI. Coexpression of RASSFla and CNKI in HEK293 cells
leads to an increase in apoptosis. It is thought that CNKI binds the RASSFla-MSTI complex
and brings it in touch with activated Ras (Rabizadeh et al., 2004).
To conclude, RASSFla protects from aberrant proliferation by activating apoptosis and
inducing cell cycle arrest. The exact mechanisms involved in these processes are not clear yet.
1.7 TGFa and EGFR signalling
Epidermal Growth Factor Receptor (EGER)
Epidermal growth factor receptor (EGFR) belongs to the EOFR family of receptors. The other
three members of the family are HER2(ErbB2), HER3(ErbB3) and HER4(ErbB4) (Carpenter
and Cohen, 1990). They are all transmembrane receptors with an extracellular ligand binding
domain and a cytoplasmic domain containing a tyrosine kinase activity region. EGFR has at
least seven ligands including EOF, TOFu and amphiregulin (AR) (that preferentially bind
EGFR), heparin binding EGF (HB-EGF), epiregulin, epigen and betacellulin (fig.l.6). The
63
ligands are all produced as transmembrane forms and after proteolytic cleavage by
metalloproteases, they are released as the mature soluble growth factor. The mature forms
contain six conserved cysteine residues that make up the EGF motif, via which they can bind
to EGFR members. Although the ligands are similar in sequence they have distinct roles as
animal knock out models have shown. The one ligand that has been shown to have an effect
on the role EGFR has in the epithelium is TGFa which is described in more detail later.
The classical route of activation of EGFR is binding of growth factors such as EGF and others,
to the extracellular domain causing receptor homolheterodimerisation and activation of the
tyrosine kinase domain by autophosphorylation. Activation of the tyrosine kinase domain
enables transfer of the y phosphate ATP group to tyrosine kinase domains of both the receptor
and other downstream substrates. Tyrosine phosphorylation leads to activation of several
signalling pathways via downstream adaptor molecules and also to receptor internalization and
recycling allowing modulation of downstream signalling pathways (Cohen et al., 1982; Wiley
et al., 1991). Other stimuli apart from growth factors can activate EGFR (reviewed in
(Carpenter, 1999). These other stimuli include G protein-coupled receptor (GPCR) agonists
(working via c-Src), cytokine receptors (via Jak2), adhesion receptors, membrane
depolarization (increased flux of calcium that brings about EGFR activation via c-Src) and
stress response.
EGFR is a 170kDa protein initially produced from cleavage of the N terminus of a 1210
residue precursor followed by insertion of the 1186-residue protein in the cell membrane.
20% of the size of the mature EGFR is due to glysocylation of the N terminus. This
glysosylation is necessary for protein translocation to the cell membrane (Slieker et al., 1986).
An EGFR molecule consists of two ligand binding and two cysteine rich extracellular domains
and an intracellular tyrosine kinase. EGFR sequence is about 64% similar to the other
receptors of the family and can form heterodimers with them upon activation, thus expanding
the possible pathways that it can activate.
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Figure 1.6: Ligands of the EGFR family
There are six ligands binding to members of the EGFR family.
These are shown on the left column and are EGFR, TGFa, AR, HB-
EGF, betacellulin and epiregulin. EGF, TGFa and AR bind
preferentially EGFR leading to its homolheterodimeri sation. The
rest of the ligands are not EGFR specific but can bind to ErbB4 as
well. The arrows are colour coded according to their respective
ligand and show with which receptors the ligands can associate.
Figure adapted from Olayioye et. al., 2000, Oncogenel9(13):3159-
3167.
Ligands
AR
betacellulin
epiregulin
Receptors
There are several pathways activated by EGFR (fig!.7):
I. The She, Grb2, RaslMAPK pathway
2. c-Src
3. JAKISTATs
4. PLCy, PLD and PI3K
In the epidermis, EGFR signaling plays a major role in normal epithelial development. Some
of the EGFR growth factors are synthesized by normal epithelial cells. EGFR is strongly
expressed in the basal layer of the epidermis and the outer root sheath of hair follicles.
Moving on to the suprabasal layer where less proliferation takes place, the number of EGFR
receptors decreases. EGFR signalling regulates keratinocyte survival and protects them
against apoptosis. Several animal models of EGFR ligands as well as dominant negative
EGFR animal models show impaired epidermal and hair follicle development, implicating the
EGFR pathway in the normal development of epithelial cell proliferation and differentiation.
Which pathway(s) downstream ofEGFR are important in this function is still unclear.
The Shc, Grb2, Ras/MAPK pathway
Upon ligand binding, EGFR is activated by phosphorylation and as a result the SH2 domain of
Grb2 binds EGFR either directly via yl068 or yl086 or indirectly by first binding She that is
associated to EGFR (Sasaoka et al., 1994a; Sasaoka et al., 1994b). The Grb2 association with
EGFR leads to the association of SOS with Ras which leads to GTP binding on Ras thus
leading to Ras activation. Usually, Grb2 is constitutively bound to SOS and localized in the
cytosol preventing SOS from releasing active Ras. Activation of Ras leads to activation of
downstream pathways as described in section 1.5.
The Src pathway
Src is both contributing to EGFR activation and acting as a downstream effector.
Overexpression of Src proteins in fibroblasts or epithelial cells, leads to increased proliferation
and transformation that is EGF mediated. Inhibition of Src, leads to decreased proliferation
and to reversal of the transformed phenotype observed in cells overexpressing EGFR.
Phosphorylation of y845 of EGFR by Src leads to receptor activation. Src phosphorylates
EGFR on other tyrosine residues and allows EGFR mediated activation of STAT5b and PI3K
(Kloth et aI., 2003).
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Figure 1.7: EGFR signalling pathways
Binding of an EGFR ligand such as TGFu, leads to EGFR
homodimerisation and activation by phosphorylation (indicated by a
red star). Activated EGFR can recruit Pill and PLCy, activating
them and thus enabling them to carry their function in phospholipid
metabolism. Physical interaction of activated EGFR and PI3K
leads to activation of the latter which leads via other intermediate
molecules to activation of Akt that plays a role in apoptosis
inhibition. Association of activated EGFR and Grb2 via their SH2
domains and SOS recruitment leads to Ras activation by
preferential binding to GTP. Activated Ras, phosphorylates and
activates Raf, which in turn phosphorylates and activates MEKll2,
which leads to phosphsorylation and activation of ERK1I2.
Activated ERK1I2 leads to transcriptional activation of several
downstream genes. Activated EGFR leads to
homolheterodimerisation of STATs 113/5and their translocation to
the nucleus where they play a role in transcriptional activation of
downstream genes.
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Mammals have seven STAT genes (1-4,5a,5b,6). STATs are inactive transcription factors
when in the cytosol but translocate to the nucleus upon activation. STATs 1, 3 and 5 are
usually constitutively associated with inactive EGFR via their SH2 domains. Activation of
EGFR leads to homolheterodimerisation of STATs. This association activates them and leads
to their nuclear translocation. Activation of STAT by EGFR is independent of JAK activation
which is the standard for STAT activation in cytokine signalling.
PLO, PLCyand PI3-K
EGFR directly activates three enzymes involved in phospholipid metabolism; phospholipase-
Cy(PLCy), phosphatidylinositol-3-kinase (PI3K) and phospholipase D (PLD). Upon EGFR
activation, PLD physically associates with EGFR and gets activated by phosphorylation. PLD
hydrolyses phosphatidylcholine to create choline and phosphatidic acid.
PLCy binds to phosphorylated EGFR via yI173 or y 992 and gets activated. Activation ofPLCy
leads to hydrolysis of Ptd Ins(4,5)-P2 to give 1,2 diacylglycerol (DAG) and inositol 1,3,5-
triphosphate (IP3). IP3 can release Ca+2 from intracellular compartments and DAG plays a
role in activation of PKC.
PI3K phoshorylates phosphatidylinositol at the 3' position. There are three classes of PI3
Kinases depending on structure but only PI3K class la gets activated by tyrosine kinase
receptors. Phosphorylated ErbB receptors physically interact with the PI3K p85 subunit via its
SH2 domain. p85 preferentially binds ErbB3, so it is believed that there is heterodimer
formation of EGFRJErbB3 that mediates this interaction. Also Src phosphorylation of EGFR
can lead to activation of PI3K. PI3K la leads to phosphatidylinositol-3, 4, 5-triphosphate
(PIP3) formation which plays a role in Akt translocation to the plasma membrane and its
activation via phosphorylation by phosphoinositide-dependent kinase 1 (PDKl). Akt could be
the major route by which EGFR exerts its antiapoptotic effects. PI3Ky also binds Ras via its
catalytic subunit p 11O. Maybe via this association EGFR can activate and control both the
MAPK and PI3K pathways.
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EGFR and Cancer
Several studies have shown that alterations in EGFR such as amplification, rearrangements
and overexpression occur at high frequencies in human squamous cell carcinomas,
glioblastomas, breast, pancreatic, liver and colorectal cancers (Derynck, 1992; Libermann et
aI., 1985; McKay et aI., 2002). It has been shown that about 30% of human cancers express
elevated levels of EGFR and it has been correlated with poor prognosis and decreased disease-
free and overall survival rate. A natural mutant of EGFR, EGFRvIII, has a deletion of exons
2-7 and lacks the extracellular domain therefore it is constitutively active and is not
internalized thus being capable of long term signalling. This is the most common mutation in
human cancers and is detected in 50% of glioblactomas and 70% of medulloblastomas.
Transfection of EGFRvIII in glioma cell lines increases their tumorigenicity in nude mice.
EGFRvIII action is also linked to the anti-apoptotic protein Bcl-xL. In vivo expression of
EGFRvIII in inhibitors of CDK4 (INK4a) knock out mice, led to glioma formation. This
shows that EGFRvIII on its own is not enough for tumor formation but promotes proliferation.
EGFR animal models
Several knock out EGFR mice have been developed but their phenotype is strain dependent
and they do not reach weaning age. They show peri-implantation, mid-gestational death, skin,
lung, brain, liver and gastrointestinal tract abnormalities as well as disorganized hair follicles
and curly coats. Fetal death is due to placental defects or failure of epithelium maturation in
several tissues (Miettinen et aI., 1995; Sibilia and Wagner, 1995; Threadgill et aI., 1995).
Dominant negative EGFR models have been created to overcome the premature death
observed in EGFR null animals. One of these models where the transgene under control ofK5
promoter is directed for expression at the basal layer and the outer root sheath of hair follicles,
the animals that develop are smaller with short, waved hair and curly whiskers initially,
progressing to atrophic and sparse hair and finally to alopecia. Absence of EGFR has thus
prevented entry of the hair follicles into the catagen stage leading to follicle necrosis,
infiltration of the epidermis with inflammatory elements and epidermal hyperplasia (Murillas
et aI., 1995).
Inducible expression of ErbB2 in the K14-rtTA/TetRE-ErbB2 mouse led to skin hyperplasia
after 2 days of doxycycline exposure that regressed upon withdrawal of the chemical. In
prolonged induction of ErbB2, hyperplasia of the corneas, eyelids, tongue and oesophagus
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developed and the animals showed increased TGFaexpression, implying that ErbB2
cooperates with EGFR in the regulation of hair follicle and skin architecture (Xie et al., 1999).
EGFR and LMP1
Human epithelial cells (C33A and HNE2) showed upregulation of EGFR at the protein and
mRNA level upon transient or stable expression of LMPI (Miller et al., 1995). CTARI is
essential for EGFR induction but not CTAR2. Overexpression of TRAF3 (a negative
regulator of the TRAF pathway) or an amino truncated TRAF3 that inhibits NF-KB activation
from the CTAR1, led to inhibition ofEGFR expression. Since the CTAR2 mediated NF-K8 is
still active, this implies that the LMPI mediated EGFR activation may involve the TRAF
signalling pathway and not NF-KBsignalling only (Miller et al., 1998b; Miller et al., 1997). A
recent study confirms that CTARI is essential for EGFR induction and showed that LMPI can
modulate the EGFR promoter activation via NF-KB (Tao et al., 2004b). When 60 NPC
specimens were studied by means of immunohistochemistry (IHC), 41 of the samples tested
positive for LMPI and 44 tested positive for EGFR upregulation. The EGFR upregulation
was closely correlated with LMPI expression, implicating LMPI in the control of EGFR
expression in NPC (Sheen et al., 1999). Also Zheng et. al., showed that positive LMPI NPC
specimens expressed EGFR strongly and that there was an increase of EGFR expression in the
later stages ofNPC (Zheng et al., 1994a).
Regulators of EGFR ligand shedding
Metalloproteases with a disintegrin domain (ADAMs) are responsible for regulating the
cleavage of EGFR ligands and thus regulating EGFR activation and the effects this has on
tumour progression (reviewed in (Gee and Knowlden, 2003). TNFa.-converting enzyme
(TACE or ADAMI7) has been shown to be necessary for TGFa. shedding. Absence of TACE
or non functional TACE leads to defective TGFa. shedding. It has been shown that TACE is
upregulated in human breast cancer, indicating it plays a regulatory role in activating EGFR
(Borrell-Pages et al., 2003). It was thought that GPCR activated EGFR independently of its
ligands but it has been shown that ADAMlO and ADAM17 regulate cleavage of HB-EGF and
AR respectively activating the MAPK cascade and Akt signalling (Yan et al., 2002).
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TGFa
TGFa. is a mammalian growth factor that was first isolated from the culture medium of
growing retrovirally transformed fibroblasts. It is first synthesized as a 160aa transmembrane
presursor (proTGFa.). The extracellular domain ofTGFa. contains the receptor binding motifs
and is cleaved by ADAM 17 to produce the mature soluble form of TGFa. that is 50aa and
other TGFa. molecules of different sizes. Usually, TGFa. is detected as a polypeptide between
5kDa -20 kDa (reviewed in (Derynck, 1988). The difference in size its due to differences in
glycosylation. The membrane bound forms of TGFa. are biologically active but act on
adjacent cells rather than at cells at a distance. (Anklesaria et al., 1990)(reviewed in
(Massague, 1990). An experiment in which the two cleavage sites that release soluble TGFa.
were modified so that no soluble TGFa. could be released showed that transmembrane TGFa
could still activate EGFR. The transmembrane form is about 50-100 times less active than
soluble TGFa. (Brachmann et al., 1989). Defective cleavage of TGFa. in two human colon
cancer cell lines, led to the transmembrane form inducing increased phosphorylation of EGFR,
a slower EGFR internalization and transmembrane TGFa was more resistant to tyrosine
phosphatases thus enhancing activation of EGFR and giving a growth advantage to the cells.
It has been shown that TGFa. can be synthesized by various oncogenically transformed
fibroblasts and by tumour cells such as renal, squamous carcinoma, melanomas etc. There is
evidence showing that TGFa may contribute to the conversion of a normal cell to a malignant
one. However, TGFa. plays an important role in normal embryonic development. It is
normally expressed in the unfertilized oocyte, the developing embryo and tissues such as the
placenta, the kidney and the oral cavity of the developing mouse. In adult mice TGFa is
expressed in skin, brain, breast and the gastrointestinal mucosa among other organs. TGFa
also plays a role in wound healing, angiogenesis and keratinocyte proliferation and migration.
It has been suggested that TGFa. can promote skin tumorigenesis and there are several animal
models that support this as well as other experiments, for example, elevated TGFa levels have
been detected in DMBA/TP A treated mice skin tumours. Furthermore, papilloma cells
transfected with human TGFa, when grafted to nude mice produce larger tumours than
untransfected papilloma cells. In addition, there is evidence that TGFa and TPA synergise in
enhancing epithelial proliferation.
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EGFR ligands animal models
Several animal models have been created to determine the action of each of the EGFR ligands
and clarify whether they complement each other or have distinct functions.
Gain of function models
Overexpression ofTGFa. to the stratified squamous epithelia (using the human K14 promoter)
led to ear, scrotum, tail, foodpad and body skin hyperplasia, stunded hair growth, localised
psoriasis symptoms and spontaneous papilloma formation at sites of mechanical irritation.
Upon TPA treatment papillomas were formed that did not display any Ras mutations, showing
that overexpression of TGFa. in the epidermis can act as an initiator in tumorigenesis (Vassar
and Fuchs, 1991; Vassar et al., 1992). Increased expression levels of EGFR (in the olfactory
epithelium), cyclin D1, retinoblastoma, cyclin E and E2F-1 was observed suggesting a
response due to increased levels ofTGFa. (Getchell et aI., 2000). Similarly, when TGFa. was
expressed in the basal epidermal layer (human Kl promoter), epidermal hyperplasia and
hyperkeratosis was evident in the newborn mice as well as spontaneous papilloma formation
in the young adult, mostly at wounding sites. Upon TPA treatment papillomas formed that
had no H-ras mutations. However when these mice were crossed with HK1.v-fos mice, the
resulting bitransgenic animals showed a severe hyperplastic neonatal epidermis and developed
spontaneous papillomas as adults much faster. TPA treatment of these mice led to a rapid
onset of papillomas that progressed to squamous cell carcinomas that had H-ras mutations,
suggesting that v-fos and TGFa. cooperate in tumorigenesis but need an additional genetic
event such as H-ras mutation for progression (Dominey et al., 1993; Greenhalgh et al., 1993b;
Wang et al., 1994; Wang et al., 1995; Wang et al., 1999).
Other TGFa transgenic mice under the control of the MT promoter were created (Shibata et
al., 1997). Without any treatment these mice showed no phenotype, however,
bromodeoxyuridine (BrdU) treated mice showed increased DNA synthesis indicative of
increased proliferation. In DMBAITPA treated transgenic mice, the tumour load and volume
was higher than that of wild type mice. Application of only DMBA or TPA was not enough to
promote tumour formation but TPA alone, produced epidermal hyperplasia in 63% of
transgenic mice as opposed to only 20% of wild type mice. Western analysis of tumours and
skin, led to detection of EGFR downregulation in transgenic papillomas as opposed to wild
type skin tumours suggesting that a tight homeostatic control is in place to compensate for
ligand overexpression. Western analysis also led to detection of the phosphorylated forms of
74
EGFR only in transgenic skin tumours and not in wild type tumours showing that TGFa
overepression led to the activation ofEGFR. There were no inactivating pS3 mutations in any
of the lesions but there were ras codon 61 mutations in both transgenic and wild type skin
tumours.
Overexpression of EGF under the direction of p-actin, gave mice that were smaller than wild
type littermates and had necrotic regions in some regions of their liver. No lesions were
observed. However to be able to directly compare these mice to the TGFa overexpressing
mice, the EGF has to be under the direction of a promoter specifically leading to its expression
in the epithelium (Chan and Wong, 2000).
Mice overexpressing AR under the K14 promoter showed a proriasis like phenotype with
reddening, scaly skin, alopecia and rare spontaneous papilloma formation. AR overxpressing
mice using the involucrin enhancer/promoter to direct expression of the transgene to the
suprabasal epidermal layer, also showed a psoriasis like phenotype and synovial inflammation
(Cook et aI., 2004; Cook et aI., 1997).
Loss of function models
Two groups have developed TGFa null mice (Luetteke et aI., 1993; Mann et aI., 1993). The
resulting mice from both groups, were viable and fertile and it was shown by radioassay that
they had no detectable TGFa levels in skin, small bowel or kidney. Phenotypically, the mice,
showed waviness of fur and whiskers evident from day 1, more pronounced after day 12 and
less evident beyond 8 weeks of age. The null mice showed eye abnormalities such as
precocious eyelid opening and corneal inflammation in older animals. There was no
diminished wound healing ability in those mice as seen by examination of the tail stamps after
tail clipping. By cross breeding experiments it was shown that waved-I recessive mutation
and TGFa are allelic. These mice have been used in cross breeding experiments in this study
and are referred to as line 125 in this thesis.
EGF null mice have no phenotype. AR null mice show no phenotype but when crossed with
EGF null (EGF/AR null) or TGFa null mice (ARlTGFa null) or with both EGF and TGFa
null mice (EGF/ARlTGFa null) an essential role of AR in mammary ductal morphogenesis
was revealed. The triple null mice also show eye defects, dermatitis and skin ulcerations.
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1.81NK4a Locus
The INK4a locus encodes two distinct proteins that are both involved in cell cycle arrest and
growth inhibition (QueUe et al., 1995). These overlapping genes are transcribed from different
promoters and have different first 5' exons. Even though they share their second and third
exons, these are read in different frames so the two gene products p 16INK4and p 19ARF (p14ARF
is the human homolog) have no amino acid similarity (fig1.8). The locus is highly conserved
among species thus showing its importance.
p19ARF has been implicated in the regulation of the p53 tumour suppressor and p16INK4ahas
been implicated in the cyclin-D dependent kinase (CDK4)/CyclinDIlRb pathway.
The INK4 family
The INK4 family of proteins includes; the p16INK4a,p15INK4b,p18INK4Cand pI9INK4d. The first
two are located on human chromosome 9p21 and share 40% homology, p 18INK4cis located on
1p32 and p 19INK4dis located on 19p 13. The mouse and the human proteins are 90%
homologous showing how well the INK4 family members have been conserved among
species. They all have characteristic ankyrin repeat motifs. Ankyrin motifs mediate protein-
protein interactions. p 161NK4and p 15INK4bhave four ankyrin repeats whilst p 18INK4cand
p19INK4dhave five ankyrin like repeats. All of the INK4 family members have a similar
structure as shown by X-ray crystallography and similar biochemical functions. They all bind
and inhibit CDK 4 or 6. Initially p16INK4awas discovered because of its binding to CDK4.
Crystallography data have shown that the third ankyrin repeat is crucial for the interaction of
p 16INK4awith CDK4/6 (Koh et al., 1995; Noh et al., 1999).
Many human tumours carry mutations affecting p 16INK4a. These range from homozygous
deletions (14% of all human tumours), intragenic mutations (5% of all human tumours) and
promoter silencing by methylation (19% of all human tumours). Mutations of the other family
members in human cancers are rare suggesting that p 16INK4ais the member of the family with
the major tumour suppressive role. Most human tumours show inactivation of p 161NK4aby one
of the three ways described above with a frequency between 25-70%. About 98% of
spontaneous pancreatic tumours have p 16INK4ainactivation and cases of familial melanoma
and pancreatic cancer also show p 16INK4ainactivation.
Each of the four family members are regulated by different signals and show different
expression patterns during development. Normally p 16INK4aexpression is kept at very low
levels but during senescence or oncogenic stress p16INK48levels increase. The p15INK4bis
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specifically upregulated by TGF{3. The other two members, p lSINK4c and p 191NK4d show a
cyclic pattern of expression with maximum expression in the S phase. So far studies have
indicated that the four family members are not functionally redundant.
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IJ3 13kb
Figure 1.8: The INK4a locus (not to scale)
The diagram depicts the organisation of the two genes and their encoded products,
p161NK4a and p19ARF• p16INK4a is encoded by exons la, 2 and 3 (ORF in purple). p19ARF is
encoded from exons I fl, 2 and 3 (ORF in pink). Introns are indicated by angled lines. The
two promoters are indicated by arrows and are separated by approximately 13kb.
The p16INK4a/CDK4/CyclinD1/Rb pathway
Under normal conditions, Rb is unphosphorylated and bound to E2F transcription factors
preventing them from activating their downstream target genes. Rb can be phosphorylated by
the CyclinD/CDK4/6 complex. Phosphorylation releases E2F that can now activate
downstream signalling pathways and allow progression of the cell cycle from 00/01 to the S
phase (fig.1.9). p16INK4apreferentiallybinds CDK4/6, forcing the CDK4/6/CyclinD complex
to dissociate. Unbound CyclinD is then degraded by the ubiquitin dependent proteasome
degradation pathway. In this way CyclinD cannot activate CDK4/6 which cannot
phosphorylate Rb thus inhibiting E2F from activating its targets and thus arresting the cells in
00/01. Most of the inactivating mutations of the p161NK4agene are found in the third ankyrin
repeat thereby preventing p16INK4afrom binding CDK4/6 (fig.l.9). Release of E2F also plays
a role in the control of the p19ARFIMDM2/p53 pathway and this will be discussed later.
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Figure 1.9: The p161NK4a role in inhibiting S phase entry
In GO/G 1, Rb binds E2F factors preventing them from transcribing genes that
would promote S phase entry. On mitogenic signals, Cyclin D complexes with
eDK4/6 to phosphorylate Rb and release E2Fs that can promote S phase entry.
Abnormal mitogenic signals lead to activation of p161NK4a that prevents
association of Cyclin D and eDK4/6 thus inhibiting Rb phosphorylation and
inhibiting S phase progression leading to G 1 arrest.
The p19ARF protein
The p19ARF protein was discovered after p16INK4awhen it was realised that the INK4a locus
could encode a further protein in another reading frame (ARF). It was shown early on that the
ectopic expression of p 19ARF could also inhibit cell cycle progression both at Gland G2 via
the p53 pathway (Kamijo et al., 1997).
The p 19ARF gene has been identified in only four species; human, mouse, rat and opossum.
The human and mouse genes have 49% homology whereas the human and mouse p16INK4a
genes show 63% homology thus showing that the p 19ARF gene is less well conserved among
species.
The p19ARF protein acts in the MDM2/p53 pathway as well as having other pS3 independent
functions. For example triple null mice for pI9ARF,MDM2 and p53 develop a wider variety
of tumours than mice null for p 19ARF or p53 alone, implying that the p 19ARF IMDM2/p53
pathway is not entirely linear. There is evidence that p 19ARF exerts its tumour suppressor
function not only by stabilising pS3 but also by leading to regression of vessels as suggested
by the finding that p 19ARF null mice become blinded soon after birth due to the persistence of
blood vessels in the vitreous of the eye. Normally expression of p 19ARF would lead to
regression of these blood vessels thus preventing any damage to the eye from the subsequent
proliferation of neighbouring cells (McKeller et al., 2002).
The p19ARF/MDM2/p53 pathway
The tumour suppressor p53 is found inactivated in about 50% of human cancers. The levels of
p53 are determined by ubiquitination and subsequent proteolytic cleavage. pS3 can negatively
regulate itself by activating the ubiquitin ligase MDM2 (HDM2 is the human homologue).
MDM2 can target p53 for proteolytic cleavage. p19ARF can prevent this cleavage in two ways;
by binding to MDM2 and preventing it from targeting p53 for degradation and by actively
sequestering MDM2 into the nucleolus thus physically separating it from p53. In this way
p19ARF leads to stabilisation ofp53 levels. Usually the levels ofp19ARF are very low. This is
believed to be the result of repression of p 19ARF by E2F3 (Aslanian et al., 2004) or by E2F 1
(Bates et al., 1998). Oncogenic stimuli such as activated Ras, c-myc, E2F, EIA and v-Abl (de
Stanchina et al., 1998; Dimri et al., 2000; Kamijo et al., 1998; Palmero et al., 1998; Radfar et
al., 1998; Serrano et al., 1997; Zindy et al., 1998) lead to increased levels of p19ARF thus
ensuring that p53 is unbound. The tumour suppressor p53 exerts its anti-oncogenic function in
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two ways; first it can induce cell cycle arrest and second it can induce apoptosis. Unbound
pS3 can act as a transcriptional activator of genes such as the cell cycle inhibitor p21c1P1and
the pro-apoptotic gene bax.
The two pathways p19ARF/MDM2/p53 and p16INK4a/CDK4/6/CyclinD/Rb do not act in
isolation but in a synergistic way. Interaction is at two levels, the first being E2F factors
activating or repressing p 19ARF and the second being pS3 activating p21 Cipl that can inhibit
Cyclins ElA interaction with CDK2 thus inhibiting entry into the Sphase. p 161NK4aalso
mobilises p27kip1 that can inhibit the activity of CDK2 (fig. I. I 0). Using siRNA against either
p16 or p19 in MEFs, Camero et. al., showed that p161NK4and p19ARF have overlapping roles.
siRNA against p 16 or p 19 only, led to colony formation, no senescence and immortalisation.
Restoration of function ofp16INK4ain MEFs that were treated with siRNA against p16INK4aand
subsequent treatment with siRNA against p19ARF, led to continuous proliferation. When the
p19ARF function was restored in MEFs treated with p19ARF siRNA and their subsequent
treatment with p 16INK4asiRNA led to growth arrest. These results show that p 19ARF
suppression of immortalisation overlaps with the function of p 16INK4abut that p 19ARF has also
another role in suppressing immortalisation that is independent of p 16INK4afunction.
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Figure 1.10: pl9ARF signalling and p161NK4a adapted from Lowe and Sherr,
Curro Opio. Genet. Dev., 2003,13(1): 77-83
Activation of pl~RF leads to the inhibition of MDM2 mediated degradation of
p53. Active p53 can induce apoptosis. Ras activated CyclinD/CDK leads to Rh
phosphorylation and release of E2F allowing for progression of cell cycle and at
the same time reinforcing pl~RF activation.
Transgenic Mouse Models of INK4a locus
The first mouse model to be developed was the INK4a null model where exons 2 and 3 of the
INK4a locus were replaced with a neomycin cassette (Serrano et al., 1996). The mice lack
p16INK4aprotein. It is not clear whether they lack p19ARF completely since there is an intact
exon 1f3, and these mice may express a truncated p19ARF product. The mice are viable and
fertile. However, 69% of the mice spontaneously show tumour formation by 29 weeks of age,
mostly lymphomas. When these mice are carcinogen treated almost all of them succumb to
tumours such as sarcomas and lymphomas. When MEFs from these mice were compared to
wild type MEFs or heterozygous MEFs, they showed an increase in growth rate, higher
cellular densities, higher efficiency in colony formation and they could also escape
senescence. They could also form foci in culture when Ras but not c-myc was introduced and
these cells could form tumours in nude mice. These experiments showed that the INK4a locus
is powerful in tumour suppression. (Note these mice have been used in the studies described in
this thesis and are referred to as line 113).
Subsequently, mice lacking specifically the p19ARF gene were created (Kamijo et al., 1997).
These mice become blind soon after birth but they are viable and fertile. They develop
sarcomas, T-cell lymphomas, carcinomas and neurological tumours and about 80% of them
are dead within a year of birth2(Sharpless et al., 2004). Since the phenotype between INK4a
null and p19ARF mice was quite similar it was suggested that p 19ARF maybe more important in
tumour suppression in mice.
More recent models include one that leads to production of an unstable form of p16INK4a
protein (due to a stop codon insertion in exon 2) (Krimpenfort et al., 2001) and mice that are
null only for p16INK4a( due to exon If3 deletion) (Sharpless et aI., 2001). MEFs from both of
these models had the same growth rate, same Rb phosphorylation and same pattern of growth
arrest when serum starved as wild type MEFs but p19ARF null MEFs were very susceptible to
transformation and could escape growth arrest whilst p16INK4anull MEFs were not acting in
this manner.
2 Sharpless et aI, 2004, reported the generation of p19ARF null mice. These mice were created
onl~t~r com~arison reasons with the pI6INK4a null mice (Sharpless et al., 2001). These new
p19 null mice were also more prone to tumours than wild type animals.
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Both mouse models showed increased tumour load after chemical carcinogen treatment when
compared to wild type siblings but the mice harboring the mutant p161NK4ashowed no
difference in spontaneous tumour formation unlike the INK4a null mice.
Comparing these results between p 161NK4anull or mutated protein and p 19ARFnull mice it is
shown that both p 161NK4and p 19ARFare important as tumour suppressors but they play a
different role in different tumour types. A recent study argues that in humans the most
important tumour suppressor is p 16INK4aand not p 19ARF. This is consistent with
epidemiological studies that have shown point mutations, deletions and promoter
hypermethylation affecting only p16INK4aand not p14ARF (the human homolog of pI9ARF)
(Ruas and Peters, 1998). In the study by Voorhoeve and Agami, 2003, human primary
fibroblasts were used along with siRNAs against Rb, p53, p14ARFor p161NKN4a.It was shown
that inhibition of p14ARFleads to fibroblast increased growth only in the presence of p53 but
these cells do not readily form tumours in nude mice (Voorhoeve and Agami, 2003). In
contrast inhibition of p 16INK4adoes not play a role on fibroblast growth rate but instead
cooperates with the loss of p53 to increase growth rate and cause transformation, thus
suggesting that loss of p 16INK4ais more important for human tumours.
LMP1 , NPC and p161NK4a
NPC primary tumours and xenografts show homozygous deletion of the INK4a locus as well
as silencing of p 16INK4adue to promoter hypermethylation (Lo et al., 1996; Lo et al., 1995).
When NPC cell lines were treated with 5' -aza-2' -deoxycytidine that reverses
hypermethylation, p161NK4aprotein levels increased. It was therefore implied that p 161NK4a
could be involved in the development ofNPC.
As described in section 1.3, LMP 1 inhibits p 16INK4aexpression in rodent fibroblasts by
relocalising its effectors (Ohtani et al., 2003; Yang et al., 2000a; Yang et al., 2000b).
However, inhibition ofp161NK4awas not observed in LeLs, implying that either LMPI cannot
inhibit p 161NK4aor it is not sufficient for p 161NK4ainhibition (Hayes et al., 2004). Data
generated from chemical carcinogenesis treatment of mice expressing LMPI in the epidermis
but with INK4a null mutation, showed that INK4a locus products (either p161NK4aor pI9ARF)
inhibit lesion growth. Heterozygous loss of INK4a leads to intermediate growth, therefore a
cell with an INK4a mutation (ie.heterozygous) and EBV infection with LMPI expression will
grow faster than an EBV infected cell with no mutation. Also loss of INK4a in the absence of
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EBV shows reduced risk of lesion outgrowth. It is therefore the specific combination of loss
ofINK4a and EBVILMPI that leads to increased risk (Macdiarmid et al., 2003).
1.9 Mouse models of LMP1 expression in the epithelium
In order to investigate the role LMP1 plays in the formation and the development of EBV
associated carcinoma in vivo, mouse models were developed that would express LMP1 in the
epithelium. There are many advantages to using an in vivo model to study a disease. An in
vivo model enables the researcher to gain access to affected tissues and study the different
stages of the disease from the outset. Directing expression to epidermis allows ready
observation and monitoring of a developing phenotype. Moreover, carcinogenesis in the
mouse skin has been extensively characterised as described in section 1.5.
The Structure of the Skin
Epidermis is a type of stratified epithelium. Epithelia line all the cavities and free surfaces of
the body. Cells in epithelia are tightly bound together and provide a barrier to environmental
agents and bacteria as well as regulating water, solute and cell movement. All epithelia are
avascular and depend on the underlying connective tissue for nutrients. Simple epithelia are
single sheets of cells while stratified epithelia consist of layers of multiple cells usually of
different types. Pseudo stratified epithelia appear to consist of different layers whereas in
reality they consist of a single layer of cells. Epithelia are categorised according to the shape
of the cells that make them up. There are cuboidal epithelia where the cells are cubed shaped,
columnar epithelia where the cells are rectangular and squamous epithelia where the cells are
flat. Epithelia can contain cells that can form keratins or not. The epidermis is a stratified
keratinising epithelium whilst the epithelium lining the mouth, the nasopharynx and the
gastrointestinal tract consists of simple squamous or columnar non keratinising epithelium.
NPC arises from the simple squamous non keratinising epithelium of the nasopharynx. In the
transgenic mice, we are modelling EBV associated disease in the stratified keratinising
epithelium of the skin and the gastrointestinal tract.
The skin consists of the epidermis, the underlying dermis and the skin appendages which
include hair follicles and sweat glands (fig. I. II). Its purpose is to protect internal organs from
injury, infectious agents and dehydration and serve for insulation, vitamin D production,
sensation and excretion (Fuchs and Byrne, 1994; Fuchs and Raghavan, 2002).
The dermis is developmentally derived from the mesoderm and is usually much thicker than
the epidermis. It consists of two layers; the innermost thicker layer is the reticular dermis and
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Figure 1.11: Structure of the skin
The diagram shows the structure of the skin; consisting of the epidermis the
dermis and the basement membrane. The skin appendages like hair follicles
and sweat glands are not shown. The different epidermal layers are depicted.
The proliferating basal layer is shown in pink, the differentiating suprabasal
layer in purple, the granular layer in peach and the cornified layer in brown.
the outermost thinner layer is the papillary dermis. The dermis consists mainly of collagen
and elastic fibers, capillaries and blood vessels. It is in the reticular dermis that all the
epidermal appendages such as hair follicles and sweat glands lie. The dermis main cell type is
the fibroblast which is responsible for producing collagen elastic fibers. Other cell types
found in the dermis include macrophages and mast cells that playa role in immunity.
Dermis is separated from the epidermis by the basement membrane which is made up of
extracellular matrix proteins including laminins, collagen and proteoglycans. The epidermal
cells are attached to the basement membrane via special adherens junctions called
hemidesmosomes and the basement membrane is attached to the dermis via anchoring fibrils.
The basement membrane separates the dermis from the epidermis but at the same time allows
communication between these two layers. For example, signalling molecules, lymphocytes
and Lagerhans cells can pass from the dermis to the epidermis.
The epidermis is much thinner than the dermis ranging from O.Imm to Irnm. The soles of the
feet and the palms of the hand have thicker epidermis whereas the eyelids have very thin
epidermis. Developmentally the epidermis is derived from the ectoderm. In fury mammals
like the mouse the epidermis is much thinner than the human epidermis. The epidermis
consists of mainly of keratinocytes (85%), Lagerhans cells, Merckel cells and melanocytes.
The primary role of keratinocytes is to produce keratins. Melanocytes produce melanin which
protects the keratinocytes from UV light. Lagerhans cells can present foreign antigens to the
immune system. Merckel cells are found in certain parts of the epidermis and allow pressure
to be felt. The epidermis is a stratified keratinised squamous epithelium that is replaced every
3-4 weeks and is made up of five distinct layers. These are:
• Stratum basale (basal cell layer)
Startum basale (the innermost layer of the epidermis) is composed of a single layer of
columnar or cuboidal keratinocytes that are attached to the basement membrane via
hemidesmosomes. These keratinocytes are mitotically active and can proliferate. These
cells detach from the basement membrane and move further up the surface of the skin to
the spinous layer where they are terminally differentiated. In the stratum basale one can
find melanocytes, Lagerhans and Merckel cells.
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• Stratum Spinosum (spinous layer or suprabasallayer)
Stratum spinosum consists of 8-10 layers (humans, 1-2 layers in the mouse) of irregularly
polygonal flattened cells. These cells are alive and are separated by clefts that are spanned
by spine like cytoplasmic extensions of cells.
• Sratum Granulosum (granular layer)
Stratum granulosum consists of 3-5 layers (humans, 1-2 layers in mouse) of flattened
polygonal cells with disintegrating nuclei. These cells accumulate keratohyalin granules.
They also contain lamellar granules that shed their lipid contents into the interstitial space
and form a seal that prevents entry of water or foreign objects in the skin. The cells of this
layer are not dividing.
• Stratum Lucidum
Stratum lucidum is a translucent, thin layer of extremely flattened dead cells. In some
cells the nuclear outline may be slightly visible but most of these cells are enucleated.
Only the intermediate filaments and desmosomes are retained.
• Stratum Corneum (cornified layer)
The stratum corneum consists of 25-30 (human,IO layers in mouse) layers of dead,
enucleated, flattened, keratinised cells. The cells closer to the surface of the epidermis are
loosely connected to each other and are constantly shed from the skin in a process called
desquamation.
The epidermis is constantly in a state of dynamic equilibrium and growth and differentiation
must be tightly regulated in order for this equilibrium to function properly. Increase in the
number of dividing cells can lead to epidermal hyperproliferation and disorders such as
psoriasis, and basal- and squamous-cell carcinomas. On the other hand, premature
differentiation can lead to very thin skin. The epidermis is also receiving signals that affect its
homeostatic control from the underlying dermis. Therefore, when one studies epithelial
abnormalities all these factors must be taken into account.
One of the important roles of keratinocytes within the epidermis is to produce different
keratins. There are two types of keratins; type I are acidic (pKi = 4.5-5.5) and small (40-
56.5kDa) whilst type II are basic (pKi = 5.5-7.5) and larger (53-67kDa). The keratins form
heterodimers of these two types. About 20,000 pairs assemble into an intermediate filament
that give the epidermis its structure. At the different layers of the epidermis different keratin
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pairs are expressed. In the basal layer only keratins 5,14 and 15 are expressed. As the cells
enter the suprabasallayer, expression of these keratin pairs is downregulated and other keratin
pairs such as keratins I, 10 and 11 are expressed. In response to injury, retinoic acid treatment
or hyperproliferative diseases like cancer, the subrabasallayer can produce keratins 6 and 16
(K16 has no murine homologue). Therefore keratin pairs can serve as markers of proliferation
or differentiation (Fuchs, 1995; Fuchs and Byrne, 1994; Fuchs and Raghavan, 2002).
The other components of the skin are the epidermal appendages which are derived from the
epidermis and include hair follicles, sebaceous glands, eccrine, apocrine glands, nails and
teeth. Their function is to protect the skin and to regulate skin homeostasis.
LMP1 transgenic models
With the above in mind, several transgenic mice were created in order to study the role of
LMPI in carcinoma genesis and progression.
The first series of mice were created using the Py promoter to direct expression of the
LMP1895•8 to the epidermis. 12 founders were created that gave rise to 9 lines. Out of these, 2
lines expressed the LMPI in the epidermis and these were lines 5 and 53 (Wilson et al., 1990).
Line 5 showed high levels of LMPI expression but also showed insertional mutation that led
to line extinction. Line 53 showed a lower LMPI expression and was viable and therefore
subsequent studies were performed using line 53. Transgenic pups of this line are slightly
smaller initially than their wild type siblings and also show an epidermal hyperplasia that is
most evident from day 3 to day 7 (fig.1.12). They also show a delay in eye opening and fur
growth. These phenotypes resolve as the mouse matures and are not evident in adults of the
line. The adults show a progressive increase in claw growth and in the C57BU6 strain, a
colour coat change from black to patches of ginger as they age. Expression analysis
performed on tissues of mice of this line and line 5 showed that the transgene was expressed in
the skin both at the mRNA and protein level and at low levels in the tongue. Consistent with
hyperplasia, keratin 6 and 14levels (proliferation markers) in the skin of transgenic mice were
upregulated by 2.5 times compared to wild type sibling skin in line 53 (higher in line 5)
(Curran et al., 2001; Wilson et al., 1990). In further studies in which these mice (in FVB
strain) were treated with topical chemical carcinogens, the transgenic mice developed more
papillomas than the wild type siblings and it was shown that LMPI could augment the activity
of TPA (Curran et al., 2001). However, growth expansion of these small papillomas into
larger lesions was inhibited in the LMPI expressing mice. When these mice were bred into an
90
AATAAA
Py LMPIB95-8 EBV-L2
Figure 1.12a: Construct used to generate line 53
The purple rectangle and diamond represent the polyoma enhancer and
promoter, the turquoise coloured area represents EBV sequence, the blue area
represents the LMP 1B95-8sequence. The black bars represent the two introns
found in the LMPI gene. The pink oval represents the EBV -L2 promoter.
Figure 1.12b: Phenotype of line 53 pups
In the above picture, 4 pups offine 53 are shown. The two on the left are
wild type (-) whilst the two on the right are transgenic (+) for LMPIB95-8, as
indicated. The pups shown above are 3-7days old and the transgenic ones
are smaller than their wild type siblings, showing epidermal hyperplasia.
INK4a null background, the growth inhibition was removed, demonstrating that the LMPI
induced inhibition of lesion growth was mediated by products of the INK4a locus (p161NK4lI
andlor pI9ARF). Loss of INK4a also promoted carcinoma progression (Macdiarmid et al.,
2003). This study showed that LMPI plays a role in the early stages of tumourigenesis, acts
as a promoter and exerts a growth inhibitory effect via p16INK4lI andlor p19ARF and therefore
implies that LMPI is not sufficient to inhibit expression of one or both of these products.
Since the LMPI CAO strain was isolated from an NPC and has been postulated to be more
oncogenic, this form of LMPI was used to create further transgenic lines in order to explore
its activity in vivo. The LMPI CAO gene (Hu, 1991) was expressed under the control of the
EBV ED-L2 promoter to drive expression of LMPlcAO in the epithelium (Stevenson et al, in
press)(fig.l.13). 5 lines of mice were created. These were lines 104, 117, 105B, 105A and
106, the strength of phenotype indicated according to their order. For example, line 104
showed the strongest expression and more intense phenotype and all the mice of this line died
before further breeding. Line 106 had little or no phenotype. Here I wiII describe only the
lines that have been used in this PhD study: lines 117, 105A and 105B. Line 117 and 105B
transgenic animals show extensive epidermal hyperplasia on the ears and the tail with evident
vascularisation as adults. The ear phenotype progressively worsens with age. For the purpose
of the study described in this thesis, the progressive phenotype was categorised in stages
(fig.1.14). When line 117 and 105B were bred into the FVB background, the transgenic
animals started developing dorsal papillomas spontaneously (see fig.1.15).
Line 105A animals do not show any hyperplastic epidermal phenotype but develop a wasting
phenotype starting at around 1 year or older.
Note that due to the importance of the strain variation in epithelial carcinogenesis, all line 117
animals used in the chemical carcinogenesis experiments and the spontaneous papilloma
studies were mostly in FVB strain (backcross 5 or 6, the original strain being C57BL/6).
However, the cross of line 117 to 125 mice was in a mixed strain background (FVB/129/C57)
as the line 125 animals were in a mixed 125/C57 strain.
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AATAAA
EBV-L2 LMPICAO EBV-L2
Figure 1.13: Construct used to generate lines 117, 105A and 105B
The pink oval represents the EBV-L2 promoter. The blue rectangle
represents EBV sequence. The green rectangle represents LMPlcAO
sequence. The black bars in the green rectangle represent the two
introns of the LMPlcAO gene.
Figure 1.14: Ear phenotype ofliDe 117mice
The top left comer shows an ear from a wild type
mouse of same age and strain to the L2LMPI CAO
transgenic ear shown on the top right comer. Stage 1
transgenic ear, is showing vascularisation when
compared to the wild type ear, whereas stage 2
shows hyperplasia, stage 3 ear shows the beginning
of necrosis and stages 4 and 5 transgenic ears show
extensive ulceration and necrosis like a
keratoacanthoma and can progress to carcinoma.
The approximate age at which the specific phenotype
is observed is given.
wild type ear
stage 2 ear (8 weeks old)
stage 4 ear (7-12 months old)
stage 1 ear (4 weeks old)
stage 3 ear (4-6 months old)
stage 5 ear (10 months or older)
Figure 1.15: Phenotype of a 117 mouse bred into the FVB background
This mouse is backcross 3 into FVB background (87.5% FVB). At least 6
spontaneous papillomas have developed on its back at sites not related with
mechanical irritation (figure from Stevenson et. al., in press).
1.10 Aims
The purpose of my thesis was to investigate the role LMPI plays in the onset and progression
of carcinoma in vivo, using the transgenic mouse models. The investigation was subdivided
into the following analyses:
(1) To characterise the expression patterns of LMP1CAO in the transgenic lines generated
and evaluate whether the observed phenotypes correlate with the expression patterns.
(2) To investigate the action ofLMPI in conjuction with loss of the INK4a locus in order
to explore cooperative effects.
(3) To test the hypothesis that LMPI exerts its oncogenic action via upregulation of
TGFu, a ligand ofEGFR. It is known that EGFR is upregulated by LMPI in epithelial
cells and that it is also found upregulated in NPC biopsies. Upregulation of an EGFR
ligand could lead to faster cycling of the receptor and thus increased activation of the
pathways affected by EGFR. One such pathway is the RaslMAPK pathway. The
effect LMPI has on this pathway was explored.
(4) To examine the status of other signalling pathways known to be affected by LMPI in
B cells. LMPI plays a role in many cellular processes and it was important to dissect
which pathways are impacted in the tissues and therefore which may be responsible for
the induced phenotype and thus which might be implicated in NPC development.
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Chapter 2: Materials and Methods
2.1 Materials
Chemicals were purchased from Sigma except where stated otherwise. Tissue culture reagents
were from GibcoBRL.
2.1.1 Antisera
Table 2.1: Primary Antibodies Used
Antibody/ControVHybridoma Supplier/ref. Catalogue Species Dilution Protein
Cell Supernatant Number used size
kDa
Phospho-Akt (Thr308) Cell 9275 Rabbit 1:1000 60
Signaling
Phospho-Akt (Ser473) Cell 9271 Rabbit 1:1000 60
Signaling
Total Akt Cell 9272 Rabbit 1:1000 60
signaling
Cleaved caspase-3 Cell 9661 Rabbit 1:1000 17,19
Signalling
Total caspase-3 Cell 9662 Rabbit 1:1000 35,17,
Signalling (Western) 19
1:50 (IHC)
Phospho-p38 Promega V121A Rabbit 1:1000 38
Cyclin A Santa Cruz sc-751 Rabbit 1:1000 50
Cyclin Bl Santa Cruz sc-752 Rabbit 1:1000 50-55
Cyclin Dl Cell 2926 Rabbit 1:1000 36
Signalling
Elk-l Santa Cruz sc-355 Rabbit 1:1000 62
Phospho-EGFR (Tyr845) Cell 2231 Rabbit 1:1000 170
Signaling
Phospho-EGFR (Tyrl068) Cell 2234 Rabbit 1:1000 170
Signaling
Total EGFR Cell 2232 Rabbit 1:1000 170
Signaling
Phospho-ERKl/2 Cell 9101 Rabbit 1:1000 44,42
(Thr202/Tyr204 ) Signaling
Total ERK1I2 Cell 9102 Rabbit 1:1000 44,42
Signaling
Fra-l Santa Cruz sc-183 Rabbit 1:1000 42
Fra-2 Santa Cruz sc-604 Rabbit 1:1000 43
c-fos Santa Cruz sc-253-G Rabbit 1:1000 62
FosB Santa Cruz sc-48X Rabbit 1:1000 36
Phospho-GSK3(3 Cell 9336 Rabbit 1:1000 46
Signaling
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Phospho-HER2 (Tyrl112) Cell 2245 Rabbit 1:1000 185
Signaling
JunB Santa Cruz sc-46X Rabbit 1:1000 45
c-Jun Santa Cruz sc-45X Rabbit 1:1000 39
LMPI (IG6) (Nicholls et Rat 1:100 60
al.,2oo4)
LMPI (S12) (Mann et al., Mouse 2ooJ.11(JP) 63
1985) 1:500
(Western)
LMPI (CAO) cocktail (Nicholls et Rat 1:100 66
al.,2004)
Phospho-MEKl/2 Cell 9121 Rabbit 1:1000 45
(Ser217/221) Signaling
Total MEK1/2 Cell 9122 Rabbit 1:1000 44,42
Signaling
NF-KB p50 SantaCruz sc-U90 Goat 1:1000 50
NF-KB p65 Santa Cruz sc-372 Rabbit 1:1000 65
PCNA Novocastra NCL-PCNA 1:50 (IRC) 36
Phospho-PTEN Cell 9551 Rabbit 1:1000 54
Signaling
p53 Santa Cruz se-1312 Goat 1:1000 53
p16 Santa Cruz se-1207 Rabbit 1:1000 16
B-Raf Santa Cruz sc-9002 Rabbit 1:1000 95
Phospho-c-Raf Cell 9421 Rabbit 1:1000 74
Signaling
c-Raf-l Santa Cruz sc-227 Rabbit 1:1000 74
Rassf 1 Santa Cruz sc-18724 Goat 1:1000 43
Total Rb Santa Cruz se-50 Rabbit 1:1000 110
Phospho-Rb Cell 9307 Rabbit 1:1000 110
Signaling
Phospho-SAPKlJNK Cell 9251 Rabbit 1:1000 54,46
Signaling
Phospho-SEKIIMKK4 Cell 9151 Rabbit 1:1000 46
Signaling
J3 tubulin Santa Cruz sc-9935 Rabbit 1:500 54
TACE Santa Cruz sc-13973 Rabbit 1:1000 74
TGFa. Santa Cruz sc-9043 Rabbit 1:1000 11
Table 2.2: Secondary Antibodies used
Goat anti-rabbit JgG-HRP Santa Cruz se-2030 1:4000
Donkey anti-goat IgG-RRP Santa Cruz se-2020 1:4000
Goat anti-mouse IgG-HRP Santa Cruz sc-2031 1:4000
Goat anti-rat IgG-RRP Santa Cruz sc-2032 1:4000
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2.1.2 Oligonucleotides
Table 2.3: Factor Binding Sites
OLIGONUCLEOTIDE NAME SEQUENCE
AND COMPANY
ETS (Santa Cruz) 5'-GGG CTG CIT GAG GAA GTA TAA GAA
T-3'
NF-KBForward (Sigma Genosys) 5'-G AGC AGT TGA GGG GAC TTT CCC
AGGC-3'
NF-KBReverse (Sigma Genosys) 3' -TCA ACT CCC CTG AAA GGG TCC
GGA TG-5'
SRE Forward (Sigma Genosys) 5' -GAG CGG ATG TCC ATA ITA GGA
CATCT-3'
SRE Reverse (Sigma Genosys) 3'-CCT ACA GGT ATA ATC CTG TAG
AGATG-5'
SRE (Santa Cruz) 5'-GGA TGTCCA TAl TAG GAC ATCT-3'
TRE Forward (Sigma Genosys) 5'-G AGC CGC TTG ATG ACl CAG CCG
GAA-3'
TRE Reverse (Sigma Genosys) 3'-GCG AAC TAC TGA GTC GGC CIT GAT
C-5'
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Table 2.4: PCR oligos
PCR PRIMER PRIMER SEQUENCE
FRAGMENT NAME
Neomycin NeoForward 5'- TGA ATG AAC TGC AGG ACG AGG- 3'
Neo Reverse 5'- AAG GTG AGA TGA CAG GAG ATC- 3'
p16 p16 Forward 5'- GTG ATG ATG ATG GGC AAC GT- 3'
exon 2
p16 Reverse 5'- CTG GGC GAC GTI CCC AGC GG- 3'
TGFu TGFuKOl 5' -GAC TAG CCT GGG CTA CAC GT G- 3'
exon 3
TGFuK02 5' -CCG err CCT CGT GCT rrA CGG T- 3'
TGFuK03 5' - ACA TGC TGG err CTC TIC CTG C- 3'
v-H-ras v-H-ras Forward 5'- GGA TCC GAT GAC AGA ATA CAA GC- 3'
v-H-ras Reverse 5'- ATC GAT CAG GAC AGC ACA CTI GCA- 3'
c-H-Ras c-H-ras Ex2A 5' - CTA AGC CTO ITG TOT TTT GCA GGA C- 3'
c-H-ras Ex2B 5'- GCT AGC CAT AGO TGG CTC ACC GT- 3'
LMPI DSI 5'- ATG GAA CAC GAC err OAG AG- 3'
DS2 5'- TAG GCC ITO CTC TCC TIC TC- 3'
DS3 5'- AGA TGG TGG CAC CAA GTC GC- 3'
DS4 5'- GAA GAA GGC TAG GAA GAA GG- 3'
2.1.3 Cell Lines
All cell lines were developed from carcinomas following topical DMBA/TP A carcinogen
treatment of transgenic positive and negative mice as listed.
101
Table 2.5: Cell lines and their transgenic status
Cell Line Description LMPI Transgenic status
CarB Spindle (NIH mouse carcinoma) -
53.217 Cuboidal -
117.30 Spindle -
105.60 Spindle -
105.113 Spindle -
53.278a Spindle +
53.278b Spindle +
53.279 Cuboidal +
53.234a Cuboidal +
53.191 Cuboidal +
53.220 Cuboidal +
53.226a Cuboidal +
105.92 Cuboidal +
2.1.4 Frequently used solutions
Church buffer (pH7.2) 1%(w/v) BSA
1mMEDTA
500mMNaP04
7%(w/v) SDS
Denaturing Solution 0.6MNaCI
O.4MNaOH
0.5% Dispase 0.5%(w/v) Dispase in PBS
lOx ETS binding buffer 10mM Tris-HCI pH7.5
50mMKCI
5mMMgCl2
1mMEDTA pH8.0
12.5% (v/v) glycerol
0.1% Triton X
1mMDTT
2FC 49.45%(v/v) Chloroform
0.1%(w/v) 8-hydroxyquinoline
1%(v/v) Isoamyl Alcohol
49.45% Buffer Saturated Phenol
4MGT 250g guanidium thiocyanate
293ml dH20
17.6ml 0.75M sodium citrate, pH 7.0
26.4ml 10% sarcosvl
High Salt buffer (EMS A) 20mM Hepes pH7.9
O.4MNaCI
1mM EDT A pH8.0
1mMDTT
1mMPMSF
Vanadate
Aprotinin
Protease inhibitor
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Bufferred Neutral Formalin 50ml of 40%(v/v) Formaldehyde
1.7Sg NaH2P04
3.25g NazHP04
dH20 up to SOOml
lOx Loading dye (DNA or RNA) 50%(v/v) Glycerol
0.1%(v/v) Bromophenol Blue
O.l%(w/v) Xylene Cyanol
in TB pH7.5 (DEPC-treated for RNA)
lOx Loading buffer (RNA) 100~llOx MOPS (O.OOlM)
500~1 pure deionised formamide
178~1 formaldehyde pH4.0
22~1 DEPC-treated H2O
lOx MOPS-E 200mMMOPS
10mMEDTA
50mM NaOAc pH7.0
in dH20 pH7.0 wrap in foil and autoclave
PBS 2.7mMKCI
1.4mM KH2P04
137mMNaCI
4.3mM Na"P04 pHlHCI17.3
Protein Blocking buffer 5%(w/v) milk powder
TBST
Protein Blotting buffer 25mMTris
192mM Glycine
20%(v/v) Methanol (analytical grade)
2x Protein Gel Sample buffer (GSB) 125mM Tris-HCI, pH6.8
20%(v/v) Glycerol
lO%(v/v) Sodium 2-Mercaptoethanol
4%(w/v) SDS
O.OO4%(w/v) Bromophenol Blue
4x Protein Gel Sample buffer (GSB) 200mM Tris-HCI, pH6.8
30%(v/v) Glycerol
S%(w/v) SDS
10%(v/v) Sodium 2-Mercaptoethanol
O.04%(w/v) Bromophenol Blue
Protein MENSA buffer 62.5mM Tris-HCI,pH6.S
2%(w/v) SDS
50mM Sodium 2-Mercaptoethanol
Protein extraction: NET-N buffer l50mMNaCI
5mMEDTA pHS.O
50mM Tris-HCI pHS.8
0.05%(v/v) NP40
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Protein extraction: Ripa buffer ISOmMNaCI
5mM EDT A pHB.O
20mM Tris-HCI pH7.5
O.S%(w/v) Deoxycholic Acid
l.S%(v/v) NP40
0.1% SDS
BM Urea buffer 8M urea
5% (v/v) Sodium 2-Mercaptoethanol
2SmM Tris, pH9.5
Protein SDS-PAGE Running buffer 50mMTris
3BOmM Glycine
O.I%(w/v) SDS
lOx Santa Cruz binding buffer 100mM Tris pH7.S
500mMNaCl
10mMDTI
lOmM EDT A pHB.O
SO%(vfv) glycerol
Southern Stripping Solution A O.lx SSC
0.5% SDS
Southern Stripping Solution B O.Ix SSC
0.1% SDS
Southern Washing Solution A 2xSSC
0.1% SDS
Southern Washing Solution B O.Ix SSC
0.1% SDS
Solution D 0.36ml Sodium 2-Mercaptoethanol
50ml4MGT
2x Sp 1 binding buffer 30mM Hepes pH7.5
BmMMgC12
1.2mMEDTA
20% (v/v) glycerol
dH,O
2/3x SRE binding buffer lOmM Hepes pH7.9
2mMEDTA pHB.O
1M NaCI
Irng/ml BSA
10%(v/v) glycerol
20x SSC 150mMNaCI
150mM Tri-Sodium Citrate
STE buffer ImMEDTA
lOmMNaCI
lOmM Tris-HCI pH7.S
TAE (SOx stock solution, I litre) 5.71 % (v/v) Glacial Acetic Acid
100mMEDTA
2000mM Tris-HCI pHB.S
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Tail Solution lOOmM EDT A pH8.0
150mMNaCI
l%(w/v) SDS
10mMTris-HCI pH7.5
TBE(lOx stock solution, llitre) 890mM boric acid
4% (V/V) 0.5M EDTA pH8.0
890mMTris
TBS 140mMNaCI
20mMTris
TBST 140mMNaCI
20mMTris
O.l%(v/v) Tween-20
TE ImM EDT A pH8.0
lOmM Tris-HCI pH8.0
Trypsin Solution 25%(v/v) Trypsin
0.02%(v/v) Versene
Versene 0.54mMEDTA
2.7mMKCI
1.4mM KH2P04
137mMNaCI
4.3mM Na2PO,t pH/HCV7.3
2.1.5 Frequently used growth media
Agar Plates 250m} dH20
109 Tryptone Oxoid L42
5g Yeast Extract (Oxoid)
109 NaCI
make up to lL with dlf.O pH7.54 (NaOH)
Luria-Bertani (LB) 1% (w/v) Bacto-tryptone
0.5% (w/v) Bacto-yeast extract
1% (w/v) NaCI
Complete Tissue Culture Medium DMEMmedium
5-20% (v/v) FCS
2% (v/v) L-glutamine (200mM stock)
2% (v/v) Penic ill i n/Streptomyci n
(lOOOOU/mL stock)
Freezing Medium Per ml of medium added
9201-11FCS
80~DMSO
2.2 Methods
2.2.1 Animal procedures
All mouse procedures were conducted in accordance with the Home Office regulations and as
detailed in the covering project licence. Unless otherwise stated, the procedures were
conducted by me, or the animal technicians (where indicated) as covered by my Horne Office
105
personal licence. Where the use of brief anaesthesia was required, a halothane/oxygen
mixture was used in an anaesthesia chamber.
A) Breeding and record keeping of transgenic mice
All food, water and bedding requirements were handled by the animal technicians. Litters
were monitored by the animal technicians and all animals were regularly health checked.
Usually, at three weeks of age the mice were weaned and males and females separated. The
mice were given consecutive numbers for each line. The mice were anaesthetised using
halothane/oxygen before being numbered by ear punching. A small tail biopsy was taken (a
tail tip of O.Scm)and the mouse tail was causterised with a hot iron to prevent bleeding and
sterilize the wound. The tail tip was used to extract DNA and analyse the transgenic status of
the animal by Southern blotting or peR. In mice of several transgenic lines that developed a
serious ear phenotype the animals were not ear punched. Instead, the scruff of the neck was
shaved, the animal anaesthetized and a michochip was injected subcutaneously. The
microchip had a unique six-digit identification number that could be read with an appropriate
reader (microchips obtained from MID-FingerPrint Ltd cat. no: IDIOOtransponders).
B) Animal health
Animal health was monitored in accordance with procedures described in the Home Office
project licence. All animals were monitored regularly for signs of ill health and discomfort.
Animals which were subject to the development of lymphomas, hind paralysis and excessive
papilloma growth and conversion to carcinomas were monitored at least once a week. Any
animal suffering or deviating from the health status outlined in the UK guidelines for the use
of experimental animals was euthanised without delay.
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C) Mouse lines
Line Number Transgene Expression References
53 PyLMP1B9S-8 LMP1 expressed in the (Wilson et al., 1990)
epithelium
113 Neomycin cassette p16INK4a not expressed (Serrano et al., 1996)
has replaced exons 2 p19ARF truncated
and 3 of INK4a mRNA
locus
117 L2LMPlcAO LMPI CAO expressed in Stevenson et al., (in
the epithelium and press)
some lymphoid tissues
1205 HK1-H-ras H-ras expressed in the (Wang et al., 2000)
basal layer of the
epidermis
125 Neomycin cassette No TOFu expression (Mann et al., 1993)
replaced exon 3 of
TOFu gene
Table 2.6: Mouse lines used
Offspring from cross breeds are indicated ego as 117/113 indicating that line 117 has been
crossed to line 113.
D) Sample collection from mice
Animals were euthanased by a schedule 1method according to Horne Office guidelines.
DJ Dispase epidermis separation
Mouse pups 3-7 days old were euthanased, and immediately placed in a 7ml sterile plastic
Bijoux and stored on ice. The limbs and tail were amputated and stored for subsequent DNA
extraction and identification of transgene status. The body was rinsed in 70% ethanol and
dried with a tissue. The skin was removed in a single sheet by a ventrical longitudinal
excision. If total skin was needed, then it was snap frozen in liquid nitrogen. For epidermal
separation, the skin sample was floated dermis side down on a 0.5% dispase solution in a 5cm
petri dish (if samples were to be used for RNA extraction, ribonucleoside vanadyl complexes
(RVe) Sigma cat no: R3380, was added to the 0.5% dispase solution. RVe inhibits RNase A
activity but not DNase I). The sample was incubated at 4·e overnight. The skin was then
placed on a dry sterile petri dish epidermis side down, so that the epidermis could adhere to
the plastic. The thicker dermis was then removed from the epidermis with forceps leaving the
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thin, translucent epidermis on the plate. The separate epidermal and dermal samples were
placed in screw cap Nunc tubes and snap frozen in liquid nitrogen and stored indefinitely at
-70·C (Macdiarmid and Wilson, 2001).
0.11Removal of papillomas and carcinomas
The fur of the euthanased animal was wetted in 70% ethanol. Using surgical tweezers and
scissors the area around the lesion was cleared of fur and the lesion was excised removing any
excess skin. Part of the lesion was placed in 10% buffered neutral formalin fixative and the
remainder was placed immediately in a screw cap Nunc tube and snap frozen in liquid
nitrogen and stored at -70·C. A sample of tail tissue was also taken from each animal for
confirmation of transgene status if needed.
0.111Removal of internal tissues
Following incision of the abdomen, any peripheral lymph nodes were collected and the layer
of skin was pulled back and internal organs were revealed. The organ of interest was then
excised and if necessary washed in 1xPBS and snap frozen in liquid nitrogen and stored at
-70·C or fixed in 10%neutral buffered formalin for subsequent pathological analysis.
E) Chemical Carcinogen Treatment of mice
Mice that were treated with chemical carcinogens were dorsally shaved the day before
application of the agent. TPA was kept as a 40x stock (l.25mg/ml) dissolved in acetone at
-20°C. The working solution was Ix (31.25Ilg/ml) and was made by dissolving the 40x
solution in appropriate amounts of acetone. The Ix solution was also kept at -20°C in a glass
universal wrapped in aluminium foil. 200111of Ix TPA solution was applied to the shaved
back of each mouse. The procedure was performed in a ventilated sink, wearing all the
appropriate protective clothing and double gloves. The mice were left in their cage in the
ventilated sink for 45 min. after treatment so that the acetone would evaporate and were then
caged in a dedicated room for chemically treated animals in filter top cages. TPA application
was performed according to a minimal regime of twice a week for four weeks. The mice were
observed once every week and appearance and size of any papillomas or carcinomas was
recorded.
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F) Papilloma monitoring of mice
Lines 117, 117/113 and 117/113/1205 developed acanthomas or papillomas spontaneously in
the FVB strain. The lesion number and size was monitored usually by touch once every two
weeks. Lesions were observed from the start of the study until the animal was removed from
the study. A lesion was classified as papilloma if it was raised above the surface of the skin
(although several were later characterized as acanthomas). Visually papillomas look like
cauliflower-type warts. Carcinomas were classified by eye, since they have a smoother, firmer
appearance than papillomas and do not "wobble". Subsequently, lesions were examined by
histopathological analysis. Lesions were categorized subjectively by size according to the
following specifications:
Category Approximate Lesions Diameter
Size! <O.2cm
Size 2 O.2cm-O.5cm
Size 3 O.Scm-!.Ocm
Size 4 >1.0cm
Table 2.7: Lesion sizes
Mice were taken off the study and euthanased according to the project license, when their
lesion load reached a maximum, or when a single papilloma or carcinoma had reached a
diameter of 1cm, or had become ulcerated or when a lesion occurred at an orifice or a site of
irritation. Mice were also removed from the study if they were generally unhealthy.
G) Ear Monitoring of mice
The ear phenotype of line 117/125 was monitored once a week. The mice were visually
observed and their ear phenotype was compared to a chart containing the different stages of
ear phenotype as observed in line 117 (fig.1.14). The study was performed blind without
knowledge of the genotype of the animal.
2.2.2 Bacterial cell culture techniques
A) Bacterial cell culture
All plasmid propagation was performed in the E.coli strain DHS. Plasmids containing E.coli
clones were stored as viable glycerol stocks at -70·C. E.coli was cultured by taking about 1ml
of the relevant glycerol stock and adding it to 2.5ml of LB medium, supplemented with
50mg/ml ampicillin. The culture was incubated overnight at 3TC, with constant shaking. If a
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single sub-clone was required, the culture was then streaked onto an agar plate containing
50mg/ml ampicillin, and incubated overnight at 3TC. A single colony was then picked with a
sterile toothpick and used for subsequent propagation.
8) Transformation
DH5 competent cells as prepared by the laboratory technician were used. 200ml of competent
cells were thawed on ice for 10 min. IOOngplasmid DNA was added and the cells were
incubated on ice for 15min. They were heat shocked for 90 sec. at 42°C and left on ice for 1-
2 min. Warm (37°C) LB (500ml) with no antibiotics was added and the cells were incubated
at 37°C with gentle shaking for 20 minutes. This step allows for recovery of the bacteria and
plasmid gene expression. The cells were centrifuged at 9,000 xg for 1 min. and most of the
medium was removed. 10ml was plated on one agar plate and the remainder (about 90J.ll)on
another, which were incubated overnight at 37°C. The following day, distinct colonies from
each plate were picked and inoculated in 10ml of L-broth containing IOml ampicillin
overnight at 37°C with gentle shaking.
2.2.3 DNA techniques
A) Small scale extraction of plasmid DNA
The Sigma Plasmid Miniprep DNA purification kit was used for small scale plasmid DNA
isolation according to the manufacturer's protocol. It is based on a modified alkaline-SDS
lysis procedure (Birnboim and Doly, 1979) followed by adsorption of the DNA on silica in the
presence of high salts.
A colony of the desired plasmid containing bacteria was picked and inoculated overnight in
5ml of selective LB with vigorous shaking. The bacteria were then harvested in a pellet by
centrifugation at 12,000 xg for Imin. and resuspended in 200J.lIof resuspension buffer. After
that 200J.lIof lysis buffer, containing SDS-NaOH was added. The SDS solubilises the cell
membrane thus leading to lysis of the bacterial cell and release of the cell contents. The
NaOH denatures chromosomal and plasmid DNA. The mixture is neutralized by addition of
350J.lIof the neutralization solution containing acidic potassium acetate causing the covalently
closed plasmid to reanneal and remain in solution whilst the high salt concentration leads to
SDS, chromosomal and bacterial protein-salt complexes that precipitate and are removed by
centrifugation at 12,000 xg for 10min. The plasmid DNA is allowed to bind onto the silica
matrix of the column whilst debris is washed away by addition of 750J.lIof wash solution and
elution takes place in 100J.lIof water or Tris-EDTA buffer.
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B) Large scale extraction of plasmid DNA
The Quiagen Plasmid Maxiprep DNA purification kit was used for large scale plasmid DNA
isolation as per manufacturer's protocol. It is based on a modified alkaline-SDS lysis
procedure followed by adsorption of DNA on an anion-exchange resin under low salt and
appropriate pH conditions (Birnboim and Doly, 1979). The same principles apply as in
section 2.2.3A. As before, a colony with the plasmid containing bacteria was picked and
inoculated in Sml of selective LB. The 5ml culture was subsequently added to 200ml of
selective LB and inoculated overnight. The bacteria were harvested into a cell pellet in a
250ml Nalgene tube by centrifugation at 6,000 xg for 15min. at 4°C (in a Beckman JA-14
rotor). After centrifugation, the plasmid DNA was resuspended in 20ml of buffer PI (SOmM
Tris-HCI, pH 8.0, 10mM EDTA, 1001lg/mlRNase A) and lysed in 20ml of buffer P2 (200mM
NAOH, I%SDS (w/v» by inverting the Nalgene tube 4-6 times. The lysate was neutralized
by addition of 20ml of chilled buffer P3 (3.0M potassium acetate, pH S.5) and chilled on ice
for 20min. A fluffy, white precipitate consisting of genomic DNA, proteins, cell debris and
SDS was formed. The lysate was centrifuged at 20,000 xg for 30min. at 4°C and was then
passed through a column that had been equilibrated with buffer QBT (750 mM NaCl, SOmM
MOPS, pH 7.0, IS% isopropanol (v/v), O.IS% Triton-X (v/v». The lysate was allowed to
bind the Quiagen Resin whereas debris, cellular proteins and degraded RNA flowed through.
The column was washed twice with 30ml of buffer QC (I.OM NaCI, 50mM MOPS, pH7.0,
IS% isopropanol (v/v». 30ml of the high salt buffer QF (I.2SM NaCl, SOmMTris-HCI, pH
8.S, 15% isopropanol (v/vj), was used to elute the plasmid DNA from the column and the
plasmid was desalted by isopropanol precipitation (0.7 volumes ie 21ml). The DNA pellet
was washed with 10ml of 70% ethanol and dried by centrifugation at IS,OOOxg for 10min.
The DNA was air dried and resuspended in a suitable volume (usually 100JlI) of water, TE
pH, 8.0 or 10mM Tris-HCI, pH 8.S. The columns used contain positively charged
diethylaminoethanol (DEAE) groups that interact with the negatively charged phosphate
backbone of the DNA. Elution of plasmid DNA takes place in high salt buffers during which
the cations of the column are occupied by anions provided by the high salt buffer.
C) Purification of plasmid DNA by caesium chloride (CsCI) gradient
Plasmid DNA was added to a solution of CsCI and ethidium bromide (EtBr)(2.Iml plasmid
DNA, 270ml of ISmg/ml EtBr, Sg CsCI, 3ml TE buffer) and centrifuged for 20 hrs at 49K in a
Ti70 rotor. The EtBr forms a complex with protein that shows up as a red precipitate at the
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top of the tube. Supercoiled plasmid DNA forms a band in the middle of the tube, where its
density equals that of the CsCI gradient. Chromosomal DNA forms a band above the
supercoiled DNA band. The supercoiled DNA was extracted with a syringe, and if required
added to a second CsCI gradient, and further centrifuged for 20hrs. A clearer band was visible
in the middle of the tube which was extracted with a syringe. The EtBr was removed by
adding TElbutan-I-ol saturated. EtBr goes in the organic phase and can be removed. The
aqueous phase was repeatedly extracted in this way until there was no red colour indicating
that all the EtBr had been removed. The DNA was precipitated by adding 2 volumes of 100%
EtOH at room temperature.
D) Extraction of genomic DNA
Phase Lock Gel™ tubes (supplier VWR cat. no: 427353P) were used to extract protein from
mouse tissue, tail segments and cell pellets. Phase Lock Gel™ tubes contain a quantity of
Phase Lock GeJTMthat effectively separates organic phenol and interphase from the aqueous
layer. This is due to the density of the Phase Lock Gel™ which is higher than the aqueous
layer and lower than the organic layer. The tissue samples were digested by adding 700ml of
tail solution (2.1.4) and 35ml of Proteinase K (lOmg/ml), and shaking overnight at 55°C in an
Eppendorf thermomixer. The Phase Lock Gel™ tubes were briefly centrifuged and the
digested sample was added to them. The proteins were extracted by adding 750 ml of 2FC,
shaking the samples vigorously about 20 times and then centrifuging for 15min. at 18,000 xg
in a Beckman microcentrifuge. Phenol is used to extract proteins and chloroform to stabilise
the boundary between aqueous and organic layer. Phenol is trapped under the gel of the Phase
Lock Gel™ tubes and the aqueous solution was then transferred to a new Phase Lock GeITM
tube that had been briefly centrifuged and 750 ml of chloroform: isoamyl alcohol solution was
added, shaking the samples vigorously for about 20 times and then centrifuging for 15min. at
18,000 xg. Isoamyl alcohol aids the separation of the organic and aqueous layers. Chloroform
was trapped under the gel of the Phase Lock Gel™ tubes and the aqueous solution was
transferred to microfuge tubes and 100ml of 10M NH40Ac and 750ml of ice cold 100%
ethanol was added, shaking vigorously and centrifuging for 2 min. at 9,000 xg. A white
precipitate was visible. The ethanol was carefully decanted and 1ml of ice cold 70% ethanol
was added, shaken vigorously and the DNA was pelleted by centrifugation at 9,000 xg for 2
min. The supernatant was removed, the samples were left to air dry for 15 min. and
resuspended in 215ml ofTE pH8.0. The samples were then heated at 65°C for 30 min. with
gentle agitation and stored at 4°C indefinitely. Ethanol precipitation is used as a purification
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step for the DNA and to remove any residual phenol and chloroform. Washing the precipitate
with 70% ethanol removes any excess salts from the precipitation step.
E) Quantification of DNA
The concentration of DNA in a sample was obtained by measuring the optical density (Ofr) of
a dilution of the sample at 260nm. IOml of sample was added to 290ml of TE buffer,
thoroughly resuspended and transferred to a quartz cuvette measured in a spectrophotometer.
The concentration of the sample was calculated using the formula:
DNA concentration = OD26ox 50 x dilution factor (=30) x lIlight path (=0.5)
Genomic DNA samples were then adjusted to 0.33Jlg/ml and stored at 4°C. Plasmid DNA
samples were adjusted to 1Jlg/Jll (or appropriate concentration) and stored at -20°C.
F) Restriction Digestion of Genomic DNA for Southern blotting
5Jlg of genomic DNA was restriction digested in a total volume of 40ml. For the various
transgenic lines the enzymes listed in table 2.8 were used for the digest. A typical reaction
mixture consisted of 15JlIof DNA, 4Jll of IOxbuffer, 2-4Jll of restriction enzyme and 19m1of
dH20. The samples were mixed by brief centrifugation and incubated overnight at 3TC.
Next morning, the reaction was stopped by heating at 65°C for 5 minutes and 10% (v/v) of lOx
Loading Buffer was loaded to each sample.
G) Agarose Gel Electrophoresis of DNA
The restricted digested DNA samples were electrophoresed through an agarose gel in order to
separate the fragments by size. For high molecular weight genomic DNA 0.8% agarose gels
were used. To separate smaller fragments, for example PCR samples and plasmid DNA,
higher percentage of agarose gels, up to 3% (Nusieve gels), were used. 5JlI of 10mg/mi
EtBr/iOOml was added to the gel before it was poured to visualize the DNA. The gel was
placed in a horizontal electrophoresis tank and IxTAE was poured to cover it. DNA samples
that were prepared by adding IO%(v/v) lOx DNA loading buffer, were loaded into the slots
alongside Img of lkb DNA ladder as size control. The gel was run at 120V (0.8A) for 3.5 hrs
or 50V (0.3A) overnight (for genomic DNA) and at 100V (0.6A) for 1 hr (for low molecular
weight DNA). DNA was visualized on a short wave UV transilluminator and a photograph
was taken. The long wave UV transilluminator was used for visualising plasmid fragments
that would be collected and used for probe production.
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H) Southern blotting of DNA
The agarose gel was trimmed to remove the 1kb DNA ladder, the loading wells and any
excess gel. The gel was then soaked in denaturing solution for 30 min. on a shaking platform
to denature the dsDNA. The gel was then washed 2 x 15min. in a 1x TAE buffer. The DNA
was then transferred onto a Biodyne B membrane by electroblotting for 3 hrs at I.SA, (34V) in
O.SxTAE in a Hoeffer electroblotting tank. The DNA was then baked for 2 hrs at 80·C and
then cross linked onto the membrane using a Stratalinker. The blot was stored at room
temperature.
I) Generation of specific probe fragments
The DNA fragments used for generating probes for Southern blotting were derived from
recombinant plasmid vectors propagated in E.coli. To generate a probe fragment, the relevant
plasmid (see table 2.8) was propagated in E.coli ,a large scale plasmid prep was performed to
extract the plasmid DNA and then the plasmid DNA was restriction digested to isolate the
relevant fragment. The digested DNA was electrophoresed at 80V on a 1% low-gelling
temperature agarose (LGT-agarose) gel in lx TAE with Sml of IOmg/ml EtBr/lOOml. The gel
was run until the relevant fragment was well separated from other fragments and visualised on
a long wave transilluminator to prevent degradation of the DNA. The DNA quantity was
estimated by comparing the intensity of the band with that of a known standard. The fragment
was cut out, placed in a microfuge tube and melted at 70·C. The volume was estimated and
concentration was adjusted to Sng/ml with TE buffer and stored at -20·C.
Line Probe Plasmid# Genomic Plasmid Fragments Probe
DNA Digests Digests Generated Fragment
53 LMPI 139 BglII Bamffi+EcoRI 3.8kb 3.8kb
2.8kb
113 p16 454 Bam HI XhoI lkb lkb
3kb
1205 Ras 233 XbaI Sacl 3.Skb 2.4kb
2.4kb
2.Skb
1.6kb. .Table 2.8: Genomtc Digests and Probe Fragments
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J) 32p radioactive Labelling of probe fragment and hybridisation
The probe fragment generated was radioactive labelled with a32PdCTP using the Stratagene
Prime It II Random Primer Labelling Kit (cat. no: 300385).
The probe fragments were used as the template for Klenow polymerase with random
hexanucleotide primers and dATP, dGTP, dTTP and the a32PdCTP. The reaction was
incubated for at least 30 min. at 3TC, after which the reaction reaches a plateau and no more
new DNA strands are generated. The DNA probe was purified to remove any unincorporated
nucIeotides by passing it through a NucTrap®Probe purification column, (Stratagene cat. no:
400701). Unincorporated small nucleotides are trapped in the column resin whereas the probe
passes through the column with STE buffer (2.1.4) and is collected. lul of purified probe was
used to count the specific activity of the labelled DNA and the specific activity was calculated.
The probe was used for hybridisation only if the specific activity was greater than 5x108 cpm.
The blot was prehybridised by placing it in a hybridisation tube and adding 10mi of Church
buffer. The Bovine Serum Albumin (BSA) in Church buffer coats the membrane thus
inhibiting non specific binding of the probe. The tube was rotated in a hybridisation oven for
at least 2 hrs at 65°C. The purified probe was denatured at 95°C for 5 min. and was then
added to the hybridisation tube with the blot. The tube was rotated overnight in a
hybridisation oven at 68°C. The single stranded radioactively labelled probe will hybridise to
complementary DNA fragments on the blot.
K) Washing of Southern blots
After hybridisation the blot was washed to remove any probe that did not specifically bind to
the DNA and any non specific DNA that bound at low melting temperature. The blot was first
washed 4 x 10 min. at room temperature on a shaking platform in solution A. The blot was
then washed 2 x 30 min. in solution B at 68°C in a shaking water bath. The blot was then
wrapped in a polythene bag, placed in an autoradiography cassette with an intensifying screen
and exposed to Kodak XAR film at -70°C for the appropriate time and the film was developed
in a Kodak X-Omat developer.
L) Stripping of Southern blots
Southern blots were stripped of hybridised probe in order to re-hybridise with a different
probe. The blot was washed 2x 15 min. at 900 in southern stripping solution A (2.1.4). The
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blot was then washed lx30 min. in southern stripping solution B (2.1.4) at 65°e. The blot was
either prehybridised directly for reprobing or stored in a sealed bag at -200e until further use.
M) Amplification of DNA fragments using peR
peR was used to amplify short DNA fragments. peR 1.1x Reddy mix'" peR Master Mix
(Abgene cat. no: AB0575) was used as the master mix in all the peR reactions in order to
increase reliability and uniformity of the reactions. Reddy mix gives a final reaction
composition of 1.5mM Mgeh, 0.2mM of each of the 4 deoxynucleotide triphosphates
(dNTPs), 1.25 units of thermostable Taq DNA polymerase, 0.01% (v/v) Tween 20, 75mM
Tris-H'Cl pH8.8 and 20mM ammonium sulphate. Each reaction was set up with 45ml 1.1x
Reddy mix'" peR Master Mix, the two primers, DNA and water to a total volume of 50mI.
DNA and primer concentration for each amplified fragment is shown in tables 2.9 and 2.10.
The reactions were placed in a PTe200 thermocycler for 35 cycles of amplification. The first
step in any peR reaction is to denature the template strand and this is done at 95°e for 15sec.
to 2 min. The next step is annealing the primers to the two single stranded templates and this
is conducted at a reduced temperature of 40-60' (depending on the melting temperature of the
oligos) for 60sec. This step allows annealing of the oligos to the template. Polymerisation of
the new strand is conducted at an increased temperature of 72° for as long as needed to create
the size required (roughly 30 sec per 500bp). A final 72°e step is often included to allow
polymerisation reaction completion.
Each peR reaction was optimised depending on the length of the fragment that needed to be
amplified. 10 or 20 ~l of peR product was electrophoresed through a 1.5% TAE agarose gel
or a 2% NuSieve, 1% agarose TBE gel for very small fragments (eg. <200bp).
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PCRName
Table 2.9: Reverse transcribed (RT)-PCR programs
PCR reaction components PCRProeram
CDNA step RNA- 2J..llDNase treated
Anchored oligo dT-I,.11
dNTPs- 1,.11
RT (or water) - IJ..lI
1. 47°C for Ihr
2. 75°C for 10 min
3. 4°C unlimited
DNase step I. 42°C for 30min
2. 75°C for IOmin
3. O°C unlimited
LMPI
DSI andDS4
RNA -2J.lg
DNase- 5J.lI
DEPC H20- up to 100J.lI total
volume
DNA-300ng(IJ.lI)
dH20- IJ.lI
Forward primer DSI - IJ.lI
Reverse primer DS4 - IJ.lI
1. 94°C for 2min
2. 94°C for 30sec
3. 50°C for 30 sec
4. 72°C for Imin
Go to step 2-3, 4 times
5. 94°C for 30 sec
6. 55°C for 30sec
7. 72°C for 1 min
Go to step 6-7, 29 times
8. 72°C for 5 min
9. 4°C unlimited
LMPI NESTED
DS2 andDS3
I. 94°C for 2min
2. 94°C for 30sec
3. 50°C for 30 sec
4. 72°C for lrnin
Go to step 2-3, 4 times
5. 94°C for 30 sec
6. 55°C for 30sec
7. 72°C for Imin
Go to step 6-7, 29 times
8. 72°C for 5 min
9. 4°C unlimited
DNA-300ng(IJ.lI)
dH20- IJ.lI
Forward primer DS2 - 1J.ll
Reverse primer DS 3 - 1J.lI
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Table 2.10: rca programs
PCR Fragment PCR reaction components PCRProgram
NeomycinJp 16 DNA-300ng (l~l) 91°C 30s
dH20- 1~ 2. 53°C 30s
Forward primer - 1~ (lOpmoles) 3. 72°C 30s
Reverse primer- 1~ (lOpmoles) Go to step 2-3, 35 times
Reddy Mix- 45~1 4. 72°C lOmin
5. 4°C unlimited
TGFa-knock out DNA-300ng(1).1I) 1. 95°C 150s
dH20- 1).11 2. 95°C 50s
TGFaK01- 1).11(10pmoles) 3. 63°C for 50s
TGFaK02- 1).11(lOpmoles) 4. 72°C for 70s
Reddy Mix- 45~ Go to step 2-4 , 34 times
5. 4°C unlimited
TGFa-wild type DNA-300ng(I).11) 1. 95°C 150s
dH20- 1).11 2. 95°C 50s
TGFaK01- 1).11(lOpmoles) 3. 63°C for 50s
TGFaK03- 1).11(lOpmoles) 4. 72°C for 70s
Reddy Mix- 45~ Go to step 2-4 , 34 times
5. 4°C unlimited
v-H-ras (transgene) DNA-300ng (1).11) 1. 95°C for 5min
dH20- 1).11 2. 93°C for lmin
Forward primer- 1).11(25pmoles) 3. 50° for lmin
Reverse primer- 1).11(2Spmoles) 4. 72°C for 2min
Reddy Mix- 45~1 Go to step 2-4, 34 times
5. 72°C for 15 min
6. 4° unlimited
N) Purification of DNA for peR
Genomic DNA samples that were to be genotyped using the neomycinJp16 program were first
purified using the Bio-I 0 1 Geneclean kit as per manufacturer's instructions (Anachem, cat.
no: 1101-400). Briefly, DNA binds to a silica matrix in high concentrations of chaotropic salt
and is eluted in low salt. Removal of the salt and rehydration of the silica matrix breaks the
cation bridges that formed between the silica matrix and the negatively charged phosphate
backbone of the DNA thus allowing the DNA to be eluted. Using this method any impurities
can be removed and the purified DNA can be used in sensitive applications such as PCR.
Empirically, it was found that for these particular PCR reactions Genecleaning of the DNA
was needed for success.
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2.2.4 Protein techniques
A) Protein sample preparation from tissue
For most analyses, protein was extracted in Ripa buffer containing freshly added phosphatase
inhibitors (Sigma cat. no: P5726) and protease inhibitors (Sigma cat. no: P2714). Phosphatase
inhibitor cocktail contains sodium vanadate, sodium molybdate, sodium tartrate and imidazole
that can inhibit acid/alkaline and tyrosine protein phosphatases. The protease inhibitor
cocktail contains AEBSF, E-64, bestatin, leupeptin, aprotinin and sodium EDTA that can
inhibit serine/cysteine/aspartic and metalloproteases. lrnl of Ripa buffer and inhibitors was
added to the tissue sample in a 4ml Falcon tube. The sample was homogenised using a
Kinematica polytron homogeniser. Skin samples are tougher than soft tissues and need to be
homogenised at higher settings usually 8-10 and for longer. Before and after each sample was
processed, the polytron was washed with 1% (v/v) SDS, 3 washes of dH20 and finally 70%
(v/v) ethanol. Once homogenised, the samples were transferred to microfuge tubes, vortexed
and left to stand on ice for 5 min. The samples were then centrifuged at 18,000 xg in a
microfuge for 10 min. at 4·C. The supernatant was removed to new microfuge tubes and 5111
of it was used for protein quantification. Once concentration of the protein was known the
sample was aliquoted in IOOllgaliquots and stored at -70·C. The same process as above was
followed when samples were extracted in 8M urea buffer except that no protease or
phosphatase inhibitors were added and after homogenisation the samples were transferred to
microfuge tubes and heated at 55°C overnight with shaking. The rest of the procedure was the
same as for Ripa extracted samples.
B) Protein sample preparation from cultured mammalian cells
Mammalian adherent cells were grown on 100mm2plates. When confluent, the medium was
removed, the cells washed with ice cold 1x PBS and the cells were scraped off the plate using
a silicon cell scraper. The cells were collected in Ix PBS, washed, pelleted, PBS removed,
frozen in liquid nitrogen and stored at -70°C. 300ml of Ripa buffer with phosphatase and
protease inhibitors was added to the cell pellet and it was vortexed thoroughly until a
homogenate was formed and then left to stand on ice for 5 minutes. Then it was microfuged at
18,000 xg for 10 min. at 4·C. The supernatant was transferred to a new microfuge tube and
5ml of the supernatant was used for protein quantification. Once the sample concentration
was established, it was aliquoted in IOOllgaliquots and stored at -70·C.
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C) Protein Immunoprecipitation (IP)
Sepharose-G beads (Sigma cat. no: P3296 Protein G on Sepharose® 4B fast flow resuspended
in 20% ethanol, 45-165~m) were used for protein IP. The beads were rotated for Ihr at 4°C in
either Ripa buffer or Net-N at 50% (v/v) (50% beads, 50% buffer). The beads were
centrifuged at 18,000 xg for 5min. at 4°C and the supernatant discarded. This wash step was
repeated twice in order to completely remove the ethanol in which the beads were stored. The
beads were then resuspended in equal volume of the appropriate buffer (SO%(v/v» and stored
at 4°C for future use. If not immediate, prior to use, the beads were washed one more time.
Usually 500~g of protein was used for the IP per sample. If the sample was prepared in 8M
urea, the appropriate volume ofNET-N and protease inhibitors was added to dilute the urea to
IM and allow renaturation of proteins. Appropriate amounts of phosphatase inhibitors were
added to each sample and 70~1 of 50%Protein-G sepharose beads were added. The samples
were rotated for 2hrs at 4°C and were then centrifuged at 18,000 xg for lOmin. at 4°C. The
supernatants were transferred to fresh microfuge tubes. To the clarified samples, 30~1
SO%Protein-Gsepharose beads washed in Ripa buffer (or NET-N in the case of urea samples)
were added. The samples were rotated for 2hrs at 4°C and were then centrifuged at 18,000 xg
for 10min. at 4°C. The supernatants were transferred to fresh microfuge tubes and appropriate
amounts of antibody were added (in the case of S12 ascites 2~1 were added, for other
antibodies 200~1 were added). The samples were rotated overnight at 4°C. The next day,
30~1washed SO%Protein-G sepharose beads were added and rotated for 30min. at 4°C. The
samples were centrifuged at 18,000 xg for IOmin. at 4°C and the supernatants were discarded.
The precipitates were washed by vortexing in Iml ofNET-N, pH8.0 and centrifuged at 18,000
xg for 1min at 4°C. The supernatant was discarded and the wash step was repeated with 1ml
of TBS (table 2.1.4). To elute the protein from the beads, 30~1 of 2X GSB was added. The
samples were vortexed and heated for 5min. at 95°C. The samples were centrifuged at 18,000
xg for Imin. at room temperature. The sample supernatant was then either directly loaded
onto an acrylamide gel or frozen at -70°C for future use.
D) Quantification of protein concentration
Protein concentration was determined using the Bradford assay. A set of protein concentration
standard reactions was prepared using BSA as shown on table 2.11. S~l of the sample was
diluted in 795ul of the appropriate lysis buffer. 200~1 of Biorad dye was added, the samples
were vigorously mixed and left to stand for 5 minutes for the colour to develop. Then the
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protein concentration was read at A=595nm. A standard curve was drawn using the values
obtained from reading the set of standard protein concentration samples, and the concentration
of each test sample was determined.
BSA )lg BSA 100)lg/ml Lysis Buffer
added ()II) ()II)
16 160 635
8 80 715
4 40 755
2 20 775
1 10 785
0 0 795
Table 2.11: Standard Protein Curve Reactions
E) SOS Polyacrylamide Gel Electrophoresis of protein samples
Polyacrylamide gels were made up as shown on table 2.12. First the running gel was poured,
overlaid with saturated butan-l-ol and allowed to set. Then, the butan-I-ol was discarded,
washed off with dH20 and the stacking gel was poured and then the combs were placed. The
gels were 2mm thick and were made up of about 25ml running gel and 5ml stacking gel.
Reagents 5% Stack Gel 7.5% Running 10% Running 15% Running
Gel Gel Gel
Bis-Acrylamlde 2.4ml 9.4ml 12.5ml 18.75ml
Tris pH 6.8 2.5ml -------- ------- --------
Tris pH 8.8 -------- 12.5ml 12.5ml 12.5ml
10% SDS 0.2ml 0.5ml 0.5ml 0.5ml
H2O 14.8ml 27.35ml 24.25ml 18ml
TEMED 0.05ml 0.05ml 0.05ml 0.05ml
10% APS 0.500ml 0.250ml 0.250ml 0.250ml. .Table 2.12: The composltlon of running and stack gels for Western blotting
F) Western blotting of protein gel
Usually, 100mg of total protein extract was used per track. An equal volume of2xGSB or 115
of the final volume of the sample of 5xGSB was added to each extract. The samples were
heated for 5 mins at 95°C and placed on ice until loaded. 10ml of markers (Gibco BRL
BenchMarkTM pre-stained protein ladder cat.no: 10748-010, New England Biolabs Prestained
Protein Marker cat. no: P7708G) were loaded along with the samples and separated by
variable percentage SDS PAGE with 5% stacking gel at 200V for 3 V until the dye front
reached the bottom of the gel. The Immobilon-P membrane (Millipore cat.no: IPVH 00010)
was pre-wet in methanol for 15seconds, dH20 for 2 min. and transfer buffer for at least 5min.
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Following transfer, non-specific sites on the membrane were blocked in blocking buffer
containing TBST and 5% non-fat dried milk overnight at 4°C with gentle agitation. The
membrane was then incubated overnight with primary antibody (see table 2.1.1) at the
indicated dilution in blocking buffer at 4°C, usually overnight and then washed lx15min. and
3x5min. in TBST buffer. The secondary antibody (that is HRP conjugated - see table2.1.1)
was added, diluted in blocking buffer, for lhr at room temperature. The membrane was then
washed as for the primary antibody.
To visualise antibody binding, 8ml of Solution A (containing ECL + substrate in Tris buffer)
and 250ml of solution B (acridan solution in dioxane and ethanol) of the ECL+ System kit
(Amersham, cat.no: RPN 2132) were mixed and added to the membrane. This reaction
converts acridan with the use of peroxide and horseradish peroxidase in slightly alkaline
conditions, to acridinium esters that produce a high intensity chemiluminescence that can be
detected on a photographic film. The solution was left on for 5mins at room temperature. The
membrane was then drained of excess solution and was placed in a plastic bag and sealed.
The membrane was exposed to X-AR photographic film in cassette for the required time and
the film developed in an X-Omat developer. Densitometric analysis of the scanned autorads
was performed using the program Kodak ID 3.5.2 USB as described in the relevant chapters.
Note that once the film has been exposed, it cannot get any blacker so many of the high
intensities that were observed in certain autorads have been underestimated when calculating
the fold difference. Also since the densitometric analysis was performed on a computer image
and not the actual autorad the values obtained are not entirely accurate.
G) Stripping and reprobing of western blots
The membrane was incubated at 55°C with 20ml pre-heated MENSA buffer for 30mins. The
membrane was rinsed with SDS wash buffer to remove the excess stripping buffer, and it was
then washed 2x20mins with TBST at room temperature. The membrane was then blocked and
reprobed as described above. Membranes were stored in plastic wrap at 4°C.
H) Electrophoretic Mobility Shift Assay (EMSA)
H.I Protein sample preparation from tissues
Protein was extracted in high salt buffer containing fresh phosphatase and protease inhibitors.
O.5ml of the high salt buffer plus inhibitors was added to the frozen tissue sample in a 4ml
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Falcon tube. The sample was homogenised in a Kinematica polytron homogeniser. Before
and after each sample was processed the polytron was washed with 1% (v/v) SDS, 3 washes of
dH20 and finally 70% (v/v) ethanol. Once homogenised the samples were transferred to
microfuge tubes, vortexed and let to stand on ice for 5 min. The samples were then
centrifuged at 14,000 xg in a microfuge for 10 min. at 4·C. The supernatant was removed to
fresh microfuge tubes and 5J.lIof it was used for protein quantification. Once concentration of
the protein was known the sample was aliquoted in 10J.lgaliquots and stored at -70·C.
HJI Labeling Oligonucleotide and probe purification
For annealing single stranded sticky ended oligos to create the double stranded oligo, 2ml
(200pmoles) each of forward and reverse oligos, 10J.lISM NaCI (2S0mM) and 186J.lITE were
added and heated at 80°C for 10min. They were allowed to cool down at room temperature,
aliquoted 10J.lIper tube and frozen at -20°C. Two different labelling reactions were performed
for probe preparation depending on whether the double stranded oligos were blunt or sticky
ended. Blunt ended oligos were kinase labelled, SOng of oligos were mixed with 2J..LIof lOx
T4 Polynucleotide kinase (PNK) buffer and dH20 up to 20J.l1.20mCi ofy 32pdATP and IJ.lIof
T4 PNK was added to the reaction. The reaction was incubated at 37°C for 45min. To prepare
the probe using the annealed sticky ended oligos, Ipmol annealed oligo (l ul) was mixed with
33J.ll dH20, 10J.lldCTP buffer, 50J.lCi a32pdCTP and IIII Klenow and incubated at 37°C for
30min. For both types of oligo the same procedure was followed for probe purification. A
NICKTM Column (Amersham, cat. no: 17-0855-01) was equilibrated with 3ml TE that was
allowed to run through the column but without allowing the matrix to dry. The labelled probe
was added to the column. 400lli TE was added and allowed to run through the column. A
further 400J.lI TE was added and this time the eluent was collected in a microfuge tube. The
purified probe was stored in a lead container at -20°C. NICKTM columns are packed with
Sephadex® 0-50 and are used for the separation of oligonucleotides from unincorporated
nucleotides.
H.l1I Polyacrylamide Gel preparation for EMSAs
A 6% non-denaturing polyacrylamide gel was used for electrophoresing EMSA samples.
7.5ml of 40%(v/v) acrylamide was mixed with 2.5ml10xTBE, 39.625ml dH20, 350ml (v/v)
10%APS and 25ml TEMED. The gel was 2mm thick and its volume was 30ml. The gel was
polymerised for an hour and then pre-run with 0.5xTBE buffer at 200V for 30minutes to warm
the gel.
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H.lV Sample Preparation for EMSAs
dH20 was added to each sample to bring them all to the same volume of 10111.Then for each
sample 20111of the appropriate binding buffer was added along with 2111 of polydLdC
(2mg/reaction) or 0.2111 salmon sperm (Zug/reaction) according to the protocols used.
Competitor (unlabelled oligo) was added to one aliquot of each test sample (usually between
50 to 200x in excess of hot oligo was needed for successful competition) and the samples were
left to incubate on ice for lOmin. The probe (0.2-lng) was added and the samples were left to
incubate on ice for a further 30min. (For the SRE oligo, samples were incubated on ice
15min., and a further 15min. at room temperature.) The samples were loaded on the gel that
had been pre-run (H.IIl). 10111of dye was loaded in the first well to visualise a dye front
during running. The samples were run at 150V for about 2hrs until the dye was about 5cm
from the bottom of the gel. The buffer was discarded in the "radioactive sink" and the plates
were separated. Using double thickness 3MM paper, the gel was carefully lifted, wrapped in
saran wrap and dried for 2 hrs at 80°C. The dried gel was exposed to X-AR Kodak film for
the required time and developed in an X-Omat developer.
2.2.5 RNA techniques
RNA extraction
To avoid RNA degradation all solutions were made up using diethyl-polycarbonate (DEPC)-
treated and autoclaved water. DEPC inactivates ribonucleases by covalent modifications.
Microfuge tubes and tips were autoclaved. All surfaces and equipment to be used were
washed with 1% (w/v) SDS and then 75% (v/v) ethanol made with DEPC-treated water.
Gloves were worn and frequently changed to avoid contamination with RNAses.
A) Total RNA Extraction
Two methods were used by me for extracting RNA; the Chomczynski and Sacchi method and
the Tri-Reagent ™method. For the first method, the sample was vortexed or homogenised
using a polytron as appropriate in 1.5 ml of solution D (0.36ml 2ME, SOml4M GT). The
sample was kept on ice and 0.1 volume (150111) of 2M NaOAc, pH4.0 in acetic acid, was
added and thoroughly mixed. Then 1 volume (I.Sml) of H20 saturated pure grade phenol was
added and thoroughly mixed. Finally, 0.2 volumes (300111) of chloroform:isoamyl alcohol
(49: 1) were added and thoroughly mixed. The sample was microfuged at 10,000 xg for
20min. at 4°C and the acqeous phase was transferred to fresh tubes. 1 volume of isopropanol
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(1.5mL) was added and kept at 4°C overnight. The sample was microfuged at 10,000 xg for
20min at 4°C and the supernatant was discarded. The wet pellet was resuspended in 300J.lIof
solution D and vortexed. 600J.ll of 100% ethanol was added and the solution was kept at
-20°C for 2hrs or overnight if needed. The sample was microfuged at 10,000 xg and the pellet
washed twice in 1ml of 75% ethanol. The pellet was allowed to air dry and was resuspended
in 220J.ll of 0.5%TE, 1% SDS or dH20. The sample was heated at 65°C for 10min. with
vortexing. The RNA was stored at -70°C for subsequent use (Chomczynski and Sacchi,
1987).
The second method used to extract RNA was using the Tri-Reagent ™ (Sigma cat. no: T-
9424). This is a kit form modification of the Chomczynski and Sacchi method. Use of Tri-
Reagent ™which is a phenol and guanidine thiocyanate solution, enables RNA, DNA and
protein to be extracted and isolated after tissue homogenisation simoultaneously. In this case
only the RNA was used. Chloroform addition, separates RNA and DNA into the aqueous
layer and proteins in the organic layer. In subsequent steps only the aqueous phase was
collected. To frozen tissues of 50-100mg or cell pellets, 1ml of Tri-Reagentt" was added and
the tissue or cell pellet was homogenised in a Kinematika polytron homogeniser. The sample
was kept at room temperature for five min. to ensure dissociation of all nucleoproteins.
Chloroform, 0.2ml for every lrnl of Tri-Reagentl'" used, was added to the sample, mixed for
15 sec. and the sample was left at room temperature for 15min. Chloroform allows separation
of RNA, DNA and proteins into different phases. The sample was centrifuged at 8,000 xg for
15 min. at 4·C in a Beckman JA-14 rotor. The sample was separated into an upper aqueous
layer containing the RNA, a middle fatty layer and an organic layer containing proteins. The
aqueous layer was transferred to a new Falcon tube and isopropanol (0.5ml for every 1ml Tri-
Reagentr» used) was added. The sample was mixed and left at room temperature for 10min.
It was then centrifuged at 8,000 xg for 10 min. at 4· in a Beckman JA-14 rotor. The
supernatant was discarded and the pellet was washed and suspended in 1ml 75% ethanol for
every 1ml Tri-Reagent'< used and transferred to 1.5ml microfuge tubes. The sample was
centrifuged in a microguge at 14,000 xg for 5 min. at 4·C. The pellet was allowed to dry and
resuspended in 300J.llTE/O.l%SDS at 65·C for about 10 min. Lithium chloride (lOOJ.lIfrom
10M stock) was added and the sample left at 4·C overnight to selectively precipitate RNA.
The following day, the sample was centrifuged at 16,000 xg for 30 min. at 4·C. The pellet
was then washed in lrnl 75% ethanol and microfuged at 16,000 xg for 10 min. at 4·C. The
pellet was allowed to dry at room temperature and resuspended in an appropriate volume of
TE/O.1%SDS and stored at -70°C.
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B) Quantification of RNA
The concentration of RNA in a sample is obtained by measuring the OD of a dilution of a
sample at 260nm. SJ.lIof sample was added to 29SJ.lIof TE/O.l %SDS buffer and transferred to
a quartz cuvette where its concentration was measured in a spectrophotometer. The
concentration of the sample was calculated using the formula:
RNA concentration = 00260 X 40 x dilution factor (=60) x l/light path
To determine the purity of RNA the optical density of a sample was also measured at 280nm.
The ratio between OD260/0D280 gives the purity of RNA or DNA, ie whether there are any
proteins in the sample. Pure RNA or DNA samples give a ratio of OD26010D280 of 2.0 while
proteins increase the 00280 reading.
C) Formaldehyde gel electrophoresis of RNA
To determine quality of RNA samples are run on an agarose gel. Pure RNA samples show the
28, 18 and SS bands. The RNA samples that were extracted were electrophoresed in a mini
1% agarose gel containing formaldehyde in order to check the integrity of RNA (presence of
three ribosomal bands). 10mg/mlEtBr/l00ml was added to the gel before it was poured to
visualize the RNA. For a 100mi gel, 10ml lOxMOPS-E, 84.Sml water and 1.0g of agarose
were mixed and melted. When the temperature was 60°C, 5.2ml formaldehyde was added and
allowed to set. The gel was placed in a horizontal electrophoresis tank and lxMOPS-E was
poured to cover it. lug RNA samples were prepared by adding 16ml of RNA loading buffer,
mixed and heated at 6SoC for 10 minutes to denature any secondary structure. Then 2111of
lOx loading dye (RNA) was added, the samples were briefly centrifuged and loaded on the gel
along with lkb DNA ladder and run at 100V for 30 minutes. RNA was visualized on a short
wave UV transilluminator and a photograph was taken.
D) Electrophoresis and Northern blotting of RNA gels
The gel tank and combs were washed in 1% SDS overnight and rinsed with DEPC-treated
water and ethanol before use. 20llg of total RNA was precipitated with 3M NaOAc. The
RNA pellet was resuspended in 4111DEPC-treated water by heating at 6SoC and vortexing
well. 16J.lIof lOx loading buffer (RNA) was added and the sample was heated to 68°C for
10minutes and then placed on ice. 2111of lOxRNA loading dye was added and the samples
loaded on a formaldehyde gel. 1% (w/w) agarose in 95ml lx MOPS was melted and cooled to
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60°C before adding 17.8% (v/v) formaldehyde (of the 38% stock solution) and poured. The
gel was electrophoresed in 1x MOPS buffer at 100V for 1hr in the cold room.
The gel was then viewed on a UV transilluminator, trimmed and soaked 3x20mins in IxTAE
and electroblotted onto a Biodyne B membrane as described for Southern blotting in section
2.2.3H but using only RNase free solutions. The membrane was then hybridised exactly as
described previously for Southems.
2.2.6 Cell culture techniques
All culture techniques were performed either by myself or by Liz Hill, the laboratory technical
manager.
A) Explantation of papillomas and carcinomas
The explantation of papillomas and carcinomas was performed under sterile conditions with
all the surfaces washed with 100%(v/v) ethanol. Part of the papilloma or carcinoma was
washed with 100%(v/v) ethanol allowed to dry briefly and placed in transfer medium on ice.
The rest of the lesion was snap frozen in liquid nitrogen or fixed in formalin for
histopathological analysis.
The lesion was transferred to a Petri dish, cut in small pieces with a sterile scalpel and
trypsinised in IOml trypsin solution with agitation, for 30 minutes at room temperature. Then
the sample was centrifuged at 194 xg for 5min. and the cells resuspended in 10ml of 20%FCS
and plated in a Petri dish where it was incubated for 5-10 days. Cell growth was monitored
and when the cells were confluent they were sub-cultured and later frozen in 10% DMSO in
FBS.
8) Sub-culturing of mammalian cells
When the adherent cell cultures reached 90% confluence, they were sub-cultured onto fresh
tissue culture plates. The medium was aspirated from the cells, and the cells were washed
once in versene, which removes residual serum, and the EDTA chelates calcium and
magnesium ions. Trypsin, a protease, was then layered on the cells and the plate was agitated
to dislodge the cells. The cells were resuspended in fresh complete tissue culture medium
(serum aids to inactivate the trypsin) and transferred to new plates at the required density,
Cells were incubated at 3TC and 5% CO2•
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C) Freezing viable cells in liquid nitrogen
Cells were cultured on 5cm2 plate. One plate of cells (about 2x106cells) was stored per
cryotube. The medium was aspirated from a confluent plate. The cells were washed once in
cold PBS. Using a cell scraper most of the cells were dislodged from the plate. The cells
were collected in cold PBS, transferred in a Falcon tube and pelleted in a Heraeus 400
centrifuge at 194 xg for 5 min. The cell pellet was resuspended in 1ml freezing medium
(10%DMSO, 90% FBS) and the cells transferred to a cryotube and frozen in a cryoflask at -
70'C overnight. The cryoflask ensures gradual (l 'Czmin.) chilling of the cells. The vials were
then transferred to liquid nitrogen for long term storage.
D) Revival of frozen stocks
Cells were stored in liquid nitrogen tanks. When cells were required, they were brought up
from liquid nitrogen then quickly defrosted in the tube at 37'C in a water bath. The cells were
then washed in complete tissue culture medium to remove DMSO and were pelleted by
centrifugation in a Heraeus 400 centrifuge at 194 xg for 5 min. The cells were resuspended in
6ml of complete tisuue culture medium and transferred to a 25cm2 tissue culture flask. Cells
were incubated at 37'C and 5% CO2•
E) Transfection of cells with plasmid and selection
Cells were grown on tissue culture dishes until they were about 70% confluent. 51lg of
linearised plasmid DNA (in TE) was diluted in medium without serum or antibiotics to a
maximum volume of 150lli. The solution was mixed and spun briefly. 20111of Superfect®
transfection reagent (Quiagen cat.no:30 1305), was mixed with the DNA solution. The
Superfect® transfection reagent is an activated dendrimer that has a spherical shape with
branches coming out from a central core and terminating at charged amino groups. In this
way, the DNA is assembled into compact structures thus making it easier for DNA to enter the
cell. The Superfect-DNA complex is positively charged and this enables binding to negatively
charged receptors on the cell surface thus enabling entry. Superfect has a second property,
that upon entry into the cell it can buffer the lysosome thus inhibiting lysosomal nucleases
from working and allowing greater stability of the Superfect-DNA complex.
The solution was incubated for 10 minutes at room temperature to allow for Superfect-DNA
complex formation to take place. Meanwhile, the growth medium was removed from the cells
and the cells were washed with 4ml PBS. After incubation, 1ml of medium containing serum
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and antibiotics was added to the DNA solution, mixed and transferred to the cells. The cells
were incubated at 37C and 5% C02 for 2hrs. Then the medium was removed and the cells
were washed 4 times with PBS. Fresh medium was added with serum and antibiotics and the
cells were left to incubate for 48hrs. Then they were passaged with the appropriate selection
reagent (depending on what antibiotic the transfected plasmid was resistant to, usually
geneticin or hygromycin) and clones were picked as they appeared.
Before, proceeding with the transfection, a death assay was performed on each cell line that
was to be transfected in order to determine what concentration of the selection agent would be
used after transfection. In that assay, cells were allowed to grow in tissue culture dishes until
they were approximately 70% confluent. Different antibiotic concentrations (usually from
50llg/ml to 400llg/ml in 50llg/ml increments) were added to each plate. The antibiotic and
medium was refreshed every three days. Every day, the cell population was counted by using
Trypan Blue. This was repeated every day for fifteen days. The number of viable cells was
plotted against the number of days and the lowest antibiotic concentration at which all the
cells were dead at the end of the fifteen days was chosen to be used later
F) Viable Cell Counting with Trypan Blue
Adherent cells were brought into suspension using trypsin and resuspended in a volume of
complete media as described in section 2.2.6B. 20111of the cell suspension was removed and
added to 80111of Trypan Blue (0.4% Trypan Blue stain in 0.85% saline, from Gibco BRL cat.
no: 15250-061). The haemocytometer was cleaned with 70% ethanol and the coverslip was
moistened and placed over the chamber of the haemocytometer until Newton's refraction rings
appeared. IOll1of the cell suspension in trypan blue was loaded onto the chamber and the
cells were viewed under a light microscope at x20 eyepiece magnification. The number of
viable cells that do not take up the stain (bright cells) was counted. Dead cells absorb trypan
blue and are stained blue. Usually the cells in 5 squares were counted. The total number of
viable cells per ml was calculated in the following way:
Cells/ml = (Total viable cells counted! number of squares) x dilution factor xl 04
2.2.7 Immunohistochemistry
Tissue collection was performed by myself whereas tissue sectioning and staining was
performed by Mr Colin Nixon, a trained histotechnologist. Pathological analysis was
performed by Dr Adrian Phelby, a trained pathologist. Tissue was collected and fixed in 10%
neutral buffered formalin and embedded in paraffin wax. Paraffin sections of Zum were cut
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from the tissue block and placed onto coated slides. The immunohistochemical analysis used
an indirect two-step technique that was performed using DakoCytomation EnVision kits (cat
no:K400? for mouse monoclonal antibodies and K4011 for rabbit polyclonal antibodies). The
sections were placed in Histo-clear to remove excess paraffin wax and then through a series of
decreasing graded alcohols to water before starting the staining procedure. The antibodies that
were used were the proliferating nuclear cell antigen (PCNA) and total caspase-3. For antigen
retrieval, the sections were heated in O.OIMSodium Citrate (pH6.0) buffer in a microwaveable
pressure cooker for 2 min. in order to allow exposure of the antigen site. The buffer was
allowed to cool down for 20 min. and the sections were placed in dH20. The endogenous
peroxidase activity of the sections was blocked using the peroxidase block solution (0.03%
hydrogen peroxide) of the DakoCytomation kit. This buffer was washed with O.OIMTBST
(pH7.5) for 5 min. After the wash step the primary antibody (PCNA or total caspase-3) was
applied on the sections in the appropriate dilution (1:50) which was determined before hand.
The antibody was diluted in O.OIMTBS (pH?5). The sections were incubated with the
antibody for an hour at room temperature. After incubation, the samples were washed with
TBST (pH?5) for 5 min. The secondary antibody, as supplied in the DakoCytomation kit,
was applied to the samples for 30 min. at room temperature. Application of the secondary
antibody allows complex formation between primary and secondary antibody that will enable
subsequent visualisation of the staining pattern of the primary antibody. The secondary
antibody is either a goat anti-mouse polyclonal (in the case of PCNA) or rabbit polyclonal (in
the case of total caspase-3) and is HRP conjugated. To visualise the complex, 3,3
diaminobenzidine (DAB) chromogen solution and the DAB substrate buffer (in hydrogen
peroxide, pH? .5), supplied in the DakoCytomation kit were mixed and used as per
manufacturer's instructions. DAB is applied on the sections for ten minutes at room
temperature. The sections are microscopically monitored to allow for the desired staining to
develop. DAB allows formation of a brown insoluble complex (the complex cannot dissolve
in alcohol or other organic solvents) and allows the antibody-antigen complex to be visualised.
The sections were counterstained with Gills Haematoxylin (cat no: 261103G, BDH) and
mounted in DPX mountant for microscopy (cat no: 360294H, BDH). A negative control (ie.
no primary antibody was applied) was run in parallel. For each antibody a known positive
control was run beforehand to confirm that the primary antibody was working and to optimise
the dilution of the antibody.
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Chapter 3: Characterisation of LMP1 transgenic
mouse lines
The aim of the work presented in this chapter was to characterise the expression patterns of
LMP1 in the transgenic mouse lines 117, 105A and 105B and determine if this correlates with
the observed phenotype.
These mouse lines harbour the transgene LMPI CAO under the L2 EBV promoter (as described
in section 1.9). When the PyLMP1895-8 mice were created (Wilson et al., 1990), it was evident
from Northern blots that a transcript derived from the ED-L2 promoter was showing relatively
high expression in epithelial tissues including skin. Given the epithelial specificity of the ED-
L2 promoter in those mice, ED-L2 was used to drive expression of the Cyclin Dl gene to
mucosal stratified squamous epithelia such as tongue, oesophagus and forestomach
(Nakagawa et al., 1997). As such, a similar pattern of expression may be predicted for the
L2LMPI CAO mice, but transgene expression patterns and levels cannot be precisely
predetermined and must be characterised for each line.
Elucidating trans gene expression is important as it will allow an understanding of the
phenotype observed in these lines and enable the design of further relevant experiments.
3.1 Outline of approach
For the expression analyses three techniques were employed: RT-peR, Northern and Western
blotting. RT-peR can be used to detect low levels of RNA. Northern blotting is not so
sensitive as RT-peR but can reveal the full size transcript and Western blotting shows whether
there is any translation of the transgene message to produce the protein.
Tissues were collected from transgenic and wild type siblings from each line investigated and
stored at -70oe until processed for the technique employed.
The purpose of these experiments was to answer the following questions:
1. In which tissues of the transgenic mice is LMPlcAO expressed?
2. What is the pathology/phenotype of tissues from these transgenic lines and does it
correlate with transgene expression?
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3. Does LMPI CAO lead to a similar response in the tissue as LMPI B95-8 does after
chemical carcinogen treatment of the mice? In this context can it replace the need for
an activated ras in a chemical carcinogenesis setting?
4. Does loss of the INK4a locus cooperates with LMPlcAO in a similar fashion to
LMPIB95-8?
For the phenotypic studies of LMPI transgenic lines three approaches were taken:
1. In order to examine tissue pathology, tissues were collected and stained for
histological examination.
2. In order to monitor the incidence of spontaneous papilloma formation on lines 117
and 117/113, mice were monitored once every two weeks and lesion load was
recorded.
3. In order to determine ifLMPIcAO acts as a tumour initiator, a minimal carcinogen
treatment was performed on line 117 animals.
3.2 Histopathology AnalYSis
Tissues were collected, fixed in formalin, paraffin embedded and stained for histological
examination. Dr Adrian W. Philbey, a trained pathologist, performed the pathological
examination and interpretation of the sections.
Following histological examination, it was deduced that ears of 117 wild type mice showed a
normal pathology whereas ears of line 117 transgenic mice showed a variety of phenotypes
ranging from epidermal hyperplasia (stage 1-3, see fig.l.14 for staging) to keratoacanthomas
(stage 3-5) to squamous cell carcinomas (stage 5)(fig.3.I). Keratoacanthomas are rapidly
growing spontaneous lesions that resemble inverted papillomas that can regress
spontaneously, whilst a squamous cell carcinoma is a neoplastic tumour of the squamous cells
(flat, thin cells found on the outer layer of the skin). An ear classified as keratoacanthoma was
described by the pathologist "as a proliferative epidermal mass consisting of a large irregular
central crateriform depression, lined by hyperplastic stratified squamous epithelium and filled
with keratin laminae, along with degenerate cells and scattered colonies of bacteria. Shallow
islands of stratified squamous epithelium with central keratinisation extent into the
surrounding dermis. Rupture of these islands with release of keratin into the dermis is
associated with locally extensive infiltrates of neutrophils, macrophages, lymphocytes and
132
Figure 3.1: A Haematoxylin & Eosin staining of an ear
of a transgenic mouse of line 117
An ear from a trasgenic mouse of line 117 was fixed in
formalin, embedded in paraffin, sectioned (211m) and stained
with haematoxylin and eosin. This section shows a
squamous cell carcinoma. For example, the black arrow is
indicating rupture of a keratin island indicative of
progression to carcinoma.
plasma cells, along with fibrovascular hyperplasia and fibrosis." Many of the ears also
showed ulcerative dermatitis accompanied by necrosis. The phenotype resembles trauma to
the ear with secondary bacterial infection, as there is fibrovascular hyperplasia of the dermis
along with neutrophils and other inflammatory cells. Lesions that spontaneously developed on
the dorsal skin of transgenic mice of line 117were classified as acanthomas.
By 8 months of age, all line 117 transgenic mice had at least one enlarged cervical lymph
node, usually the right one. This was not observed in the wild type siblings. When several
samples of swollen cervical lymph nodes were histologically examined it was shown that they
were mildly or moderately reactive indicating hyperplasia but none of them were classified as
a lymphosarcoma (figJ.2). Whether they would progress to lymphomas in older mice is not
known as most mice of the line were sacrificed at 16 months due to the extent of the ear
phenotype. Most of these lymph nodes examined contained pseudocysts, which consist of
expanded spaces within the lymphoid tissue that contain small amounts of eosinophilic
proteinaceous fluid, fibrin strands and scattered degenerate lymphocytes.
Oesophagus, forestomach, glandular stomach, trachea, pancreas and spleen of line 117
transgenic animals were described as normal.
Tongue, oesophagus, forestomach, glandular stomach and liver, of line 105B transgenic
animals also showed no pathology.
Tongue, trachea, oesophagus, salivary gland, stomach and pancreas of one transgenic mouse
of line 105A showing the wasting phenotype, were described as normal. However, lymph
nodes, thymus, spleen, liver, glandular stomach and the junction of forestomach and glandular
stomach of another transgenic mouse of line 105A exhibiting the wasting phenotype, were
described as showing evidence of lymphosarcoma. The architecture of the tissues was
replaced by dense sheets of large neoplastic lymphocytes that had large round nuclei, a high
ratio of nucleus to cytoplasm and 10-20 mitoses per high power field. Macrophages were also
seen that gave rise to a "starry sky" appearance. This was an individual case and the
phenotype has not been followed for mice of this line as yet.
Most of the dorsal lesions collected and examined from line 117/113 were described as
keratoacanthomas but on a single instance out of 5 cases examined, one of the larger lesions
(size >4) was classified as a squamous cell carcinoma (Appendix 1).
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Figure 3.2: A Haematoxylin & Eosin stained section through
an enlarged cervical lymph node of a transgenic mouse of line
117.
An enlarged cervical lymph node from a transgenic mouse of line
117 was fixed in formalin, paraffin embedded, sectioned (2Jlm)
and stained with haematoxylin and eosin. The staining reveal s
lymphoid follicles with active germinal centers. There is mild
expansion of lymphocytes in the paracortical zone and a moderate
number of plasma cells in medullary cords. This lymph node is
mildly hyperplastic.
3.3 LMP1 expression patterns in transgenic lines 117, 10SA and
1058 mice
3.3A RNA Expression
RNA was extracted from frozen tissue using Tri-Reagent'P' or according to the method of
Chomczynski and Sacchi (Chomczynski and Sacchi, 1987) (see section 2.2.5) using
guanidium thiocyanate and acid phenol.
Initially the RT-PCR technique was employed to examine LMPI specific RNA expression.
Briefly, RNA obtained from the tissues was DNase I treated and used to make complememnt
DNA (cDNA) using a polydT primer. The cDNA was used in a PCR reaction using primers
DSI and DS4 (fig. 3.3). These two primers span the second exon of LMPI and the small
introns 1 and 2 and allow amplified genomic DNA and processed RNA to be distinguished by
the size of the product. The product expected from genomic DNA using these primers is
S99bp and the cDNA product is 439bp. After repeated assays with this primer pair, no visible
products were detected on EtBr stained agarose gels. Consequently, a further amplification
step was included using nested primers (DS2 and DS3, figJJ). The genomic DNA product
expected from this primer pair is 492bp and the RNA derived product is 332bp. To further
control for genomic DNA derived versus RNA derived products, replicate samples were
assayed with and without reverse transcriptase (RT). Also as a further control, samples from
wild type animals were used with or without RI and in those samples no bands of the
appropriate size either from DNA or RNA products were observed. It was repeatedly
observed that a 492bp band was seen in the RT samples but not in the no RT samples (eg. fig.
3.4 tongue). Despite the size, this suggested the product was derived from RNA and not from
DNA contamination of the samples. It is possible that the 492bp band is derived from
unprocessed nuclear LMPI RNA. If this is the case, the transgene is expressed in these tissues
but it is not clear to what degree the RNA is processed or translated. Some tissues yielded
RT-PCR products of the expected size from an LMPI RNA transcript (332bp). These include
line 117 ears, heart, (fig. 3.4) and line 10SA heart (fig. 3.5). The 492bp product was seen in
line 117 tongue, lymph node, forestomach, lung and heart; line 105A ear, oesophagus
(fig.3.5); line 10SB thymus, spleen, forestomach, lymph node, ear, heart, lung, trachea, brain,
glandular stomach and liver (fig.3.6). Due to DNA contamination in the samples from line
117 testicle, liver; line I05A lymph node, tongue, kidney, lung, testicle and liver no
conclusion could be drawn for LMPlcAO expression in these tissues. Blotting some of the gels
and probing with an LMPI probe did not reveal any other bands of the RNA product size.
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Figure 3.3: Diagram depicting the three exons of LMPI and where the primer
pairs used for RT-peR correspond
Primers DS1 and 4 start at nucleotide 169474 and 168876 of exons 1 and 3 respectively.
The DNA product expected from this pair is 599bp where as the cDNA product is
439bp. Nested primers DS2 and 3 start at nuleotide 169400 and 168909 of exons 1 and
3. The expected genomic DNA product from this pair is 492bp and the cDNA product
is 332bp. The respective positions of the three LMPI promoters are shown as EDL-1,
lA and 2. Note that the diagram is not to scale.
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Figure 3.4: A nested RT-peR of tissues from line 117
2% Nuseve, 1% agarose TBE gels stained with EtBr, showing the
products of nested RT-peR. Tissues from a transgenic animal of line 117
were used. RNA was extracted and DNase! treated. A first round of
amplification with primers DS1 and 4 was conducted, followed by a
second round of amplification using nested primers DS2 and 3. A
positive control (Raji) was included. RNA samples were incubated with
(+) or without (-) RT. The RNA derived product should be seen at 332bp
whilst any genomic DNA product should be seen at 492bp. Note that
testes and liver samples show clear evidence of DNA contamination
within the RNA sample as bands are evident in the no RT (-) tracks.
tng. =tongue, l.n. = lymph node, fst. = forestomach, g.st. = glandular
stomach, s.gld = salivary gland, test. = testes
A brain heart spleen ear oes. In. tng.
+ + + + + + +
B cIn. thy. kid. fst. gst. lung testiclej, liver
-- -- -- -- -- -- -_.a'
+- +- +-+ -+-+ -+-~ +
Figure 3.5: A nested RT-PCR of tissues from line l05A
2% Nuseve, 1% agarose TBE gels stained with EtBr, showing the products
of nested RT-PCR. Tissues from a transgenic animal of line l05A were
used. RNA was extracted and DNase! treated. A first round of
amplification with primers DS1 and 4 did not give any visible products on
an EtBr stained gel. A second round of amplification using nested primers
DS2 and 3 gave the products shown. A positive control (Raji) was included.
RNA samples were incubated with (+) or without (-) RT. The RNA derived
product should be seen at 332bp whilst the genomic DNA product band
should be seen at about 492bp. Note that lymph node, tongue, kidney, lung,
testicle and liver samples show clear evidence of DNA contamination within
the RNA sample as bands are evident in the no RT (-) tracks.
oes. = oesophagus, In.= lymph node, tng. = tongue, cln. = cervical lymph
node, thy. = thymus, kid.= kidney, fst. = forestomach, gst. = glandular
stomach.
Figure 3.6: A nested RT-PCR of tissues from line 105B
2% Nuseve, 1% agarose TBE gels stained with EtBr, showing the
products of nested RT -peR. Tissues from a transgenic animal of
line 105B were used. Two rounds of amplification as for lines 117
and 105A were used. RNA samples were incubated with (+) or
without (-) RT. The RNA derived product should be seen at
332bp whilst the genomic DNA product band should be seen at
about 492bp. Note that ear sample shows clear evidence of DNA
contamination within the RNA sample as bands are evident in the
no RT (-) tracks.
sal. gland = salivary gland, fst. = forstomach, In.= lymph node,
gst.= glandular stomach.
thymus sal. gland spleen kidney
fst. In. ear heart
+ + + +
lung
+
brain
+ Raji
trachea testicle
c + +
gst. liver
D + +
While this approach gave some indication ofLMPl CAD expression, due to persistent DNA
contamination and the possibility of detecting unprocessed RNA it was not conclusive.
Therefore, it was decided to investigate LMPI CAD expression using Northern and Western
blotting, to determine whether the unprocessed RNA was finally processed and translated.
Northern blotting is not as sensitive as RT-PCR. However, it was thought important to use it
as RT-PCR was giving inconclusive results. Using Northern blotting, LMPI expression is
evident in the Raji positive control but not in Ramos negative control as expected. From the
tissues examined, ear, tongue, forestomach, swollen lymph node, glandular stomach,
heart, oesophagus and kidney show the 2.5kbp transcript corresponding to full length
LMPI CAD (fig.3.7). Lung, salivary gland and testicle show a smaller transcript. Note, that it
was repeatedly observed in this lab that the Chomczynski and Sacchi method gave more and
better quality RNA than the Tri-reagent'" for Northern blotting.
3.3B Protein expression
Standard protein extraction buffers such as Ripa buffer or boiling mix (see section 2.2.4) failed
to yield detectable epidermal LMP1 as was seen from initial Western blotting experiments,
even though these methods were efficient in extracting LMP 1 from B cells. It is known that
LMPI co-localises with vimentin and possibly does so with the keratins of keratinocytes
(Liebowitz et al., 1987). Keratins in skin become cornified and are difficult to solubilise,
requiring denaturing extraction buffers. This may also be true of epidermal LMPI. Given
these difficulties, it was decided to use extraction buffers that are used to detect keratins.
Initially, three different buffers were used in a trial. The conventional keratin extraction buffer
(8M urea, 5%2ME, 25mM Tris, pH9.5), Shindai buffer (5M urea, 2.6M thiourea, 5% 2ME,
25mM Tris, pH 8.5) and a "New" buffer (9M urea, 2M thiourea, 2%CHAPS) (Nakamura et
al., 2002) were used. Proteins were extracted from the samples in these buffers at 55°C
overnight as detailed in section 2.2.4. Extracts were separated by SDS-PAGE, Western
blotted and probed with anti-LMPI antibodies.
Extracting LMPI using the "New" buffer was the most successful in terms of specific versus
non specific band detection (Le. transgenic versus wild type tissue)(fig.3.8). However, the
"New" buffer extracted the least amount of specific protein compared to the other two buffers
used. Since the aim of these experiments was to detect LMPI CAD expression in tissues, the
buffer that extracted the most LMPI CAO was chosen for further experiments and this was the
conventional buffer.
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Figure 3.7: A Northern OD tissues from a 117 transgenic mouse
20!lg of total RNA extracted using the Chomczynski and Sacchi method,
were electrophoresed through a 1% formaldehyde gel, transferred onto a
nylon membrane and probed with an LMPI specific probe (probe 139). A
film was exposed to the blot for varying time periods and developed through
an X-Omat developer. Raji positive control and Ramos negative for LMPI
control were included. Autorad A was underexposed whilst autorad B was
overexposed. As can be seen, the 2.5 kb LMPI transcript is observed in the
Raji, ear, forestomach, glandular stomach, oesophagus, lymph node, heart,
tongue, kidney. Lung, salivary gland and testicle show a smaller product.
tng= tongue, fst= forestomach, In= lymph node, gst= glandular stomach, 19=
lung, sg= salivary gland, hrt= heart, sI = spleen, tes= testicle, th= thymus,
oes= oesophagus, tr= trachea, kd= kidney.
Figure l.IA aDd B: Western blot of trial extraction buffen
probed with aDti-LMPl 812 (A) aDd IG6 (B) aDtibodies
l00Jl8 of protein extract was separated by 10010SDS-PAGE and
blotted. A Raji (EBV+ BL cell line) positive control, a Ramos
(EBV - BL cell line) negative control, a 117 transgenic ear sample
(tg.e) and a wild type ear sample (wt.e) were extracted with three
different buffers; conventional, Shindai and "new" buffers were
tested. Blot A was probed with the primary antibody S12 (1:500).
The secondary antibody used was goat anti-mouse IgG-HRP
(1:4000) and visualised with ECL+. The Western blot was
stripped and reprobed with the IG6 antibody (1:100)(B). The
secondary antibody used was goat anti-rat IgG-HRP (I :4000) and
visualised with ECL+. Transgenic and wild type tissue samples
were electrophoresed in adjacent tracks to allow direct
comparison. The Raji positive control gives an LMPIB9S.a specific
band at 63kDa whilst the transgenic ear sample gives a band at
66kDa corresponding to LMPICAO. Smaller bands of about 50,
40 and 35kDa are also observed in the transgenic ear sample.
Note, that there is a cross reacting band of about 67kDa observed
in the transgenic and wild type ears irrespective of the method or
antibody used for detection.
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In order to confirm the results obtained from this Western blotting analysis, three different
antibodies directed against LMPI were used. These were S12 (Hennessy et al., 1984;Mann et
al., 1985), 106 and the CAO cocktail (Nicholls et al., 2004). S12 is a mouse monoclonal
Ig02a antibody directed towards the carboxy terminus of LMP1, recognising both LMP1CAO
and LMPI 895-8. 106 is a rat monoclonal Ig02a antibody that recognises both the B95.8 and
CAO version ofLMPI. The CAO cocktail antibody consists of the rat monoclonal antibodies
505, 7F8 and 7D7. This cocktail does not recognise the B95.8 version of LMPI but
recognises CAO.
LMPlcAO is larger than LMPIB95-8, comprising 404 amino acids instead of 386 (Hu, 1991).
As seen from fig.3.9, a band at about 66kDa, predicted for LMPI CAO, is seen in transgenic
ears, larger than the 63kDa band seen in the Raji positive control cell line extract. However,
there is also a cross reacting band at about 67kDa that is observed in all samples (compare to
wild type tracks) albeit at lower intensity. LMP1CAO migrates very slightly faster than this
band. Smaller products, a predominant one of 50kDa and minor bands at 40,35 and 25kDa
are observed with the S12, 106 and CAO cocktail antibodies. Bands at about 45kDa are
observed with the 106 and the CAO cocktail. These smaller bands are seen only in the
transgenic samples. As such they could either be cleaved products of LMP1, in vitro
breakdown products or products derived from transcripts from the ED-LIA promoter of
LMPI. Moorthy and Thorley-Lawson (Moorthy and Thorley-Lawson, 1990), detected a
25kDa cytoplasmic product that they demonstrated to be a cleaved product of LMPI. They
also detected a 35kDa cell membrane product that was not always extracted. Since in these
experiments 8M urea was used, this 35kDa product is likely to be extracted. Products derived
from LMPI CAO may be larger than LMPI B95-8 and therefore migrate slower through an SDS
gel. Further reports (Baichwal and Sugden, 1987; Wang et al., 1985) describe breakdown
products of 54kDa, 43kDa and 49kDa whereas a 52kDa product is described as the product
derived from the ED-LIA promoter. Hudson et al., also predicted LMPI size to be 42kDa and
the ED-LIA product to be 28kDa (Hudson et al., 1985). Given that subsequent experiments
showed that LMP1CAO migrates slower through an SDS gel it is possible that the LMP1CAO
ED-LIA product migrates at about 50kDa.
A prominent band of about 50kDa is observed in 117 transgenic ears (fig. 3.9). Identification
of the 66kDa band was difficult at times due to the cross-reacting bands seen in both
transgenic and wild type samples with the different antibodies used. However, reprobing blots
with all3 antibodies allowed the LMPI CAO, 66kDa band, to be unequivocally identified. The
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Figure 3.9A and B: Western blot of line 117 tissues using 812
(A) and CAO cocktaH (B) antibodies
100J,lgof protein extract was separated by 10010SDS-PAGE and
blotted. The primary antibody used in A was S12 ascites (1:500).
The secondary antibody used was goat anti-mouse IgG-HRP
(1:4000). The Western blot was stripped and reprobed with the
CAO cocktail antibody (1:100) (B). The secondary antibody used
was goat anti-rat IgG-HRP (I :4000). A positive control for LMPI
(Raji) and a negative control (Ramos) were used. Transgenic tissue
samples (+) and wild type tissue samples (-) were electrophoresed
in adjacent tracks to allow direct comparison. The 63kDa
LMPI895-Bband is seen in the Raji sample in A. The LMPlcAO
66kDa band as well as further smaller products are seen in the
transgenic ear extract but not in the wild type ear extract. The
LMPlcAO band is detected in nasopharyngeal area (npa), tongue
(tng.), oesophagus (oes.) and focestomach (fst). There is also a
prominent 50IDa band that is present only in transgenic tissue
extracts. A smaller product of about 40kDa is observed in the
transgenic ears, npa and tng (A). No LMPI specific band is
observed in the Raji positive control in B as the CAO cocktail
antibody does not recognise the LMPI895-B.A band at about 66kDa
is clearly seen in transgenic tongue (tng.) and oesophagus (oes.)
but not in wild type tissue. An extensive cross reacting band in ear
sample does not allow ready detection of the LMPICAOband.
Smaller bands of about 40kDa are clearly seen in transgenic ear,
npa, tng. and oes. Note, that 812 cross reacts with a non specific
protein at about 67kDa that is present in all tracks making it hard to
identify the LMPlcAO band in A. The CAO cocktail also cross
reacts with non specific bands seen in the wild type samples (-) in
B.
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A Raji Ramos + + + + +
35kDa
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smaller products observed are possibly products of transcription of the lytic ED-LIA promoter
or proteolytic products of LMPI CAO, were much easier to identify and were only present in
transgenic samples thus indicating that in that tissue LMPlcAO or derivatives were expressed.
First tissues from line 117 were examined. The LMPlcAO specific band at 66kDa is detected
in transgenic ears, nasopharyngeal area, tongue, oesophagus, forestomach (fig.3.9), dorsal
skin, swollen lymph node (fig.3.10B), testicle, thymus, kidney and small intestine (data not
shown). Smaller LMPI specific products are detected in transgenic ear, nasopharyngeal area,
tongue, oesophagus, forestomach (fig.3.9), dorsal skin (fig.3.10A), trachea (data not shown),
lung and heart (fig.3.1OB). The strongest expression of LMPI CAO 66kDa band was observed
in transgenic ears. In order to examine if this expression varied with age and phenotypic
stage, ear extracts of phenotypic stages 1-3 were examined (fig.3.11). From that examination,
it was concluded that LMPlcAO expression is strong irrespective of phenotypic stage.
Tissues from lines 105A and B were also examined. In line 105B, the LMPlcAO 66kDa band
was observed in transgenic ears, trachea, oesophagus, tongue, glandular stomach (fig.3.12)
forestomach, nasopharyngeal area and testicle (data not shown). Smaller LMPI specific
products were observed in transgenic ears, trachea, oesophagus, tongue, glandular stomach,
forestomach (fig3.l2), dorsal skin, kidney, heart and thymus (data not shown). In line 105A,
the LMP 1CAO 66kDa band was detected in transgenic oesophagus, forestomach, tongue
(fig.3.l3) and nasopharyngeal area (data not shown). Smaller LMPI specific products were
observed in transgenic trachea, lung, kidney and heart (data not shown). Table 3.1 summarises
the expression patterns of the tissues of the different lines that show expression of LMP1CAO
and related products by using all three antibodies (fig3.9, 10, 12, 13). The expression pattern
shows consistency with the phenotype. For example, line 117 and 105B animals show a
hyperplastic ear phenotype whereas line 105A animals do not. This is consistent with
LMPI CAO expression as only ears of 117 and 105B transgenic animals show LMPI CAO
expression whereas line 105A ears do not. Line 117 transgenic animals consistently show
enlarged cervical lymph nodes and this is in agreement with LMPI CAO expression in the
expanded lymph nodes. Also line 117 animals show spontaneous papilloma formation and
this is consistent with expression of LMPlcAO in the dorsal skin. Line 105B animals show
spontaneous papilloma formation but to a lesser extent and much later in life and this is
consistent with the lower level of LMP1CAO expression in this line compared to line 117. Note
that the western blots shown are representative samples of several repetitions with all
transgenic positive samples showing the specific pattern of expression.
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Figure 3.10A and B: Western blot or line 117 tissues using
anti-LMPI 812 antibody.
lOOt'g of protein extract was separated by 10010 8D8-PAGE and
blotted. The primary antibody used was rabbit anti-mouse LMPI
812 ascites (1:500). The secondary antibody used was goat anti-
mouse IgG-HRP (1:4000). A positive for LMPI control (Raji)
and a negative control (Ramos) were used. Transgenic tissue
samples (+) and wild type tissue samples (-) were
electrophoresed in adjacent tracks to allow direct comparison.
The 63kDa LMPIB9S-1band is seen in the Raji samples. The
LMPlcAO 66kDa band as well as further smaller products are
seen in the transgenic ear extract but not in the wild type ear
extract. The LMPlcAO band is detected in ear, dorsal skin
(d.skin), trachea (tr). lung (lng.) and heart (hrt.). There are also
smaller breakdown products of about 50kDa and 45kDa observed
in transgenic ear, d.skin, oesophagus (008.) and forestomach (fst.)
tissue extracts. An extensive cross reacting band that runs at
about 67kDa makes identification of the 66kDa LMPI CAOband
extremely hard.
Tng, = tongue. npa.= nasopharyngeal area, sint.= small intestine,
s.gl.= salivary gland, sl. = spleen, Iv.= liver, th.= thymus. Ln. =
lymph node, br. = brain, kd. = kidney.
LMPICAO '=~"
LMP1 B95-8
ear d.skin
A + + tng. npa. oes. sint. tr. s.gl.
ear
B lng. sl. hrt. Iv. tho l.n. fst. br. kd.
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LMP1 B95-8
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Figure 3.11: A Western blot for LMP1cAO on ear
extracts of line 117 mice of different phenotypic stages
LMPICAO transgenic ears are indicated according to their
phenotypic stage (stl-3) . Wild type age matched controls
are indicated with c.
Protein extracts were prepared using the conventional
method. 100llg of extract/track were separated by lO%SDS-
PAGE and the gel was blotted. The blot was probed with
S12 primal)' antibody (1:500) and a secondary antibody goat
anti-mouse IgG-HRP (1:4000) and visualised with ECL+.
The 66 kDa LMPI CAO band is indicated.
ear trachea oes. tng. gl.st. fst.
+ + + + + +
LMPIC4
50kDa---.
Figure 3.12: Western blot of line l05B tissues using 812
antibody
Protein was extracted using the conventional extraction buffer.
100llg of protein from both transgenic (+) and wild type (-)
tissues was separated by 10% SDS-PAGE and blotted. Primary
antibody used was rabbit anti-mouse 812 ascites (1:500). The
secondary antibody was goat anti-mouse IgG-HRP (1:4000). A
band at 66kDa corresponding to LMPI CAO is detected in the
transgenic ears, trachea, oesopUflguS (oes.), tongue (tng;)-.and
faintly in the glandular stomach (gl.st.) and forestomach "'(fst.).
There is also a 50kDa b~f;) present in trasgenic ears, trachea,
oesophagus, tongue and faintly in transgenic glandular stomach
and forestomach.
LMPIC4
LMPlb95-~
50kDa-'
ear trachea fst. tng.oes.
Raji Ramos + + + + +
Figure 3.13: Western blot of line I05A tissues using Sl2 antibody
Protein was extracted using the conventional extraction. 100flg of
protein from both transgenic (+) and wild type (-) tissues were
separated by 1O%SDS-P AGE and blotted. The primary antibody used
was rabbit anti-mouse S12 ascites (1:500). The secondary antibody
used was goat anti-mouse IgG-HRP (1:4000). A positive control (Raji)
and a negative control (Ramos) were included. The 63kDa LMP 1B95-8
band is seen in the positive control. No 66kDa LMPlcAO can be
detected in transgenic ears and this is consistent with the phenotype of
this line. The 66kDa LMPI CAO is clearly detected in transgenic
oesophagus (oes.), forestomach (fst.) and tongue (tng.).
Tissue 117 105A 105B
Ear V - V
Dorsal skin V - s
'I'ongue V V V
Nasopharyngeal area v v v
Salivary gland - - -
Oesophagus v v v
Trachea s s v
Forestomach v v v
Small intestine v - -
Lung s s -
Kidney v s s
Heart s s s
Liver - - -
Spleen - - -
Thymus v nt s
Brain - - -
Testes/ovary v nt v
Expanded lymph node (I17 onlv) v
Table 3.1: Table sbowing presence oftbe LMPlCAO 66kDa product in tissues from lines
117, 105A and 105B.
This table gives a summary of all the LMPI products either fullength or smaller that have
been detected using the various antibodies.
The symbol (Y) indicates presence of the LMPlcAO 66kDa product. The letter (s) indicates
expression of smaller LMPI specific products detected in the absence of detection of the
66kDa product. The symbol (-) indicates that no LMPI expression was detected.
(nt) = not tested.
3.4 Spontaneous papilloma formation on lines 117, 117/113 and
117/113/1205
It has been well documented that mice from different genetic backgrounds have a different
susceptibility to developing lesions after topical chemical carcinogen treatment and have
different resistances to malignant conversion of such lesions. Studies have indicated that FVB
strain mice that developed cutaneous papillomas following chemical carcinogen treatment
were much more prone to show malignant conversion to carcinomas than C57BLl6 mice
(DiGiovanni et aI., 1991; Hennings et aI., 1993). In our lab, it was noted that when line 117
mice were brought into an FVB background (backcross 2, approx. 75% FVB), 40% of the
mice spontaneously developed cutaneous papillomas. Initially the line 117 colony was
maintained in a C57BLl6 background and no papilloma formation was observed.
In order to characterise this observation further, a cohort of 21 transgenic and 10wild type 117
mice at backcross 3 (87.5% FVB) were monitored from 6 weeks of age up to 65 weeks of age
for spontaneous papilloma formation. The mice were monitored once every fortnight and the
lesion load was recorded in size categories as shown in table 3.2. Note that this categorisation
is subjective, however it should be internally consistent.
Category Lesion
diameter
Size 1 <0.2 cm
Size 2 0.2-0.5 cm
Size 3 0.5- 1.0 cm
Size4 >l.Ocm
Table 3.2 Categorisation of lesions by size
Of the 21 transgenic mice in the study, a total of 12 (57.14%) transgenic mice had developed
papillomas by the end of the study (fig.3.14A). No papillomas developed on the wild type
siblings throughout the study period. Of these 12 mice that did develop papillomas the
average maximum number of papillomas per mouse was 2.58. The first onset of papillomas
was at 6 weeks of age. The papillomas that formed remained small, mostly in category 1 (fig.
3.14B,C). Note that the severity of the ear phenotype, necessitated removal of animals from
the study at different time points. Sudden drops on the curve indicate that papillomas
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Figure 3.14: Development of spontaneous cutaneous lesions in
mice ofline 117
2 1 transgenic and 10 wild type siblings of line 117 mice, were
monitored for 59 weeks (from 6 weeks old) for the appearance of
cutaneous lesions.
A) The percentage of mice developing a lesion through the study
period is shown, at the age of first lesion appearance. Transgenic
mice are shown by a blue line and wild type mice are shown by a
pink line.
B) A graph showing the average (mean) number of lesions per
mouse alive at each weekly count according to lesion size; size 1
(purple), size 2 (pink), size 3 (light blue), size 4 (dark blue). Note
that sudden drops indicate papilloma regression or removal of a
moouse bearing lesions from the study.
C) A graph showing the cumulative average (mean) number of all
lesions that developed on all transgenic mice during the study
according to size; size 1 (purple), size 2 (pink), size 3 (light blue),
size 4 (dark blue). In this representation, if a mouse was removed
from the study, its lesion load is shown as a constant to the end of the
study period. As such, drops in the average lesion load represent
lesion regression.
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regressed or changed size category or that a mouse that had papillomas was withdrawn from
the study. In order to allow for this, the cumulative lesion load is shown in the graph in
fig.3.14e in which the lesion load of a mouse at the time of removal from study is shown as a
constant to the end of the study period. As seen from this graph (fig. 3.14e) some lesions
regressed. However, some fluctuation in the count can also be attributed to experimental error
in missing some small papillomas and to the subjectivity of categorisation of a lesion
particularly at the border between categories from one week to the next.
It is seen that LMP 1CAO alone can pre-dispose to papilloma formation as no papillomas
developed on the wild type sibling control mice. However, LMPlcAO on its own is not
sufficient to lead to a large number of papillomas per mouse or to many large papillomas. The
maximum number of papillomas that a mouse on this study ever developed was 4 (although
more have been noted on some mice not in this cohort). Most of the papillomas formed were
size 1 or 2 with the exception of a few size 4 papillomas that developed towards the later
stages of the study. Finally, no papillomas from the ones sent for pathological examination
showed evidence of conversion to carcinomas but larger lesions (size>4) were not examined.
Further details about the animals used in this study can be found in Appendix 2.
These results suggest that LMP 1CAO can initiate a proliferation pathway that leads to
papilloma formation. However, this proliferation pathway must be limited as only a few small
papillomas develop per mouse that do not readily progress.
In order to investigate whether the pathway that limits this proliferation is acting via INK4a
locus products (p16INK4aand p19ARF ), line 117 mice were crossed with INK4a null, line 113
mice (see section 1.8). In order to determine the genotype of the mice at the INK4a locus two
techniques were used, peR and Southern blotting. For the peR reaction, two sets of primers
recognising either a pl61NK4afragment or the neomycin insertion cassette, were used (figJ.15).
There were persistent problems with the neomycin peR, since a false positive band was
frequently seen in samples, so it was decided to use Southern blotting as an alternative
genotyping method. After digesting genomic DNA with several enzymes, and probing with
an INK4a containing probe, it was shown that BamHI digest gave the clearest results. A band
at about 2.8kbp is observed in wild type samples, this band is observed in heterozygotes at half
the intensity and no band is seen in the null (figJ.l6). However, due to unequal loading and
the fact that distinguishing wild type from heterozygote was based on band intensity, it
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A Ladder het kowt
p16
B wt ko
neomycin
Figure 3.15: Genotyping of line 117/113 mice using peR
300 ng of genomic DNA are used along with p16 (A) or neomycin
(B) primers for peR assays. lOll] of the product were run on a
1.5%Eillr stained agarose gel. Gel A shows the DNA ladder along
with peR samples using p16 primers for wild type (wt),
heterozygous (het) or knock out (ko) mice for the INK4a locus.
The 306bp product of the p16 primers is indicated and is observed
in wt and het samples only.
Gel B shows the peR samples with neomycin primers for wt and
ko mice for the INK4a locus. The 150bp product of the neomycin
primers is indicated and is observed in the ko sample only.
Presence of the p16 band only indicates wt, presence of both bands
indicates het and presence of the neomycin band only indicates ko
genotype.
kb ko hetwt
Figure 3.16: Southern blot genotyping of line 117/113
Genomic DNA (Sug) was digested with BamHI overnight and
separated by electrophoresis on a 0.8% agarose gel. A probe
comprising exon 2 of the INK4a locus genes was used to
detect wild type (wt), or heterozygous (het) samples. The wt
or het band was observed at about 2.8kb. The knock out (ko)
sample showed no such band. Note that the intensity of the
band observed in the het sample, is less than the intensity of
the band observed in the wt sample. This banding pattern was
repeatedly observed on a number of known control samples.
The Southern gel showed equal DNA loading of similar
quality in all tracks shown in this figure.
was quite hard to reliably determine whether genomic DNA displaying that band
corresponded to a wild type or a heterozygous mouse. As a consequence it was decided to
group wild type and heterozygous for INK4a mice together in order to observe the effects of
the null on lesion formation. Although this approach is not optimal, as there may be a
heterozygous effect, it was the only approach that could reasonable be taken with this data set.
6 LMP 1CAO / INK4a null, 40 LMP 1CAO / INK4a heterozygous or wild type, 17 LMP 1CAO wild
type / INK4a null and 40 LMPlcAO / INK4a heterozygous or wild type mice, were monitored
for spontaneous papilloma formation from 5 weeks of age to 70 weeks old.
No papillomatous lesions were formed on any of the mice that were wild type. The
papillomatous lesions formed on LMPI transgenic mice were grouped according to size as
previously (table 3.2). As seen from figure 3.17, the average number oflesions developing on
LMPlcAO / INK4a null mice is always higher than the average number of lesions developing
on LMPI CAO 1 INK4a heterozygous or wild type mice. With the small number of mice in the
null group it is difficult to conduct a meaningful statistical significance test at single time
points. Using the nonparametric Mann-Whitney Confidence Interval and Test to compare the
lesions that developed on all INK4a null and all INK4a heterozygous and wild type mice at
weeks 9 and 28, no statistical significant difference between the two groups was found
(P=0.5123 and 0.1262 respectively). However, as can be seen from the graph (fig.3.17), the
average number of lesions that developed on the INK4 null mice was always more than the
average number of lesions that developed on the INK4a heterozygous and wild type mice,
throughout the study period (over 42 weeks while INK4a null were on study). If the values
between the two groups were randomly distributed, it would be expected that from one
sampling (week) to the next, either group could show the higher average. This is clearly not
the case. In order to show this statistically a Runs Test was used comparing the distribution of
a pattern over time. If the values in one group are consistently higher (or lower) than the other
group, the Runs Test will evaluate the probability that this pattern can happen by chance.
When a Runs Test was performed on the difference between the average number of lesions
developed on INK4 null and INK4 heterozygous and wild type mice from week 5 to week 47
it is evident that there is a "single Run". That is, at no time did the average for the INK4a null
group fall below the average for the INK4a heterozygous and wild type group. As such P=O
and therefore the pattern between the two groups shows very high statistical significant
difference. Only one of the 6 INK4a null mice did not develop any papillomas but was
removed from study (due to lymphoma) early in the study at week 26. By contrast 8/40 (20%)
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Figure 3.17: Development of spontaneous cutaneous lesions in mice
of line 117/113 and line 117
6 INK4a locus null (-1-)(blue line) and 40 INK4a locus wild type (+1+)
or heterozygous (+I-)(pink line) mice were monitored for 65 weeks
(from 5 weeks old) for the appearance of spontaneous cutaneous lesions.
Note that all the mice shown here are LMP1CAO transgenic.
The graph shows the average number of lesions per mouse alive at each
weekly count. The yellow line shows the data derived from the line 117
mice, transgenic for LMP1CAO and wild type for the INK4a locus
(previously shown in figure 3.14). Note that sudden drops indicate
papilloma regression or removal of a mouse from the study.
mice in the INK4a heterozygous and wild type group never developed a lesion throughout the
study period. The highest lesion load on a single mouse in the study was recorded on an
INK4a null mouse which developed a maximum of 9 papillomas. By comparison the highest
lesion load on a single INK4a heterozygous and wild type mouse was 6. The maximum
number of papillomas developed on a mouse that were equal to or greater than size 2 was 7
and they developed on a null mouse. The earliest time point that papillomas could be detected
on mice from line 117/113 was 5 weeks. Since observation started at 5 weeks, it is possible
that some mice developed papillomas earlier. One out of five of the lesions of line 117/113
that were collected and pathologically examined was shown to be a squamous carcinoma.
This lesion came from a LMPlcAO transgenic I INK4a null mouse. Taken together, these data
demonstrate that papilloma load in the INK4a null background is always larger than the
papilloma load in the presence ofINK4a (either one or both alleles).
In order to assess if the INK4a heterozygous genotype was affecting the data in the
heterozygous and wild type group, the data derived from the previously described cohort of
mice, line 117 transgenic INK4a wild type have been plotted on the graph in figure 3.17.
Since these data are very similar, to the data from the wild type and heterozygous grouped
mice of the cross 117/113 it suggests that the heterozygous genotype is not affecting the
observed phenotype.
Figure 3.l8A shows no obvious differences between INK4a null or heterozygous and wild
type in size 1 lesions that developed except at one time point between weeks 43-49. The most
striking difference is observed when the lesions equal or greater than size 2 for the INK4a
null, heterozygous and wild type mice are plotted. The INK4a null mice appear to show
development of more larger (>size 2) lesions than the heterozygous and wild type mice
(fig.3.l8B). Lesions greater than size 2 presented a similar picture as the total number of
lesions. Also at the beginning of the study when the mice are 5 weeks old, the null mice have
a higher average number of papillomas (0.67) that are equal to or greater than size 2, whereas
the wild type and heterozygous mice start with fewer lesions equal to or greater than size 2
(0.05). Note that at 49 weeks all the null mice have been removed from the study due to the
incidence of lymphoma in this strain. Sudden drops in the curve represent the removal of a
mouse bearing lesions from the study.
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Figure 3.18: Development of spontaDeous
cutaneous lesions in mice of line 117/113
A graph showing the average (mean) number of
lesions size 1 (A) or equal to size 2 or greater (B) per
mouse alive at each weekly count. INK4a null mice
are shown by a blue line and wild type and
heterozygous for INK4a locus mice are shown by a
pink line. All the mice included in this graph are
LMP 1CAO transgenic positive. Note that sudden
drops indicate papilloma regression or removal of a
mouse from the study.
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In order to investigate whether LMPI CAO can activate Ras, an indirect approach was taken to
cross mice of line 117/113 to line 1205 mice. Line 1205 mice bear an activated H-ras
transgene under the control of the HKl promoter, directing oncogenic Ras expression to the
skin epithelium (see section 1.8). As a result of this preliminary study, 4 LMPlcAO +1H-ras +
(Group A), 15 LMPlcAO + 1H-Ras - (Group B), 4 LMPlcAO - 1H-Ras + (Group C) all of
which were in a heterozygous or wild type INK4a background and 7 LMPI CAO +1 INK4a -1- 1
B-Ras - (Group D) were produced. 2 out of 4 mice of Group A (number of lesions developed
on each mouse: 2, 6), 0 out of 15 mice of Group B, lout of 4 mice in Group C (number of
lesions: 6) and 2 out of7 mice in Group D (number of lesions developed on each mouse: 2,3),
developed lesions. In summary, a few lesions formed on mice that were transgenic for
LMPI CAO, or H-ras or both, but there was no obvious difference between the bitransgenic or
the single transgene lesion load. However, the number of mice in each group is too small to
draw any conclusions.
3.5 Does L2LMP1 CAO act as a chemical initiator?
Mice of line 117 show spontaneous papilloma formation when in an FVB strain background.
It was therefore hypothesised, that LMPI CAO could act as a weak tumour initiator. Previous
studies using PyLMP1B95-8 mice demonstrated that LMPI activity augmented chemical
promotion but could not substitute for chemical initiation. To explore this further, a cohort of
mice from line 117 was treated using a minimal chemical carcinogen treatment without
carcinogen initiator and monitored for papilloma or carcinoma formation.
DMBA initiation leads to activation of the H-ras gene as described in the introduction (section
1.5). If overexpression of an oncogene can functionally replace activated H-ras this will make
the use of a chemical initiator redundant (Quintanilla et al., 1986). Since line 117 mice
develop papillomas, the hypothesis is that LMP1cAO can act as an initiator in chemical
carcinogenesis and substitute for an activated H-ras.
A complete topical carcinogenesis regime involves a single application of DMBA followed by
20 biweekly applications of TPA. Different minimal regimes were previously used with line
53 (PyLMP1B95-8) mice showing that LMP1 can partially substitute for the promotion stage
(Curran et al., 2001). In order to test if LMP1CAO in line 117 can act as an initiator, a minimal
regime was followed ofTPA treatment without initial application ofDMBA. IfLMPlcAO can
indeed act as an initiator, then the transgenic mice treated with TPA would show a larger
papilloma load than wild type siblings treated with TPA (section 1.5). In total, 23 animals of
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FVB backcross four (93.75%) and five (96.88%) at 5-6 months old were included in the study.
10 animals were transgenic positive and 13 wild type. The lesion load was monitored from
week 1 after the first TPA application up to week 43 and lesions were recorded according to
their size as previously described (section 3.4).
It was observed that upon TPA application the transgenic mice developed a rough, red and
raised surface to the skin, described as papillomatosis. The papillomatosis phenotype was
persistent throughout the TPA treatment and only evident on transgenic animals (fig.3.19.C).
60% of the transgenic mice in this study developed papillomas by the end of the study period
and the average number oflesions developed was very small (fig.3.19.A, B). None of the wild
type mice developed papillomas. This is not statistically significant (P= >0.25 X2 = 0.033
df=I)' when compared to the percentage of mice that spontaneously developed papillomas.
This implies that minimal TPA treatment did not promote increased papilloma formation and
suggests that LMPlcAO is not acting as a powerful initiator able to replace the activation of the
Il-ras gene in chemical carcinogenesis. However, as seen from fig.3.19.C only the transgenic
mice showed this papillomatosis upon TPA treatment. The last day of the TPA application
was day 25 and 9/10 of the transgenic mice showed this hyperplastic response. A week later
on day 32, 4/10 of the transgenic mice still showed this hyperplasia. Three weeks after the
treatment had stopped (day 46) this phenotype had regressed completely. None of the wild
type mice showed this phenotype so this cannot be a TPA effect alone. It implies that
LMP 1CAO is augmenting the action of TPA as shown in previous studies using PyLMP 1B95-8
(Curran et aI., 2001). At this point, it is not clear why papillomatous lesions form on the
L2LMPIcAO mice and not on PyLMPIB9s-8•
3 The chi-squared test investigates whether a variance in a normal distribution has a specified
value. The formula is :X2=l: [Co-eifel. In this case observed (0) value was 6 and expected (e)
value was 5.714 (since 57.14% of line 117 spontaneously developed lesions and the trangenic
size of this group is 10). This value is later compared on a table with P values at the
appropriate degrees of freedom (df) to determine whether the P value is less than 0.05 and thus
of statistical significance.
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Figure 3.19A, Band C: Development of cutaneous lesions in mice of line 117
that have been TPA treated
10 transgenic and 13wild type siblings of line 117 mice, were monitored for 43
weeks after the first TPA treatment for the appearance of cutaneous lesions.
A) The percentage of mice developing a lesion through the study period is shown,
at the days following the first TPA treatment. Transgenic mice are shown by a blue
line and wild type mice are shown by a pink line.
B) A graph showing the average (mean) number oflesions per mouse alive at each
weekly count. Transgenic mice are shown by a blue line and wild type mice are
shown by a pink line. Note that sudden drops indicate papilloma regression or
removal of a mouse from the study.
C) A graph showing the percentage of mice that showed papillomatosis upon TPA
treatment. Transgenic mice are shown by a blue line and wild type mice are shown
by a pink line.
3.6 Conclusions and Discussion
From the above studies, it is shown that LMPlcAO under the ED-L2 promoter, is expressed in
a wide variety of tissues in the transgenic animals created and this is not restricted only to
epithelial tissues. Lymphoid organs such as cervical lymph nodes and thymus show
expression of the 66kDa LMPICAD at least in line 117. In line 105A and 105B lymph nodes
were not tested for LMPI expression and in line 105B the thymus shows expression of a
smaller product of LMP1 and the full 66kDa LMPICAD was not detected. Other tissues (heart,
kidney and lungs) made up of epithelial cells showed expression of either the 66kDa
LMPI CAD or smaller products. The significance of LMPI expression in these tissues has not
yet been established.
It is not yet clear whether the smaller products observed in the transgenic samples are actually
derived from expression of truncated LMPI or whether this has an effect on the function of
full length LMPl. For example,the 50kDa product observed in the transgenic tissues by
Western blotting could be the lytic LMPI protein or a breakdown product of full length LMPI
or a product of another LMPI promoter other than L2. To date this has not been clarified.
There are at least three promoters associated with LMPI. The first to be detected was ED-Ll
which is 5' upstream of exon 1 ofLMPl and gives rise to 2.8kbp mRNA and the 63kDa full
length LMPI polypeptide. ED-LIA is an internal promoter in intron 1 giving rise to a 2.6 kbp
mRNA and a 50kDa polypeptide (Chen et al., 1995). Also a promoter 5' upstream ofED-Ll
and situated into the first terminal repeat was discovered (LI-TR) that gives rise to a 3.5kbp
mRNA that is preferentially detected in NPC cell lines rather than LCLs (Sadler and Raab-
Traub,1995). Another group has discovered another 5' ofED-Ll promoter, the ED-LIE, that
gives rise to a 3.5kbp mRNA and is specifically activated in epithelial cells. This promoter
has about 5x increased activity when compared to ED-Ll (Chang et al., 1997). An early lytic
cycle promoter that is found 3' of the LMPI gene and just 5' of the LMP2A gene- the ED-L2,
and gives rise to a 0.6kbp mRNA was used to generate the LMPlcAO transgenic mice.
A recent study (Pandya and Walling, 2004) has revealed that presence of the 50kDa lytic
LMPI protein along with full length LMPI leads to decreased half life of the latter and also
decreased LMPI induced activation ofNF-KB, API and STAT in RHEK-l epithelial cells. It
is therefore possible that this occurs in the transgenic tissues of line 117. If the 50kDa band
observed is the lytic form, then the ratio between full length LMPI and lytic LMPI protein
may playa role as to whether there is an observed phenotype in a tissue or not. For example,
both ears and tissues of the gastrointestinal (01) tract of transgenic animals of line 117 show
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the 66kDa LMPlcAO protein. However, a phenotype is observed only in ears and not in the
GI. It could be that this has to do with the fact that in ears the 66kDa protein is expressed at
much higher levels than the GI tract tissues or it could be that a smaller ratio between 66kDa
and SOkDaprotein leads to decreased LMPI CAD function. Note however, that the SOkDais not
seen strongly in 10SA or B transgenic tissues and this argues against any role that the SOkDa
may have.
The expression patterns of LMPI CAD, is consistent with the observed phenotype. Line 117
transgenic mice show hyperplastic ears and enlarged lymph nodes. This is consistent with the
observation that LMPI CAD is expressed at high levels in the ears and it is also expressed in the
lymph nodes. Similarly, line 10SB transgenic animals show the hyperplastic ear phenotype
whereas I05A transgenic animals do not. LMPlcAO is expressed in ears of line 10SB but not
in ears of line 10SA.
Some line 10SA transgenic animals show a wasting phenotype as they grow older. Organs of
the GI tract of transgenic animals of this line show LMPI CAD expression. One hypothesis is
that LMP ICAO expression can lead to aberrant proliferation in those tissues disrupting the
differentiation pattern of the lining of the digestive system leading to problems in nutrient
absorption. However, this is not apparent from the pathological examination of those tissues
and the GI tract tissues of transgenic animals of lines 117 and 10SB also show LMPICAD
expression but no wasting phenotype. An alternative explanation could be that the transgene
in line 10SA has disrupted a cellular gene and the observed phenotype is unrelated to the
LMPI CAO expression. Also, in one case, a lymphoma was observed in these tissues. Perhaps
this interferes with GI function in other wasted animals but this has not been examined.
The appearance of spontaneous papillomas on line 117 prompted the investigation as to
whether LMPI CAO is acting as an initiator or as a promoter. It was subsequently shown that
LMPI CAO cannot act as an initiator in the context of chemical carcinogenesis but rather acts as
a tumour promoter and replaces TPA. This is in agreement with previous data obtained in this
laboratory using LMPI895-8 transgenic animals in chemical carcinogen studies (Curran et al.,
2001). However, the observed phenotype of line 117 mice where S7.14% of the mice
spontaneously develop papillomas, shows that LMPI CAD can lead to activation of signalling
pathways that initiate the process of carcinogenesis but that LMPI CAO does this to a low level,
since only a few and small spontaneous papillomas develop per mouse and few ears go on to
become squamous cell carcinomas.
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From the data described here and published (Curran et aI., 2001; Macdiarmid et aI., 2003), it
was found that the two LMPI strains - B95-8 and CAO - show no significant differences in
terms of initiation in the context of chemical carcinogenesis. A more progressed phenotype is
observed on the LMPI CAO animals when compared to the LMPI B95·8 animals. Even though
we cannot at the moment exclude the hypothesis that LMP 1CAO may be more tumourigenic, as
has been suggested by several groups in the past, we cannot confirm it either. The expression
of the transgene in lines 53 and 117 is still not known. Initial studies performed in this
laboratory using the LMP1895•8 (line 53) transgenic animals indicated that the transgene
expression is probably localised to the suprabasal layer. This is the non proliferative
differentiating layer of the epidermis. Despite repeated attempts of mine to investigate
expression patterns by RNA in situ, on tissues from line 117 these proved unsuccessful. It is
possible however, that the LMP 1CAO transgene is expressed in the basal epidermal layer. This
is the proliferating layer of the epidermis and so it is expected that if LMP 1 plays any effects
on proliferation, differentiation or apoptosis that these could be magnified just by the fact that
the transgene is expressed in a proliferating compartment. This can be seen in other transgenic
mouse models, for example the TGFatransgenic animals. As has already been discussed,
suprabasal expression of TGFa leads to hyperkeratotic skin (Dominey et al., 1993) whilst
basal TGFa expression leads to ear thickening and spontaneous papilloma formation (Vassar
and Fuchs, 1991). Similarly, Ras transgenic animals show an increase in the severity of the
phenotype when the transgene expression is in the basal layer than if the trans gene expression
is in the suprabasal layer (Bailleul et al., 1990; Brown et al., 1998; Dajee et aI., 2002;
Greenhalgh et aI., 1993a). Elucitating the spatial expression ofLMP1 transgene in lines 53 and
117 is of utmost importance as this will allow direct comparison of the effects of the two
strains in the epithelium in vivo.
Upon removal of the INK4a locus (i.e. no p 16INK4a or p 19ARF expression), an increased lesion
load both in terms of numbers and size is observed on the transgenic for LMP1 CAO mice.
Furthermore, a spontaneous lesion that appeared on an LMPI CAO+ 1 INK4a null mouse of line
117/113 was described as a squamous cell carcinoma rather than as a keratoacanthoma which
was what was usually observed on mice of line 117. These results are in agreement with
previous results obtained in the laboratory with mice of line 53 (PyLMPI B95.8) crossed to an
INK4a null strain (Macdiarmid et aI., 2003). When the 53/113 mice were chemically treated
and the lesion load recorded, it was observed that LMPI895-8+ 1 INK4a null mice developed
more lesions faster that became larger in size and progressed to carcinoma. Taken together,
these data show that there is a cooperation between the effects ofLMPlcAO and loss ofINK4a
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locus in vivo. This would explain what is observed in NPC where the INK4a locus is deleted
or hypermethylated during the development of the lesion. The data presented here with
respect to LMP 1CAO are in accord with published data from this laboratory concerning
LMPI 895-8 indicating that LMPI mediates a lesion growth inhibition effect through products of
the INK4a locus (pI6INK4aor p I9ARF). However, this seems to be contrary to the published
reports that LMPI inhibits both pI6INK4aexpression and function (Ohtani et al., 2003; Yang et
al., 2000a). Nevertheless, it has been found that in LCLs, LMPI does not lead to pI6INK4a
inhibition, or its not sufficient for its inhibition (Hayes et al., 2004).
It is not clear if ras activation is part of tumourigenesis in line 117 mice. To examine this,
sequencing of lesions that spontaneously developed on line 117 transgenic mice, with the
focus on codons 12, 13, 60 and 61 of the ras gene that are known to develop spontaneous
activating mutations, is needed.
Another phenotype observed is that of the reactive cervical lymph node. These lymph nodes
do not show evidence of neoplasia at the stage analysed but appear to be reactive. This
phenotype is not observed in the transgenic negative and is observed in 100% of the transgenic
mice. Since LMPI CAO is not a foreign protein to these mice, it could be that it leads to "fake"
CD40 signalling thus simulating the interaction between B- and T-cells and showing this
phenotype. It would be interesting to investigate this further by identifying whether it is the B
or T cell compartments that are expanded in those lymph nodes and in which LMP1 IS
expressed.
To conclude, expression of LMPI CAO in the transgenic animals, is predominantly directed to
epithelial tissues as well as some lymphoid tissues. Its expression leads to hyperplasia and
spontaneous papilloma formation when in a genetically susceptible strain background.
However, LMP1CAO expression is not sufficient to replace the need for a chemical initiator in
the context of chemical carcinogenesis. Nevertheless, lesions developing in the ear can
progress to carcinoma.
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Chapter 4: Signalling Pathways Activated by LMP1
The primary aim of the work described in this chapter was to examine signalling pathways
affected by LMPICAOin the epithelium in vivo, with an emphasis on the RaslMAPK pathway.
Previous studies showed upregulation of EGFR levels in both NPC biopsies and epithelial
cells (C33A) in vitro in response to LMPI expression (Miller et al., 1998a; Miller et al., 1997;
Sheen et al., 1999; Zheng et al., 1994a). Given these facts and the similarity in phenotype
between LMPI transgenic mice and TGFa transgenic mice (see 1.7), it was hypothesised that
LMPI may act via upregulating TGFa. Among the pathways activated by EGFR is the
Ras/MAPK cascade. A previous report showed LMPI activation of MAPK in a Ras-
dependent way in Rat-I fibroblasts (Roberts and Cooper, 1998), therefore, it was decided to
investigate this pathway using the affected tissues from the transgenic mouse lines generated
in the laboratory.
The aims of this chapter were:
1. Does LMPI cAolB9s-sleadto upregulation ofTGFa?
2. Does LMPI CAOlead to upregulation or increased activation ofEGFR?
3. Does LMPI CAOaffect the RaslMAPK in any way?
4. Does LMPlcAO activate the PI3K1Akt pathway? (another major pathway activated by
EGFR)
5. What other pathways are activated by LMPI CAO in the epithelium in vivo?
4.1 Outline of Approach
In order to explore the status of several signalling pathways, affected tissues (ears) from mice
of line 117 and (adult skin, pup epidermis, pup dermis) from line 53, both transgenic and age
matched sibling controls were collected. The transgenic ears were staged according to their
phenotype (see fig.1.14). Skin from 3-7 day old pups from mice of line 53 was collected and
separated into the epidermal and dermal components. In order to detect the levels of total or
activated protein, protein extracts were prepared using Ripa buffer and analysed by Western
blotting. In order to examine DNA binding activity whole protein extracts from affected
tissues were prepared as described previously (see 2.2.4H) and used in EMSA experiments.
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Results
4.2 LMP1 CAO and the TGFaJEGFRIRasIMAPK Signalling Pathway
Initially, expression levels of TGFu were examined. Figure 4.1 shows that TOFu is found
upregulated in the phenotypic transgenic pup epidermis (5 days old) of mice of line 53 but not
in transgenic dermis or adult skin or when compared to control samples. The cleaved soluble
product of TOFu ranges from 5-20kDa depending on the degree of glycosylation. The 10kDa
product observed in fig.4.1, could therefore be a soluble product ofTGFu. Similarly, TOFu
was also detected in ear protein extracts of line 117mice (Stevenson et. al., in press). Protein
was also extracted from cell pellets derived from carcinomas that developed after chemical
carcinogen treatment on transgenic and wild type mice of lines 53 and 117. When these
samples were separated by SDS-PAGE, the gel blotted and probed with anti-TOFu antibody,
there was no evidence of either the uncleaved or the cleaved form of TOFu (fig.4.2). It is
possible that in these cell pellets the TOFu soluble form is secreted into the cell culture
medium or it has a very fast turnover. In order to test this, cell culture medium from these
cells could be examined for the presence of TGFu using an enzyme linked immunosorbent
assay (ELISA) approach or by an IP followed by a Western blot. It is also possible that since
these cells are established immortalised cell lines, that overexpression of TOFu is not selected
for.
The next logical target was to investigate whether EGFR, the receptor for TOFu, was affected
in any way as a result of increased expression of its ligand. Total EGFR levels were slightly
higher in transgenic ears (fig.4.3). However, levels of total EOFR decreased as the phenotype
progressed (stage 1: 1.36 fold, stage 2: 1.1 fold, stage 3: 0.85 fold when compared to controls
normalised against ~ tubulin, see table 5.3). In contrast, smaller EGFR products (sizes
approximately 70, 66 and 50kDa) were observed in transgenic ears of increasing phenotype
severity (stage 1: 1.13, stage 2: 1.60, stage 3: 3 fold when compared to controls normalised
against ~ tubulin, see table 5.3). Similar results were obtained when using line 53 tissues
(fig.4.4). Total EOFR levels are higher in the wild type epidermis as compared to transgenic
epidermis whilst using an antibody specific for the phosphorylated EOFR form, led to
detection of increased possible breakdown products of EGFR (50, 45, 40kDa) in the
transgenic epidermis as compared to the wild type epidermis. It is of interest that when cell
pellet protein extracts were probed with anti-total EGFR, the 170kDa band did not show any
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Figure 4.1: TGFa expression in the skin of line 53 mice
(PyLMPI B95-~.
5 day old pup skins were collected and separated into
epidermal and dermal components. Whole adult skin was also
collected. Protein was extracted using Ripa buffer. 75J.lgof
protein extract/track was separated by 15% SDS-PAGE and
the gel was blotted. The blot was probed with a rabbit anti-
mouse TGFa primary antibody (1:1000) and a goat anti-rabbit
IgG-HRP secondary antibody (1:4000) and visualised with
ECL+. The lOkDa band corresponding to TGFa is indicated.
Molecular weights according to the marker track are shown.
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Figure 4.2: TGFa expression in LMPI transgenic and
control carcinoma derived cell lines.
Protein was extracted from 5 day old pup epidermis (epi.)
and from cell pellets using ripa buffer. 100llg of protein
extract/track was separated by 15% SDS-P AGE and the
gel was blotted. The blot was probed with a rabbit anti-
mouse TGFa primary antibody (1: 1000) and a goat anti-
rabbit IgG-HRP secondary antibody (1 :4000) and
visualised with ECL+. The lOkDa band corresponding to
TGFa is indicated. Molecular weights according to the
marker track are shown.
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Figure 4.3: EGFR expression in the ears of line 117 (L2LMPlcA<»
mice.
Protein extracts were prepared from ear samples of increasing
phenotypic stage, stage 1(st1), stage 2(s12), stage 3(s13) along with a
stage 1 aged matched control (cl).
100~g of protein extract/track was separated by 7.5% SDS-PAGE and
the gel was blotted. The blot was probed with a rabbit anti-mouse total
EGFR primary antibody (1:1000) and a goat anti-rabbit IgG-HRP
secondary antibody (1:4000) and visualised with ECL+. The 170kDa
band corresponding to total EGFR is indicated. Molecular weights
according to the marker track are shown.
The blot was stripped and re-probed with f3 tubulin as a loading control
(shown below).
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Figure 4.4: Total EGFR and phospho-EGFR (TyrS45)
expression in the epidermis of 5 day old pups of line 53
(PyLMPI B95-,,).
Protein extracts were prepared from epidermis samples of 5 day
old pups both transgenic (+) and wild type siblings (C).
100J,lgof protein extract/track was separated by 7.5% SDS-
PAGE and the gel was blotted. The blot was probed with a
rabbit anti-mouse total EGFR primary antibody (1:1000) or
after stripping with a rabbit anti-mouse phospho-EGFR (Tyr
845) antibody (1: 1000) as indicated and a goat anti-rabbit IgG-
HRP secondary antibody (1:4000) and visualised with ECL+.
The 170kDa band corresponding to total EGFR is indicated.
Molecular weights according to the marker track are shown.
decrease in transgenic samples, instead levels of total EGFR were shown to be equivalent or
higher in cell pellets derived from transgenic animals. The smaller products of EGFR are
prominent in the cell pellets obtained from transgenic positive carcinomas (fig.4.5a) and when
an antibody against the phosphorylated EGFR was used, it was shown that some of the smaller
products are phosphorylated forms ofEGFR (fig.4.5.b).
If the breakdown products observed reflect faster turnover of activated EGFR in the transgenic
tissues, then this would suggest that this is due to an increase in EGFR activation and hence
activation of downstream pathways. The first of the EGFR pathways that was investigated
was the Ras/MAPK pathway (fig.4.6). Levels of total and phosphorylated c-Raf-I were
examined using antibodies against the total or phosphorylated form of the protein. However,
the specific 74kDa band corresponding to c-Raf-I was not detected on the blot (data not
shown). Use of a positive control for c-Raf-I would have clarified this.
The next target examined in the pathway was MEK1I2. Levels of total MEK1I2 and
phosphorylated MEKI/2 were examined in line 117 tissues (fig.4.7). In order to quantify the
difference in the levels of MEKI/2 and phosphorylated MEKI/2 expression in ear samples,
the respective autorads were scanned and using the Kodak ID 3.5.2 program, the bands of
interest were manually selected and analysed. The background sum intensity value was
subtracted from the total sum intensity value of each of the bands to give the net sum intensity.
The ratio of phosphorylated MEKI/2 band net intensity over total MEKI/2 band net intensity
was calculated for each of the samples. For example the phosphorylated MEK1/2 net intensity
of control lover the total MEK1I2 net intensity of control I gave a value of 0.173. For each
of the transgenic phenotypic stages, this value was compared to the value of the corresponding
control. For example transgenic stage 1 to control 1 ratio is 4.40 (0.762/0.173) (Table 4.1). In
this way the levels of phosphorylated MEK1I2 to total MEK1I2 were calculated.
Sample Ratio Phospho-MEKl/2: total Stage x: control
MEK1/2 x
Cl 0.173
C2 0.264
C3 0.226
Stl 0.762 4.40
St2 0.789 3.00
St3 0.167 0.74
Table 4.1: Densitometric analysis of phospho-MEK1I2 to total MEK1I2.
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Figure 4.5: EGFR and pbospbo-EGFR expression in cell
pellets derived from line 53, lt7 and 100B carcinomas.
Protein was extracted from cell pellets and lOOJlg of protein
extract/track was separated by 10010 SOS-PAGE and the gel
blotted. The blot was probed with a rabbit anti-mouse total
EGFR primary antibody (1: 1000) stripped and reprobed with a
rabbit anti-mouse phospho-EGFR (Tyr 845) primary antibody
(1:1000) and a goat anti-rabbit IgG-HRP secondary antibody
(1:4000) and visualised with ECL+. The 170kDa band
corresponding to total EGFR is indicated. Molecular weights
according to the marker track are shown. The blot was tripped
and reprobed with IJ tubulin to indicate loading levels (shown
below).
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Figure 4.6: EGFR activates the RaslMAPK cascade
A simplified pathway diagram indicates TGFa binding to EGFR
causing the receptor to homolheterodimerise. This leads to its
autophosphorylation and activation. The activated receptor can
recruit GRB and SOS that allow exchange of GDP for GTP thus
activating Ras. Activated Ras leads to Raf activation by
phosphorylation (indicated by a red star). Activated Raf can lead to
phosphorylation and activation of MEK1I2 which in tum leads to
phosphorylation and activation of ERKI12. Downstream targets of
ERKI12 include transcriptional factors Elk-I, C-Myc, C-Jun, C-Fos
and Sap-I.
Figure 4.7: Total MEKll2 and phospho-MEKll2 of
ean of line lt7 mice (L2LMPlcA~
Protein extracts were produced from ear samples of
increasing phenotypic stage, stage I(stl), stage 2(st2),
stage 3(stJ) and stage 1-3 age matched controls (cl-J).
lOOJ.lgof protein extract/track was separated by 10010SDS-
PAGE and the gel blotted. The blot was probed with a
rabbit anti-mouse phosphorylated MEK 1/2 primary
antibody (1:1000) (A) and a goat anti-rabbit IgG-HRP
secondary antibody (1:4000) and visualised with ECL+.
The blot was stripped and reprobed with a rabbit anti-
mouse total MEKII2 (1:1000), followed by a goat anti-
rabbit IgG-HRP secondary antibody (l:4000). The 45kDa
doublet corresponding to MEl< 112 is indicated. Molecular
weights as per marker track are shown. The blot was
stained with Ponceau's stain to indicate loading levels (C).
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It was found that the levels of phosphorylated MEK1I2 were higher in stages 1 and 2 of
phenotypic ears (stage 1: 4.4 fold, stage 2: 3 fold, compared to controls normalised against
total MEK 112) but stage 3 phenotypic ears showed a decrease in levels of phosphorylated
MEK1I2 down to control levels (stage 3: 0.74 fold). Levels of total MEKI/2 were relatively
equal in all samples (fig.4.7). This suggests that MEK1/2 is activated in the phenotypic tissue
to a greater extent than controls but that this activation is "turned off' as the phenotype
progresses over time, perhaps by a negative feedback loop.
In cell pellets once again, using total MEK showed no difference among transgenic and wild
type samples (fig.4.8).
Levels of total and phosphorylated ERK1I2 (the downstream target of MEK1I2) were
examined by using an antibody against anti-phospho-ERK1I2, stripping and reprobing the blot
with an antibody against total ERK1I2. Densitometric analysis of these data was performed as
described earlier. Whereas total ERKI/2 levels are relatively constant across the control and
transgenic samples (fig.4.9b), the levels of activated ERK1I2 increase from stages 1 to 3 of the
transgenic ears (fig.4.9a). Lanes corresponding to cl and c2 which are the age matched wild
type controls of transgenic stages 1 and 2 are clearly relatively underloaded as seen from the
Ponceau stain (fig.4.9c). The ratio of phosphorylated to total ERK2 for stage 1-3 ears was
1.49, 1.80 and 1.30 fold respectively when compared to controls normalised against total
ERK1I2 (table 4.2).
Sample Phospho-ERK1I2: total ERK1I2 Stage x: control x Phospho-ERK1I2
(stage x):
phospho ERK1I2
(control x)
Cl ERK2 0.296
C2 ERK2 0.344
C3 ERK2 0.465
Stl ERK2 0.440 1.49 0.94
St2 ERK2 0.621 1.80 1.46
St3 ERK2 0.605 1.30 1.57
CIERKI 0.666
C2 ERKI 0.475
C3 ERK.l 0.600
Stl ERKI 0.626 0.94 1.10
St2 ERKI 1.160 2.44 2.02
St3 ERKI 0.500 0.83 2.17. .Table 4.2: Densitometric analysis ofphospho-ERK1I2 to total ERK1I2 •
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Figure 4.8: Total MEKI/2 expression in LMPI and
control carcinoma derived cell lines.
Protein extracts were produced from cell pellets. LMP 1
status is indicated by wt =wild type; tg= transgenic.
100llg of protein extract/track was separated by 10% SDS-
PAGE and the gel was blotted. The blot was probed with a
rabbit anti-mouse total MEK1I2 primary antibody (1: 1000)
and a goat anti-rabbit secondary antibody (1:4000) and
visualised with EeL+. The 45kDa doublet corresponding
to MEKI12 is indicated. Molecular weights according to the
marker track are shown.
Figure 4.9: Total aDd pbospho-ERKlIl expressioD ia the
un ofIDe tt7 (L2LMPtCA~mice.
Protein extracts were prepared from ears of increasing phenotype
stages 1-3 and age matched controls cl-3. lOOpg of protein
extract/track was separated by lOOAlSDS-PAGE and the gel was
blotted. The blot was probed with a rabbit anti-moose phospho-
ERKII2 (A) primary antibody (1:1000) and a goat anti-rabbit
IgG-HRP secondary antibody (1:4000) and visualised with
ECL+. Subsequently, the blot was stripped and reprobed with a
rabbit anti-mouse total ERKII2 (8) primal)' antibody (1:1000).
The 44 and 42kDa bands correspooding to ERK1I2 are shown.
Molecular weights according to the marker track are indicated.
The lower panel (C) is a Ponceau staining of part of the blot to
indicate loading levels. Note that eland c2 are underloaded but
c3 and stl-3 are equally loaded.
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The ratio of phosphorylated to total ERKI for stage 1-3 ears was 0.94, 2.44 and 0.83 fold
respectively. This suggests that ERK1I2 is activated in the transgenic tissues compared to
controls. For both ERKI and ERK2 the activation is higher at stage 2 than at stage 1. From
these data it is not clear if this activation is reduced again in real terms at stage 3, since
(compared to the Ponceau stain) there may be more total ERK1/2 at stage 3. Comparing the
levels of phospho-ERKI and 2 at stage 3 to stage 2, suggests that ERK remains active in the
transgenic samples compared to controls. It is possible that MEKl/2 is activating ERKI
directly since they are both activated in the transgenic samples but ERK2 must be activated by
another kinase independent ofMEK1I2 at later stages when MEK1I2 is no longer activated.
ERK1I2 can activate several downstream transcription factors including Elk-l , c-Myc, c-Jun,
c-Fos and CIEBP beta. In order to investigate whether activated ERK1I2 could activate
downstream transcription factors, the levels of Elk-l protein in control and transgenic ear
samples, were examined using an antibody against Elk-I. This failed to reveal any bands that
correspond to correct Elk-I size (data not shown). Elk-l is a transcription factor that can bind
the sequences of the serum response element (SRE) and activate transcription of linked genes.
SRE is an AIT rich DNA sequence found upstream of many genes including genes of the los
family. Serum response factor (SRF) is one of the factors that bind to the SRE along with
other transcription factors such as Elk-l to form the ternary complex factor (TCF). SRF binds
and activates transcription by binding to SRE sequences in a TCF dependent and TeF
independent way. Activation of TCF can be achieved through the RasIMAPK, p38 MAPK
and the JNK pathways.
In order to examine the transgenic and control extracts for the presence of activated factors
which can bind to specific DNA elements, an EMSA using an oligo containing the SRE site
was performed.
Whole protein extracts from transgenic ears and age matched sibling controls, were incubated
with a labelled SRE oligo. Specific binding was competed out using an excess (SOx) of
unlabelled oligo. A positive control extract from NIH3T3 cells, known to show SRE binding
activity was used. A band (A) representing specific binding was detected in transgenic
extracts (fig.4.IO). This band was barely visible or not apparent in control samples.
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Figure 4.10: An EMSA showing specific binding of ear extracts
of line 117 (L2LMP1 CAO) to SRE binding oligo.
Protein was extracted from transgenic (+) and wild type ears (-)
(Iuug/track) incubated with labelled SRE oligo and then separated
by 6% PAGE. IOug ofNIH3T3 cell extracts were used as positive
control (c). No extract is indicated by (0). 50x competitor
(unlabelled oligo) was added to the samples indicated (+). The
transgenic samples (mouse numbers: 347 and 349) show specific
binding to the SRE sequence while the wild type samples (mouse
numbers: 351 and 353) show comparatively little binding activity.
The specific SRE binding band is indicated (A).
In order to ascertain if these extracts were of equal quality and quantity, binding to the
recognition sequence for Sp1, a ubiquitous transcription factor, was conducted in parallel
(fig.4.II). From this it can be seen that control extract 353 may be of lower quality and/or
quantity than the transgenic extracts. However, control extracts 351, 375 and 362 (used in
subsequent assays) show equal if not stronger Sp1 oligo binding activity compared to the
transgenic samples. Therefore, the transgenic positive extracts shown in figure 4.10, show a
greater SRE binding activity than controls.
Binding levels of protein extracts of control and transgenic ears to an oligo containing the
ETSI binding site were also investigated. Some of the ETS family members such as Elk-I and
SAP-I are activated by ERK1I2. From the EMSA results, there seems to be no significant
differences between transgenic and wild type samples (fig. 4.12). These results are not
entirely clear as in the wild type samples the ETS1 specific band and other non specific bands
are not clearly observed, so ETSI remains a possible ERKI/2 target in this system.
In conclusion, LMPI CAO can upregulate TGFa. expression in these tissues, possibly leading to
faster EGFR turnover and MEK1I2 activation. MEK1I2 activation may be countered by a
negative feedback loop that prevents the increased activation as the phenotype worsens.
LMPlcAO can lead to activation ofERK1I2 and in the advancing stages of the phenotype this
activation is independent of MEKl/2 activation. Downstream targets of activated ERK1I2
such as transcriptional factor Elk-I may then be activated leading to increased binding to SRE.
As seen from these results, LMPlcAO can activate the Ras/MAPK pathway in the epithelium
in vivo, possibly via TGFa. upregulation and EGFR activation.
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Figure 4.11: An EMSA showing specifIC binding of ear
extracts ofline 117 (L2LMPlcA<» to Spt binding oligo.
Protein was extracted from transgenic (+) and wild type ears (-)
and 5J1WU"ackwere separated by 6% PAGE. 5J1g of A431 cell
extracts were used as positive control (c). Labelled oligo
without extract (0) was also added as an extra control. lOOx
competitor (unlabelled oligo) was added to the samples
indicated (+). The transgenic samples (mouse numbers:
347,349,359) show specific binding to Spl sequence as
indicated by the specific bands A and B and these are competed
out upon addition of the competitor. The same is true for wild
type samples (moose numbers: 367,375,351, 353,362. Sample
numbers 367 and 353 show weaker specific binding and this
may reflect lower quality or quantity of these two samples. The
non specific band C, is seen in all the samples.
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Figure 4.12: An EMSA showing specific binding of ear extracts of line
117 (L2LMPlcA<» to ETSI binding oligo.
Protein was extracted from transgenic ears (+) and wild type ears (-) and
5Jlg/track were separated by 6% PAGE. 5Jlg ofNIH3T3 cell extracts were
used as positive control (c). Labelled oligo without extract (0) was also
added as an extra control. lOOx competitor (unlabelled oligo) was added to
the samples indicated (+). The ETSl specific band A that is partially
competed out upon addition of the competitor is seen in sample numbers 347,
349 and 359. Band A is not seen in samples 367 and 375 but these samples
also show weaker bands Band C. The non specific bands Band Care
indicated.
4.3 LMP1cAO and P13K1Aktpathway
Another target ofEGFR signalling that plays a role in oncogenesis is the PI3K1Akt pathway.
Ligand binding to EGFR, can activate PI3K by phosphorylation. Active PI3K can generate
PIP3s that go on to activate PDKI, by phosphorylation. Active PDKI and PIP3s together
activate Akt by binding to its plekstrin homology domain and phosphorylating it at Thr308.
Phosphorylation at Ser473 is also needed but it is still unclear whether PDKI can
phosphorylate Ser473 or whether another protein kinase specifically phosphorylates Ser473
(Hill et aI., 2002). A negative regulator of PI3K and PDKI is protein phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) that catalyses the dephosphorylation of PIP3s.
Activated Akt, translocates to the cytosol where it is dephosphorylated and inactivated by
PP2A. Activation of Akt affects several pathways. Active Akt inactivates Caspase-9 and Bad
thus inhibiting apoptosis, it can activate NF-KB and destabilise p53. It can also inhibit
p211cipllwafl and p27/kipl from inducing cell cycle arrest by directly phosphorylating them
thus leading to the release of cyclins. It also phosphorylates and inactivates glycogen synthase
kinase 3 ~ (GSK3~) thus inhibiting CyclinDI degradation. Akt can also activate endothelial
nitric oxide synthase (eNOS) that increases blood supply to tumour cells and increases
metalloprotease production.
In order to investigate the activation status of this pathway in LMP 1CAO tissues, antibodies
against activated Akt (Ser473 and Thr308), total Akt, PTEN and phosphorylated GSK3~ were
used with both tissue and cell pellet extracts. Protein extracts from transgenic ears of
increasing phenotype stages (stl-3) of line 117 and transgenic pup epidermis of line 53
alongside age matched sibling controls (c1-3) were separated by SDS-PAGE and the gels were
blotted and incubated with the appropriate antibodies. Levels of phosphorylated Akt (Ser
473) in line 117 ear protein extracts, possibly show a slight decrease in stages 2 and 3
(fig4.13). Levels of phosphorylated Akt (thr) also show a decrease in transgenic ears from
stages 1-3 (fig.4.I4). Levels of total Akt (fig.4.14) may be slightly reduced in stages 1-3, as
the Ponceau staining of the blot suggests that each track is equally loaded, however, this is not
unequivocal. Levels of total Akt show no difference among wild type and transgenic samples
when further samples were analysed (fig.4.15).
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Figure 4.13: Phospho-Akt (ser) expression in the ears of Hne1l7
(L2LMPI CA<» mice.
Protein extracts were prepared from ears of line 117 of increasing
phenotypic stages 1-3 (stI-3) alongside age matched controls (cI-3).
IOOJlg of protein extract/track was separated by 10% SDS-PAGE and
the gel was blotted. The blot (A) was probed with a rabbit anti-mouse
phospho-Akt (ser) primary antibody (1:1000) and a goat anti-rabbit
IgG-HRP secondary antibody (1 :4000) and visualised with ECL+. The
60kDa band corresponding to phospho-Akt is indicated. Molecular
weights according to the the marker track are shown. A Ponceau's
staining of the blot to indicate loading levels is shown (B).
Figure 4.14: Phospbo-Ald (dlr) od total Akt expression in
ean of line 117 (LlLMPlcA,,) mice.
Protein extracts were prepared from ears of line 117 of
increasing phenotypic stages 1-3 (stl-3) alongside age matched
controls (cl-3). l00~g of protein extract/track was separated by
loolo SDS-PAGE and the gel was blotted. The blot (A) was
probed with a rabbit anti-mouse phospho-Ala (tbr) primary
antibody (1:1000) and a goat anti-rabbit IgG-HRP secondary
antibody (1:4000) and visualised with ECL+. The blot was
stripped and reprobed with rabbit anti-mousetotal Akt (1:1000)
primal)' antibody (B) and secondary antibody as before. The
60kDa band corresponding to Akt is indicated. Molecular
weights according to the marker track are shown. A Ponceau's
staining of the blot (C) used as a loading control is shown.
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Figure 4.15: Total Akt expression in the skin or ears of
lines 53, 105A, 105B, 104, 106 and 117 mice.
Protein extracts were prepared from epidermis (epi.) and/or
ears oflines 53, 105A, 105B, 104, 106 and 117 mice. 100Jig
of protein extract/track was separated by 10% SDS-PAGE
and the gel was blotted. The blot was probed with a rabbit
anti-mouse total Akt primary antibody (1:1000) and a goat
anti-rabbit IgG-HRP secondary antibody (1:4000) and
visualised with EeL +. The 60kDa band corresponding to
total Akt is indicated. Note that samples 104 and 106, have
been shown from previous experiments to be degraded.
Molecular weights according to the marker track are shown.
Densitometric analysis on the two blots shown in fig.4.14, showed that when the ratio of
phosphoAkt (thr) to total Akt from stage 1 was compared to the corresponding ratio for
control 1 there was a slight decrease as this comparison gave a value of 0.82 fold. Similarly,
stage 2 and stage 3 ears when compared to their corresponding controls showed a reduced Akt
(thr) activation (0.68 and 0.85 fold respectively)(Table 4.3).
Sample Ratio Phospho-Akt (thr) : total Akt Sta2e x: control x
Cl 0.097
C2 0.096
C3 0.096
Stl 0.079 0.82
St2 0.065 0.68
St3 0.081 0.85
Table 4.3: Densitometric analysis of phospho-Akt to total Akt.
In support of this result, analysis of further samples from phenotypic transgenic ears of lines
105B and 117, show a decrease in the levels of phosphorylated Akt both at serine and
threonine residues (fig.4.16). As a control, transgenic ears of line 105A that are not
phenotypic and do not express LMPI CAO, show no difference when compared to non
transgenic sibling ears of line 105A. This indicates that the change in activation of Akt is due
to the expression of LMP I and phenotypic consequences. Levels of total Akt were
investigated in cell pellets and were found to be comparable between transgenic positive and
transgenic negative cell lines (data not shown). One of the effects activated Akt has is to
induce an anti-apoptotic effect. The above results suggest that in transgenic tissues, apoptosis
in not inhibited through the Akt pathway.
An inhibitor of Akt activation is PTEN. In order to investigate PTEN status in these tissues, a
panel of tissue extracts from several LMPI transgenic mouse lines generated in the laboratory
was examined. Levels of PTEN appear to be equivalent in the control and the transgenic
tissues examined (fig4.17a).
One of the downstream targets of Akt is GSK3~. In order to investigate the status of
phosphorylated GSK3~, the same panel of tissue extracts from the LMPI lines were
examined. In the epidermis, both wild type and transgenic, phosphorylated GSK3~ is absent
or below detection. In the ears examined, there is no difference in the levels of
phosphorylated GSK3~ between wild type and transgenic samples (fig4.17b). Levels of
phosphorylated GSK3~ in cell pellet extracts showed no difference (fig.4.l8).
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In conclusion, it seems that LMPI leads to a reduction in the activation status of Akt in
transgenic phenotypic tissues. This appears to be independent of the upstream inhibitor of
Akt, PTEN and does not show any measured effect on the downstream factor GSK3~.
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Figure 4.16: Phospho-Akt (ser) and (thr) expression in
the ears of lines 105A, 105Band 117mice.
Protein was extracted from ears of both wild type and
transgenic mice. 100llg of protein extract/track was separated
by 10% SDS-PAGE and the gel was blotted. The blot was
probed with a rabbit anti-mouse phospho-Akt (ser for A and
thr for B) primary antibody (1:1000) and a goat anti-rabbit
secondary antibody (1:4000) and visualised with ECL+. The
60kDa band corresponding to phospho-Akt is indicated.
Molecular weights as per marker track are shown.
Figure 4.17: PTEN and pliospho-GSK3fS expression in skiD
aDd earsofliaa 53, l05A, 105B, 113 aDd 117 Blice.
Protein was extracted from 5 day old pup epidermis (line 53) and
ears both wild type and transgenic (lines 105A, 105B, 113 and
117). l00",g of protein extractJtrack was separated by 10010
SDS-PAGE and the gel was blotted. The blot was probed
initially with a rabbit anti-mouse pbospbo-PTEN primary
antibody (l:1000) and a goat anti-rabbit secondary antibody
(1:4000) and visualised with ECL+ (A). The blot was stripped
and reprobed with a rabbit anti-mouse pbospbo-GSlOJ\ primary
antibody (1:1000) and a goat anti-rabbit secondary antibody
(1:4000) and visualised with ECL+ (B). The 54kDa PTEN and
46kDa band corresponding to GSlOp are indicated. Molecular
weights according to the marker track are shown. The bid was
stripped and reprobed with a goat anti-mouse actin primary
antibody (l:1000) and a donkey anti-goat secondary antibody
(1:4000) and visualised with ECL + in order to determine loading
levels (C).
Note that the wild type line 53 ear track and the transgenic line
53 epidemnis samples are underloaded as seen by the actin blot.
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Figure 4.18: Pbospbo-GSK3Jl expression in LMPI and
control carcinoma derived cell lines.
Protein was extracted from cell pellets derived from
carcinomas of both wild type (wt) and transgenic (tg) mice
of lines 53, 105B, 113 and 117. 100J,lg of protein
extract/track was separated by 10% SDS-PAGE and the
gel was blotted. The blot was probed with a rabbit anti-
mouse phospho-GSK3f3primary antibody (1:1000) and a
goat anti-rabbit secondary antibody (1:4000) and
visualised with ECL+. The 46kDa band corresponding to
GSK3f3is indicated. Molecular weights according to the
marker track are shown.
4.4 LMP1 CAO and the p38 MAPK pathway
Several other pathways apart from MAPK and PI3KJ Akt have been shown to be activated by
LMPI in epithelial cells, B cells and rat fibroblasts in culture. These include the p38MAPK
pathway, the JNKJAPI, the NF-KB pathway and the JAKISTAT pathway. In order to
investigate whether LMPI CAO could activate these other pathways in the epithelium in vivo,
control and transgenic ear extracts from line 117 were examined by Western blotting.
The first of these pathways to be investigated was p38MAPK. An antibody specifically
directed against activated p38 was used. Levels of activated p38MAPK are increased in
transgenic samples (fig.4.19). This is evident from stage 1 but the difference becomes more
intense in stages 2 and 3. This pathway was not investigated any further as the main focus of
the thesis was the MEKIERK pathway.
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Figure 4.19: p38 activation in ears of line 117 (L2LMPlcA~
mice.
Protein extracts were produced from ears of line 117 mice of
increasing phenotypic stage, stages 1-3 (stl-3) alongside age
matched stage 1-3 controls (cl-3). 100J-lg of protein
extract/track was analysed on a 10% SDS-PAGE and the gel
blotted. The blot was probed with a rabbit anti-mouse phospho
p38 primary antibody (1:1000) and a goat anti-rabbit IgG-HRP
secondary antibody (1:4000) and visualised with ECL+. The
38kDa band corresponding to phospho-p38 is indicated.
Molecular weights according to the marker track are shown.
4.5 LMP1cAO and the AP1 family
API is a transcription factor complex, composed of Jun family homodimers or heterodimers
between Jun and Fos family proteins or heterodimers between Fos or Jun and ATF/CREB
proteins. The Jun family consists of c-Jun, JunB and JunD. The Fos family consists of c-Fos,
FosB, Fra-I and Fra-2. API can become activated by phosphorylation of these components.
AP 1 regulates the expression of genes involved in proliferation, differentiation, apoptosis,
immunity and inflammation and regulates genes such as the tumour suppressors p16, P19, p53,
p2I and cell cycle protein Cyclin D1. Activation of AP1 leads to its binding at TPA response
element (TRE) sites and transcriptional activation or sometimes repression of its target genes.
Growth factors, TPA and oncogenes are among some of the factors that can activate AP1.
Several pathways have been involved in API activation including Ras/MAPK, JNK and
p38MAPK.
Using a pan-fos antibody that recognises all four members of the Fos family, it was possible to
detect upregulation of FosB and Fra-I and/or-2 in the transgenic tissues of line 117 when
compared to their wild type sibling controls in contrast to c-fos with equivalent expression
levels across the samples (figA.20a). Line 53 epidermal tissues do not show any difference in
the low level of the Fos family proteins between control and transgenic samples. When levels
of Fra-I and Fra-2 were specifically examined, it was found that Fra-l is upregulated in line
117 transgenic tissues whereas Fra-2levels are unchanged (fig.4.21.a, b). Examining levels of
c-Jun, it was found that there is no apparent difference between transgenic and wild type
samples of lines 53 and 117 (figA.20b). On the other hand, JunB is strongly upregulated in
transgenic samples from line 117 at all three stages examined (fig.4.22) (stage 1: 1.98 fold,
stage 2: 2.44 fold, stage 3: 1.43 fold compared to controls).
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Figure 4.20: Pan Fos and c-Jun expression in the skin and
ean of lines 53 (PyLMPl~ and 117(L2LMPlcAO) mice.
Protein extracts were produced from epidermis of 5 day old
pups of line 53 both transgenic (+) and wild type siblings (-)
and ears of mice of line 117. The protein extracts from ears
were produced from increasing phenotypic ears of stages 1-3
(stl-3) and age matched sibling controls (cl-3). Extracts from
NlH3T3 and A431 cell pellets were used as positive controls
for fos family members and c-Jun. lOOJ1g of protein
extract/track was separated by 100/0SDS-PAGE and the gel was
blotted. The blot (A) was probed initially with a rabbit anti-
mouse pan fos primary antibody (1:1000) and a goat anti-rabbit
IgG-HRP secondary antibody (1:4000) and visualised with
ECL+. The blot was then stripped and reprobed with a rabbit
anti-mouse c-Jun primary antibody (1:1000) and a goat anti-
rabbit IgG-HRP secondary antibody (1:4000) and visualised
with ECL+ (B). Molecular weights according to the marker
track are shown. The 62kDa band corresponding to c-fos, the
42kDa and 43kDa bands corresponding to fra-I and -2 and the
36kDa band corresponding to fos B are indicated in A. The
39kDa band corresponding to c-Jun is indicated in B. The
bottom picture ( C ) is a Ponceau' s staining that was used to
show loading.
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Figure 4.21: Fra-l and -2 expression in ears of line 117
(L2LMPlcA<» miee.
Protein was extracted from ears of increasing phenotypic stages;
stagesl-3 (stl-3) alongside age matched controls (cl-3). lOOJlg
of protein extract/track was separated through a 10010SDS-
PAGE and the gel was blotted. The blot (A) was probed with a
rabbit anti-mouse Fra-l primary antibody (1:1000) and a goat
anti-rabbit IgG-HRP secondary antibody (1:4000) and
visualised with ECL+. B was probed with a rabbit anti-mouse
Fra-2 primary antibody (1:1000) and a goat anti-rabbit IgG-
HRP secondary antibody (1:4000) and visualised with ECL+.
The bands corresponding to Fra-l (43kDa) or Fra-2 (42kDa) are
indicated. Molecular weights according to the marker track are
shown.
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Figure 4.22: JunB expression in ears of line 117
(L2LMPI CA~ mice.
Protein was extracted from ears of increasing phenotypic
stage (stl-3) and their aged matched sibling controls (cl-3).
100J-lgof protein extract/track was separated through a 10%
SDS-P AGE and the gel was blotted. The blot is a reprobe
of the Fra-2 probed blot shown in fig.4.21. In this case it has
been stripped and reprobed with goat anti-mouse JunB
primary antibody (LlOOO) and a donkey anti-goat
secondary antibody (1 :4000) and visualised with ECL+. The
doublet (45kDa) corresponding to JunB is indicated.
Molecular weights according to marker track are shown.
In order to assess the DNA binding activity of API factor in line 117 ear tissues an EMSA was
performed using the oligo containing the TRE binding site (figA.23). The control A43I cell
extract showed a specific band A that was competed with excess (200x) unlabelled oligo.
Transgenic samples 347, 349 and 359 showed enhanced specific binding compared to wild
type tissues 367 and 375 that show little or no binding. When an Spl EMSA was performed
on these samples to check for sample quality and quantity (figA.ll) it was shown that sample
367 may be of poorer quality. However, sample 375 is of equal if not better quality and
quantity than the transgenic samples. Given this, it is concluded that there is enhanced API
activity in transgenic samples as compared to control samples. Several trials using specific
antibodies to Fos and Jun family members to supershift the API specific band in order to
determine which components of each family make up the API factor have failed.
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Figure 4.23: An EMSA showing specific binding of ear extracts of line
117 (L2LMPl CAO) to TRE binding oligo.
Protein was extracted from transgenic (+) and wild type ears (-) and
5Jlg/track were separated by 5% PAGE. Sug of A431 cell extracts were
used as positive control (c). Labelled oligo without extract (0) was added
as an extra control. 200x competitor (unlabelled oligo) was added to the
samples indicated (+). The transgenic samples (mouse numbers: 347, 349
and 359) show specific binding to the TRE sequence while the wild type
samples (mouse numbers: 367 and 375) show comparatively little binding
activity (see band A). The specific TRE binding band is indicated with an
arrow (A) and non specific indicated by B. Spl binding by these extracts
was shown in fig.4.11. Sample 367 showed weak binding while sample
375 showed as strong binding as 359, which was stronger than 347 and
349.
4.6 LMP1 CAO and NF-KB
The final pathway that was investigated, in this study was the NF-KBpathway. Levels ofNF-
KBwere initially investigated using Western blotting and antibodies against p50 or p65; two
of the components of NF-KB. However, no specific bands corresponding to either of these
components could be clearly identified. The DNA binding activity of NF-KB in transgenic
and control samples was assayed by an EMSA using an oligo containing the NF-KB binding
site. NIH3T3 control extracts show two specific bands A and B which are competed away
using excess of unlabelled oligo (figA.24) while band C is non specific. Transgenic samples
also show specific bands A and B. In order to determine which components of the NF-KB
family are involved in complex formation, a supershift analysis was performed (figA.25).
Upon addition of antibody specific to the p50 component of the NF-KB complex, a band
migrating more slowly is readily detected in NIH3T3 controls and possibly in the transgenic
sample (mouse number 347). Upon addition of the antibody specific to p65, a band even more
slowly migrating is readily detected in both NIH3T3 controls and the transgenic sample,
concominant with a reduction in the intensity of band A. This demonstrates that the NF-KB
complex activated in transgenic samples contain p65 and may also contain p50. Further
components have not been assayed.
The above studies show that LMPI CAO can activate at least p38MAPK and NF-KB in the
epithelium in vivo. It probably can activate the JNK pathway but this has not been specifically
shown in these sets of experiments although members of the API family are upregulated and
AP 1 is activated.
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Figure 4.24: An EMSA showing specific binding of ear extracts of
line 117 (L2LMPlcA<» to NF-ICB binding oligo.
Protein was extracted from transgenic (+) and wild type ears (-) and
IOug/track were separated on a 6% PAGE. l Oug ofNllI3T3 cell
extracts were used as positive control (c). 50x competitor (unlabelled
oligo) was added to the samples indicated (+). The control cells and
transgenic samples (mouse numbers:347, 349, 359) show specific
binding to NF-KB sequence while the wild type samples (mouse
numbers: 367, 362) show no binding activity (bands A and B). Non
specific band C is seen in all samples.
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Figure 4.25: An EMSA showing supershifting in ear extracts of line 117
(L2LMPlcA<» to NF-lCB binding oligo.
Protein was extracted from transgenic (+) and wild type ears (-) and Iuug/track
were separated on a 6% PAGE. l Oug of NIH3T3 cell extracts were used as
positive control (c). 50x competitor (unlabelled oligo) was added to the samples
indicated (+). The control and transgenic sample (mouse number:347) show
specific binding to NF-KB sequence while the wild type sample (mouse number:
375) shows no binding activity (bands A and B). Non specific band C is seen
in all samples. Upon addition of 0.6 ug of p50 antibody, a slower migrating
band (d) appears in the control and transgenic sample. Upon addition ofO.6llg
of p65 antibody an even slower migrating band (e) appears in the control and
transgenic sample. There is no evidence of bands d and e in the wild type
sample.
4.7 Conclusion and Discussion (summary in table 4.4)
The phenotypic similarity between LMPlcAO and TGFa transgenic mice prompted an
investigation of the levels of TGFa in the affected tissues of LMPlcAO mice. Indeed as
shown, TGFa levels are upregulated in affected tissues. This upregulation in TGFa
expression appears to be a direct effect ofLMPl as it is observed early in the phenotype and is
consistent at all stages and in line 53 expression was limited to phenotypic epidermis.
EGFR is activated as a response to its ligand upregulation. Initially levels of total full length
EGFR are increased in comparison to the wild type control but the levels decrease as the
phenotype progresses. This is consistent with what has been previously observed in
TGFa transgenic animals that showed decreased levels of total EGFR (Shibata et al., 1997).
This reflects the tight homeostatic control at work in the skin and as a response to increased
ligand binding, the tissue is recycling the receptor and downregulating its expression. This is
partially in agreement with previous studies that have shown upregulation of EGFR (in C33A
cells) as a response to LMP1 expression (Miller et al., 1998a; Miller et al., 1997). NPC tissue
also shows upregulation in the expression of EGFR (Zheng et al., 1994a). The difference that
is observed with these studies is that as the phenotype worsens levels of full length EGFR
decrease. This is possibly due to the loss of homeostatic controls or negative feedback loops
that exist in a preneoplastic tissue, upon carcinogenic progression. In agreement with these
studies, cells obtained from carcinomas that developed on LMPI transgenic mice, were shown
to have equal if not higher EGFR expression to transgenic negative cell lines.
Levels of phosphorylated smaller EGFR products increase as the phenotype worsens,
suggesting that EGFR is activated and recycled. It is possible that these smaller products
represent EGFR that has translocated to the nucleus. In a recent study using breast cancer
cells, it was shown that the intracellular part of ErbB4 - a member of the EGFR family -
could get cleaved and translocate to the nucleus where it controlled activation of its
transcriptional target STAT5 (Williams et al., 2004). It is not yet known if EGFR can go
through a similar procedure.
Two of the downstream pathways that can be activated by EGFR are the Ras/MAPK cascade
and PI3K1Aktpathway. Previous reports have shown that LMPI in rodent fibroblasts leads to
ERKI/2 activation. In our system, there is initial activation of MEKl/2 which decreases as
the phenotype worsens, while there is constant activation of ERK2 in transgenic positive
samples. There may be a negative feedback loop in place, downregulating aberrant MEKI/2
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activation, with an as yet unidentified kinase activating ERK2 in a MEKl/2 independent
fashion. Direction of activated MEKI to the suprabasal layers of transgenic mice led to
increased proliferation and disruption of proper terminal differentiation leading to a
hyperplastic epidermal phenotype along with skin inflammation and spontaneous papilloma
formation on older animals (Hobbs et al., 2004). This phenotype greatly resembles what has
been seen in the LMPI CAO mice consistent with the finding that MEKI is active in the
transgenic LMP1CAD system.
It is interesting that no activation of c-Raf was observed in these tissues when MEKl/2
activation was observed. It could be that other homologs of c-Raf are activated in this system,
for example BRaf or Araf. When a variant of E6 of the human papilloma virus (HPV) was
studied, it was shown that it preferentially led to BRaf activation (Chakrabarti et al., 2004). It
could be that this is true in the LMPICAD system and this needs further investigation.
Akt is deactivated as a consequence ofLMPI expression in trangenic tissues. Others (Dawson
et al., 2003) have shown that LMPI leads to activation of Akt in epithelial cells again
highlighting possible differences between a precancerous tissue and carcinoma cells. Other
groups have concluded that there is a cross talk between the RaslMAPK and the PI3K1Akt
pathways. For example, in HEK293 epithelial cells, Akt can downregulate ERK1I2 activity
thus leading to a decrease in the activity of the MAPK pathway (Galetic et al., 2003). It is not
known if ERK112similarly affects Akt activation. In fact when Ras inducible mice were
generated, it was found that the MAPK pathway was activated whereas the PI3K1Aktwas not
(Tarutani et al., 2003). The lack of change in PTEN levels when there is an Akt deactivation,
implies the presence of other Akt effectors. A downstream effector of Akt, GSK3~, showed
no change in phosphorylation levels. Akt has many other downstream targets and it is
possible that in this system, deactivation of Akt impacts other targets. Further study is needed
to clarify this.
NF-KB components p65 and possibly p50, were found to form the NF-KB complex that shows
increased binding in the transgenic samples compared to controls. This is consistent with
previous studies that identified increased activation ofNF-KB as a direct LMPI consequence
and identified p50 and p65 as the members of the NF-KB complex (Thornburg et al., 2003).
Also the API complex showed increased DNA binding in the transgenic samples compared to
controls, consistent with previous studies that have demonstrated activation of API as an
effect of LMPI expression (Eliopoulos and Young, 1998). Even though the supershift
analysis, was not successful, Western blot analysis showed that there were higher levels of
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JunB, Fra-I and FosB in transgenic samples compared to controls making these possible
candidates for being the components of the active AP 1 complex. A recent study has described
a new heterodimer formation between JunB and c-Jun induced by LMPI (Song et al., 2004b).
In these tissues, increased expression of JunB, Fra-I and FosB results from LMPI expression
and not a consequence of the phenotypic progression as their upregulation is evident from the
youngest samples studied (phenotypic stage 1). Similarly, p38MAPK activation is also
observed from stage 1, but increasing phenotypic stages show further increase in p38MAPK
activation levels, implying that progression of the phenotype increases the effect. Activation
of both NF-KB and API is consistent with TGFa upregulation, as the TGFa promoter
contains AP! and NF-KB binding sites.
In conclusion, LMP! leads to TOFu upregulation possibly via activation ofNF-KB and API.
TGFu upregulation leads to activation of EGFR and its faster turnover. Activated EGFR in
vivo, probably leads to activation of the MAPK pathway, however it is not clear what leads to
deactivation of the PI3K1Akt pathway. The apparent opposing effects that LMPI has on these
two pathways may reflect mechanisms within the epidermis to control aberrant proliferation.
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Chapter 5: Does LMP1 induce hyperplasia by
upregulating TGFa?
As described in the introduction, several transgenic models overexpressing TGFa showed a
phenotype of epidermal hyperplasia, ear thickening and spontaneous papilloma formation that
resembles the phenotype observed in PyLMPI895-8 and L2LMPI CAO transgenic lines. Given
the results described in Chapter 4, where TGFa upregulation and activation of the RaslMAPK
pathway was shown in tissues from line 117, it was hypothesised that LMPICAO may exert its
proliferative effects via upregulation of TGFa. In order to test this hypothesis it was decided
to entirely remove TGFa from the system by crossing LMPI expressing animals to TGFa null
animals and examine the resulting phenotype and the signalling pathways involved.
Testing of this hypothesis will extend the understanding of the role of LMP 1 In
turnourigenesis and could contribute to the design of targeted interventions.
5.1 Outline of approach
Mice of lines 53 (PyLMPI895-8) and 117 (L2LMPI CAO) were separately crossbred with TGFa
null animals. A detailed description of the TGFa null animals used can be found in section
1.7. These animals are referred to in this work as line 125. Line 125 mice were crossed with
lines 53 or 117 to produce mice heterozygous for TGFa. These progeny were crossed
together to generate TGFa null, heterozygous or wild type. The TGFa genotype was tested
by PCR as described in figure.5.l and section 2.2.3M.
Subsequently the animals produced were monitored for any phenotypic changes. Affected
tissues from animals that expressed the LMPlcAO transgene in a TGFa null background were
examined by Western blotting to determine if absence of TGFa affects any of the pathways
already analysed in Chapter 4.
Further analyses included examination by histopathological staining of affected tissues from
both LMPI CAO transgenic animals in wild type and null TGFa background with markers of
proliferation and apoptosis.
These studies were aimed at answering the following questions:
1. Does LMPI induce hyperplasia primarily by upregulating TGFa?
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2. What effect does absence of TOFa have on the signalling pathways deregulated by
LMPI?
3. Does LMPI in a TOFa null background playa role in proliferation or apoptosis of
epithelial cells?
Results
5.2 Phenotypic examination of LMP1/TGFa null mice
The first cross conducted was between line 53 (PyLMPIB95-8) and line 125 (TOFa null). In
total 84 pups were produced from the 53/125 cross. All pups were euthanased between days
3-5 and the skin and whisker phenotype was observed and noted (fig.5.2A and 5.3). Genomic
DNA extracted from the tissues was used to confirm their genotype compared to the observed
phenotypes. 7 LMPI B95-81TOFa null, 34 LMPI B95-81TOFa heterozygous, 3 LMPI B95-81TOFa
wild type, 26 LMP1895-8 negative/ TOFa null and 14 LMP1895-8 negativelTOFa heterozygous
mice were produced and observed. It is observed that the expected Mendelian inheritance
pattern is not followed with respect to the number of LMPI B95-8 positive mice in a TOFa null
background. Whereas the expected number of LMPI transgenic offspring that are TOFa
heterozygous or null is 18.5 respectively, 30 of the offspring are TOFa heterozygous and only
7 are TOFa null. Conducting a X2 test on these data shows that the numbers deviate from the
expected ratios with statistical significance (P=O.0005). This might suggest that LMPI in a
TOFa null background leads to reduced embryonic fitness (table 5.1).
Out of the 7 LMPIB95-8/TOFa null animals produced, 4 showed the scaly skin phenotype
(57.14%) (table 5.2). Although this is less than LMPI in a heterozygous TOFa background
(29/34)(85.29%) the numbers are too few to be able to conduct a meaningful statistical
analysis. In the LMP1 negative mice, a few mice are noted on having a scaly skin irrespective
of TOFa status (table5.2). While this study was subjective and too few mice used for a
meaningful statistical comparison, it did reveal that absence of TOFa did not abolish the
LMP 1 induced scaly pup skin phenotype, or increase it in a marked way.
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Figure 5. 1: Genotyping of line 125 by peR
Primers TGFa KOl and 2 were used to detect the 1300bp band
corresponding to TGFa disrupted by the neomycin cassette. A
control band at 500bp is routinely observed, whereas a non specific
band of 1000bp is also observed in some of the reactions. Use of the
primer pair TGFa KOl and 2 leads to identifiation of mice that are
either heterozygous (het) or null (ko) for TGFa.
Primers TGFa KO} and 3 are used to detect a lOOObp band
corresponding to exon 3 of the TGFa gene which is disrupted by the
neomycin cassette. This pair of primers leads to identification of mice
that are wild type (wt) or het for TGFa.
Simoultaneous use of these two primer pairs leads to identification of
all three genotypes of mice for the TGFa gene.
Figure 5.2: Whisker phenotype of 53/125 pups (A) and 1171125
adult (B and C) mice.
A shows two 53/125 pups. The one on the left is heterozygous for
TGFa ( +1-) and the one on the right is TGFa null (-1-). As indicated
by the red arrows, the TGFa -1- pup has markedly curly whiskers,
whereas the TGFa +1- has relatively straight whiskers
indistinguishable from wild type. Note that the coat colour (albino
on the left and agouti on the right) is independent of TGFa status
reflecting the FVB/C57/129 mixed strain background.
Band C show the ear and whisker phenotype of 117/125 adult mice
that are LMPlcAO transgenic and TGFa null (B) or heterozygous
(C). B has curly whiskers whereas C has straight whiskers.
BLMPI CAO + / TUFa _/_
c
LMPI CAO + ITGFa +/-
Figure 5.3: Skin and tail phenotype of 53/125 pups
The three pups shown above come from the 53/125 cross. The one on the
left is LMPIB95-8 transgenic (+) and the two on the right are LMPIB95-8
negative (-). Wrinkly tail and scaly skin is observed on the transgenic
pups and not the wild type pups.
Parental Litter No No No No No No
genotype Size of of of of of of
(LMPI I pups pups pups pups pups pups
TGFa) LMPI TGFa TGFa TGFa LMPI LMPI
+ +1+ +1- -1- + +
and and
TGFa TGFa
+1- -1-
- / .}: x + / +/- 10 5 0 6 4 5 0
- / .t: x + / +/- 12 4 0 6 6 4 0
- / -/- x + / +/- 12 8 0 8 4 7 1
+/ +/ - x - / +/- 11 7 3 6 2 4 0
- / -/- x + / +/- 2 1 0 1 1 1 0
- / .t: x + / +/- 13 10 0 9 4 7 3
- / -/- x + / +/- 10 4 0 5 5 3 1
- / .t: x + / +/- 14 5 0 7 7 3 2
Cross
- I -1-x + 1+1-
Total no of No of No of No of No of No of
pups born: 73 LMPI TGFa TGFa LMPl+ LMP1+
+ +1- -1- andTGFa and TGFa
+1- -1-
Observed 37 42 31 30 7
Expected 36.5 36.5 36.5 18.5 18.5
df 1 1 1 2 2
xl 0.01 1.658 1.658 14.43 14.43
P value >0.25 >0.25 >0.25 0.0005 0.0005
Cross
+ I +1- x - 1+1-
Total no of No of No of No of No of No of No of No of
pups born: LMPI TGFa TGFa TGFa LMPl+ LMPl+ LMPl+
11 + +1+ +1- -l- and and andTGFa
TGFa TGFa -1-
+1+ +1-
Observed 7 3 6 2 3 4 0
Expected 5.5 2.75 5.5 2.75 1.75 3.5 1.75
df 1 1 1 1 2 2 2
)(;2 0.82 0.273 0.273 0.273 2.71 2.71 2.71
P value >0.25 >0.25 >0.25 >0.25 >0.25 >0.25 >0.25
Table 5.1: 531125 litter genotyping and Mendelian inheritance
The top table shows the various litters produced and the pup genotype along with the totals of
the different genotypes from two genotypic crosses: TGFa null x TGFa heterozygous cross
(black) and a TGFa heterozygous x TGFa heterozygous cross (blue). The following two tables
show the totals observed and expected proportions of each genotype and the chi squared
analyses for the specific crosses shown.
LMPIIJ9S.8 + ffGFa -1- LMPIIJ95.8+ LMPIIJ95.8+
ffGFa+l- ffGFa+l+
Total number of 7 34 3
pups
Number of pups 4 (57.14%) 29(85.29%) 2 (66.66%)
with scaly skin
Number of pups 3 (42.86%) 4 (11.76%) 1 (33.33%)
without a scaly
skin
No phenotype 0 1 (2.94%) 0
Dead at birth
LMPIBll5-8- ffGFa -1- LMPIBll5-8- LMPIB95-8_
ffGFa+l- ffGFa+l+
Total number of 26 14 0
pups
Number of pups 2 (7.69%) 4 (28.6%) 0
with scaly skin
Number of pups 23(88.46%) 10 (71.43%) 0
without a scaly
skin
No phenotype 1 (3.85%) 0 0
Dead at birth
Table S.2: Correlation of genotype and observed phenotype of cross S3/125 pups
The above tables show the number of LMPlcAO transgenic positive (top) and transgenic
negative (bottom) in each TGFa genotypic group. The number of animals in each group
showing a specific phenotype is given. The percentage values (%) shown are out of the total
number of animals in each specific genotypic group.
A more informative experiment was provided by the second cross between line 117
(L2LMPlcAO) and line 125 (TGFa null). In total60 animals were monitored from 4 weeks of
age to about 30 weeks. Of these, 8 were LMPlcAO/TGFa null, 9 LMPlcAolTGFa
heterozygous, 7 LMPI cAo/TGFa wild type and 36 mice were negative for LMPI CAO, the
latter did not show any ear phenotype. These ratios do not suggest any loss of LMPI CAol
TGFa null genotype group. The animals were monitored once a week and the ear phenotype
was visually categorised according to the ear stages figure (fig.1.14). The dorsal skin of these
mice was also monitored for spontaneous papilloma formation. No papilloma formation was
detected in any of the animals. However, it should be noted that the strain background of
these mice differs from the 117 line under study in chapter 3 which was largely FVB. The
introduction of the TOFa null strain also introduced a 129/C57 mouse strain component and
papilloma formation is strain sensitive. In monitoring the ear phenotype it was observed that
the LMPlcAo/TGFa null mice developed an ear phenotype that was more progressed than the
LMPlcAO/TOFa heterozygous or wild type ear phenotype (fig.5.2B and C).
In order to quantify this, the proportion of mice with ears at the phenotypic stages have been
plotted against age (fig.5.4). As seen from the graphs (fig. 5.4), at about 5 weeks of age all the
TGFa heterozygous or wild type animals show a stage 1 ear phenotype whereas 80% of the
TGFa null mice show stage 1 ear phenotype and 20% exhibit a progressed ear phenotype of
stage 2. At 7 weeks of age, 100% of the TOFa heterozygous and wild type mice show stage 1
ear phenotype whereas only 50% ofTGFa null mice show stage 1 ear phenotype. By 9 weeks
all null and wild type ears show a stage 2 phenotype, while 50% of the heterozygous ears
show stage 2. A more consistent difference between TGFa null and the heterozygous or wild
type groups becomes apparent at the later stages, 4 and 5 of the phenotype. By 15 weeks 50%
of the null mice developed a stage 4 phenotype and by 20 weeks some mice began to develop
a stage 5 phenotype. By contrast, the TOFa heterozygote and wild type mice did not start to
develop the stage 4 phenotype until 22 and 20 weeks respectively and in the time frame of this
study this phenotype did not progress to stage 5. The phenotype progression in heterozygous
and wild type mice follows largely the same pattern.
There is a general trend apparent that the null mice ear phenotype progresses faster than the
heterozygous and wild type mice. This is contrary to what would be expected if the
hypothesis was correct in that the LMPI induced ear phenotype is mediated via upregulation
of TGFa alone. While the data is subjective in nature it was absolutely clear that loss of
TGFadid not negate the LMPI induced phenotype. However, upregulation of other EGFR
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ligands has not been examined in this system and it is possible that upon withdrawal ofTGFa,
other EGFR ligands can compensate.
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Figure 5.4: Graphs showing the phenotypie
progression of ears of mice from line 1171125.
Ears from LMPI CAO transgenic animals that were null (A),
heterozygous (B) or wild type (C) for TGFa were
observed once every two weeks for 22 weeks and
categorised into phenotypic stages. Phenotypic stage 1
ears are represented by purple colour, stage 2 are magenta,
stage 3 are yellow, stage 4 are light blue and stage 5 are
dark purple. The percentage of mice from each genotypic
group that showed the particular ear phenotype stage is
indicated on the Y-axis of each graph. Note that a mouse
was categorised according to the ear of worse (higher
number) stage if its ears were different.
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5.3 Analysis of signalling pathways activation in LMP1cAO/TGFa null
mice
A. TGFaJEGFBlRas/MAPK pathway
Initially, the status of the receptor for TGFu was investigated. Protein extracts using Ripa
buffer were prepared from transgenic ears of line 117 mice of different phenotypic stages
along with age matched transgenic negative controls. Protein extracts using Ripa buffer, were
also prepared from transgenic ears of line 117/125 mice both null and heterozygous for TGFu
along with age matched transgenic negative controls. Details of the animals used in these and
subsequent studies are given in Appendix 3. 100llg (unless otherwise stated) of protein extract
per track was separated by SDS-PAGE, the gel was blotted and the appropriate antibodies
were used to detect the desired proteins. Densitometric analysis was routinely performed
where needed, to compare levels of the detected protein under study to its non-phosphorylated
form or to P tubulin, which was used to indicate loading levels. These analyses were
performed as was previously described (chapter 4.2).
Expression of total EGFR was examined (fig.5.5). It is apparent that the antibody to total
EGFR not only can detect the 170kDa EGFR but also smaller EGFR products at 75,65 and
50kDa. It is observed that levels of total full length EGFR are increased at stage 1 in the
LMPlcAO ITGFu null ears (1.36 fold compared to controls, normalised against ~
tubulin)(table 5.3) but this decreases with advancing phenotype (stage 2: 1.1 fold, stage 3: 0.91
fold) and this is concomitant with the appearance of smaller EGFR products (as reported in
chapter 4). This decrease in the 170kDa EGFR and the increase in the smaller EGFR products
appears to be independent of TGFu loss. Some of these smaller products react with two
antibodies that specifically recognise phosphorylated EGFR at specific tyrosine residues
(tyrosine 845 (fig.S.6) and tyrosine 1068 (fig.5.7». Phosphorylation ofEGFR at tyrosine 1068
is a result of autophosphorylation of the receptor and can lead to GRB2 recruitment whilst
phosphorylation of EGFR at tyrosine 845 is a result of Src phosphorylation. Using anti-
phosphorylated EGFR (tyr 845), it was shown that levels of the smaller phosphorylated
products initially decrease at stages 1 and 2 in the LMPI CAolTGFuwild type ears but increase
at stage 3 by 3 fold compared to controls normalised against p tubulin. In the LMPlcAO 1
TGFu null ears, levels increase from stages 2 to 4 (stage 2: 1.23 fold, stage 3: 2.32 fold, stage
4: 4.36 fold when compared to controls) (table 5.4). The increase in phosphorylated products
detected with the antibodies to tyrl068 EGFR mirrors the results
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LMPlcAO
+/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
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c4 4
~ tubulin
Figure 5.5: Total EGFR western blot of protein
extracts from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears,
stages 1-3 (stl-3) from mice that were transgenic for
LMP1(+) and wild type (+1+), heterozygous (+1-) or null
(-1-) for TGFa. Age matched control extracts from ears
of LMPlcAO transgenic negative siblings (-) were also
prepared. 100Jlg of protein extract/track was separated
by 7.5% SDS-PAGE and the gel was blotted. The blot
was probed with a rabbit anti-mouse total EGFR
primal)' antibody (1:1000) and a goat anti-rabbit IgG-
HRP secondary antibody (1:4000) and visualised with
ECL+. The] 70kDa corresponding to total EGFR is
indicated. Molecular weights according to marker track
are shown. The bottom picture shows the ~ tubulin
reprobing of the blot to show relative loading levels.
Genotype A B C
LMPI TGFa Phenotypic EGFR (170kDa): tJ LMPlcAo: Null to wild
stage tubulin wild type type in
EGFR smaller respect of
bands: tJ tubulin TGFa
- +1+ Cl 0.11 10.02 1
+ +1+ 1 0.15 10.02 1.36 I 1.13
+ +1+ 2 0.12 I 0.04 1.10 I 1.60
+ +1+ 3 0.10 10.06 0.85 I 3
+ +1+ 3 (average)
- -1- Cl 0.11 10.03
- -1- C4 (average)
+ -I- I 0.10 10.03 0.96 I 0.98 0.68 I 1.23
+ -1- 2 0.13 I 0.03 1.17 11.01 1.02 10.80
+ -1- 4 0.07 I 0.13 0.68 I 4.34 0.70 I 2.17
+ -1- 3 0.05 I 0.05 0.44 I 1.72 0.50 I 0.83
Table 5.3: Densitometric analysis on the levels of total full length EGFR I smaller EGFR
products respective to tJ tubulin loading control.
Wild type (-) and transgenic (+) mice for LMP ICAO, wild type (+1+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMPlcAO negative
mice do not have an ear phenotype but animals that were aged matched controls ofLMPlcAO
+ mice of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A : Total EGFR: f3 tubulin (black), smaller EGFR products: f3 tubulin (blue)
Column B: LMPlcAo: control (TGFa wild type are black for full length EGFR, blue for
smaller products, TGFa null are pink for full length EGFR, green for smaller products)
Column C: LMPlcAO / TGFa null: LMPlcAO / TGFa wild type (black for full length EGFR,
blue for smaller EGFR products).
Note that LMPI CAOnegative in a TGFa null or wild type background give some reading.
Figure S.6: Pbospborylated EGFR (tyr 84S) western blot of
protein extracts from ean ofmiee oflines117 and 117/125.
Protein extracts were prepared fran phenotypic ears, stages 1-3
(stl-3) from mice that were transgenic for LMP1(+) and wild
type (+1+), heterozygous (+1-) or null (-1-) for TGFa. Age
matched control extracts from ears of LMPlcAO transgenic
negative siblings (-) were also prepared. lOOJ.lgof protein
extract/track was separated by 7.5% SDS-PAGE and the gel was
blotted. The blot was probed with a rabbit anti-mouse phospho-
EGFR (tyr845) primary antibody (I: 1000) and a goat anti-rabbit
IgG-HRP secondary antibody (l :4000) and visualised with
ECL+. Molecular weights according to marker track are shown.
The blot was stripped and reprobed with total EGFR and fl
tubulin to show relative loading levels.
stage
+/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
- + + + + - - + + + + - +
cl 1 2 3 3 cl c4 1 2 4 3 c4 4
TGFa
LMPlcAO
TGFa +/+LMPlcAO +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
+ + + + + + + +
stage
c4 1 2
~ tubulin
Figure 5.7: Phosphorylated EGFR (tyr 1068) western blot of
protein extracts from ears of mice oflines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-3 (stl-
3) from mice that were transgenic for LMP1(+) and wild type (+1+),
heterozygous (+1-) or null (-1-) for TGFa. Age matched control
extracts from ears ofLMPlcAO transgenic negative siblings (-) were
also prepared. 100Jlgof protein extract/track was separated by 7.5%
SDS-PAGE and the gel was blotted. The blot was probed with a
rabbit anti-mouse phospho-EGFR (tyr1068) primary antibody
(1:1000) and a goat anti-rabbit IgG-HRP secondary antibody
(1:4000) and visualised with ECL+. Molecular weights according to
marker track are shown. The blot was stripped and reprobed with ~
tubulin to show relative loading levels.
Genotype A B C
LMPI TGFa Phenotypic pEGFR LMPlcAo: wild Null or
stage (tyr845) : type hetto
ptubulin wild type
in
respect
ofTGFa
- +1+ Cl 0.16 1
+ +1+ 1 0.11 0.66
+ +1+ 2 0.07 0.45
+ +1+ 3 0.48 3.00
+ +1+ 3 (average)
- -1- Cl 0.22
- -1- C4 (average)
+ -I- I 0.16 0.73 1.45
+ -1- 2 0.27 1.23 3.59
+ -1- 4 0.96 4.36 2
+ -1- 3 0.51 2.32 1.06
Table 5.4: Densitometric analysis on phosphorylated EGFR (tyr845) levels
Wild type (-) and transgenic (+) mice for LMPlcAO , wild type (+1+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMPI CAO- mice
do not have an ear phenotype but animals that were aged matched controls of LMPlcAO +
mice of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A: Phosphorylated EGFR (tyr845): f3 tubulin
Column B: LMPlcAo: control (TGFa wild type are black, TGFa null are pink)
Column C: LMPlcAO I TGFa null: LMP ICAOI TGFa wild type
Note that LMPlcAO negative in a TGFa null or wild type background give some reading.
obtained with tyr845 EOFR. This indicates that removal of TOFa does not lead to reduced
signalling through EOFR and suggests instead that it may lead to over-compensation by other
EOFR ligands thus leading to increased EOFR activation.
In order to examine whether other EGFR family members are involved in LMPI signalling, a
HER2/ErbB2 antibody that recognises phosphorylated HER2/ErbB2 (tyr 1112) was used to
probe a western blot of lines 117 and 117/125 ear extracts (fig.5.8). As with EOFR, there is
increase in the levels of phosphorylated smaller HER2lErbB2 products in the LMpCAO 1TGFa
wild type ears when compared to the LMPlcAO negative 1 TGFa wild type ears and this
increase seems to be even higher in the LMP1CAO transgenic ears in a TOFa null background.
The blot could not be reprobed for f3 tubulin in order to ascertain loading levels. Note that a
smaller product at about 66kDa, recognised by the phosphorylated HER2/ErbB2 antibody, is
observed only in LMPI CAO transgenic ears of phenotypic stages 3 in the TGFa wild type
background and at stages 4 in the TOFa null background. The identity of this protein is
unknown.
In order to investigate whether TGFa upregulation and faster EGFR cycling playa role in
Ras/MAPK signalling, the levels of total c-Raf, BRaf, MEKl/2, ERK1/2 and their
phosphorylated forms were examined by probing Western blots, with the appropriate
antibody. Levels of total and phosphorylated c-Raf could not be clearly detected from the
experiments as the specific antibodies did not show any bands of the appropriate size
corresponding to c-Raf (data not shown). Total BRaf was used to probe a western blot
(fig.5.9). Levels of BRaf are equivalent in LMPI CAO 1 TGFa wild type stage 1 and stage 3
ears compared to wild type controls (stage I: 1.03 fold compared to controls normalised
against f3 tubulin, stage 3: 1.02 fold) but are slightly reduced in stage 2 ears (stage 2: 0.74
fold). This slight decrease observed in BRaf levels is also observed in LMPI CAol
TGFanull ears. This effect seems to be an LMPI effect and not an effect of the absence of
TGFa. However, the values obtained are not markedly different from the LMPI CAO negative I
TGFa wild type control ears so it is not clear if this observed decrease is artifactual or not
(table 5.5).
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TGFa +/+
LMP1cAO
+/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/- +/+
+ + + + + + + + +
stage cl 1 3 3 cl 4 2
66kDa_.
Figure 5.8: Phosphorylated HER2lErbB2 western blot of
protein extracts from ears of mice of lines 117 and 117/125.
This is a reprobe of the blot shown in figure 5.18. The blot was
stripped and reprobed with rabbit anti-mouse phosphorylated
HER2 primary antibody (1:1000), a goat anti-rabbit IgG-HRP
secondary antibody (1:4000) and visualised with ECL+. The
80kDa band corresponding to phosphorylated smaller HER2
product is indicated. Molecular weights according to the marker
track are shown.
stage
+/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
- + + + + - - + + + + - +
cl I 2 3 3 cl c4 1 2 4 3 c4 4
TGFa
LMPlcAO
66kDa
45kDa
~ tubulin
Figure 5.9: BRAF western blot of protein extracts from ears of
mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-3 (stl-3)
from mice that were transgenic for LMP1(+) and wild type (+1+),
heterozygous (+1-) or null (-1-) for TGFa. Age matched control extracts
from ears of LMPlcAO transgenic negative siblings (-) were also
prepared. 100J.Lgof protein extract/track was separated by 7.5% SDS-
PAGE and the gel was blotted. The blot was probed with a rabbit anti-
mouse BRAF primary antibody (1: 1000) and a goat anti-rabbit IgG-
HRP secondary antibody (1 :4000) and visualised with ECL+. The
95kDa band corresponding to BRAF is indicated. Molecular weights
according to marker track are shown. The bottom blot shows ~ tubulin
probing used as a loading control. This blot is a reprobe of the blot
probed with phospho-EGFR (tyr 1068) shown in figure 5.7.
Genotype A B C
LMPI TGFa Phenotypic BRAF: p LMPI CAO : wild Null or
stage tubulin type het to
wild type
in
respect
ofTGFa
- +1+ Cl 0.61 1
+ +1+ 1 0.67 1.03
+ +1+ 2 0.45 0.74
+ +1+ 3 0.62 1.02
+ +1+ 3 (average)
- -1- Cl 0.71
- -1- C4 (average)
+ -I- I 0.55 0.77 0.82
+ -1- 2 0.43 0.61 0.96
+ -1- 4 0.51 0.72 0.82
+ -1- 3 0.36 0.51 0.58
Table 5.5: Densitometric analysis on BRAF levels
Wild type (-) and transgenic (+) mice for LMP1cAO , wild type (+1+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMPlcAO - mice
do not have an ear phenotype but animals that were aged matched controls of LMPlcAO +
mice of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A: BRAF: ~ tubulin
Column B: LMPlcAO: control (TGFa wild type are black, TGFa null are pink)
Column C: LMPlcAO ITGFa null: LMPlcAO I TGFa wild type
Note that LMPI CAO negative in a TGFa null or wild type background give some reading.
Confirming the observations in chapter 4, levels of total MEK1I2 were equivalent throughout
the sample panel (fig.5.10B). Once again, levels of the phosphorylated form ofMEKI/2 show
differences according to phenotypic stage (fig.5.10A). As the densitometric analysis shows
(table 5.6), there is an initial increase in activated MEK 1/2 in LMP1CAO transgenic ears stages
1 and 2 (stage I: 8.19 fold compared to controls normalised against total MEK1I2, stage 2:
4.67 fold). As the ear phenotype progresses to stage 3, this activation is decreased (stage 3:
2.57 fold) returning to control levels. A similar pattern is observed in the LMPI CAO 1TOFu
null ears (stage 1: 3.28 fold, stage 2: 2.83 fold, stage 3: 1.43 fold, stage 4: 1.57 fold). It is
evident that MEK1I2 is activated to a lesser extent in the TOFu null LMPI CAO transgenic ears.
Note that stage 4 ears in LMPlcAO 1TOFu wild type were not examined.
It can also be seen from this western blot (fig.S.IO) that there are a number of proteins cross
reactive to this phospho-specific antiserum that show expression or activation changes in
respect to phenotypic stage. Note a band at approximately 60kDa present only in non
transgenic samples, a series of bands in the IOO-200kDarange that are strong in controls at
stage I, decreasing though at stages 2-4. A band at approximately 25kDa similarly strong in
controls and decreasing with increasing phenotypic stage. The bands may represent phospho-
proteins that are activated or deactivated in response to LMP1 signalling, effectors or targets.
What is clear from these studies is that only a small fraction of the changes induced by LMPI
can be examined in this approach.
Levels of total ERK1I2 were equivalent in all samples (fig.5.IlB). Levels of phosphorylated
ERK1I2 show a modest increase in LMPlcAO transgenic ears that is more evident as the ear
phenotype worsens (stage 1: 1.59 fold, stage 2: 1.26 fold. stage 3: 2.18 fold compared to
controls normalised against total ERK1I2) (table5.7). This increase is not observed in the
LMPlcAO / TGFu null ears. This might suggest that the increase in activated ERKl/2 is
mediated by TOFu. However as the increase noted in the wild type background is modest the
consistency of this result should be tested in further samples of both wild type and null
background. Note that cross reactive bands at 66kDa and at 35kDa are observed in LMPI CAO
irrespective of TOFu status in stage 2, 3 and 4 ears.
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Figure 5.10: Phosphorylated MEKlI2 (A) and total MEK1/2
(8) western blot of proteiD extracts from an of mice of line
117 and 1171125.
Protein extracts were prepared from phenotypic ears, stages 1-3
(stl-3) from mice that were transgenic for LMPl(+) and wild
type (+1+), heterozygous (+1-) or null (-1-) for TGFa. Age
matched control extracts from ears of siblings (-) were also
prepared. l00llg of protein extract/track was separated by 10%
SDS-PAGE and the gel was blotted. The blot was probed with a
rabbit anti-moose phospho-MEKl12 (A) and a goat anti-rabbit
IgG-HRP secondary antibody (1:4000) and visualised with
ECL+. The blot was stripped and reprobed with rabbit anti-
mouse total MEK 112 (B) primary antibody (1:1000) and a goat
anti-rabbit IgG-HRP secondary antibody (1:4000) and visualised
with ECL+. The 45kDa band corresponding to MEK1I2 is
indicated. Molecular weights according to marker track are
shown.
TGFa +/+ +/+ +/+ +/+ -/- +/+ -/- +/-
LMPlcAO
-/- -/- -/- -/- +/-
+ + + + + + + + +
stage
A
B
30kDa
MEK
Genotype A B C
LMPI TGFa Phenotypic PMEK: LMPI CAO : wild Null or
stage totalMEK type hetto
wild type
in
respect
ofTGFa
- +1+ Cl 0.05 1
+ +1+ 1 0.42 8.19
+ +1+ 2 0.24 4.67
+ +1+ 3 0.10 2.57
+ +1+ 3 (average)
- -1- Cl 0.07
- -1- C4 (average)
+ -I- I 0.23 3.28 0.55
+ -1- 2 0.20 2.83 0.83
+ -/- 4 0.11 1.57 1.10
+ -/- 3 0.10 1.43 1.00
Table 5.6: Densitometric analysis on the levels of pMEK to total MEK1I2 loading
control.
Wild type (-) and transgenic (+) mice for LMPlcAO , wild type (+1+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMP ICAOnegative
mice do not have an ear phenotype but animals that were aged matched controls ofLMPlcAO
+ mice of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A: Phosphorylated MEKl/2 : total MEKl/2
Column B: LMPlcAo: control (TGFa wild type are black, TGFa null are pink)
Column C: LMPlcAO I TGFa null: LMPlcAO I TGFa wild type
Note that LMPlcAO negative in a TGFa null or wild type background give some reading.
Figure 5.11: Phospho-ERKlI2 and total ERKII2 western blot of
protein extracts from ean of mice of line It7 and tt7/l15.
Protein extracts were prepared from phenotypic ears, stages 1-3 (stl-3)
from mice that were transgenic for LMP1(+) and wild type (+1+),
heterozygous (+1-) or null (-1-) for TGFa. Age matched control extracts
from ears of LMPlcAO transgenic negative siblings (-) were also prepared.
l00J.lg of protein extract/track was separated by 10010 SDS-PAGE and the
gel was blotted. The blot was probed with a rabbit anti-mouse phospho-
ERK1/2 (A) and a goat anti-rabbitlgG-HRP secondary antibody (1:4000)
and visualised with ECL+. The blot was stripped and reprobed with rabbit
anti-mouse total ERKII2 (B) primary antibody (1:1000) and a goat anti-
rabbit IgG-HRP secondary antibody (1:4000) and visualised with ECL+.
The 44 and 42kDa bands corresponding to ERKII2 are indicated.
Molecular weights according to the marker track are shown.
Note cross reacting bands at approximately 66kDa and 35kDa are
detected stroogly in stage 3/4 LMPlcAO transgenic samples in wild type,
heterozygous and null TGFa background. The identity of these proteins
is not known.
TGFa +/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
LMPlcAO
+ + + + + + + + +
stage 4
A
ERK1I2
B
ERKI
Genotype A B C
LMPI TGFa Phenotypic pERK: LMPI CAD: wild Null or
stage totalERK type hetto
wild type
in
respect
ofTGFa
- +1+ Cl 0.50 1
+ +1+ 1 0.79 1.59
+ +1+ 2 0.63 1.26
+ +1+ 3 1.09 2.18
+ +1+ 3 (average)
- -1- Cl 0.87
- -1- C4 (average)
+ -I- I 0.63 0.73 0.80
+ -1- 2 0.85 0.98 1.35
+ -/- 4 1.09 1.25 1
+ -/- 3 0.62 0.71 0.57
Table 5.7: Densitometric analysis on ERK1I2 levels
Wild type (-) and transgenic (+) mice for LMPlcAO , wild type (+1+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMPlcAO - mice
do not have an ear phenotype but animals that were aged matched controls of LMPlcAO +
mice of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A: Phosphorylated ERK 112:total ERK 112
Column B: LMPlcAo: control (TGFa wild type are black, TGFa null are pink)
Column C: LMP 1CAOI TGF a null : LMP 1CAO/ TGFa wild type
Note that LMPIcAO negative in a TGFa null or wild type background give some reading.
Other MAPKs that were investigated was the phosphorylated forms of SEKlMKK4 and
SAPKlJNK. The western blot for phosphorylated SEKlMKK4 is not very clear and even
though the 46kDa band corresponding to phosphorylated SEKlMKK4 is observed, no reliable
comparison can be made to the ~ tubulin reprobe to determine if there is a difference in
activation levels or not (fig.5.I2). For the SAPKlJNK, there may seem to be an initial
upregulation of the 54kDa phosphorylated JNK2/3 at stage 1 of the LMPI CAOtransgenic ears
(fig.5.13). What is apparent is that the levels of phosphorylated JNK2/3 decrease as the ear
phenotype progresses. However, levels of the 46kDa band corresponding to phosphorylated
JNKI seem to be constant throughout irrespective ofLMPI or TOFu background. Itwas not
possible to reprobe this blot with f3 tubulin to allow an accurate comparison to be made,
however, a cross reacting band at about 40kDajust below the phosphorylated JNKI complex,
seems to equivalent in all tracks suggesting equal loading.
B. Apoptotic and Progression proteins
The ear phenotype progression in LMPI CAo/TOFu null animals appeared faster than in
LMPI CAOtransgenic animals that are in the heterozygous or wild type TOFu background as
presented in section 5.1. This progression in phenotype is accompanied by increased
ulceration and necrosis. In order to investigate this phenotype and to determine whether
apoptotic proteins play a role, levels of caspase- 3 and anti-apoptotic protein Akt were
investigated. Levels ofMMP9, a progression marker were also investigated.
Levels of full length and cleaved caspase-3 were examined using the respective antibodies
(fig.5.14A, B). Full length caspase-3 (35kDa) levels increase in LMpCAOtransgenic ears as
the phenotype progresses (stage 1: 2.23 fold, stage 2: 4.80 fold, stage 3: 4.50 fold compared to
controls, normalised against ~ tubulin) and this is irrespective of TGFu background as the
levels in LMPI CAo/TOFunull ears show (stage 1: 1.90 fold, stage 2: 4.27 fold, stage 3: 1.16
fold, stage 4: 4.63 fold) (table5.8). The 17 and 19kDa corresponding to cleaved caspase-3 can
be seen in LMPIcAO/ TOFu wild type stage 3 ears and in LMPIcAO/ TOFu null stage 3 and 4
ears when the blots are probed with either the full length caspase-3 antibody (fig.5.14A) or the
antibody to cleaved caspase-3 (fig.5.14B). Note that there are bands at about 60 and 40kDa
recognised by the full length and the cleaved caspase-3 antibodies that are evident only in the
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Figure 5.12: Phosphorylated SEKlMKK4 western blot of protein
extracts from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-3 (stl-3)
from mice that were transgenic for LMP1(+) and wild type (+1+),
heterozygous (+1-) or null (-1-) for TGFa. Age matched control
extracts from ears of LMP1cAO transgenic negative siblings (-) were
also prepared. 100f,lgof protein extract/track was separated by 10%
SDS-PAGE and the gel was blotted. The blot was probed with a rabbit
anti-mouse phospho-SEKlMKK4 primary antibody (1:1000) and a
goat anti-rabbit IgG-HRP secondary antibody (1:4000) and visualised
with ECL+. The 46kDa corresponding to pSEK!MKK4 is indicated.
Molecular weights according to marker track are shown. The bottom
picture shows the ~ tubulin reprobing of the blot to show relative
loading levels.
stage
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Figure 5.13: SAPKlJNK western blot of protein extracts
from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-3
(stl-3) from mice that were transgenic for LMPl(+) and wild
type (+/+), heterozygous (+/-) or null (-/-) for TGFu. Age
matched control extracts from ears of siblings (-) were also
prepared. IOOllg of protein extract/track was separated by 10%
SDS-PAGE. The blot was probed with a rabbit anti-mouse total
SAPKlJNK (Thr183/Tyrl85) primary antibody (1:1000) and a
goat anti-rabbit secondary antibody (1:4000) and visualised
with ECL+. The 46kDa doublet corresponding to
phosphorylated JNK1 and the 54kDa doublet corresponding to
phosphorylated JNK2/3 are indicated. Molecular weights as per
marker track are shown.
Figure 5.14: Total and activated easpase-3 western
blots of proteiD extracts from ean of mice of liDes
117 and 117/125.
Protein extracts were prepared from phenotypic ears,
stages 1-3 (stl-3) from mice that were transgenic fa-
LMP1(+) and wild type (+1+), heterozygous (+1-) or
null (-1-)for TGFu. Age matched control extracts from
ears of siblings (-) were also prepared. l00JIg of protein
extract/track was analysed on a 10010 SDS-PAGE. The
blot was prcoed with a rabbit anti-mouse total caspase-
3 (1:1000) and a goat anti-rabbit secmdary antibody
(1:4000) and visualised wi1h ECL+. The activated
caspase- 3 bl« is a reprobe of the pS3 blot shown in
figure 5.21. After stripping, it was reprobed with a
rabbit anti-mouse activated caspase-3 (1:1000) primary
antibody and a goat anti-rabbit secondary antibody
(1:4000) and visualised with ECL+. Molecularweights
according to the marker track are shown.
TGFa +/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
LMPlcAO
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stage cl I 2 3 3 cl c4 I 2 4 3 c4 4
A
B
total
caspase3
~ tubulin
20kDj
~14kDa~ ~ __ ~
length
caspase-3
Full length
caspase-3
cleaved
caspase-3
Genotype A B C
LMPI TGFa Phenotypic Total Transgenic: Null to
stage caspase-3: fl Wild type in wild type
tubulin respect to in
LMPI respect
ofTGFa
- +1+ Cl 0.11 1
+ +1+ 1 0.24 2.23
+ +1+ 2 0.53 4.80
+ +1+ 3 0.50 4.50
+ +1+ 3 (average)
- -1- Cl 0.40
- -1- C4 (average)
+ -I- I 0.50 1.90 2.06
+ -/- 2 1.13 4.27 2.14
+ -1- 4 1.22 4.63 1.67
+ -1- 3 0.31 1.16 1.24
Table 5.8: Densitometric analysis on full length caspase-3 levels
Wild type (-) and transgenic (+) mice for LMPlcAO , wild type (+/+) and null (-1-) for
TGFa are shown. The phenotypic stage of the ears used is also shown. Note that
LMPI CAO - mice do not have an ear phenotype but animals that were aged matched
controls of LMP1CAO + mice of a particular phenotypic stage were used and that stage is
indicated.
Values given are after the deduction of the background intensity.
Column A: Full length caspase-3: (3 tubulin
Column B: LMPI CAO : control (TGFa wild type are black, TGFa null are pink)
Column C: LMPlcAO I TGFa null: LMPlcAO I TGFa wild type
Note that LMPlcAO negative in a TGFa null or wild type background give some reading.
LMPICAO/TOFu wild type samples stage 3 and in the LMPlcAO/TOFu null samples stage 4
only. The identity of these proteins is unknown.
It is obvious that both levels and activation of caspase-3 is affected by the increase in the
severity of the ear phenotype and corellates with the observed necrosis and ulceration at stages
3 and4.
In order to further examine this ear phenotype and whether TOFu plays a role in proliferation
or apoptosis, ears ofLMPlcAo/ TOFu wild type or null and LMPlcAOnegative / TOFu wild
type or null were collected, fixed in 10% neutral buffered formalin, paraffin embedded,
sectioned (2J.1m)and stained with PCNA to assess for proliferation levels or full length
caspase-3 antibody to assess for apoptosis. Sectioning of the tissues and antibody staining was
performed by Mr. Colin Nixon, a trained histotechnologist. A number of other staining trials
using the antibodies to cleaved caspase-3, total and phosphorylated EOFR were not
successful.
From the PCNA staining, it can be seen that LMPlcAOtransgenic ears irrespective of TOFu
background show an extensive proliferation that takes place in the basal layer of the epidermis
and extends into the thickened suprabasal layers (fig.5.l5). Normal epidermis has a one cell
thick basal layer (as indicated by a red arrow on fig.5.15.B) to which proliferation is confined.
It was not possible to accurately quantify the degree of proliferation and deduce whether the
presence or absence of TOFu, in an LMPlcAO transgenic animal leads to an increase in
proliferation or not.
Staining the sections with an antibody to full length caspase-3, gave similar results as PCNA
staining. Whereas little or no staining, was observed on wild type ear sections irrespective of
TOFu background, the basal layer of both TOFu wild type and null LMPlcAOtransgenic ears
was stained. This staining was not limited to individual cells but to the whole of the basal
layer (fig.5.l6). It was not possible to quantify whether TOFu leads to increased apoptosis or
not although the staining does appear stronger in the wild type background.
Total levels of Akt may show some decrease, with increasing phenotypic stage as was seen in
fig. 4.14 but this is not clear (fig.5.l7B). However, levels of phosphorylated Akt (Thr) in
LMPI CAOtransgenic samples show a dramatic reduction with increasing phenotype (stage I:
0.76 fold, stage 2: 0.09 fold, stage 3: 0 (equals the background level), when compared to
controls, normalised to total Akt)(table 5.9) confirming the observation made previously in
chapter 4.
261
Figure 5.15: PCNA !taiDiDl ODan froBlIi_ 117 .Dd
1171125
Ears from LMPI negative (-) 1 TGFu wild type (+1+)
(A,B), LMPI transgenic (+) 1 TGFu +1+ (C,D), LMPI
negative !TGFu null (-1-) (E) and LMPI transgenic 1
TGFu null (F, G) stage 3 ears were collected, fixed in
10010neutral bufferred formalin and paraffin embedded.
Sections of 2J1m thickness were cut and stained with
PCNA primary antibody (1:50). The secondary antibody
of the DakoCytomation EnVision kit was used and
visualised with DAB which stains specific antibody
recognition sites brown. The lens magnification used to
take the pictures is indicated on the right bottom comer.
On picture B, the red arrow indicates the one cell thick
basal layer, u indicates the other layers of the epidermis
and f\ the dennis layer.
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LMPI CAO - / TGFa +/+
D
c
LMPI CAO + / TGFa +/+
E.... ".
LMPI CAO - / TGFa -/-
LMPI CAO + / TGFa -/-
Figure 5.16: FuH leugtll caspase-3 staiRiDg OD ean
from IiDe 117 aDd 1171125
Ears from LMPI negative (-) I TGFa wild type (+1+)
(A,B), LMPI transgenic (+) 1TGFa +1+ (C,D), LMPI -I
TGFa null (-1-) (E.F) and LMPI+ 1TGFa-l- (G,H)were
collected, fixed in loeA neutral bufferred formalin and
paraffin embedded. Sections of 2pm thickness were cut
and stained with total caspase 3 primary antibody (l:50).
The secondary antibody of the DakoCytomation
EnVision kit was used and visualised with DAB which
stains specific antibody recognition sites brown. The
lens magnifICation used to take the pictures is indicated
on the right bottom comer.
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Figure 5.17: Phosphorylated Akt (thr) aad total
Akt westem blot of proteiD extradl froDl ean of
Dliee ofliDe 117 and 117l125.
Protein extracts were prepared from phenotypic ears,
stages 1-3 (stl-3) from mice that were transgenic for
LMPI(+) and wild type (+1+), heterozygous (+1-) or
null (-1-) for TGFa. Age matched control extracts
from ears of LMPlcAO transgenic negative siblings
(-) were also prepared. lOOpg of protein
extractltmck was separated by loolo SDS-PAGE and
the gel was blotted. The blot was probed with a
rabbit anti-mouse phospho Akt (thr) (A) primary
antibody or a rabbit anti-mouse total Akt (B)
(1:1000) and a goat anti-rabbit 19G-HRP secondary
antibody (1:4000) and visualised with ECL+. The
60kDa corresponding to Akt is indicated. Molecular
weights according to marker track are shown.
stage
A
TGFa
LMPlcAO
+/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/-
+ + + + + + + +
1 2 3
B
Genotype A B C
LMPI TGFa Phenotypic Akt (thr): Transgenic: Null or
stage total Akt Wild type in het to
respect to wild type
LMPI in
respect
ofTGFa
- +1+ Cl 0.87 1
+ +/+ 1 0.67 0.76
+ +1+ 2 0.09 0.09
+ +1+ 3 0 0
+ +1+ 3 (average)
- -1- Cl 0.93
- -1- C4 (average)
+ -I- I 0.24 0.26 0.36
+ -1- 2 0.28 0.31 3.32
+ -1- 3 0.14 0.15 0
+ -1- 3 0.06 0.07 0
Table 5.9: Densitometric analysis on the levels of AId (thr) to total Ald.
Wild type (-) and transgenic (+) mice for LMPlcAD ,wild type (+/+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMPI CAD - mice
do not have an ear phenotype but animals that were aged matched controls of LMPI CAO + mice
of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A: Phosphorylated Akt (thr): total Akt
Column B: LMPlcAo: control (TGFa wild type are black, TGFa null are pink)
Column C: LMP ICAO I TGFa null: LMPlcAO I TGFa wild type
Note that LMPlcAO negative in a TGFa null or wild type background give some reading.
This decrease in Akt activation, implies that there is less protection against apoptosis in the
LMPICAD transgenic ears.
Levels of uncleaved MMP9 (92kDa) are higher in LMPI CAD transgenic ears irrespective of
TGFa background (fig.S.18). This increase is more evident as the ear phenotype worsens
comparable with MMP9 being a marker of progression. The cleaved MMP9 (84kDa) is seen
in LMPI CAO/ TGFa null ears stages I and 2 but is less apparent in the more progressed
phenotypic stages. MMP9 is a matrix metalloprotease, an enzyme that can degrade the
extracellular matrix allowing angiogenesis and tumour progression.
TNFa convert~ngenzyme (TACE) levels, a metalloprotease that cleaves the membrane bound
form of TNFa (and TGFa) to release soluble TNFa (and TGFa) was also investigated
(Borrell-Pages et al., 2003). Repeated probing proved unsuccessful to detect the 74kDa
product expected in the ear tissue.
C. Proliferation and Cell cycle suppression
In order to investigate how LMP}CAO affects cell cycle progression in the presence or absence
of TGFa, several cell cycle related proteins were examined.
Jun B (and not c-Jun) was seen to be upregulated in LMPl CAD transgenic ear tissue (fig.4.22).
The larger band (approximately 46kDa) was detected in control samples while both the larger
and the smaller (approximately 44kDa) JunB bands were detected in LMP} transgenic
samples upregulated compared to control, but relatively consistent across the phenotypic
stages. Comparison in a TGFa null background revealed that this strong upregulation is
independent of TGFa (fig.S.19). Also the upregulation observed in both the 44 and 46kDa
bands is constant across the stages (not increasing), suggesting that this is an early response of
the tissue to LMP}CAD.
JunB regulates the expression of the cell cycle suppressor p161NK4a, s the latter has upstream
API promoter elements (Passegue and Wagner, 2000). When pl61NK4aprotein expression was
examined this did not correlate with the consistently high levels of JunB observed in
LMPlcAO transgenic samples (fig.S.20). pl61NK4aexpression was detected in LMPlcAD/
TGFa null ears that are stage 3 or 4 only. Previous experiments in the laboratory by another
investigator, showed that LMPlcAO/ TGFa wild type ears of phenotypic stage 4/5 did show
p16INK4aexpression, confirming that p 16INK4aexpression is induced at later phenotypic stages
in both TGFa wild type and null samples (Stevenson et. al. in press). The levels ofp19ARF
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Figure 5.18: MMP9 western blot of protein extracts from
ears of mice oflines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-
3 (stl-3) from mice that were transgenic for LMP1(+) and
wild type (+1+), heterozygous (+1-) or null (-1-) for TGFu.
Age matched control extracts from ears of LMP1CAO
transgenic negative siblings (-) were also prepared. IOOllg of
protein extract/track was separated by 10% SDS-PAGE and
the gel was blotted. The blot was probed with a goat anti-
mouse MMP9 primary antibody (1:1000) and a donkey anti-
goat IgG-HRP secondary antibody (1:4000) and visualised
with ECL+. The 92kDa corresponding to MMP9 is indicated.
The cleaved 84kDa MMP9 band is also shown.
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Figure 5.19: Jun B western blot of protein extracts from
ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-3
(stl-3) from mice that were transgenic for LMP1(+) and wild
type (+1+), heterozygous (+1-) or null (-1-) for TGFa. Age
matched control extracts from ears of LMP1cAO transgenic
negative siblings (-) were also prepared. 100llg of protein
extract/track was separated on 10010 SDS-PAGE. The blot was
probed with a rabbit anti-mouse Jun B primary antibody
(1:1000) and a goat anti-rabbit secondary antibody (1:4000) and
visualised with ECL+. The bands (46 and 44kDa)
corresponding to Jun B are indicated. Molecular weights
according to the marker track are shown.
TGFu
LMP ICAO
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Figure 5.20: p16INK4awestern blot of protein extracts
from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears,
stages 1-3 (s11-3) from mice that were transgenic for
LMPI(+) and wild type (+1+), heterozygous (+1-) or null
(-1-) for TGFu. Age matched control extracts from ears
of LMPlcAO transgenic negative siblings (-) were also
prepared. 100llg of protein extract/track was separated
on 10% SDS-PAGE and the gel was blotted. The blot
was probed with a rabbit anti-mouse p16INK4a primary
antibody (1:1000) and a goat anti-rabbit secondary
antibody (1:4000) and visualised with ECL+. The
16kDa band corresponding to p16INK4a is indicated.
Molecular weights according to the marker track are
shown.
p16
protein were also investigated but the 19kDa band corresponding to p19ARF could not be
detected by Western analysis of those tissues, despite repeated efforts and using O.05%SDSin
the transfer buffer to aid transfer of p19ARF due to its neutral charge.
The cell cycle protein p53 was also investigated. Levels of p53 are upregulated in LMPI CAO
transgenic ears irrespective of TGFa background (fig.5.21). Note that there is a cross reacting
band at approximately 30kDa that is detected strongly in the stages 2, 3 and 4 of LMPI CAO
transgenic ears irrespective of TGFa background. The identity of this protein is unknown.
Also the band at 45kDa is relatively constant by comparison suggesting that the increase
observed is not due to a loading error.
Levels of total Rb and phosphorylated Rb were examined (fig.5.22, 5.23). There is a group of
reactive bands at the 11OkDaregion (fig.5.22). Without a definitive positive control for Rb it
is difficult to determine which band corresponds to total Rb and therefore no conclusions can
be drawn. However, using an antibody to phosphorylated Rb, the 110kDa product is clear
(fig.5.23). LMPI CAO negative 1TGFa wild type ears show low levels ofphospho-Rb. Stage I
LMPI CAO transgenic ITGFa wild type ears show an initial increase but stage 2 and 3 levels are
lower. The phospho-Rb band is apparent in all the TGFa null samples, whether LMPlcAO
transgenic or not. Maybe Rb phosphorylation is independent of LMPl, or TGFa loss may
cause the phosphorylation of Rb consistent with the increased severity in the phenotype of
117/125 mice. However, two samples (stage 4 LMPlcAO/ TGFa null and stage 3
LMPI cAolTGFa wild type) contradict the above hypothesis. It could be that the two samples
have been mixed up or that the above hypothesis is wrong and a larger number of samples
needs to be examined. Note that there is a cross reacting band at approximately 220kDa that
parallels the phosphorylated Rb levels and it could possibly be an Rb complex (fig5.23). Also
another cross reacting band at about 50kDa is observed predominantly in stages 3 and 4 of
LMP1CAO transgenic ears irrespective of TGFa background. The identity of this protein is not
known.
Rassfl is a mediator of apoptosis from Ras signalling and has been observed to be
downregulated by promoter methylation or deletion in NPC lesions. In order to investigate the
Rassfl levels in the LMPI transgenic tissues, a specific antibody detecting Rassfl protein was
used to probe a Western blot of lines 117 and 117/125 ear extracts (fig.5.24). Rassfl levels
are higher in all the LMPI CAO 1 TGFa wild type samples (stage 1: 6.59 fold, stage 2: 12.53
fold, stage 3: 4.33 fold compared to controls, normalised against ~ tubulin)(table5.IO).
However, in the absence of TGFa in LMPI CAO transgenic ears, Rassfl remains at the level
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detected in control samples suggesting that LMPI CAOupregulates Rassfl via TGFa. Note that
a stage 3 LMPICAOj TGFa wild type sample does not show this increase. It is possible that
this sample is not of the best quality. Also a TGFa heterozygous sample shows low level
expression. Further samples need to be examined in order to confirm the observation.
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Figure 5.21: pS3 western blot of protein extracts from
ears of mice ofline 117and 117/125.
Protein extracts were prepared from phenotypic ears, stages
1-3 (stl-3) from mice that were transgenic for LMP1(+) and
wild type (+1+), heterozygous (+1-) or null (-1-) for TGFa.
Age matched control extracts from ears of siblings (-) were
also prepared. lOOllgof protein extract/track was separated
through a 10% SDS-PAGE and the gel was blotted. The blot
was probed with a goat anti-mouse pS3 primary antibody
(1:1000) and a donkey anti-goat IgG-HRP secondary
antibody (1:4000) and visualised with ECL+. The doublet
corresponding to pS3 is indicated. Mol ecular weights
according to markers track are shown. Note that there is a
cross reacting band at 30kDa which is more prominent in the
stages 2,3 and 4 of LMPlcAO + ears irrespective of TGFa
background. The identity of this protein is not known.
TGFa
LMP ICAO
+/+ +/+ +/+ +/+ +/+ -/- -/- -/- -/- -/- -/- +/- +/-
+ + + + + + + + +
stage
Figure 5.22: Total Rb western blot of protein extracts
from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages
1-3 (stl-3) from mice that were transgenic for LMP1(+) and
wild type (+1+), heterozygous (+1-) or null (-1-) for TGFa.
Age matched control extracts from ears of siblings (-) were
also prepared. 100Jlg of protein extract/track was analysed
on a 10% SDS-PAGE. The blot was probed with a rabbit
anti-mouse total Rb (1:1000) primary antibody and a goat
anti-rabbit secondary antibody and visualised with ECL+.
The 11OkDadoublet corresponding to total Rb is indicated.
Molecular weights according to the markers track are
shown.
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Figure 5.23: Phosphorylated Rb Western blot of protein
extracts from ears of mice ofline 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-3
(stl-3) from mice that were transgenic for LMPl(+) and wild
type (+1+), heterozygous (+1-) or null (-1-) fer TGFa. Age
matched control extracts from ears of siblings (-) were also
prepared. 100J.1gof protein extract/track was separated through a
10% SDS-PAGE and the gel was blotted. The blot was probed
with a rabbit anti-mouse phospho-Rb primary antibody (1: 1000)
and a goat anti-rabbit IgG-HRP secondary antibody (1:4000) and
visualised with ECL+. The 110kDa corresponding to pRb is
indicated. Molecular weights according to markers track are
shown. This blot is a reprobe of the blot probed with phospho-
and total MEK shown on figure 5.10. Note that there is a cross
reacting band at about 220kDa that mirrors the phosphorylated
Rb expression levels and it could possibly be an Rb complex.
Also a cross reacting band at about 50kDa is detected strongly in
the stages 3 and 4 of LMP1cAo+ ears irrespective of TGFa
background.
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Figure 5.24: Rassfl western blot of protein extracts
from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears,
stages 1-3 (stl-3) from mice that were transgenic fer
LMP I(+) and wild type (+1+), heterozygous (+1-) or null
(-1-) for TGFa. Age matched control extracts from ears
of LMP1cAO transgenic negative siblings (-) were also
prepared. 100llg of protein extract/track was separated
by 7.5% SDS-PAGE and the gel was blotted. The blot
was probed with a goat anti-mouse Rassfl primary
antibody (1:1000) and a donkey anti -goat JgG-HRP
secondary antibody (1:4000) and visualised with ECL+.
The 43kDa corresponding to Rassfl is indicated.
Molecular weights according to markers track are shown.
The bottom picture shows the ~ tubulin reprobing of the
blot to show relative loading levels. This blot IS a
reprobe of the total EGFR blot shown in figure 5.5.
Genotype A B C
LMPI TGFa Phenotypic Rassfl (A): Transgenic: Null or
stage ~tubulin Wild type in hetto
respect to wild type
LMPI in
respect
ofTGFa
- +1+ Cl 0.03 1
+ +1+ 1 0.18 6.59
+ +1+ 2 0.34 12.53
+ +1+ 3 0.13 4.33
+ +1+ 3 (average)
- -1- Cl 0.07
- -1- C4 (average)
+ -I- I 0.01 0.16 0.06
+ -1- 2 0.12 1.67 0.35
+ -1- 4 0.06 0.83 0.46
+ -1- 3 0.07 1.00 0.54
Table 5.10: Densitometric analysis on the levels of Rassfl respective to ~ tubulin loading
control.
Wild type (-) and transgenic (+) mice for LMP ICAO , wild type (+1+) and null (-1-) for TGFa
are shown. The phenotypic stage of the ears used is also shown. Note that LMPlcAO - mice
do not have an ear phenotype but animals that were aged matched controls ofLMPlcAO +
mice of a particular phenotypic stage were used and that stage is indicated.
Values given are after the deduction of the background intensity.
Column A: Rassfl: f3 tubulin
Column B: LMPlcAO: control (TGFa wild type are black, TGFa null are pink)
Column C: LMPI CAO I TGFa null : LMPI CAO I TGFa wild type
Note that LMPlcAO negative in a TGFa null or wild type background give some reading.
In order to investigate the cell cycle arrest hypothesis further the levels of expression of
cyclins A, B and 01 were investigated in these tissues (fig.5.25, 5.26, 5.27). Cyclins are
proteins that playa role in the progression of the cell cycle. Analysis of the expression levels
ofCyclin A (fig.5.25), cyclin B (fig.5.26) and cyclin 01 (fig.5.27) did not reveal an obvious or
consistent pattern with respect to LMPI transgenic status or TOFa null status. Interpreting the
steady state levels in a whole tissue is complicated by the fact that higher levels may indicate
increased proliferation but might also be evidence of a block at a certain cell cycle stage. It is
therefore difficult to interpret these data. However, a cross reactive band with the antibody to
cyclin B at approximately 66kOa is observed in phenotypic stages 2, 3 and 4 of LMP 1CAO
transgenic ears in both wild type and null TOFa background. The identity of this protein is
not known.
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Figure 5.25: Cyclin A western blot of protein
extracts from ears of mice of line 117 and 117/125.
Protein extracts were prepared from phenotypic ears,
stages 1·3 (stl-3) from mice that were transgenic for
LMP1(+) and wild type (+1+), heterozygous (+1·) or null
(-1-) for TGFa. Age matched control extracts from ears
of siblings (-) were also prepared. 100JIg of protein
extract/track was separated through a 10% SDS-PAGE
and the gel was blotted. The blot was probed with a
rabbit anti-mouse Cyclin A primary antibody (1:1000)
and a goat anti-rabbit IgG-HRP secondary antibody
(1:4000) and visualised with ECL+. The 50-55kDa
corresponding to Cyclin A is indicated. Molecul ar
weights according to markers track are shown. The
bottom picture shows the ~ tubulin probing of the blot
used as a loading control.
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Figure 5.26: Cyelin B western blot of protein extracts
from ears of mice of line 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages
1-3 (stl-3) from mice that were transgenic for LMPl(+) and
wild type (+1+), heterozygous (+1-) or null (-1-) for TGFa.
Age matched control extracts from ears of siblings (-) were
also prepared. 100J.lgof protein extract/track was separated
through a 10% SDS-PAGE and the gel was blotted. The blot
was probed with a rabbit anti-mouse Cyclin B primary
antibody (1:1000) and a goat anti-rabbit IgG-HRP secondary
antibody (1 :4000) and visualised with ECL+. The 50kDa
corresponding to Cyelin B is indicated. Molecular weights
according to markers track are shown. The bottom picture
shows the f3 tubulin probing of the blot used as a loading
control. Note croos reacting band at approximately 66kDa is
detected in stages 2, 3 and 4 of LMPI CAO transgenic samples
in both wild type and null TGFa background. The identity
of this protein is not known.
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Figure 5~27: eyelin Dl western blot of protein extracts
from ears of mice of lines 117 and 117/125.
Protein extracts were prepared from phenotypic ears, stages 1-
3 (stl-3) from mice that were transgenic for LMP1(+) and
wild type (+1+), heterozygous (+1-) or null (-1-) for TGFa.
Age matched control extracts from ears of LMPlcAO
transgenic negative siblings (-) were also prepared. 100J.lgof
protein extract/track was analysed on a 10% SDS-PAGE. The
blot was probed with a rabbit anti-mouse cyelin Dl primary
antibody (1:1000) and a goat anti-rabbit secondary antibody
(1:4000) and visualised with ECL+. The 36 kDa band
corresponding to eyelin DI is indicated. Molecular weights
according to markers track are shown.
5.4 Conclusions and Discussion (summary in table 5.11)
Results presented in this chapter explore the impact of removal of a known oncogene (TGFu)
from the system on the phenotype and signalling pathways known to be affected by LMPI and
its downstream targets. The results presented show that this removal of TGFu did not lead to
alleviation of the observed phenotype. For example, 53/125 mice that were LMPI 895-8/ TOFu
null mice still exhibited the scaly skin phenotype and 117/125 mice that were LMP1CAO
transgenic in a TOFu null background still exhibited the hyperplastic ear phenotype. Both
phenotypes are LMPI induced. Contrary to the initial hypothesis that LMPlcAO may exert its
proliferative effects via TOFu, it was shown that complete removal of TOFu did not alleviate
the phenotype but instead led to its worsening in cross 117/125. Phenotypic examination of
the ears of 117/125 mice, revealed that the LMP ICAO / TOFu null ears show a faster
phenotypic progression than the LMPI CAO/ TOFu heterozygous or wild type ears. This study
therefore suggests that if TOFu upregulation is a mechanism whereby LMPI CAO exerts its
proliferative effects it is clearly not the only route since EOFR signalling is still active in the
transgenic tissue. Moreover, removal of TOFu seems to potentiate the EOFR signalling
further rather than reduce it.
When the EGFR signalling pathway was analysed using Western blotting, it was shown that in
LMPI CAO transgenic ears there is an increase in total EOFR levels when compared to
transgenic negative ears at an early phenotypic stage. However, this increase in levels of total
EOFR decreases as the phenotypic stage progresses. There was an increase in smaller -EOFR
related products- observed in LMPI CAO transgenic ears. These smaller products were shown
to be phosphorylated when phospho-specific EGFR antibodies were used. When activation of
a second receptor of the EGFR family was examined, it was shown that phosphorylated
HER2lErbB2 levels were increased in the LMPI CAO transgenic ears, more so in TGFu null
ears. These results collectively show that LMPI induction of EGFR is not TOFu dependent.
It is possible that other ligands such as EGF are compensating for TOFu loss by upregulating
their action. In an experiment using keratinocytes null for TOFu, other factors such as
amphiregulin, betacellulin and HB-EGF were found to be upregulated in squamous tumours
produced from grafting those keratinocytes onto nude mice (Dlugosz et aI., 1995). It is
possible that these other EOFR ligands are also upregulated by LMPI CAO in these transgenic
ears and possibly upregulated to a greater extent in the absence of TOFu. This needs to be
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explored in order to fully understand the route of EGFR activation along with an examination
of the status ofHER3 and 4.
The MAPK pathway was examined in this system as an EGFR target. Expression of c-Raf-I
was not detected and this could be either due to failure of the particular antibody to detect the
murine c-Raf-l or that c-Raf-I levels in these tissues are too low for reasonable detection. A
recent publication (Chakrabarti et al., 2004) showed that a variant of the E6 protein of HPV
preferentially led to BRaf and not c-Raf-I activation via Rap. When levels of BRaf were
investigated in 117 and 117/125 tissues the results were not conclusive.
MEKI/2 showed marked activation at the phenotypic stage I, which was possibly reduced in
the TGFa. null background. However, this activation decreased with increasing age and
phenotype of the mice. These results show that in order for the tissue to exert homeostatic
control on this aberrant MAPK signalling due to activated EGFR a negative feedback loop
acting directly on MEK1I2 is in place. This suggests that TGFa. contributes to MEK1I2
activation.
In contrast to MEKl/2 activation, levels of activated ERK1I2 increase slightly in LMPlcAO
transgenic tissues independent ofTGFa. background throughout all the phenotypic stages and
therefore ERK1I2 must be activated via another route and not only via MEK1I2 directly.
Conversely a decrease in phosphorylated JNK2/3 is observed in the later phenotypic stage of
LMPlcAO transgenic ears compared to controls independent of TGFa. background. Since
previous studies have shown that JNK3 expression is specific to the brain, heart and testicles,
it might be that the observed products are due to JNK2 alone (for review see (Bogoyevitch et
al.,2004). Knock out mice studies have revealed considerable information about the roles of
JNKs as have the studies concerned with mouse chemical carcinogenesis. It was shown that
mice that were JNKI null had an increased load of tumours when they had undergone a
chemical carcinogenesis regime whilst JNK2 null mice showed an inhibition of
tumourigenesis in a similar setting (Chen et aI., 2001; She et al., 2002). This would imply that
the loss of JNK2 activation would have a tumour inhibitory effect on these tissues and may
result from a tissue homeostatic response to the increase in proliferation. It is clearly not a
direct effect of LMPI as it is not seen in stage 1 tissue samples. Why JNK2 seems to be
decreasing in LMPI transgenic tissues when other studies have reported upregulation of JNK
by LMPI and in these tissues there is API activation is not clear. Possibly this decrease is due
to the tissue homeostatic control. It is possible that the API activation observed is solely due
to the upregulation of Fra-I and JunB that is observed in these tissues or due to activation of
287
other pathways that lead to API activation such as p38. Another explanation for the reduced
JNK activation observed in the LMPI transgenic tissues is that maybe there is cross talk
between activated ERK and JNK. For example, a study using MDCK cells showed that
scatter factor/hepatocyte growth factor led to activation of ERK and inhibition of JNK. API
was still activated in those cells (Paumelle et aI., 2000). Also a second study using human
microvascular endothelial cells showed that VEGF led to activation ofERK 1/2 and inhibition
of JNK leading to apoptosis (Gupta K, 1999). It has been shown that VEGF is upregulated in
LMP1 transgenic ear samples and this may be a potential route via which JNK activation is
reduced (Stevenson et. al., in press). Further investigation of this hypothesis is needed in
order to ascertain which protein plays a role in this JNK deactivation.
Examination of pro- and anti-apoptotic proteins in line 117 and 117/125 tissues, has shown
that LMPI enhances apoptosis. Levels of full length caspase-3 were increased in LMPI CAO
transgenic ears and this increase was proportional to the phenotypic stage. The cleaved
caspase-3 was observed only in the more progressed ears consistent with the phenotype.
Furthermore, p53 - another mediator of apoptosis- levels in LMPI CAO transgenic ears are
increased. Levels of activated Akt (thr) are significantly decreased in LMPI CAO transgenic
ears in a way proportional to the phenotypic stage. The decrease in activated Akt (thr) and
possibly total Akt levels is consistent with an increase in caspase-3 levels and activation of
apoptosis in the transgenic tissues. Why activated EGFR does not lead to increased Akt
activation as would be expected is not clear. It could be that EGFR is translocated to the
nucleus and is therefore unavailable to activate the PI3K1Akt effectors. However, this is not
consistent as MEK1I2 activation is observed. Alternative since the p85 subunit of PI3K
preferably associates with ErbB3 and not EGFR it is possible that in the LMPI transgenic
mouse model ErbB3 is at reduced levels. Examination of the status of ErbB3 is needed. Also
even though EGFR phosphorylation at Tyrl068 can activate the PI3K1Akt pathway, it is
phosphorylation at Tyrl086 that preferentially leads to Akt activation. The phosphorylation
status of Tyrl086 has not been studied in the LMPI transgenic tissues. It could be that this
specific tyrosine is not phosphorylated in these tissues. Also other phosphatases leading to
Akt deactivation could be involved but this is not known.
The effect the phenotype has on the expression of proteins is more clearly demonstrated with
MMP9. Whereas uncleaved MMP9 accumulates at the more severe phenotypic stages of
LMPlcAO transgenic ears irrespective of I'Gf'c, the low level cleaved MMP9 form is observed
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at stages 1 and 2 only. Enhanced vascularisation is apparent from the early stages and the
activation of MMP9 may facilitate this process.
Levels of JunB are upregulated in LMP 1CAO transgenic ears irrespective of TGFo.. However,
pl6INK4alevels do not correlate with this upregulation, implying that in this system pl6INK4ais
either activated by another protein or is inhibited (overriding JunB) at the early stages.
Upregulation of p 16INK4ais observed in the later phenotypic stages and even though in this
study it is observed in stage 3/4 LMPlcAO / TGFo. null ears only, it has been also observed in
LMPI CAO / TGFo. wild type stage 4/5 ears as well (Stevenson et. al., in press). This effect
therefore results from the phenotypic progression and is not the direct consequence of LMPI
expression. Even though this result contradicts other studies that have shown that LMP 1
inhibits p l6INK4aexpression, it is consistent with what is observed in NPC progression and
chemical carcinogenesis studies. If LMP 1 did inhibit p l6INK4aexpression, there would be no
selective pressure to silence p 16INK4ain NPC development or cooperative effect in expression
ofLMPl and loss ofINK4a. It is important to examine levels ofp19ARF, the other product of
the INK4a locus, to determine its role in the LMPl expressing mice and in NPC development.
Another tumour suppressor gene that is often found silenced or deleted in NPC is Rassfla. In
this study, Rassfl expression was examined and it was observed that LMP 1 led to increased
Rassfl levels. It did so in both a wild type and null TGFo. background, however, removal of
TGFo. greatly decreased this LMPI induced Rassfl expression, implying that LMPI mediates
the increase in Rassfl expression via TGFo.. This observation discriminates between the
action of TGFo. and EGFR and the other receptors or ligands. Somehow TGFo. activates a
pathway that very specifically leads to Rassfl activation. It is still not known how Rassfl a
becomes activated. A recent study has revealed more about its role in mediating apoptosis. It
was shown that NOREllRASSFl complexes can associate with the pro-apoptotic protein
MSTl and inhibit its activation, but can also localise it close to activated Ras and increase its
activity thus selectively inducing apoptosis (Praskova et al., 2004). This would be consistent
with the apparent decrease in caspase-3 levels that is observed in TGFo. null ears. These ears
show reduced levels of Rassfl. This could possibly lead to a decrease in MSTl activation and
a decrease in apoptosis and this is confirmed by the reduced levels of total caspase-3 observed
in TGFo. null ears when compared to TGFo. wild type ears. Investigation of the status of
MST1I2 is needed.
LMP 1 led to the activation of Rb and this activation seems to be increased in the absence of
TGFo.from the tissues. This increase in Rb activation is not consistent with the increased
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p16INK4alevels observed in the LMPI transgenic ears. It could be that the p16INK4ais not
functional in these tissues, or that the spatial expression of pl6INK4and Rb differ, or it could
be that Rb gets suppressed in the presence of TOFu. How TOFu could induce this is not
known. The effect that Rassfl may have on p16INK4aand Rb is still not known.
It can be concluded from the above that LMP1 expression leads to activation of the MAPK
pathway. It also leads to increased apoptosis and induction of several tumour suppressors
such as Rassfl and pS3. However, their expression is not enough to overcome the observed
proliferative effects. It could be that the aberrant proliferation signal is too strong for the
tumour suppressors to control or that spatial expression of the tumour suppressors is different
from the spatial expression of the aberrant signal. For example, in this study, whole skin was
examined. It could be that tumour suppressors were induced not directly via LMPI but due to
the phenotypic effect and it is possible that they were expressed in the dennis, for example or
in an epidermal compartment different from the proliferative pathway.
It is not clear from this study why TOFu loss does not seem to have any major effect on the
pathways activated by LMPI. It may be that in this system upon withdrawal of one of the
EOFR ligands, the other five EOFR ligands can compensate. Indeed, a recent study where
amphiregulin (one of the EOFR specific ligands) was overexpressed in the basal layer of
murine epidermis, showed that the transgenic mice generated had a hyperplastic epidermis
with thickened tail and ears (Cook et al., 2004). The phenotype of these animals greatly
resembles the phenotype of the L2LMPI CAO, PyLMP1895-8 animals and of transgenic TOFu
animals. When EOF transgenic animals were created EOF was not targeted towards an
epithelial compartment and so direct comparison with the LMPI mouse model or other EOFR
ligand transgenic animals cannot be made (Chan and Wong, 2000; Erwin et al., 1999;
Krakowski et al., 1999; Wong et al., 2000). No other transgenic mouse models have been
described overexpressing epiregulin, betacellulin or HB-EOF, the other ligands of EOFR.
However, from what is seen upon targeted overexpression of specific EOFR ligands to the
epithelium, one can conclude that the overexpression of EOFR specific ligands leads to similar
phenotypes. Oiven the similarity between the LMPI mouse model described here and the
EOFR ligand transgenic models a preferable therapeutic route would be to target inhibition of
the actual receptor and not its ligands. An approach to analyse this would be to cross breed
LMPlcAO mice to EOFR knock out animals however, EOFR knock out animals show either
embryonic or perinatal lethality (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill
et al., 1995). Another approach would be to cross breed mice harbouring dominant negative
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EGFR in the basal layer (these mice are viable and fertile), given that LMPlcAO expression in
line 117 is confirmed to be in the basal layer (Murillas et al., 1995). Indeed, a previous study
in which mice overexpressing TOFa in type II cells under the control of the human lung-
specific surfactant protein C eSp-C) were crossed to mice expressing dominant negative EGFR
under the human SP-C promoter, showed an improvement of the lung phenotype (Hardie et
al., 1996). A different approach would be topical application of chemical EOFR inhibitors or
even topical application of MEK and/or ERK inhibitors on the LMPI expressing mice as a
first step towards developing a therapeutic approach relevant to LMP1 expressing NPC.
The results presented in this chapter suggest that LMPI via TGFa may be signalling to the
tumour suppressor Rassfl possibly via the MAPK pathway. Further work is needed to unravel
the exact mechanism of action of TOFa on Rassfl. If in this system Rassfl acts as a tumour
suppressor, then its decrease in the TGFa null ears could explain the observed worsening in
the ear phenotype.
To summarise, in this system TOFa may act as a control for some of the LMPI mediated
signalling pathways. However, its withdrawal does not lead to any phenotypic alleviation,
instead it has quite opposite effects.
291

Chapter 6: Final Discussion
The aim of this project was to investigate the role LMPI CAD plays in the genesis and
development of epithelial tumours such as NPC using transgenic mice as a model. A
considerable amount of information is known about the functions of LMP1, mostly from B
cell studies, whereas very little is known about its role in disease in the epithelium in vivo. A
series of transgenic mice that were generated in the laboratory expressing LMP 1CAD in the
epithelium, under the direction of the viral ED-L2 promoter were used for this study
(Stevenson et. al., in press). The expression pattern of the transgene and the occurring
phenotype was investigated. Signalling pathways activated by LMPI CAD, in the epithelium in
vivo, were examined with an emphasis on the RaslMAPK pathway. In order to deduce
whether LMPlcAO exerts its action via TGFa. upregulation, a TGFa. null mouse strain was
used.
6.1 LMP1cAO as a tumour promoter or initiator?
It has been shown in rat fibroblasts that LMPI acts as a classical oncogene inducing a
transformed phenotype. It has also been shown that LMP 1 expression in the murine
epithelium under the Py promoter leads to epidermal hyperplasia (Wilson et al., 1990). Using
the ED-L2 promoter to direct expression of LMPlcAO to the murine epithelium leads to a
hyperplastic ear phenotype which progresses from benign keratoacanthoma to squamous cell
carcinoma in some cases and leads to spontaneous formation of benign lesions in susceptible
mouse strains as described in this thesis (Stevenson et. al., in press). Genetic susceptibility is
thought to be a risk factor of NPC development. Certain ethnic backgrounds such as
S.Chinese, Alaskan and African Mediterranean populations show an increased risk for NPC.
In the transgenic mouse, the fact that LMP 1CAD led to spontaneous lesions only in a
genetically susceptible mouse strain demonstrates the importance of genetic background to the
action of the primary oncogene of EBV. A previous study in which PyLMP1895-8 mice were
chemically treated showed that LMP1895-8 acts to augment the action of TPA but cannot
replace DMBA in this model of carcinogenesis thus showing that LMP1895-8 is acting as a
tumour promoter (to induce proliferation) and not as an initiator (Curran et al., 2001). Given
the above, it was of interest to explore if LMP 1CAO acts differently to LMP1895-8 in this
respect. IfLMPI CAD could replace chemical initiation in this approach, supply ofLMPI in the
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form of a transgene would make use of a chemical initiator such as DMBA in the process of
chemical carcinogenesis redundant.
The results obtained from this thesis, confirmed that LMPI CAO is acting as a tumour promoter
and not as an initiator in the epithelium in vivo, just as LMPI B95-8. However, the fact that
lesions appear at all on untreated mice, implies that LMPI CAO is supplying a weak initiation
signal. Whether LMP1CAO is more tumourigenic than LMP 1B95-8 is still not clear from these
studies. When L2LMPl 895-8 mice were created, only two founders were born and those had a
severe phenotype and died early before establishing a line. However, the small number of
L2LMP 1895-8 mice generated does not allow for a formative comparison to be made.
Furthermore the fact that no spontaneous papillomas form on PyLMPI895-8 mice does not
necessarily show that LMPI CAO is more tumourigenic. Since the epidermal compartment
where the L2 and the Py transgenes are expressed is unknown, this could be a site specific
effect and not an LMP1 effect. Creating PyLMP1CAO or further L2LMP1895-8 mice would be a
way to directly compare these two LMPI strains in vivo.
6.2 LMP1cAO and INK4a locus
It has been shown in this study using 117/113 mice and in a previous study using 53/113 mice
(Macdiarmid et al., 2003) that loss of the INK4a locus in conjuction with LMPI expression
leads to increased lesion load, with larger lesions and progression to malignancy. These
results imply that there is cooperation between LMPI and loss of either p16INK4a and/or p19ARF
leading to both lesion expansion and conversion. In NPC and EBV associated gastric
carcinoma, loss of heterozygosity on chromosome 9 (a region encoding INK4a, INK4b and
ARF), is an early event that is thought to precede EBV infection. EBV infection has not yet
been identified in pre-malignant lesions of the nasopharynx or the gastric mucosa. This
suggests that loss of heterozygosity of INK4a and/or ARF is predisposing the affected area,
following EBV infection to malignant progression. Consistent with this, the above studies
using 53/113 and 117/113 mice have demonstrated a cooperation between EBV LMPI and
INK4a loss.
Other studies have shown using murine and human fibroblasts that LMPI leads to the
inhibition of p161NK4aexpression and action (Ohtani et al., 2003; Yang et al., 2000a).
However, in the LMPlcAO transgenic epithelium p16INK4a expression is upregulated at the later
phenotypic stages of the affected tissue. This would suggest that this is not a direct LMP1CAO
effect but rather a subsequent response to the developing phenotype. The apparent
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contradictory results described above, may be due to the nature of the studies. For example, it
is possible that in vivo the LMPI induced phenotype leads to pI6INK4a upregulation and thus
loss of p16lNK4ais advantageous in carcinogenic progression whereas in an established
fibroblast cell line in vitro, the growth status of the cell is very different and several
checkpoints have already been overcome by mutation.
In support of this premise, whereby the cellular environment determines the effect LMPI may
have on p16, it has been recently reported that LMPI is not sufficient to inhibit p16lNK4a
expression in LCLs (Hayes et al., 2004).
6.3 LMP1 CAO and the Ras/MAPK pathway
Activating ras mutations are a common feature of many human cancers (Bos, 1989). In NPC
ras mutations have not been found. One hypothesis for this observation is that LMP1 can lead
to activation of ras therefore, there would be no selective advantage for constitutive ras
mutation during tumour development or another hypothesis is that LMPI activation may lead
to ras pathway inhibition. The signalling pathways that were investigated in this thesis
showed that LMPlcAO leads to TGFa upregulation, EGFR activation and subsequent initial
activation of MEK1I2 that is then deactivated, and a continuous activation of ERK1I2 and
several downstream transcription factors. These results have confirmed a previous
observation showing that LMPI led to ERK activation in rat fibroblasts in vitro (Roberts and
Cooper, 1998) and is the first report to show that LMPI activates the EGFRlMAPK pathway
in the epithelium in vivo. It supports previous studies demonstrating that LMPI induced
upregulation of EGFR, correlated with EGFR expression in NPC biopsies and a study that
showed that LMPI regulates EGFR nuclear translocation and therefore its function in HNE2
epithelial cells (Tao et aI., 2005; Zheng et aI., 1994a). As can be deduced from the above,
even though the status of ras in this system has not been specifically investigated, one of its
upstream activators (EGFR) and one of its downstream pathways (MAPK) are activated by
LMPlcAO, possibly suggesting that ras or related protein (eg. Rap) can be activated by LMPI
signalling and thus activating mutations are not selected for in tumourigenesis. In order to test
this, papillomas that spontaneously develop on line 117 transgenic mice could be assayed in
order to identify any ras activating mutations by sequencing. Similar assays could be
performed using lesions that developed on LMP1 transgenic mice after chemical carcinogen
treatment. Absence of ras mutations in the spontaneous lesions, would imply that LMPI CAO
295
overrides or inhibits any selection for activating ras mutations in the development of these
lesions.
Incidental evidence comes from the observation that LMPI CAO expression leads to
spontaneous papillomas in line 117mice. Appearance of these lesions suggests that LMP1CAO
could be activating ras or a parallel pathway to a degree even if this activation is not strong
enough to completely replace activated ras. However, not all lesions develop as a result of ras
activation so this is unequivoval. Also when line 53 mice were crossed with transgenic ras
mice the bitransgenic mice developed fewer lesions than the monotransgenic ras mice. Since
LMPI activates the MAPK pathway, supplying an extra proliferating signal by transgenic ras,
could lead to anti-proliferative responses such as upregulation ofp16lNK4a. For example, this
has been seen in line 117 ears where as the phenotype becomes worse, there is upregulation in
the expression ofpl61NK4a and this is mediated possibly via activation of ras. Also another
tumour suppressor that is found to be upregulated as the phenotype worsens is Rassfl. In both
NPC and EBV associated gastric carcinomas, loss of heterozygosity on chromosome 3 that
contains the gene that encodes Rassfl is an early event, prior to EBV infection. Extensive
hypermethylation of Rassfla and its subsequent silencing is also observed. Studies have
shown that activated ras can lead to upregulation of Rassfl. In this study, it was shown that
LMPI leads to Rassfl upregulation via TOFu. Taken together, these data suggest that LMPI
in the murine epithelium in vivo, is activating a key ras signalling pathway and that removal of
growth inhibitors activated by this pathway, such as p16 and Rassfl are critical in LMPI (and
thus EBV) associated carcinogenesis.
6.4 LMP1 CAO and Other Signalling pathways
Other MAPKs such as p38 were found to be activated by LMPI CAO, this being consistent with
the observation that LMPI leads to p38 activation in epithelial cells in vitro (Eliopoulos et al.,
1999). In contrast, even though EOFR was activated, Akt was found to be deactivated by
LMPlcAO, giving the opposite result from what was observed in epithelial cells in culture
(Dawson et al., 2003). It is possible that the PI3K1Akt pathway is not activated by EOFR as
the status of the specific tyrosine needed for Akt activation has not been studied and it may be
possible that activation of the MAPK pathway has opposing effects on PI3K1Aktactivation. It
is possible that in these tissues, EOFR may be sequestered away in a different compartment
and therefore not even basal level Akt activation is observed. Also the fact that Dawson et.
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al., are using carcinoma cells that have already surpassed all the control mechanisms that are
in place in a live, responsive tissue may explain this apparent contradictory observation.
API and NF-KB were found to be activated in the transgenic tissues and it was shown that
LMPIcAO leads to activation of apoptosis (increased caspase-3), activation of tumour
suppressors (p53, Rb and Rassfl) and activation of the invasion pathway (increased MMP9
levels). Activation of Rb by phosphorylation leads to release of E2F that can increase pI9
expression that leads to stabilisation of p53. Both stabilised pS3 and Rassfl activation can
lead to an increase in apoptosis.
A novel effect ofLMPI on the tumour suppressor Rassfl has been observed, showing that one
of the actions of LMP1 may be to keep the proliferation under control. Whereas at the same
time LMPI is activating proliferative pathways such as MAPK, it also leads to increased
expression of Rassfl that has been shown to inhibit proliferation by promoting apoptosis and
cell cycle arrest. This observation is consistent with the smaller size of lesions observed in
mice of line 53 compared to wild type that were chemically treated (Macdiarmid et al., 2003).
This is the first study that examines the action of LMPI CAO in the epithelium in vivo, and as
noted above some opposing results have been obtained highlighting the differences between a
carcinoma cell line that harbours multiple mutations in cellular oncogenes and tumour
suppressor genes and has lost several of its growth control mechanisms and a pre-cancerous
tissue that still has most of the negative feedback loops intact.
When TOFu is removed from this system, an increase in severity of the phenotype is
observed. However, this does not negate any significant changes in the signalling pathways
studied. For example, there is still LMP ICAO induced EOFRJHER2 and MEK 112 activation,
although the latter is to a lower degree. It is possible that TOFu loss is compensated for by
upregulation of other EOFR ligands. For example in a study using murine keratinocytes,
activation of ras was not affected by TOFu loss and other ligands were found to be
upregulated (Dlugosz et al., 1995). In the transgenic tissue it is possible that TOFu is acting
as a regulator of LMPI action, since its removal leads to a worsening of phenotype. By
overexpression of an oncogene such as TOFu, it is possible that cell cycle arrest or apoptotic
pathways are activated. Alternatively removal of TOFu may lead to overcompensation of
other EOFR ligands leading to a stronger proliferative signal. In either scenario TOFu
appears to dampen the consequences of LMP I action indicating that as well as its known
oncogenic role in proliferation it may also serve as a regulator of this activity.
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The exact role EGFR activation plays in murine carcinogenesis is still not very clear. A recent
study has suggested that its role is more important in tumour invasion than in cellular
proliferation (Scott et al., 2004). This would be consistent with the observed upregulation of
MMP9, VEGF (Stevenson et. al. in press) and Fra-l (which was shown to enhance
invasiveness in mammary epithelial cells) (Kustikova et aI., 1998) in the LMP1 transgenic
tissues.
The signalling mechanism that we propose is summarised in figure 6.1. LMPI, activates NF-
KB and API complexes that lead to TGFa upregulation which in tum activates EGFR.
Moreover, EGFR contains NF-KB binding sites in its promoter and it has been shown that
LMPl directly upregulates EGFR via NF-KB (Tao et al., 2004c). EGFR signalling leads to
activation of the MAPK cascade. A possible consequence of this is the observed induction of
JunB, p161NK4aand Fra-I. How this precisely impacts proliferation, apoptosis and invasion is
not clear. TGFa upregulation seems to playa role in controlling LMPI induced EGFR action.
In the viral context, it is possible that LMPI may promote growth pathways and differentiation
of cells in order to support viral production and release. Under normal circumstances, EBV
infected peripheral B cells express only LMP2 and possibly EBNA1but upon a cellular trigger
such as differentiation, EBV may switch into the lytic cycle and produce virions. LMPI is the
only latent protein to be expressed in the lytic cycle, so it may playa role in viral reproduction
in B cells. EBV epithelial infection is a rare event. It is possible that in an epithelial cell
context, LMPI activation of the EGFRlMAPK pathway leading to excessive proliferation of
the epithelium may be an inadvertent consequence of the signalling pathways activated by
LMPI designed to promote the viral life cycle in a B cell.
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Figure 6.1: Possible pathway of LMPI CAO action in line 117 ears.
In the line 117 ear tissue, LMP1CAO activates both NF-KBand AP1 to
increase factor binding to NF-KB and TRE sites (respectively). Binding
elements for both exist in the promoter of the TOFu gene. LMPI CAO
leads to TOFu upregulation probably via activation of the promoter.
NF-KB binding elements also exist in the EOFR promoter possibly
leading to direct upregulation of EOFR expression by LMPI. In
conjuction with TOFu upregulation (and possibly other EOFR ligands)
this leads to an increase in EOFR and HER2 activation. EOFR and
HER2 can form homolheterodimers with each other to activate
downstream pathways. (Other heterodimers with other receptors of the
EOFR family have not been investigated.) One of the pathways
examined was the MEKIERK pathway, where initial activation of
MEK1I2 followed by deactivation in the later phenotypic stage ears was
observed. This suggests that there is a negative feedback loop acting on
MEK1I2 (represented by a dotted line). ERK1I2 is activated by LMPI
and increased binding at SRE containing sites is observed. ERK1I2
activation can upregulate fra-I and p16INK4a• p16INK4a can block Rb
activation. Therefore it is not clear how Rb remains active when
p161NK4a is expressed. It is not known ifLMPl can directly activate Rb
at this stage. Rassfl is upregulated via TOFu but whether this is a Ras
mediated effect is not known. LMPI can activate other MAPKs such
as p38. Another pathway affected by EOFR signalling is the PI3K1Akt
pathway. In ear tissues deactivation of Akt is observed. Note that the
red star implies activation, the blue box deactivation and where the
pathway is not direct from one molecule to the next a dotted line was
used.
~~~
.. via <lOe>
NF-lCB t>~<\
.......... ?
'.'.'.'.'.'.'.
<,~
# ••••••••••••••••••••••••••••••••••••••
p16t
6.5 Future Directions
It has not yet been clarified in exactly which epidermal layer the LMPI CAO and the LMP1895-8
transgenes are expressed. It is important to determine this either by IHC or by RNA in situs,
in order to allow a direct comparison of the effect of the two strains to be made. When
L2LMP 1895-8 mice were created, the 2 transgenic pups born died due to a severe phenotype
before a line could be established. This could imply that either the LMP1895-8 variant is more
potent in hyperplasia and apoptosis or that its expression in the specific epidermal layer alters
its effects. This would not be surprising since other oncogenes for example, ras and TOFu
when expressed in different epidermal layers have quite different effects. The small number
of pups created does not allow for a definitive comparison to be made.
It is also important to find out where (epidermal layer or dermis) the different upregulated and
activated products are expressed/present by IHC. For example, an increase in p16 expression
and activation of Rb may not be taking place in the same cells but in different cells of the
tissue. Also MMPs are typically expressed in mesenteric tissues such as dermis and the
observed MMP9 upregulation may not be occurring in the same cells as LMP1 is expressed
but upregulated in a responsive tissue (eg. TOFu can affect neighbouring cells and tissues).
Such a finding, could significantly impact the interpretation of these data.
Further investigation of pathways that could be activated by LMPI CAO is still pending. For
example, the JAKISTAT pathway has not been investigated in this study and is one of the
pathways known to be activated by LMPI in fibroblasts. During the preparation of this thesis,
Chan and co-workers reported that EOFR activation during murine skin chemical
carcinogenesis led to STAT activation, particularly STAT3 (Chan et al., 2004). Since the
STAT pathway is activated by both EOFR and LMPI it would be very interesting to examine
STAT3 levels and activation in the transgenic tissues.
The hypothesis that TOFu loss may be compensated for by the action of the other EOFR
specific ligands needs to be tested by Western blot analysis.
However, even if the other ligands are compensating, their functions are not completely
overlapping as some observations (such as Rassfllevels and Rb phosphorylation) are different
in the absence of TOFu, so it would be interesting to determine what effect the loss of TOFu
will have in spontaneous papilloma formation and how TOFu specifically causes these effects.
So far, the analysis of the effects of TOFu loss in cooperation with LMPlcAO expression, was
performed in tissues that came from mice of mixed strain C57BL/6IFVB and 129 background.
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It has been highlighted extensively in this thesis the effect that strain background can have on
the phenotype. It would therefore be interesting to bring the 117/125 mice into the FVB strain
and observe whether loss of TOFu leads to any changes in the spontaneous lesion formation.
It is predicted that possibly there would be an increase in the number of papillomas observed
compared to 117mice.
Examining the activity of ras and related proteins such as Rap in the 117 mice is important.
This could be done by sequencing of spontaneous papillomas as described before or by assays
measuring the ratio between Ras-OTP and Ras-ODP. For example, use of the Ras binding
domain of Raf-I preferentially binds Ras-OTP precipitating it from cell suspension (de Rooij
and Bos, 1997). Determining whether Raf-I, Braf or Araf is involved in MEK activation is
also of interest and this can be done by further controlled Western blots using the appropriate
antibodies. Mutated forms of Braf have been shown to lead to increased ERK activation from
Rap. It would be interesting to determine whether Braf in the transgenic tissues is activated.
Further examination of the PI3K1Akt pathway would be informative. For example only
OSK3f3 has been examined so far whereas other downstream targets such as Bad have not
been examined. Examining the status of the specific tyrosine of EOFR responsible for
activation of PI3K1Akt by Western blot would clarify whether the Akt deactivation observed
is due to the tyrosine not being activated. It would also be interesting to deduce in which
cellular compartment activated EOFR goes.
So far, the most striking difference observed between LMPI transgenic TOFu wild type and
null ears lies in the decreased levels of Rassfl observed in the TOFu null ears. It is known
that Rassfl a expression is silenced not only in NPC but in a variety of other human tumours.
The mechanism of action of Rassfl a is not entirely clear and it would be important to
investigate the relationship between TOFu expression and Rassfl. It has been recently
suggested that Rassfl is involved in the TOFf3/Smad signalling pathway and so investigation
of the status of this pathway in line 117 and 117/125 tissues would be informative. When
exogenous Rassfla was transfected into epithelial nasopharyngeal carcinoma cells lacking
Rassfla and an oligonucleotide array was performed. it was shown that expression of Rassfla
led to an increase in arrestin beta E - a TOFf3/Smadpathway effector, and downregulation of
inhibitor of differentiator (Id) 2 - a TOFf3/Smad downstream target (Lo KW Oral
presentation). Ids (1-4) bind to E proteins and prevent them from binding to DNA thus
inhibiting regulation of expression by E proteins. Ids are downstream targets of the MAPK
pathway as well and it will be very interesting to investigate Id levels in the transgenic tissues
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to see if these observations correlate in the epithelium in vivo (reviewed in (Ruzinova and
Benezra,2003). One might predict that Id2 may well be downregulated in the transgenic
tissues as they show overexpression of Rassfl. It has been shown by two groups that LMPI
leads to upregulation of Id1 and Id3 in epithelial cells in culture (Everly et al., 2004; Li et al.,
2004). It is possible that LMPI in the transgenic tissues, leads to Idl and 3 upregulation thus
preventing E2A binding to transcription factors and activating p 16. Inhibition of p16 allows
Rb phosphorylation.
With respect to potential therapeutic approaches the future plan is to treat mice of lines 117
and 117/125 with EGFR chemical inhibitors either by topical application or in drinking water
in order to assess the therapeutic potetial in targeting inhibition of the receptor.
Clearly, TGFa removal alone does not lead to an alleviation of the observed phenotype. On
the contrary it seems to accelerate the phenotype. It is therefore, important not to target
ligands with therapies without this kind of in vivo analysis. Moreover, targeting receptors
should be fully investigated before taken to clinical trials. For example, Iressa™ (an EGFR
inhibitor developed by AstraZeneca) is not increasing survival rate in non-small cell lung
cancer and its action in vivo models may not have been fully explored. However, it does show
some benefit such as tumour shrinkage and its efficacy in other types of cancer is still under
investigation. Therefore, caution needs to be taken before inhibiting a pathway as the opposite
results may be obtained.
In conclusion, the above study has highlighted the critical role that examination of an in vivo
model plays in order to correctly target a factor for therapy. As was concluded, complete
withdrawal of the ligand that was proposed to cause or contribute to the phenotypic effect not
only did not alleviate the phenotype but led to its worsening highlighting the fine tuning of the
homeostatic controls that are in place in a living tissue. As such, before any potential
therapies are taken to human trials, a thorough examination in suitable in vivo models would
be highly advisable.
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Appendices
Line, ID, Tissue Description
Transgenic
Status
105A.l74 Thymus Lymphosarcoma. The architecture of the thymus is
LMPlcAo+ replaced by dense sheets of large neoplastic
Wasting lymphocytes that have large round nuclei, a high
phneotype ratio of nucleus to cytoplasm and 10 to 20 mitoses
per high power field. Frequent apoptosis creates a
"starry sky" pattern.
Glandular Lymphosarcoma. The base of the lamina propria is
stomach infiltrated with large neoplastic lymphocytes similar
those infiltrating the thymus.
Tongue Unremarkable
Forestomach Bacteria are adherent to some segments of the
surface of the epithelium in the forestomach.
Trachea Unremarkable
Thyroid
gland
Muscle
Junction of Lymphosarcoma. The base of the lamina propria of
forestomach the glandular stomach is infiltrated with large
and neoplastic lymphocytes similar those infiltrating the
glandular thymus.
stomach
Liver Lymphosarcoma. Portal areas and sinusoids in all
areas of the liver are densely infiltrated with large
neoplastic lymphocytes similar those infiltrating the
thymus.
Spleen Lymphosarcoma. The white pulp and multifocal
locally extensive areas of the red pulp of the spleen
are infiltrated with large neoplastic lymphocytes
similar those infiltrating the thymus.
Lymph node Lymphosarcoma. The architecture of the lymph
node is effaced by sheets of large neoplastic
lymphocytes similar those infiltrating the thymus.
344
117.44 Lymph node Reactive lymph node. The lymph node has
LMPlcAo+ multiple active lymphoid follicles with well-
defined mantles and germinal centres. There is
hyperplasia of the paracortical zone with frequent
apoptosis, producing a "starry sky" pattern.
Medullary cords are filled with plasma cells. The
lymph node is reactive. There is no evidence of
neoplasia.
117.30 Ear Keratoacanthoma and Squamous cell
LMPlcAO + carcinoma. A proliferative epidermal mass
consists of an irregular, central crateriform
depression lined by stratified squamous
epithelium and filled with keratin laminae,
degenerate cells and scattered colonies of
bacteria. Multiple islands and cords of squamous
epithelial cells with 1 to 3 mitoses per high
power field and central keratinisation extend into
the surrounding dermis. Microabscesses are
formed by exudation of neutrophils in the centre
of many epidermal islands. There are infiltrates
of neutrophils, lymphocytes and plasma cells in
the surrounding dermis, along with mild fibrosis.
Immunohistochemistry for cytokeratins 1 reveals
staining of spinous and granular layer epithelial
cells in proliferating islands and cords.
Immunohistochemistry for vimentin' is
uninformative.
117/113.31 Papilloma size> 4 Squamous cell carcinoma. There is
LMPlcAO + / downgrowth of cords and islands of stratified
INK4a -/- squamous epithelial cells with a prominent
granular cell layer and central keratinisation.
Intermixed with these moderately well-
differentiated cells, there is proliferation of cords
and sheets of poorly differentiated squamous
epithelial cells that have pleomorphic, ovoid
nuclei, open heterochromatic chromatin,
eosinophilic nuclei, variable amounts of
eosinophilic cytoplasm and 2 to 4 mitoses per
high power field. Proliferation of spindle-shaped
cells with a fibroblastic appearance is also
evident. Hyperkeratosis and serocellular crusting
is evident on the surface of the skin.
Immunohistochemistry for cytokeratins reveals
staining of spinous and granular layer epithelial
cells in the epidermis and proliferating islands
and cords of cells in the dermis, as well as poorly
differentiated sheets of spindle-shaped cells,
supporting a diagnosis of poorly differentiated
squamous cell carcinoma. Immunohistochemistry
for vimentin is uninformative.
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117.23986 Skin: Ear A Keratoacanthoma. Early squamous cell
LMP1cAo+ carcinoma. Ulcerative dermatitis. The skin of
the ear has segmental acanthosis and marked
hyperkeratosis, with localized downgrowth of
cords and islands of epidermal cells that have
concentric foci of keratinisation. At one margin
of this proliferative lesion, there is shallow
downgrowth of irregular cords of squamous
epithelial cells into the underlying dermis. The
squamous epithelial cells have evidence of
keratinisation and there are 1 to 2 mitoses per
high power field. There is extensive segmental
ulceration, with necrosis, exudation of
neutrophils, formation of a serocellular crust and
proliferation of coccoid bacteria. Locally
extensive fibrovascular hyperplasia is evident in
the underlying dermis, along with diffuse
infiltration by neutrophils and lesser numbers of
lymphocytes, plasma cells and other
inflammatory cells. This lesion appears to be a
shallow keratoacanthoma that has been
traumatised, leading to extensive ulceration,
formation of granulation tissue and secondary
growth of bacteria. There is early transformation
to a squamous cell carcinoma.
Appendix 1: Histopathology analysis of tissues from lines 105A, 117 and 117/113 mice
The above table shows the results of histological examination obtained from tissues of several
transgenic mice from lines 105A, 117 and 1171113.
346
MouseID Age in Age in weeks Week of first Max number of
weeks at of last count papilloma papillomas
start of
count
1 6 65 0 0
2 6 65 6 3
3 6 65 6 4
4 6 42 7 3
10 6 15 0 0
11 6 15 0 0
12 6 15 0 0
13 6 39 6 1
14 6 55 29 2
15 6 55 55 1
16 6 17 0 0
30 6 65 21 1
31 6 65 0 0
37 6 65 24 6
38 6 65 27 1
39 6 65 0 0
40 6 60 0 0
41 6 55 0 0
44 6 15 9 2
45 6 46 9 4
46 6 65 9 3
Appendix 2: Spontaneous lesion recording of transgenic mice of line 117
The table above is showing the identification number, the age of the mice, week of first
papilloma appearance and the maximum number of papillomas that each mouse developed
during the 59 weeks of observation.
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Mouse Id Genotype Ear phenotypic Age
LMPI TGFa stage (months)
117.22152 (BK6) - +1+ Cl 1
117.22151 (BK6) + +1+ 1 1
117.23549 (BK6) + +1+ 2 3
117.24882 (BK6) + +1+ 3 4
117/125.56 + +1+ 3 4
117/125.A404C - -1- Cl 1.5
117/125.M23277A - -1- C4 2.5
117/125.A404 + -I- I 1
117/125.24789A + -1- 2 2
117/125.23995A + -1- 4 2.5
117/125.55 + -1- 3 4
117/125.67 - +1- C4 4
117/125.58 + +1- 4 4
Appendix 3: Details of the mice used for the western blotting experiments in chapter S.
The table above is showing the mouse identification number or batch number, their genotype,
phenotypic ear stage and age at which they were sacrificed. Transgenic positive mice for
LMPlcAO are indicated by (+), transgenic negative by (-). Null mice for TOFu are indictaed
by (-1-),heterozygotes by (+1-) and wild type by (+1+).
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